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Abstract 
Histone deacetylase (HDAC) enzymes are one of the best characterised 
epigenetic targets; aberrant activity of one or more of the 11 zinc-dependent HDAC 
isoforms has been associated with many different cancers, as well as several other 
diseases. Some HDAC inhibitors have been proven to be efficacious in treating cancer; 
three are FDA approved for treating cutaneous T-cell lymphoma or multiple myeloma. 
Animal models of other diseases have shown that HDAC inhibitors have potential as 
therapeutic agents. However the clinical use of HDAC inhibitors is currently limited by 
toxicity and side effects, amongst other problems, possibly arising because the 
inhibitors are not isoform selective. This thesis focuses on attempts to synthesise novel 
HDAC inhibitors with increased isoform selectivity. 
A series of mocetinostat analogues substituted at the 4-poisition of the terminal 
2-aminophenyl ring, was synthesised and tested for inhibition of HDAC isoforms, but 
no improvement over mocetinostat was found.  
Subsequently multiple series of compounds containing a chiral heterocycle, in 
place of the pyrimidine ring in mocetinostat, were prepared and evaluated against a 
selection of HDAC isoforms. The development of highly convergent methodology 
enabled the rapid synthesis of these chiral mocetinostat analogues. Several compounds 
were discovered that are more potent and selective inhibitors than mocetinostat against 
HDAC3. Those compounds containing a 2-amino-linked dihydrooxazole ring were the 
most potent, and in all cases the amino-linked heterocycle outperformed its thioether-
linked analogue. Mocetinostat and a novel chiral analogue were shown to be slow, tight-
binding inhibitors of HDAC2 and HDAC3. 
Attempts were made to discover a novel zinc-binding group; a selection of 
potential bi-dentate zinc-chelating fragments was assayed and 8-hydroxyquinoline 
emerged as a promising candidate for HDAC8 inhibition. Accordingly some substituted 
8-hydroxyquinolines were prepared in order to conduct a brief SAR study of the novel 
zinc-binding group, however no improvement on the unsubstituted 8-hydroxyquinoline 
was found. 
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Abbreviations 
δ  chemical shift 
Ac acetyl 
ADP adenosine diphosphate 
AMC 7-amin-4-methylcoumarin 
anh. anhydrous 
aq.  aqueous  
Ar aryl 
AUC area under the curve 
Bn  benzyl 
Boc tert-butoxycarbonyl 
BOP benzotriazole-1-yl-oxy-tris-(dimethylamino)-phosphonium 
hexafluorophosphate 
br. broad (spectral) 
Bu  butyl 
CI chemical ionisation 
d doublet (spectral) 
DCM  dichloromethane 
DDQ  2,3-dichloro-5,6-dicyano-1,4-benzoquinone 
DIBAL diisobutylaluminium hydride 
DIPEA  diisopropylethylamine 
DMF dimethylformamide 
DNA deoxyribonucleic acid 
EDC 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide 
eq.  equivalent(s) 
EI electron impact ionization 
ES electrospray ionisation 
Et  ethyl 
FDA US food and drug administration 
HRMS high resolution mass spectrometry 
h  hour(s) 
HAT histone acetyl transferase 
HDAC histone deacetylase enzyme 
HMT histone methyltransferase 
HOBt hydroxybenzotriazole 
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HPLC high performance liquid chromatography 
IC50 half maximal inhibitory concentration 
IR  infrared 
J  coupling constant (Hz) 
m  multiplet (spectral) 
MDAP mass directed auto purification 
Me  methyl 
min  minute(s) 
mp  melting point 
m/z  mass:charge ratio 
n normal 
NAD
+
/H
 
nicotinamide adenine dinucleotide oxidised/reduced 
NBS N-bromosuccinimide 
NCoR nuclear receptor co-repressor 
NMR  nuclear magnetic resonance 
PDB protein data bank 
Ph  phenyl 
ppm parts per million 
rt  room temperature 
s singlet (spectral) 
SAR structure-activity relationship 
SUMO small ubiquitin-like modifier 
t triplet (spectral) 
t (tert) tertiary 
TBS tert-butyl dimethylsilyl 
TFA trifluoroacetic acid 
THF  tetrahydrofuran 
TLC  thin-layer chromatography 
TSA trichostatin A 
νmax  IR absorption maxima 
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1 Introduction 
1.1 Project Aims 
This thesis focuses on attempts to synthesise an isoform selective HDAC 
inhibitor, the enzyme targeted specifically is HDAC11 (the most recently discovered, 
and smallest member of the HDAC family). Other than targeting HDAC11, the aim is to 
synthesise a HDAC inhibitor with improved isoform selectivity for one isoform, 
compared to the current best inhibitors. 
The purpose of developing an isoform selective HDAC inhibitor is twofold, 
firstly to use it as a ‘tool compound’ that can be used to probe the biological processes 
associated with that specific isoform, and to find out if that specific isoform is 
responsible for, or at least directly implicated in disease development or progression. 
The second reason for preparing an isoform selective HDAC inhibitor is so that it can 
be utilised as a therapeutic agent, although the aim of this project is only the discovery 
of a lead compound, not to develop a clinical therapeutic agent. The desire for an 
isoform selective HDAC inhibitor as a therapeutic agent is driven by the desire for a 
better safety profile compared to current pan-selective HDAC inhibitors. 
The methods used to achieve isoform selectivity will focus on three different 
concepts; modification of known zinc-binding groups (particularly extension of the 
benzamide zinc-binding group into the acetate-release pocket), discovery of a new zinc-
binding group (with inherent isoform selectivity) and introduction of a chiral centre into 
the cap region (to exploit subtle differences in the three-dimensional surfaces of the 
different isoforms). 
The compounds prepared will undergo different evaluations, including 
measuring basic physiochemical properties to check their suitability for the desired final 
purposes (e.g. in vivo). Compounds will also be tested against a panel of different 
recombinant HDAC isoforms in an in vitro assay, in order to identify those compounds 
which have some isoform selectivity. A selection of the more promising compounds will 
also be tested in a cell based assay, to investigate HDAC inhibition in a cellular 
environment. 
1. Introduction 
 
Christopher Matthews  10 
1.2 HDACs and their cellular role 
Histone deacetylase enzymes (HDACs) are a class of enzymes that catalyse the 
deacetylation of lysine residues in the amino terminal tails of core histones. Histones are 
basic proteins that in their protonated forms bind to the negatively charged phosphate 
backbone of the DNA double helix, forming a complex with DNA known as chromatin.
1
 
The DNA within this chromatin structure is highly compact, and it is not possible for 
the transcriptional machinery to access the genetic information when the chromatin is in 
this condensed form.
2
 There are several methods by which genetic information can be 
made available for transcription, including post-translational modification of the histone 
proteins. Histones contain a high proportion of lysine and arginine residues which 
makes these proteins particularly susceptible to a number of post-translational 
modifications.
3
 Post-translational modifications include acetylation of lysine residues by 
histone acetyltransferases (HATs), sumoylation of lysine residues by the small 
ubiquitin-like modifier (SUMO), methylation of lysine and arginine residues by histone 
methyltransferases (HMTs), serine phosphorylation by serine kinases, ubiquitination by 
ubiquitin ligases, and poly ADP-ribosylation by poly ADP-ribose polymerase.
4
 All 
known covalent histone modifications are reversible, and therefore the extent to which a 
modification is present relies on a dynamic equilibrium, with enzymes responsible for 
both attachment and removal of the modifying group present in the nucleus at the same 
time.
5
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Figure 1.2-1: Equilibrium of competing HAT vs HDAC 
Of these modifications, acetylation is one of the best characterised; several 
classes of proteins have been identified as histone acetyltransferases (HATs) each 
displaying different specificities.
1
 When a lysine residue becomes acetylated, it is no 
longer protonated and therefore it cannot bind to the phosphate backbone of the DNA 
which in turn gives rise to a less condensed region of chromatin that is more accessible 
to the transcriptional machinery.
6
 The competing deacetylation reaction is catalysed by 
HDACs and it is the balance of these two processes (Figure 1.2-1), acetylation and 
deacetylation that control the openness of the chromatin structure and therefore the 
transcriptional status of the genetic information. Hypoacetylated (under-acetylated) 
chromatin is very condensed and leads to gene silencing,
7
 whereas hyperacetylaed 
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(over-acetylated) chromatin is very open and leads to increased gene expression.
8
 
Acetylation also affects the recruitment of DNA binding factors, for example the 
bromodomain ‘recognises’ acetylated lysines and binds to them. This bromodomain is 
present in over 40 human proteins and these proteins are involved in recruiting other 
transcription factors. Bromodomains have received considerable attention recently from 
the medicinal chemistry community as another epigenetic target for treating diseases. 
  
Figure 1.2-2: Modification of chromatin structure and  
transcriptional status by HDAC and HAT.
9
 
There are 18 different enzymes which have been found to deacetylate acetylated 
histones in mammals and they are grouped into classes based on their primary 
sequences. Eleven of these enzymes share a highly conserved zinc dependent active site, 
and it is these enzymes which are known as HDACs 1-11. The other 7 enzymes have an 
NADH dependence and are known as the sirtuin proteins (or class III HDACs), this 
project does not concern these enzymes since their different mechanism allows them to 
be unaffected by the majority of HDAC inhibitors. The 11 HDACs are further split into 
different classes based on their homology to two yeast proteins: class I (1, 2, 3 and 8) 
are most closely related to S. cerivisiae transcriptional regulator Rpd3, class II (4, 5, 6, 
7, 9 and 10) are more similar to yeast deacetylase Hda1. HDAC11 is the most recently 
identified HDAC enzyme and it is the only member of class IV; it is not very 
homologous to either Rpd3 or Hda1 and so it does not fit well into class I or II. 
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Figure 1.2-3: Comparison of HDAC isoforms. Length of bars indicate the length of 
protein, the light grey is the location of the deacetylase domain (DAC) and black is the 
nuclear localisation domain. The sub-cellular localisation is indicated on the right. 
TDAC; tubulin deacetylase domain, UB; ubiquitin binding.
10
 
In vitro, HDACs predominantly function in multi-protein complexes which 
include DNA-binding, chromatin remodelling and recruitment proteins. Recombinant 
HDACs that are expressed in human cells or other eukaryote cell expression systems, 
such as insect cells, are functionally active. Although in some cases co-expression of the 
HDAC with the deacetylase activation domain of the complex as a fusion protein gives 
the HDAC an increase in activity approximately 100 fold. Typically HDACs expressed 
in prokaryotes are not functionally active, with the exception of HDAC8 which lacks 
the C-terminal tail associated with (functionally activating) post-translational 
modifications in other HDACs. 
The first crystal structures published were of HDAC8 in 2004 by two separate 
groups, all of them with the protein bound to a hydroxamic acid inhibitor.
11,12
 Since then 
many more crystal structures of HDAC8 have been published and recently crystal 
structures of other HDAC isoforms have also been published. Currently there are crystal 
structures in the protein data bank for HDAC1, 2, 3, 4, 7, and 8 (of the deacetylase 
domain at least). This opens up the possibility of using computational techniques and in 
silico docking to aid the development and design of HDAC inhibitors. 
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Figure 1.2-4: Active site of HDAC3 (PDB 4A69) with residues bound to zinc (green) 
and those lining the tunnel shown in pink. The surface of the tunnel is shown in dark 
grey and the acetate-release pocket can be seen extending to the right of the zinc.  
The active site of all HDACs is very highly conserved; it consists of a zinc atom 
that is buried between 7 and 8 Å within a narrow (~5 Å diameter) hydrophobic tunnel. 
The zinc atom is bound by the carboxylates of two conserved aspartic acid residues and 
by a conserved histidine (Figure 1.2-4). It is thought that the carbonyl oxygen of the 
acetyl lysine and a water molecule also coordinate to the zinc ion during the catalytic 
cycle (Figure 1.2-5). This makes the carbonyl more electrophilic and the water 
molecule is also made more nucleophilic by the neighbouring aspartate-histidine charge 
relay system. The zinc ion also stabilises the tetrahedral intermediate, which HDAC 
inhibitors aim to mimic with their zinc-binding groups.  
 
Figure 1.2-5:Schematic diagram showing the proposed model of how the acetylated 
lysine would interact with the HDAC8 catalytic machinery.
11
 
1.3 HDACs and disease 
Aberrant expression and activity of HDACs has been associated with many 
different diseases and even many different disease types. In many cases, animal models 
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of these diseases have shown that after removing the corresponding HDAC activity, by 
either gene knock down of the HDAC isoform or by expression of an inactive variant of 
the isoform, the symptoms of the disease can be alleviated. This suggests that inhibitors 
of HDAC enzymes have the potential to treat these diseases,
13,14
 and HDAC inhibitors 
have been investigated as therapeutic agents for treating a range of disorders. However 
because of toxicity and the side effects associated with many HDAC inhibitors (possibly 
due to their lack of isoform selectivity), cancer is the disease area that has been most 
investigated. A brief discussion about the role of HDACs in cancer, and then in a 
selection of other diseases will follow. 
1.3.1 Cancer 
A disease that results from unregulated cellular proliferation, and has the 
potential to spread to other parts of the body, is known under the broad term cancer. 
Tumours may form when cells stop being correctly controlled by the mechanisms that 
regulate normal cell growth. However tumours can be benign or malignant, the 
difference being that benign tumours are not classified as cancerous because they lack 
the ability to metastasise (invade adjacent or distant tissues), since they have retained 
control of differentiation. 
HDACs play an important role in cell-cycle progression and differentiation, 
since loss of acetyl groups from lysine residues cause decreased gene expression and 
reduced DNA repair.
15,16
 Overexpression of HDACs and the resulting histone 
hypoacetylation is associated with several cancers in a range of different human 
tissues.
17
 Additionally, HDACs can drive formation and growth of cancers by being 
abnormally recruited to certain gene promoting complexes by oncogenic fusion 
proteins.
18
 
Some HDAC inhibitors transform cancer cells into non-proliferating cells 
(normal phenotype) by inducing differentiation. It is also known that HDAC inhibitors 
cause growth inhibition and induce apoptosis (programmed cell death), as well as 
reducing angiogenesis (growth of blood vessels).
19
 Growth inhibition and apoptosis, 
induced by HDAC inhibitors, are often linked to up-regulation of p21, a tumour 
suppressor protein.
20
 
 Individual class I HDAC isoforms have been implicated in various different 
cancers; HDAC1 and HDAC2 were widely believed to be the primary targets of HDAC 
inhibitors in many cancers. For example it has been shown that HDAC 1, 2 and 3 are 
highly expressed in prostate cancers.
21
 Other isoforms have also been linked to some 
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cancers; HDAC3 has been shown to be aberrantly recruited to the promoters of 
oncogenes in acute myeloid leukaemia.
22
 HDAC8 has been identified as transcriptional 
regulator of p53 expression, mutation of the p53 gene is the most common genetic 
alteration in human cancer and it contributes to making cells resistant to anticancer 
therapy.
23
  
HDAC11, the most recently discovered HDAC, has also been identified as a 
novel drug target in many cancers, it is overexpressed in colon, prostate, breast, and 
ovarian cancer cell lines. Furthermore HDAC11 depletion in these cancer cell lines 
caused cell death and reduced metabolic activity, whereas in normal cells HDAC11 
depletion caused no changes in metabolic activity and viability.
24
 In Hodgkin’s 
lymphoma, a cancer originating from white blood cells (lymphocytes), HDAC11 is 
essential for regulating OX40L expression (OX40L is a member of the tumour necrosis 
factor family of proteins, and it is required to induce an antitumour immune response). 
Knockdown of HDAC11 in three Hodgkin’s lymphoma cell lines resulted in up-
regulated OX40L expression and induction of apoptosis.
25
 
1.3.2 Other diseases 
Inflammatory diseases share some characteristics with cancer, since the tumour 
microenvironment is dominated by inflammation, and both involve the response of the 
immune system.
26
 Inflammatory disorders cover a wide range of diseases, including 
asthma, rheumatoid arthritis and autoimmune diseases such as inflammatory bowel 
disease.  
HDAC11 has been demonstrated to be a negative transcriptional regulator of the 
gene encoding for interleukin 10 expression in mouse and human antigen presenting 
cells. Interleukin 10 is an anti-inflammatory signalling protein; it has a key role in 
inducing tolerance and preventing self-tissue damage. Since HDAC11 depletion gives 
rise to increased levels of IL-10, selective inhibition of HDAC11 could provide a novel 
therapeutic target for chronic inflammatory diseases.
27
 
A recent review on the use of HDAC inhibitors in the treatment of asthma 
concludes by stating that the results of several in vivo and ex vivo allergic models show 
HDAC inhibitors to have therapeutic promise. However the mechanisms of action are 
not fully understood since both pro- and anti-inflammatory effects are observed in 
different cell types, and treatment with HDAC2 activators can improve corticosteroid 
response.
28
 In the context of developing asthma therapeutics it is important to consider 
the effects of HDAC inhibitors with increased isoform selectivity.
29
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An analysis of peripheral blood mononuclear cells from rheumatoid arthritis 
patients showed significantly increased HDAC activity compared to cells from healthy 
individuals. Treatment with a HDAC inhibitor caused reduced production of tumour 
necrosis factor and interlukin-6 (a pro-inflammatory cytokine) in these cells.
30
 
Multiple studies on mouse models of colitis have shown that HDAC inhibitors 
can offer protection, as assessed by a variety of measures including macroscopic 
changes, such as increased colon lengths and weight gain, and also changes in levels of 
inflammatory cytokines. 
There is a wealth of growing evidence that links neurodegenerative conditions in 
vivo and in vitro with histone hypoacetylation. In many disease models treatment with 
HDAC inhibitors protect against neurodegeneration and normalise the levels of histone 
acetylation. Models of the following diseases have shown promising results by 
treatment with HDAC inhibitors: motor neurone disease, Huntingdon’s disease, stroke, 
Parkinson’s disease, and Alzheimer’s disease.31 
 Recently HDAC2 has been implicated in memory updating, and neuroplasticity, 
HDAC2 inhibition epigenetically primes the expression of neuroplasticity-related genes. 
If applied during memory reconsolidation this enables the attenuation of remote fear 
memories, and could provide a therapeutic option for those suffering from post-
traumatic stress disorder.
32
 
Friedreich’s ataxia is a progressive neurodegenerative disease caused by a defect 
in transcription that results in deficiency of frataxin (an essential mitochondrial protein) 
resulting in symptoms that include lack of coordination, slurred speech and decreased 
sensory function. Certain HDAC inhibitors (benzamides) reverse the gene silencing 
associated with Friedreich’s ataxia and increase frataxin levels, but hydroxamic acid 
HDAC inhibitors vorinostat and TSA have no effect on the transcription of the frataxin 
gene.
33
 Subsequently HDAC3 was identified as the target isoform, and the variation 
between inhibitor types was attributed to the differences in kinetics of binding (see 
section 1.4.2, p 29).
34,35
 
1.4 HDAC inhibitors 
Natural product Trichostatin A (TSA) (Figure 1.4-3) was the first HDAC 
inhibitor, identified 20 years ago (1995),
36
 since then there has been much progress 
towards understanding HDAC enzymes and many HDAC inhibitors have been 
discovered. Inhibitors of HDACs usually fit the well-defined pharmacophore that 
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consists of a zinc-binding group joined by a non-polar linker group to a cap group (or 
surface recognition group) illustrated with vorinostat and mocetinostat in Figure 1.4-1.  
 
Figure 1.4-1: Pharmacophore for HDAC inhibitors  
illustrated with vorinostat and mocetinostat.
37
  
One class of inhibitors that does not appear to fit the pharmacophore is cyclic 
peptides such as romidepsin (Istodax, FK228), a natural product isolated from 
Chromobacterium violaceum (Figure 1.4-2) used in the treatment of peripheral T-cell 
lymphoma.
38
 Romidepsin does however fit the model described here; it contains a latent 
zinc-binding group. The disulfide bridge is reduced in cells and the longer-chain thiol 
that is released becomes the zinc-binding group, making romidepsin a natural prodrug. 
The cyclic peptide moiety is a large surface recognition group which contains 
hydrophobic amino acid residues and the same is true of other cyclic peptide HDAC 
inhibitors.
39
 
 
Figure 1.4-2: Romidepsin a bicyclic depsipeptide HDAC inhibitor. 
There are some inhibitors that do not fit the pharmacophore and the most 
common deviation is inhibitors that extend beyond the zinc-binding group. In many of 
the HDAC crystal structures the active site tunnel continues into the protein past the 
zinc atom. This cavity is sometimes referred to as the ‘back pocket’ or as the ‘acetate-
release pocket’. It has been postulated that this internal cavity is involved in shuttling an 
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acetate molecule, the side product formed from deacetylation, away from the active site 
and conversely it has been postulated to play the opposite role of bringing the water 
molecule into the active site.
40
 Since the different isoforms are less well conserved in 
this region, it has been suggested that isoform selective inhibition could be achieved by 
targeting the acetate-release pocket.
41
 There have been some HDAC inhibitors made 
that extend into the acetate-release pocket (Figure 1.2-4) such as 5-substituted N-2-
aminophenyl benzamides discussed in more detail in section 1.4.2 (Table 1.4-6 and 
Table 1.4-7). 
Small molecule HDAC inhibitors are often grouped into classes characterised 
primarily by the type of zinc-binding group such as hydroxamic acids, carboxylates, and 
benzamides (Figure 1.4-3). Inhibitors are also grouped into subclasses of these groups 
by other structural features such as a cyclic or non-cyclic linker region. 
 
Figure 1.4-3: Some well-known HDAC inhibitors showing different zinc-binding 
groups. 
The hydroxamic acid binding group is the most widely explored zinc-binding 
group, and the majority of HDAC inhibitors that have been in clinical trials are 
hydroxamic acid based inhibitors.
42–44
 Indeed the first HDAC inhibitor approved by the 
FDA was a hydroxamic acid; vorinostat (Zolinza
TM
, SAHA), which has been approved 
for once-daily oral treatment of advanced cutaneous T-cell lymphoma, a rare cancer of 
the immune system.
45
 More recently two more hydroxamic acid HDAC inhibitors, 
belinostat (Belodaq
TM
) and panobinostat (Farydak
TM
) have been approved for peripheral 
T-cell lymphoma and multiple myeloma respectively.
46,47
 The hydroxamic acid binding 
group binds with a high affinity to zinc giving rise to inhibitors with high potency. 
However hydroxamic acids have poor pharmacokinetic properties and some toxic 
effects in vitro because the hydroxamic acid group binds other metal ion-containing 
proteins such as matrix metalloproteinases. In spite of this there has been a great deal of 
structure-activity relationship (SAR) studies of hydroxamic acid compounds focusing 
on different linker groups and different cap groups. Optimisation of the linker length in 
both straight chain and cyclic linker compounds has been carried out, together with 
studies into the size and nature of the cap group. Although there has been such a large 
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scale investigation into hydroxamic acid inhibitors the problems of toxicity and 
selectivity are not easily overcome. These problems can be tolerated when developing a 
treatment for a rare cancer because side effects are not such a large concern when 
developing a drug that is aiming to extend a patient’s life by several months. For the 
treatment of other diseases, especially chronic diseases such as asthma, arthritis, or 
inflammatory bowel disease, side effects pose a far more substantial problem. 
Therefore, if a HDAC inhibitor is to be developed for the treatment of such diseases a 
hydroxamic acid seems unlikely to provide the necessary selectivity and safety profile. 
1.4.1 Zinc binding groups 
Other simple zinc-binding groups bind the zinc ion less tightly and as a result 
typically give lower potency inhibitors, for example a carboxylate group, found in 
valproic acid (VPA) and sodium butyrate (Figure 1.4-3), and thiols such as the thiol 
analogue of vorinostat.
48
 Another popular zinc-binding group is the N-(2-
aminophenyl)benzamide group found in entinostat (Figure 1.4-3) discussed in more 
detail in the following section (1.4.2). There have been several other potent zinc-binding 
groups discovered such as trifluoromethyl ketones,
49
 alpha-keto amides,
50
 heterocyclic 
ketones,
51
 and some more recently such as; (R)-α-amino amide as in 1,52 the α-oxime 
amide 2,
53
 and the hydroxypyrimidine 3.
54
  
 
Figure 1.4-4: Other examples of zinc-binding groups. 
Computational studies have been carried out in order to try and identify novel 
zinc-binding groups that would give potent HDAC inhibitors. One recent study by Chen 
et al. initially focussed on the calculated binding energies of a series of potential 
chelating fragments to zinc in a small active site model.
55
 Promising fragments were 
then docked into a full active site model (HDAC2 - PDB 3MAX) to check for steric 
clashes. One interesting fragment was 8-hydroxyquinoline, which in the initial model 
had a binding energy similar to that of a hydroxamic acid (-23.5 cf. -23.7 kcal/mol) but 
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had steric clashes in the full model with HDAC2, so it was not explored further.  
A search of the literature for previous reports of 8-hydroxyquinoline HDAC 
inhibitors gave one result which showed the potential of this unit as a HDAC inhibitor; 
treatment of HeLa cell nuclear extract (which contains a variety of HDAC enzymes) 
with 500 M 8-hydroxyquinoline gave 15% inhibition (comparable to sodium 
butyrate).
56
  
Bora-Tatar et al. were primarily interested in carboxylic acids as HDAC 
inhibitors, however many of their carboxylic acids tested also contained a catechol unit, 
or in some cases an ortho-methoxy phenol. The authors suggest that the HDAC 
inhibitory activity is due to carboxylate binding the zinc atom, however it seems likely 
that in some cases at least the catechol moiety is responsible for binding to zinc since in 
the computational study by Chen et al. both catechol and ortho-methoxy phenol had 
shown promising zinc-binding energies (-19.6 and -24.2 kcal/mol respectively).
55
 Table 
1.4-1 shows some of the relevant compounds in mention and the percentage inhibition 
(measured by Bora-Tatar et al.) of HeLa nuclear extracts.  
Name Structure 
Inhibition at 
500 M (%) 
8-hydroxyquinoline 
 
15 
caffeic acid 
 
20 
ferulic acid 
 
20 
dihydrocaffeic acid 
 
14 
3-hydroxycinnamic acid 
 
4 
chlorogenic acid 
 
60 
*(375 M) 
curcumin 
 
48 
*(115 M) 
Table 1.4-1: Inhibition of HeLa nuclear extracts.  
* IC50 values against HeLa nuclear extracts.
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This indicated that catechol might also be an interesting zinc-binding group, 
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however catechol is known to be a promiscuous metal binding group and therefore 
catechol containing structures are generally avoided by medicinal chemists. An analysis 
of this data did suggest that 8-methoxy quinolines could be an effective zinc-binding 
group since the ortho-methoxy phenol ferulic acid was as potent as caffeic acid, and 
curcumin (also an ortho-methoxy phenol) was the most potent compound tested (based 
on its IC50). However both of these compounds still contain a free, non-methylated 
phenol which could be deprotonated in the active site and may make a significant 
contribution to the binding of zinc which would not be possible with an 8-methoxy 
quinoline. 
1.4.2 Benzamide inhibitors 
As mentioned above the N-(2-aminophenyl)benzamide zinc-binding group has 
become a popular choice for HDAC inhibitors and these inhibitors are often known as 
benzamide inhibitors. The name benzamide does not well describe the zinc-binding 
group of these inhibitors and in fact the benzamide unit (i.e. an amide derived from a 
benzoic acid) is not actually required; it is the N-(2-aminophenyl)amide (ortho-
aminoanilide) unit which is essential. N-(2-aminophenyl)amides derived from vinyl, 
propargyl, and even alkyl carboxylic acids have also been shown to be HDAC 
inhibitiors.
57,58
 In spite of this, these N-(2-aminophenyl)benzamide inhibitors will be 
referred to as benzamide inhibitors throughout this thesis in the interest of brevity and to 
follow what has become convention. 
It is now well known that benzamide HDAC inhibitors usually selectively inhibit 
class I enzymes more than class II enzymes and this has made benzamide compounds 
attractive to those seeking to develop HDAC1/2 inhibitors as cancer therapeutics. As a 
result of this, a huge number of different benzamide compounds have been prepared in 
recent years, and often a large series of very close analogues was made by a company 
with only sparse amount of enzyme inhibition data published. A selection of these 
benzamide inhibitors will now be discussed. 
Shown in Table 1.4-2 is a recent report of the full isoform selectivity profile of 
the first benzamide inhibitor reported (entinostat) and a close analogue chidamide 
(entries 1 and 2). This clearly highlights the class I (HDAC1, 2, 3, and 8) selectivity of 
benzamide inhibitors and in particular the higher potency against HDAC1, 2 and 3. 
Chidamide (Epidaza
TM
) has recently been approved in China for the treatment of 
peripheral cutaneous T-cell lymphoma, which represents a breakthrough since it is the 
first benzamide HDAC inhibitor approved for use in the clinic and the first orally 
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bioavailable HDAC inhibitor.
59
 Entries 3 and 4 of Table 1.4-2 highlight the selectivity 
that can be achieved using a benzamide zinc-binding group compared with a 
hydroxamic acid. In this case the linker is aliphatic, and the bulky cap group confers 
even greater selectivity for HDAC3. It is relatively uncommon to find inhibition data 
against all eleven isoforms which is (in part) because assays against all isoforms were 
not readily available in the past, and even now that they are available, testing against all 
isoforms is expensive. 
 
Entry Compound 
HDAC IC50 (µM) 
1 2 3 4 5 6 7 8 9 10 11 
1 MS-275 0.26 0.31 0.50 >30 >30 >30 >30 2.7 >30 0.25 0.65 
2 HBI-8000 0.095 0.16 0.067 >30 >30 >30 >30 0.73 >30 0.078 0.43 
3 ST2741 0.73 2.0 0.35 1.3 0.59 0.006 0.53 0.24 0.64 0.87 0.43 
4 ST3071 21.0 1.1 0.260 150.0 28.0 * * 74.0 50.0 73.0 5.80 
Table 1.4-2: Isoform selectivity profiles of some benzamide inhibitors and comparison 
with a hydroxamic acid analogue, * not determined.
58,60
 
 
Figure 1.4-5: Structures of compounds in Table 1.4-2. 
The following three compounds (Table 1.4-3) show that very small chemical 
changes can have a significant effect in vitro; they are taken from a patent by Orchid 
Research Laboratories Limited which contained a large number of benzamide HDAC 
inhibitors.
61
 Modifying a substituent on a phenyl ring in the cap group gave interesting 
results, methoxy to fluoro has a 1.2 fold decrease in IC50, but methoxy to chloro has a 4 
fold decrease in IC50. However, only HDAC1 IC50 values were reported and so any 
effect on selectivity is unknown. 
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Entry Compound HDAC1 IC50 (µM) 
1 
 
0.180 
2 
 
0.150 
3 
 
0.044 
Table 1.4-3: Inhibition of HDAC1 comparing small changes to the cap group.
61
 
In addition to some in vitro enzyme assay data, some authors also report some 
cancer cell growth inhibition data such as MTT HCT116 (Table 1.4-4 and Table 1.4-5) 
which is an antiproliferative assay using a human colon cancer cell line. The compounds 
in Table 1.4-4 show that heterocycles can occupy the cap region, however the correct 
length of inhibitor is crucial. Compounds in which the heterocycle is appended with 
another phenyl ring have a roughly 10 fold decrease in IC50, both in the in vitro HDAC1 
assay, and the cell line assay (Table 1.4-4, entries 1 and 2 cf. entries 3 and 4).  
 
Whilst the compounds in Table 1.4-4 showed a good correlation between the in 
vitro enzyme assay data and the cancer cell line data, this is not always the case as 
illustrated in Table 1.4-5. In these examples some modifications which increase potency 
against purified recombinant HDAC1 actually decrease the antiproliferative effect in the 
cell line assay (entry 3 cf. entry 4). These inhibitors have the same straight chain alkyl 
linker section and different cap groups, some aromatic and some heteroaromatic. It is 
also worth noting the difference in the HDAC1 IC50 of entinostat reported here (1 µM) 
compared with Table 1.4-2 entry 1 (0.26 µM) and Table 1.4-7 entry 3 (0.54 µM). This 
highlights that in general, comparing IC50 values from different publications is very 
difficult because there is a large degree of variability in the numbers reported (even for 
the same compound and isoform).  
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Entry Compound 
HDAC1 IC50 
(µM) 
MTT HCT116 
IC50 (µM) 
1 
 
0.5 5 
2 
 
1 5 
3 
 
0.08 0.4 
4 
 
0.07 0.3 
Table 1.4-4: Inhibition of HDAC1 and HCT116 cells by benzamide inhibitors with 
heterocyclic cap groups.
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Following this survey of different cap groups commonly found in benzamide 
HDAC inhibitors, inhibitors probing the acetate-release pocket (discussed earlier and 
shown in Figure 1.2-4) will be discussed. In the first report of entinostat (MS-275), a 
methyl substituent was ‘walked’ around the terminal amino-phenyl ring to test whether 
substitution could be tolerated on that ring. It was found that only the 5-methyl 
substituted 2-aminophenyl ring maintained inhibition of HDAC activity, and was 
slightly more potent (tested against a mixture of HDACs obtained from the cell lysate of 
human leukaemia cells). It was also found that 2-hydroxyphenyl is slightly more potent 
than 2-aminophenyl (Table 1.4-6: entry 5 cf. entry 1), and this has since been shown to 
be the case generally. 
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Entry Compound HDAC1 IC50 (µM) 
MTT HCT116 
IC50 (µM) 
1 
 
1 12 
2 
 
2 7 
3 
 
2 24 
4 
 
3 2 
5 
 
0.5 1 
6 
 
1 0.5 
Table 1.4-5: Inhibition of HDAC1 and HCT116 cells by benzamide inhibitors with 
aromatic or heteroaromatic cap groups.
63
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Entry Compound Mixture of HDACs IC50 (µM) 
1 
 
4.8 
2 
 
>100 
3 
 
>100 
4 
 
2.8 
5 
 
2.2 
Table 1.4-6: Inhibition of HDAC activity from human leukaemia K562 cells.
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Subsequently other research groups have explored 5-substitution of the terminal 
2-aminophenyl ring. The data shown below (Table 1.4-7) is taken from some work 
carried out by MethylGene, when trying to exploit sulfur-sulfur interactions with 
methionine and cysteine residues lining the walls of the acetate-release pocket. Some 
thienyl substituted benzamide inhibitors were prepared and an increase in potency 
against HDAC1 and HDAC2 was observed. Furthermore inhibition of HDAC3 and 
HDAC8 was reduced in the thienyl substituted compounds, such as CI-994 (Table 
1.4-7, entry 1 cf. entry 2). Therefore introduction of a thienyl group at the 5-position of 
the 2-aminophenyl ring increases isoform selectivity towards HDAC1 and 2. The effect 
of thienyl substitution was maintained even with different cap groups such as the 
carbamate of entinostat (Table 1.4-7, entry 4) and the aryl amine of Table 1.4-7, entry 
5. It was subsequently demonstrated to be a more general hydrophobic (or aromatic pi- 
stacking) interaction and not specific to sulfur, since a phenyl substituent had the same 
effect (Table 1.4-7, entry 6). However, the acetate-release pocket is only able to 
accommodate one additional ring and the orientation of the ring is critical (in agreement 
with the early methyl substituents above); a benzothiophene at the 5-position or a 
thiophene at the 4-position decreases inhibition of HDAC1 and HDAC2 (Table 1.4-7 
entries 7 and 8). 
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Entry Compound 
HDAC IC50 (µM) 
1 2 3 8 
1 
 
0.9 0.9 1.2 >20 
2 
 
0.04 0.1 >20 >20 
3 
 
0.54 0.5 * * 
4 
 
0.02 0.1 * * 
5 
 
0.05 0.08 * * 
6 
 
0.06 0.1 * * 
7 
 
>10 >10 * * 
8 
 
>10 >10 * * 
Table 1.4-7: Inhibition of HDAC1, 2, 3, and 8 by benzamide inhibitors showing the 
effect of substituents on the terminal 2-aminophenyl ring, * not determined.
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A thiophene at the 4-position of the 2-aminophenyl ring was detrimental for 
inhibition of HDAC1 and HDAC2 (Table 1.4-7 entry 8), and it has recently been found 
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that in some cases a fluorine at the same position is also detrimental for inhibition of 
HDAC1 and HDAC2, although to a lesser extent. Importantly inhibition of HDAC3 is 
unaffected by the introduction of a fluorine atom at the 4-position of the 2-aminophenyl 
ring, giving rise to increased selectivity for HDAC3 (Table 1.4-8 entries 2 and 4). 
However this effect is not generally applicable to all benzamide inhibitors since the 4-
fluoro analogue of mocetinostat is no more HDAC3 selective than the parent compound 
(Table 1.4-8 entries 5 and 6). 
 
Entry Compound 
HDAC IC50 (µM) after 3 h pre-incubation 
1 2 3 
1 
 
0.039 0.110 0.038 
2 
 
1.25 1.42 0.068 
3 
 
0.014 0.041 0.034 
4 
 
0.120 0.157 0.036 
5 
 
0.006 0.026 0.023 
6 
 
0.012 0.018 0.022 
Table 1.4-8: Inhibition of HDAC1, 2, and 3 by benzamide inhibitors with a 4-fluoro 
substituent on the terminal 2-aminophenyl ring.
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It is worth noting that inhibition of HDAC11 has not been reported for these 
HDAC inhibitors with substituents at the 4- or 5-position on the terminal 2-
aminophenyl ring, it might have been examined but it has not been reported. 
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1.4.3 Slow Tight Binding Inhibitors 
Certain benzamide inhibitors have been shown to be slow tight-binding HDAC 
inhibitors, although the mechanism of binding may differ between compounds and 
between isoforms. This was first reported in 2008 by Chou et al. when studying the 
explanation for the different pharmacological effects of hydroxamic acid and benzamide 
inhibitors.
67
 Initially it was shown that introducing a pre-incubation period in the in 
vitro enzyme assay resulted in changes to the measured IC50 value. With the benzamide 
4, inhibition of HDAC1 had reached equilibration after 15 minutes pre-incubation, and 
this resulted in a 3 fold decrease in IC50 value. However for HDAC3 after three hours 
pre-incubation the IC50 had decreased 15 fold (from 5.8 µM to 0.380 µM) and after this 
time equilibrium had nearly been reached. Investigating the mechanism of slow binding 
led to the interesting finding that it is different for the two isoforms, HDAC1 follows a 
single slow step of binding, whereas the mechanism for HDAC3 consists of an initial 
fast step forming a weakly bound enzyme-inhibitor complex which then undergoes a 
second slow step such as a conformational change in the structure of the protein. 
 
Figure 1.4-6: Structure of the first benzamide inhibitor  
determined to be slow tight-binding. 
Despite this publication, a great deal of enzyme inhibition data of benzamide 
compounds has been published since, without considering the effect of pre-incubation. 
However in some cases pre-incubation has been considered, and this partly accounts for 
the sometimes large differences in reported IC50 values of compounds. This can be seen 
in the next section (Table 1.4-9) comparing the different IC50 values reported for 
mocetinostat. Some of the data above also highlight this; comparing entries 1 and 3 of 
Table 1.4-7 with the same entries of Table 1.4-8 shows that a 3 hour pre-incubation 
decreases the IC50 value up to 38 fold (entinostat against HDAC1) and also shows that 
the relative differences between isoforms are not consistent between different structures. 
This is an added complication when evaluating benzamide HDAC inhibitors in vitro, 
but it can be an advantage in vivo because of prolonged effects of histone acetylation as 
is the case with HDAC3 inhibition in the treatment of Friedreich’s ataxia discussed 
above (section 1.3.2). 
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1.4.4 Mocetinostat 
The lead compound for this project is mocetinostat, also known as MGCD0103, 
discovered by MethylGene and currently in clinical trials as an anticancer agent.68 There 
is a wide range in the IC50 values reported for mocetinostat against HDAC1, and also 
for HDAC2 and HDAC3 although there are fewer reports for these isoforms, the data is 
summarised below in Table 1.4-9. There is only one published IC50 value for 
mocetinostat against HDAC11, contained in the first report from MethylGene. The data 
shown highlight the variation in reported values for many HDAC inhibitors, particularly 
benzamide inhibitors because they have a slow on rate and so their inhibition is more 
sensitive to changes in assay conditions such as pre-incubation time (as discussed 
above).  
 
R
Ref. 
HDAC IC50 (µM) 
1 2 3 4 5 6 7 8 9 10 11 
66
 0.006 0.026 0.023 * * * * * * * * 
69
 0.034 0.034 0.998 >10000 * >10000 >10000 >10000 * * * 
70
 0.102 * * * * >10000 * * * * * 
71
 0.130 * 0.610 * * #32% * * * * * 
68
 0.15 0.29 1.66 >10000 >10000 >10000 >10000 >10000 >10000 >10000 0.59 
72
 0.152 * * * * * * * * * * 
73
 0.184 * * * * * * * * * * 
74
 0.20 0.18 * >10000 >10000 * >10000 * * * * 
75
 0.82 * 0.62 * * >30000 * >25000 * * * 
76
 0.95 0.28 1.67 * * * * * * * * 
Table 1.4-9: Published IC50 values for mocetinostat. * not determined,  
# percentage inhibition at 2 µM. 
Extensive SAR analysis of mocetinostat was carried out by MethylGene and 
subsequently by others, although for many compounds detailed enzyme inhibition data 
was not published. Some of the compounds in the previous section could be considered 
mocetinostat analogues in particular those in Table 1.4-4 and Table 1.4-8 entry 6. A 
selection of some other available data will now be briefly discussed, focusing on the 
inhibition of purified recombinant enzymes. 
Entry 2 in Table 1.4-10 shows the necessity of the methylene unit between the 
central benzamide ring and the aminopyrimidine, entries 3 and 4 show the location of 
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the pyrimidine nitrogens are not important and in fact the pyrimidine can be replaced by 
a phenyl ring to give slightly increased potency. Entries 5-7 demonstrate that the 
terminal pyridine ring is solvent exposed and can be appended with various groups 
without loss of activity. Electron donating and withdrawing substituents are tolerated, 
although some angular bulky groups such as the dimethyl amide (entry 7) give rise to a 
loss of potency. The pyridine ring can be replaced with a variety of heterocycles, such as 
thiazole (entry 8), which also maintain potency.  
 
Entry Compound 
HDAC1 
IC50 (µM) 
1 
 
0.15 
2 
 
2.0 
3 
 
0.20 
4 
 
0.09 
5 
 
0.05 
6 
 
0.16 
7 
 
0.42 
8 
 
0.14 
Table 1.4-10: Inhibition of recombinant HDAC1by mocetinostat analogues.
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MethylGene summarised their SAR findings in the following diagram (Figure 
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1.4-7), however it only applies to inhibition of HDAC1 since the inhibition data used to 
generate the SAR was measured against HDAC1. Therefore the effect of different 
structural modifications on isoform selectivity is not well understood; in addition no 
chiral mocetinostat analogues have been reported and so the effect of introducing 
chirality into the cap region remains unexplored. 
 
Figure 1.4-7: SAR of N-(2-aminophenyl)-4-(arylaminomethyl)benzamides.
68
 
1.4.5 Chiral HDAC inhibitors 
The first HDAC inhibitor discovered, natural product TSA (Figure 1.4-3), 
contains a chiral centre in the linker section, but it does not confer much isoform 
selectivity since TSA inhibits all HDAC isoforms with low nanomolar IC50 (except 
HDAC8; IC50 ~0.5 µM). Cyclic depsipeptides such as romidepsin often contain several 
centres of chirality in the cap group region, but the chiral centres are distant from the 
entrance to the active site tunnel, so their effect on isoform selectivity is possibly 
reduced as a result. 
Synthetic small molecule HDAC inhibitors incorporating chirality into the cap 
group were first reported with hydroxamic acid inhibitors and this resulted in the 
discovery of compounds that were >10 fold selective for HDAC6 over HDAC1 (Table 
1.4-11). These compounds were derived from phenylalanine as a source of chirality. The 
limitation of the study is that they have only measured inhibition of two isoforms, and 
therefore the full selectivity is unknown. 
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Entry Compound 
HDAC1 
IC50 
(µM) 
HDAC6 
IC50 
(µM) 
Fold 
selectivity 
1 
 
19.19 1.77 10.8 
2 
 
10.3 1.05 9.8 
3 
 
22.86 1.69 13.5 
Table 1.4-11: Isoform selective inhibition of immunoprecipitated  
HDACs by chiral hydroxamic acid inhibitors.
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A similar strategy was employed by Smil et al.; a series of hydroxamic acids 
containing a chiral substituted 3,4-dihydroquinoxalin-2-one cap group was prepared. Of 
particular note is the discovery that absolute stereochemistry has an effect on isoform 
selectivity. In the two cases where both pairs of enantiomers were prepared, the R-
enantiomers both showed far superior HDAC6 selectivity. The most selective 
compound of the series is the 4-hydroxyphenyl compound derived from tyrosine, it has 
an impressive selectivity for HADC6 (41 fold versus HDAC2 and 91 fold versus 
HDAC8) similar selectivity against other isoforms was stated but the data was not 
shown.  
 
 
HDAC IC50 (µM) HDAC6: 
HDAC2 
selectivity 
HDAC6: 
HDAC8 
selectivity 
Entry R 2 6 8 
1 (R)-phenyl (7b) 0.26 0.01 0.53 26 53 
2 (S)-phenyl (7c) 0.46 0.22 0.21 2 1 
3 (R)-2-thienyl (7d) 0.87 0.04 0.69 21 17 
4 (S)-2-thienyl (7e) 1.48 0.31 1.19 5 4 
5 (R)-p-OHC6H4 (7g) 0.33 0.01 0.73 41 91 
Table 1.4-12: Inhibition of affinity purified recombinant HDACs. Selectivity against 
HDAC1, 3, 4, 5, and 7 was similar to HDAC 2 and 8.
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Another example of chiral inhibitors being tested against many HDAC isoforms 
is that of two α-oxime amides, prepared from glutamic acid as a source of chirality. 
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However the compounds are only weak inhibitors, and not particularly selective (Table 
1.4-13) demonstrating that introducing chirality does not always increase selectivity. 
Entry Structure 
HDAC IC50s (µM) 
1 2 3 4 5 6 8 9 10 
1 
 
81.1 >100 49.4 >100 76.7 64.2 >100 >100 98.5 
2 
 
17.5 95.9 10.6 59.2 45.8 28.7 94.6 65.7 37.8 
Table 1.4-13: Inhibition of human HDAC isoforms.
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Chiral benzamide HDAC inhibitors have also been described; in the first report 
the absolute stereochemistry does not seem to have much effect on inhibition of 
HDAC1. Furthermore the effect on selectivity remains unknown since the homochiral 
compounds were only tested against HDAC1. One racemic analogue demonstrated high 
levels of selectivity for HDAC1, however it is presumed that this selectivity arises from 
the presence of the thienyl substituent at the 5-position on the terminal 2-aminophenyl 
ring because the short, zinc-binding group that doesn’t contain the chiral centre (Table 
1.4-14, entry 6) also demonstrated similar selectivity (this was also discussed previously 
in Table 1.4-7). 
 
 
HDAC IC50s (µM) 
Entry Structure 1 2 3 4 5 6 7 8 11 
1 R=NH2   (12) 0.010 0.130 3.4 >50 >50 >50 >50 35 3.6 
2 R=NH2 (R)   (16) 0.012 * * * * * * * * 
3 R=NH2 (S)   (17) 0.011 * * * * * * * * 
4 R=NHMe (R)   (18) 0.014 * * * * * * * * 
5 R=NHMe (S)   (19) 0.022 * * * * * * * * 
6 
 
0.048 0.362 * * * * * * * 
Table 1.4-14: Inhibition of immunoprecipitated HDACs. * not determined.
80
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In a more recent example the influence of absolute configuration is more 
compelling, however there is not clear data linking changes of absolute stereochemistry 
and differences to in vitro enzyme inhibition, or isoform selectivity.
81
 In contrast a 
cellular differentiation assay is used to compare the stereoisomers, and it does show that 
changes to the absolute configuration can have a big impact on the amount of 
differentiation induced (Figure 1.4-8). For example the two most potent compounds 
share the same 2-(S), 3-(R) stereochemistry, which is interesting because these are the 
two positions that are closest to the HDAC tunnel. The exocyclic chiral centre C1 
generally did not exert as much influence on the compound’s ability to induce 
differentiation. HDAC enzyme inhibition data is only given for one compound 
(BRD8430) and it demonstrates some moderate selectivity for HDAC1 versus HDAC2 
and HDAC3, and good selectivity versus HDAC4, 5, 6, 7, 8, and 9 (Table 1.4-15). 
    
Figure 1.4-8: Structure of BRD8430, and a heat map showing area under the curve 
(AUC) for different stereochemical variants. AUC was calculated from a plot of 
differentiation score against concentration, having measured a differentiation score at 
several concentrations.
81
 
  HDAC IC50s (µM) 
Entry Structure 1 2 3 4 5 6 7 8 9 
1 (R,SR) - BRD8430 0.069 0.56 1.3 >20 >20 >20 >20 >20 >20 
Table 1.4-15: Inhibition of recombinant HDACs.
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1.5 HDAC enzyme assays 
The first HDAC assay was based on a radiolabelled substrate, chicken 
reticulocyte histones acetylated with tritium labelled acetate.
82
 After incubation of the 
HDAC enzyme with the radiolabelled histones, an extraction procedure, centrifugation 
and addition to a liquid scintillation cocktail, the radioactivity can be measured. 
However the production of the radiolabelled acetylated histone substrate is complicated 
and batch to batch variation means that standardisation of the assay is difficult.
83
 Added 
to this, the complexity of the procedure and disadvantages of using radioactivity 
(personal exposure, equipment decontamination and waste disposal) meant that non-
radioactive assays were sought. 
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The first non-radioactive HDAC substrate for assays was the fluorescent 
substrate Boc-Lys(Ac)-AMC (MAL), that is deacetylated by HDAC enzymes to give 
Boc-Lys-AMC (ML) (Figure 1.5-1), which has the same fluorescence properties as 
MAL.
84,85
 Therefore to develop the substrate for use in an assay, an extraction procedure 
was required and reverse phase HPLC used to separate MAL and ML which were 
quantified by fluorescence detection. This meant that this assay was also labour 
intensive and not suited to high throughput, so an improved extraction procedure was 
developed which enabled use of a plate reader to measure fluorescence and quantify the 
extent of deacetylation.
86
 
However a truly homogenous assay without any extraction procedure was 
subsequently developed; a derivatisation reagent, naphthalene-(2,3)-dicarboxaldehyde, 
is added after the HDAC reaction and it reacts with the deacetylated product (ML).
87
 
The amount of remaining substrate MAL can be quantified without any extraction since 
the fluorescence of naphthyl-ML product 5 is quenched.  
 
Figure 1.5-1: Deacetylation of MAL to give ML and  
conjugation with naphthalene dicarboxaldehyde. 
At the same time an alternative homogeneous assay was developed which made 
use of an enzyme in the second step.
88,89
 Trypsin, a proteolytic enzyme, selectively 
reacts with ML to release the coumarin fluorophore (AMC) which has a different 
wavelength of excitation and emission so can be quantified without separation. This 
assay had originally been developed using tripeptide and tetrapeptide substrates, but it is 
also effective using MAL (although higher trypsin concentrations are required) and 
there are also commercial assay kits that operate using this same principle,
90
 see section 
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5.1 (p 96) for more detail. 
Deacetylase activity can also be measured by detecting the acetate produced 
from deacetylation of an acetylated substrate. There are many ways in which the acetate 
can be detected, firstly by a complicated coupling of other enzymatic reactions (Figure 
1.5-2); acetic acid can be converted into acetyl-coenzyme A (acetyl-CoA) by acetyl-
CoA synthase (ACS), then this can be used to convert oxaloacetate into citrate by citrate 
synthase (CS). The oxaloacetate is made from malate using malate dehydrogenase 
(MDH); this process also converts NAD
+
 to NADH, and NADH can be monitored by 
absorption at 340 nm (Figure 1.5-2).
91
 In another assay a trifluoroacetylated substrate 
gives trifluoroacetic acid upon deacetylation, and this can be measured directly using 
19
F NMR to quantify the extent of deacetylation, but the substrate is not a good mimic 
of a natural acetylated lysine.
92
 Likewise even 
1
H NMR can be used to monitor the 
production of acetic acid from a non-labelled acetylated substrate based on p53.
93
 
However these NMR assays require relatively large amounts of enzyme to function 
correctly. 
 
Figure 1.5-2: Enzyme linked measurement of acetic acid production.
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The assays discussed so far, are all end-point assays (except the NMR assays), 
that is they measure the amount of deacetylation at the end of the assay, and so they are 
not very useful for measuring kinetic values. One such assay that has been developed in 
order to measure off rates of inhibitors is a displacement assay, where a fluorescent 
ligand (coumarin-SAHA) is added in large excess concentration to the bound inhibitor 
and HDAC enzyme mixture.
94
 During the course of the assay coumarin-SAHA 
outcompetes the previously bound inhibitor, and the coumarin SAHA has a lower 
intensity of emission when bound to the HDAC enzyme because of fluorescence 
quenching (Figure 1.5-3). The change in the intensity of the emission is proportional to 
the amount of coumarin-SAHA bound to the enzyme and this correlates with the 
displacement of bound inhibitor. However this assay only studies inhibitor binding, not 
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actual enzyme inhibition (although the two should correlate since the inhibition is 
competitive) and it is also limited by the affinity of the coumarin-SAHA reporter 
molecule’s binding to the HDAC enzyme. Furthermore the small difference in 
fluorescence intensity gives a relatively low signal-to-noise ratio. 
 
Figure 1.5-3: Structure of coumarin-SAHA and its excitation and fluorescence emission 
spectra of the free form (solid line) and when enzyme bound (dotted line).
94
 
Another assay has been reported that measures time dependent inhibition, and is 
used to quantify the kinetics of inhibitor binding. Furthermore, the assay can be used to 
determine the mechanism of slow tight-binding that is observed with benzamide HDAC 
inhibitors and certain isoforms (as mentioned above, section 1.4.2, p 29).
67
 This assay is 
a continuous monitoring assay but instead of measuring inhibitor binding, it measures 
enzymatic activity. The main concept of the assay is the same as the fluorescent assay in 
which trypsin is used to develop the fluorescent signal. Instead of adding trypsin after 
the deacetylation reaction, a more selective enzyme, endoproteinase Lys-C, is used 
together with the HDAC enzyme during the deacetylation reaction. In that way, as soon 
as the deacetylated substrate is produced, the fluorophore AMC is cleaved and then 
fluorescence can be measured continuously during the deacetylation reaction (see 
section 5.2 (p 102) for a more detailed discussion). 
Recently the development of mobility shift assay technology has enabled the 
rapid high throughput evaluation of HDAC inhibitors using a fluorescent assay without 
a coupled second step. In addition this technology allows the measurement of kinetic 
values, and does not require large amounts of protein sample. PerkinElmer’s technology 
is based upon ‘sipping’ extremely small volumes of a reaction mixture (down to 10 nL), 
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then LabChip technology separates the acetylated substrate and deacetylated product by 
electrophoresis and quantifies the relative amounts of both by LED induced 
fluorescence. This technology was originally used for evaluating inhibition of kinase 
enzymes but the Broad Institute have developed substrates that enable it to be applied to 
HDAC enzymes.
95
 
All of the above assays can be carried out with different sources of HDAC 
activity; either cell extracts from cells containing a mixture of HDAC isoforms, 
immunoprecipitated HDAC isoforms which are still in the native multi-protein 
complexes, or purified recombinant HDAC isoforms. Isoform selectivity can be 
measured when using individual isoforms by calculating an IC50 value for each isoform. 
Recently a novel assay was developed in which isoform selectivity could be determined 
using a native mixture of HDAC isoforms obtained from cell lysates. It is a 
chemoproteomics based assay and so it does not have the same levels of throughput as 
the fluorescent assays above, however it gives a more accurate reflection of the in vivo 
isoform selectivity profile.
96
 Two matrix immobilised probe molecules bind to the 
HDAC enzyme complexes (at the active site), these complexes can then be pulled out of 
the solution using the attached matrix. The proteins in the complexes are quantified by 
digesting with trypsin and then isobaric tagging and tandem mass spectrometry. By 
adding different concentrations of inhibitors to the incubation of probe molecules and 
cellular lysate, the inhibitor displaces the probe and the resulting reduction of individual 
protein levels can be measured. This gives a measure of the relative binding strengths of 
the inhibitor towards each HDAC complex and therefore allows one to calculate the 
isoform selectivity profile. 
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2 Inhibitors with occupancy of the acetate-release 
pocket 
The acetate-release pocket has previously been studied by those seeking to 
design improved HDAC inhibitors as discussed in section 1.4.2 (Table 1.4-7 and Table 
1.4-8). However in many of these cases compounds have only been tested against one 
isoform, and so there remains a possibility that these compounds could have been 
selective inhibitors of an isoform that was not tested against. Furthermore a homology 
model of HDAC11 (supplied by GSK) containing mocetinostat docked into the active 
site suggested a novel and unexpected binding pose in which the pyridine cap group is 
buried deep within the acetate-release pocket of the enzyme (Figure 1.5-1). This mode 
of binding is a reversal of the standard pharmacophore model (Figure 1.4-1, p 17); 
dockings of known HDAC inhibitors in other HDAC isoforms show the aromatic cap 
group binding to the exterior surface of the protein. The validity of this homology 
model and mocetinostat docking is unknown, and since HDAC11 is the most recently 
identified HDAC (see section 1.1, p 12) there are few reports in the literature of 
HDAC11 inhibition data. Likewise there are no crystal structures available for HDAC11 
in the protein binding database, and no other dockings reported in the literature; so it is 
not easy to assess the accuracy of the GSK model.  
a)
       
b)
    
 
Figure 1.5-1: Images showing mocetinostat (stick) docked into HDAC11 model (Zn
2+ 
ion in pink). a) Cut away of the cavity showing proximity of the benzamide to the 
surface. b) View of the cavity from the protein exterior showing that 4-substituted 
benzamides could be tolerated.  
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The observed reverse binding pose implies that the benzamide group is close to 
the surface of the protein and the 4-position (para to the amide) is solvent exposed 
(Figure 1.5-1). This led us to believe that substitution at the 4-position of the 2-
aminophenyl ring could give rise to compounds that were still active inhibitors of 
HDAC11. If this hypothesis were correct then the resulting compounds could be 
selective inhibitors, since it is known that substitution at the 4-position is detrimental for 
inhibition of HDAC1 and HDAC2 (Figure 1.4-7, p 32). So in order to investigate the 
accuracy of the GSK docking model, and to explore whether substitution para to the 
amide could be a means of enhancing the isoform selectivity of mocetinostat, a series of 
these analogues was synthesised. 
2.1 Synthesis of 4-substituted N-(2-aminophenyl)benzamides 
It is likely that the electronics of the N-(2-aminophenyl)benzamide are important 
for successful inhibitor binding since both the carbonyl oxygen and the aniline nitrogen 
atoms are involved in coordinating the zinc ion. Therefore mainly substituents that are 
largely electronically neutral were targeted but for completeness some examples of 
strongly electron donating and electron withdrawing substituents were also sought. 
Some polar and some non-polar groups were chosen as were a range of different sized 
groups. The synthesis of these compounds is now discussed. 
 
Scheme 2.1-1: a) SOCl2, MeOH, reflux, 3 h, 85%; b) 1H-pyrazole-1-carboxamidine 
hydrochloride, EtOH, refux, 3 h, 80%; c) reflux, 5 h, 83%; d) 6, propan-2-ol, reflux, 20 
h, 67%; e) LiOH.H2O, THF, H2O, rt, 24 h, 97%. 
Benzoic acid 9 (Scheme 2.1-1) was synthesised according to a literature 
procedure;
68
 condensation of 3-acetylpyridine and dimethylformamide dimethylacetal 
gave the propenone 7. Reaction of methyl-4-(aminomethyl)benzoate hydrochloride and 
1H-pyrazole-1-carboxamidine hydrochloride gave guanidine 6, which was subsequently 
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condensed with enone 7 to give methyl ester 8. Saponification of the methyl ester using 
lithium hydroxide gave the carboxylic acid 9, ready for coupling with 4-substituted 
anilines.  
The parent compound mocetinostat was made in 59% yield from a BOP-
mediated coupling of 9 with phenylene-1,2-diamine. 
 
Scheme 2.1-2: a) phenylene-1,2-diamine, BOP, DMF, rt, 24 h, 59%. 
In order to synthesise the naphthyl-substituted analogue, carboxylic acid 9 was 
first activated as the acid chloride by reaction with thionyl chloride, and then reacted 
with naphthalene-2,3-diamine to give the product 10 in 32% yield. 
 
Scheme 2.1-3: a) i) SOCl2, toluene, reflux, 3 h.  
ii) naphthalene-2,3-diamine, NEt3, DCM, DMF, 0 °C-rt, 1.5 h, 32%. 
In the case of non-symmetrical examples the diamine could not be coupled 
directly as this would give a mixture of regioisomers, therefore 4-substitued-2-
nitroanilines were coupled with the carboxylic acid 9, followed by reduction of the nitro 
group. The nitroanilines were prepared as follows.  
A Suzuki coupling of 4-bromo-2-nitroaniline and phenylboronic acid afforded 
the 4-phenyl nitroaniline 11 in 56% yield.  
 
Scheme 2.1-4: a) PhB(OH)2, Pd(PPh3)4, Na2CO3, 1,2-dimethoxyethane, H2O, 80 °C, 48 
h, 56%. 
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Protection of 4-amino-3-nitrobenzoic acid as a benzyl ester was readily achieved 
in near quantitative yield by treating with benzyl bromide and potassium carbonate in 
DMF. 
 
Scheme 2.1-5: a) benzyl bromide, K2CO3, DMF, rt, 18 h, 96%. 
For the 4-hydroxymethyl analogue; reduction of the carboxylic acid of 4-amino-
3-nitrobenzoic acid was attempted using sodium borohydride and iodine but the reaction 
only returned starting materials. So the methyl ester 13 was prepared and reduction 
attempted using sodium borohydride in both THF and ethanol but both gave complex 
mixtures and incomplete reactions. Successful reduction of methyl ester 13 was 
achieved using DIBAL to give alcohol 14 which was subsequently protected as a tert-
butyldimethylsilyl ether by reaction with tert-butyldimethylsilyl chloride and imidazole. 
 
Scheme 2.1-6: a) SOCl2, MeOH, reflux, 16 h, 94%; b) DIBAL, DCM, THF, 0 °C for 1 h, 
rt for 3 h, 98%; c) TBSCl, imidazole, DMF, rt, 16 h, 89%. 
Conditions for coupling such highly deactivated nitroanilines, which are very 
non-nucleophilic were found in the literature; BOP coupling reagent and sodium 
hydride (which activates the nitrogen as a sodium amide anion).
97
 Even using these 
conditions the couplings proceeded in low yield, and therefore in some cases couplings 
were attempted with the acid chloride of 9 having used sodium hydride to deprotonate 
the nitroaniline, but these were also low yielding (Table 2.1-1). A variety of nitro 
reduction methods were attempted although in most cases catalytic hydrogenation with 
palladium on activated carbon was most successful. A summary of the reactions can be 
found in Table 2.1-2, it is worth noting that hydrogenation of 16e did consume starting 
materials, however purification of the product was unsuccessful. 
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Scheme 2.1-7: See Table 2.1-1 below for conditions. 
 R a) 
16a Br 9, BOP, pyridine, then sodium hydride, rt 2.5 h, 70%. 
16b Ph 9, BOP, pyridine, then Sodium hydride, rt, 7 h, 39%. 
16c CO2Bn 
Sodium hydride, anh. pyridine, −10 °C, 5 min; 
then acid chloride*, rt, 2 h, 51%. 
16d CH2OTBS 9, BOP, pyridine, then sodium hydride, rt, 2.5 h, 41%. 
16e CN 
Sodium hydride, anh. pyridine, −10 °C, 10 min; 
then acid chloride*, 0 °C, 5 h, 44%. 
Table 2.1-1: Conditions for amide coupling.*Preparation of acid chloride: 9, SOCl2, 
toluene, reflux, 3 h. 
For the synthesis of a strongly electron donating analogue such as the 4-hydroxy 
substituent, the amide coupling reaction is sufficiently regioselective, because of the 
enhanced nucleophilicity of the nitrogen para to oxygen. In this way BOP mediated 
coupling of 4-methoxy-1,2-phenylene diamine with benzoic acid 9 gave the desired 
product 18 in 70% yield. Demethylation using boron tribromide then afforded the 4-
hydroxy substituted compound 19. 
 
Scheme 2.1-8: a) BOP, DMF, rt, 27 h, 70%; b) BBr3, DCM, rt, 24 h, 50%. 
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Scheme 2.1-9: See Table 2.1-2 below for conditions. 
 R
1 
R
2 
Successful conditions 
Unsuccessful 
attempts 
17a Br Br 
FeSO4·7H2O, aq. NH3, 
EtOH, 60 °C, 4 h, 61%. 
SnCl2·2H2O 
17b Ph Ph 
H2, 10% Pd/C, MeOH, 
DCM, rt, 6 h, 31%. 
FeSO4·7H2O, aq. 
NH3 
17c CO2Bn CO2Bn 
H2, 10% Pd/C, MeOH, 
DCM, rt, 5.5 h, 22%. 
- 
17d CH2OTBS CH2OTBS 
H2, 10% Pd/C, MeOH, 
CHCl3, rt, 7 h, 36%. 
- 
17e CN CN - 
H2, 10% Pd/C, 
MeOH, rt, 7 h. 
17f CO2Bn CO2H 
H2, 10% Pd/C, MeOH, 
DCM, rt, 45 h, 24%. 
- 
17g CH2OTBS CH2OH 
SnCl2·2H2O, NH4OAc, 
1:1:1 THF/MeOH/H2O, rt, 
21 h, then 50 °C, 1 h, 46%. 
- 
Table 2.1-2: Conditions for nitro reduction. 
In order to verify that it was the N-(2-aminophenyl)benzamide moiety that 
conferred both isoform selectivity, and slow tight-binding behaviour (see section 5.2) to 
mocetinostat, the hydroxamic acid analogue was synthesised. Formation of the 
hydroxamic acid 20 directly from methyl ester 8 proceeded as expected and gave the 
desired product in 42% yield. 
 
Scheme 2.1-10: a) hydroxylamine (50% aq.), NaOH, THF, 0 °C for 10 min, rt for 5 min; 
42%. 
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2.2 Enzyme assay results 
The series of 4-substituted mocetinostat analogues were evaluated for inhibition 
of HDAC2, HDAC3-NCoR1, HDAC6 and HDAC8 (Table 2.2-1). However a reliable 
assay against HDAC11 that was able to reproduce the literature IC50 value of 
mocetinostat (or even provide a sigmoidal percentage inhibition against 
log10(concentration) curve) could not be developed (see section 5.1, p 96). This meant 
that the accuracy of both the GSK docking model and the hypothesis regarding 
HDAC11 selective inhibitors could not be established. 
Of the series, 4-methoxy and 4-hydroxy substituents (18 and 19) were most 
potent against HDAC2 and HDAC3-NCoR1, although both were less potent than 
mocetinostat. For both isoforms, the 4-methoxy substituent conferred some 6-fold 
greater potency than the 4-hydroxy compound. The maintained inhibition of HDAC2 
and HDAC3-NCoR1 for 18 and 19 in this series may reflect a stronger binding to zinc 
arising from increased electron density provided by the mesomeric effect of the 
methoxy and hydroxy groups, respectively. However it is likely that a combination of 
several factors influence the differences in inhibition across the series, including both 
the steric demands in the acetate-release pocket and the polarity of the substituent.  
An aminonaphthyl terminus (10) conferred good selectivity (30 fold) for 
HDAC3-NCoR1 over all other isoforms tested, including HDAC1 (>20 µM, not shown 
in table). In contrast, a 4-phenyl derivative (17b) showed no inhibition, suggesting that 
there is a strict limit on the length of the 4-substituent to retain HDAC3 inhibition. 
However despite this increase in selectivity the aminonaphthyl containing compound 10 
was ~30 fold less potent than mocetinostat against HDAC3-NCoR1 and so this terminal 
ring was not investigated any further. Since investigation of this series of compounds 
did not disclose a substituted N-(2-aminophenyl)benzamide unit of improved potency, 
the binding moiety present in mocetinostat was used in further studies. 
As expected hydroxamic acid 20 lacks the same isoform selectivity as 
mocetinostat, it also inhibits HDAC6 and HDAC8 (Table 2.2-1), confirming that the 
origin of mocetinostat’s isoform selectivity is the benzamide zinc-binding group.  
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HDAC inhibitory activity IC50 (M) 
No. Structure  HDAC2 
HDAC3-
NCoR1 
HDAC6 HDAC8 
mocetinostat 
 
0.022±0.003 0.022±0.001 >20 35.0±4.4 
10 
 
>20 0.63±0.011 >20 >20 
17a 
 
>20 4.72±0.13 >20 >20 
17b 
 
16.7±7.2 >20 >20 >20 
17c 
 
>20 >20 >20 >20 
17d 
 
>20 >20 >20 >20 
17f 
 
>20 >20 >20 >20 
17g 
 
>20 >20 >20 >20 
18 
 
0.248±0.023 0.111±0.029 >20 >20 
19 
 
1.43±0.20 0.719±0.065 >20 >20 
20  0.219±0.027 0.031±0.001 0.042±0.019 0.41±0.1 
Table 2.2-1: Inhibition of purified recombinant HDAC enzymes. >20 less than 45% 
inhibition at 20 M. Data is from duplicate experiments and ± standard error 
measurement of the IC50 determination.
98
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2.3 Conclusion 
In summary, after careful optimisation of the synthetic procedures, it was 
possible to readily prepare a set of substituted mocetinostat analogues in moderate 
overall yield. Analogues with groups at the 4-position of the aminophenyl ring were 
targeted in order to test an in silico docking result and to measure individual HDAC 
isoform SAR previously unreported for mocetinostat derivatives. The substituents of 
analogues made, possessed a large variety of different properties and thus the 
compounds probed the acetate-release pocket in numerous ways, this included; size, 
shape, polarity, mesomeric and inductive effects, and hydrogen bonding ability. 
Unfortunately due to the unavailability of a reliable assay for inhibition of HDAC11 
(see section 5.1), verification of the in silico model was not possible. Additionally 
inhibition of the other isoforms tested was significantly weaker for all substituted 
analogues compared to inhibition by the parent, unsubstituted, mocetinostat. Therefore 
the unsubstituted terminal aminophenyl ring was retained for future work. 
3. Chiral 5-membered heterocyclic capping groups 
Christopher Matthews  49 
3 Chiral 5-membered heterocyclic capping groups 
Chiral capping groups have been shown to increase isoform selectivity in 
hydroxamic acid HDAC inhibitors
79
 but have not been thoroughly investigated in 
conjunction with the benzamide zinc-binding group. This chapter describes the 
synthesis and evaluation of several series of compounds that are analogues of 
mocetinostat in which the pyrimidine ring has been replaced by a three-dimensional, 
chiral heterocycle. Heterocycles were chosen that would match the location of 
heteroatoms in the heterocycles with the nitrogen atoms in the aminopyrimidine. The 
heterocycles were designed to mimic the overall shape of the substituted pyrimidine in 
mocetinostat, whilst at the same time being readily accessible from α-amino acids. The 
α-amino acids would be used as chiral building blocks to provide a source of chirality.  
3.1 Synthesis of dihydroimidazol-4-ones 
3.1.1 N-acetyl dihydroimidazolones 
The inhibitors were prepared according to the route initially developed by 
Yiannaki (Scheme 3.1-1).
98
 First, D-phenylalanine was heated to 100 °C with 
ammonium thiocyanate in acetic anhydride to form the 2-thiohydantoin ring (R)-21a in 
31% yield; similarly, D-tryptophan gave (R)-21b in 70% yield.
99
 These 2-thiohydantoins 
were subjected to reported S-methylation conditions, potassium carbonate and 
iodomethane in acetonitrile at room temperature for 2.5 h,
100
 to give the corresponding 
methylated products 22a/22b in 27% and 60% yield respectively. During this reaction 
racemisation of the dihydroimidazolone occurs, driven by formation of a heteroaromatic 
enolate. However since this racemisation was not detected until the end of the route 
(optical rotation measurements were waiting for a polarimeter to be fixed), no attempt 
was made to minimise racemisation by optimising conditions of the reaction. Instead 
alternative heterocycles were targeted in later work (see section 3.1.3).  
Displacement of methanethiol from 22a/22b by 4-(aminomethyl)benzoic acid 
gave the benzoic acids 23a/23b; isolated in moderate yield (49% and 53% respectively) 
simply by filtration of the cooled reaction mixture. The BOP-mediated coupling of these 
acids with phenylene-1,2-diamine gave several impurities, but the benzamides 24a/24b 
were isolated in 15% and 62% yield respectively, after purification. 
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Scheme 3.1-1: a) NH4SCN, Ac2O, 100 °C, (for (R)-21a: 1 h) (for (R)-21b: 10 min); b) 
K2CO3, iodomethane, MeCN, rt, 2.5 h; c) 4-(methylamino)benzoic acid, EtOH, reflux, 
18 h; d) BOP, NEt3, phenylene-1,2-diamine, DMF, rt, 3.5 h. 
Yiannaki had attempted to remove the acetyl protecting group to reveal the 
desired N-H compounds, however her attempts at this were unsuccessful. Briefly; acidic 
or basic hydrolysis of the final compounds 24a and 24b gave decomposition, 
presumably because of hydrolysis of the benzamide and/or the dihydroimidazole ring. 
Deacetylation of (R)-21a was successful, as was the subsequent methylation (despite a 
mixture of tautomers being observed by NMR), however displacement of methanethiol 
failed, presumably the acetyl group draws electron density away from the reacting C=N 
carbon atom, thus increasing the electrophilicity at this centre. 
 
3.1.2 N-H dihydroimidazolones 
It was anticipated that by synthesising the N(1)-Boc-2-thiohydantoins using an 
alternative cyclisation procedure,
101
 and then following the already developed route 
(Scheme 3.1-1), the Boc-protected dihydroimidazolone inhibitors could be synthesised. 
It was hoped that the conditions required for Boc-deprotection would be milder than 
those needed for deacetylation, and therefore deprotection in the final step of the 
synthesis would be appropriate. 
L-Phenylalanine and L-tryptophan were both Boc-protected by standard protocols 
to give the N-Boc amino acids 25a and 25b in excellent yield (98% and 89%).
102,103
 
Reaction of the N-Boc amino acids 25a and 25b with ethoxycarbonyl isothiocyanate 
and pyridine furnished the desired N(1)-Boc-2-thiohydantoins 26a/26b in good yield 
(90% and 82%). Selective S-methylation gave the S-methyl compounds 27a and 27b as 
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expected in 63% and 70% yield. Racemisation occurred at this point in the same way as 
it had done for the N-acetyl compounds, but it also was not discovered until the end of 
the route. Displacement of methanethiol by 4-(aminomethyl)benzoic acid was initially 
attempted using the same conditions as for the acetyl-protected compounds (heating at 
reflux overnight in ethanol). The product no longer crystallised from the cooled reaction 
mixture as expected, because the Boc group increases the compound’s solubility. The 
desired product 28a was readily purified by column chromatography, however it was 
discovered that some Boc-deprotection occurred during the reaction and this is the 
reason for the low yield (33%). A reduction in the length of reaction to four hours, for 
28b, was accompanied by a near doubling in yield (60%). Amide coupling of the acids 
with phenylene-1,2-diamine promoted by BOP was again an unclean reaction and the 
Boc-protected benzamides 29a/29b were obtained in 55% and 34% yield respectively. 
As anticipated Boc deprotection was facile; stirring with TFA in dichloromethane at 
room temperature for three hours gave the N(1)-H dihydroimidazolone inhibitors 30a 
and 30b in 72% and 98% yield. These compounds exist as a 2:1 mixture of tautomers in 
DMSO, the minor tautomer has the other endocyclic C=N bond not the exocyclic C=N 
bond. 
 
Scheme 3.1-2: a) for 25a: Boc2O, NaOH, H2O:THF, rt, 16 h, for 25b: Boc2O, NEt3, 
MeOH, rt, 16 h; b) ethoxycarbonyl isothiocyanate, pyridine, MeCN, rt, 18 h; c) K2CO3, 
iodomethane, MeCN, rt, 2.5 h; d) 4-(methylamino)benzoic acid, EtOH, reflux, 18 h (4 h 
for 27b); e) BOP, NEt3, phenylene-1,2-diamine, DMF, rt, 3 h; f) DCM, TFA, rt, 3 h. 
Now that a successful route to synthesise the dihydroimidazolone inhibitors had been 
developed, the phenylglycine-derived compound was also made, since it more closely 
resembles the lead compound mocetinostat. However the opposite absolute 
stereochemistry of amino acid was used because phenylglycine is an unnatural amino 
acid and the (R)-enantiomer was cheaper, this was eventually inconsequential because 
3. Chiral 5-membered heterocyclic capping groups 
Christopher Matthews  52 
racemsation occurred in the methylation reaction anyway. 
 
Figure 3.1-1: Extra CH2 present in phenylalanine and tryptophan analogues 
Therefore the phenylglycine-derived analogue 30c was synthesised according to the 
same route; phenylglycine was reacted with Boc2O to give 25c, which was then cyclised 
with ethoxycarbonyl isothiocyanate to give the 1-Boc-protected 2-thiohydantoin 26c in 
56% yield (2 steps). S-methylation with methyl iodide proceeded in near quantitative 
yield; however the subsequent displacement with 4-(aminomethyl)benzoic acid gave the 
acid 28c in only 39% yield. BOP-mediated amide coupling with phenylene-1,2-diamine 
proceeded in an unexpectedly good yield, giving 29c in 98% yield. The Boc group was 
removed using TFA in dichloromethane to give the phenylglycine analogue 30c in 70% 
yield. 
 
Scheme 3.1-3: a) Boc2O, NaHCO3, THF:H2O, rt, 17 h, 95%; b) ethoxycarbonyl 
isothiocyanate, pyridine, MeCN, rt, 18 h, 59%; c) iodomethane, K2CO3, MeCN, rt, 2.5 
h, 99%; d) 4-(aminomethyl)benzoic acid, EtOH, reflux, 4 h; 39%; e) phenylene-1,2-
diamine, BOP, NEt3, DMF, rt, 4 h, 98%; f) TFA, DCM, rt, 3 h, 70%. 
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3.1.3 Thioether-linked dihydroimidazolones 
A previous attempt to synthesise a thioether-linked dihydroimidazolone by 
Yiannaki had started with a successful alkylation of thiohydantoin (S)-21a using 
methyl-(4-bromomethyl)benzoate (80% yield). However the basic conditions used to 
attempt the methyl ester hydrolysis failed, giving decomposition products.  
It was decided to change to using an acid-labile protecting group for the 
carboxylic acid. It was hoped that hydrolysis of the tert-butyl ester would be possible 
without causing degradation of the product. Therefore 4-(bromomethyl)benzoic acid 
was heated at reflux in thionyl chloride for 3.5 hours; the resulting acid chloride was 
then dissolved in anhydrous diethyl ether and potassium tert-butoxide was added 
portionwise over 1.5 hours to give tert-butyl ester 31 (Scheme 3.1-4). Thiohydantoins 
(S)-21a and (S)-21b were then readily alkylated with 31 in moderate yield (73% and 
56% respectively). 
Deprotection of tert-butyl ester 32a was attempted using a 1:1 ratio of TFA in 
dichloromethane, at room temperature for two hours. The crude product 33a was 
isolated in 98% yield but there was a substantial amount of inseparable impurity (30% 
by 
1
H NMR). Reducing the concentration of TFA to 33% and reducing the reaction time 
to 45 minutes for 32b gave pure 33b, which was isolated in 82% yield. However, 
subsequent BOP-mediated coupling of 33b with phenylene-1,2-diamine failed. TLC 
indicated that 33b had been fully consumed but the desired product 34b was not 
isolated after column chromatography. 
It was hoped that by reacting the impure sample of 33a with phenylene-1,2-
diamine the desired product might be separable from the impurity. However the crude 
product from the coupling reaction was a complex mixture and column chromatography 
failed to give any of the desired product 34a. One isolated side product was identified 
by 
1
H NMR as 35 (Figure 3.1-2), which presumably was formed as a result of being 
displaced from the dihydroimidazol-4-one ring, possibly by hydroxybenzotriazole, 
possibly suggesting that the desired product might not be very stable.  
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Scheme 3.1-4: a) SOCl2, reflux, 3.5 h, then Et2O and t-BuOK, rt 1.5 h. b) (S)-21a or 
(S)-21b, NEt3, MeCN, 40 °C, (for (S)-21a: 15.5 h) (for (S)-21b: 2.5 h). c) for 32a: 
TFA:DCM 1:1, rt, 2 h OR for 32b TFA:DCM 1:2, rt, 45 min. d) BOP, NEt3, phenylene-
1,2-diamine, DMF, rt, 3.5 h. 
 
Figure 3.1-2: Side product 35. 
Owing to the difficulties encountered above whilst synthesising the thioether 
analogues it was envisaged that a convergent synthetic approach may be more 
successful. If 4-(bromomethyl)benzoic acid could be coupled with phenylene-1,2-
diamine prior to alkylation of the 2-thiohydantoin, then no protecting group for the 
carboxylic acid would be required. This would provide a highly expedient route to the 
thioether analogues, as it is expected that alkylation with 36 would proceed smoothly.  
Several conditions were attempted for the coupling (Figure 3.1-3) however all 
were unsuccessful (Table 3.1-1); evidently the benzylic bromide was too reactive, 
leading to a mixture of side products. From one such attempted coupling using BOP as 
the coupling reagent, a side product was isolated that was identified by 
1
H NMR as 37, 
the coupled product but containing a hydroxybenzotriazole unit in place of the bromide. 
Hydroxybenzotriazole is an excellent alpha-effect nucleophile, and unsurprisingly it had 
reacted with the very electrophilic benzylic bromide. Hydroxybenzotriazole is released 
from BOP during the coupling process and it acts as a nucleophilic catalyst after its 
release; since it is not only an excellent nucleophile but a good leaving group also. It 
was therefore hoped that the isolated product 37 could be used to alkylate the 2-
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thiohydantoins directly; however after heating thiohydantoin (S)-21a, 
hydroxybenzotriazole side product 37 and NEt3 at 60 °C for three hours no reaction was 
observed by 
1
H NMR. 
 
Figure 3.1-3: Attempted synthesis of 36 (Table 3.1-1 for conditions). 37, an isolated 
side product 
BOP, NEt3, phenylene-1,2-diamine, DMF, rt, 4 h. 
EDC, phenylene-1,2-diamine, DCM, rt 8 h. 
a) oxalyl chloride, DMF, DCM, 0 °C, 3 h; b) phenylene-1,2-diamine, toluene:hexane, rt, 
16 h. 
a) SOCl2, reflux, 3.5 h ; b) phenylene-1,2-diamine, pyridine, Et2O, rt, 30 min. 
Table 3.1-1: Failed conditions attempted for the above coupling 
An alternative convergent route was attempted by forming the amide bond before 
installing the benzyl bromide via a benzylic bromination reaction (Scheme 3.1-5). The 
reaction of p-toluoyl chloride 38 with Boc-protected phenylene-1,2-diamine 39 
proceeded smoothly giving the benzamide 40 in 91% yield. A survey of the literature 
indicated that it might be possible to carry out the selective “side-chain” bromination 
whilst avoiding aromatic bromination,
104
 therefore benzamide 40 was heated at reflux 
with N-bromosuccinimide (NBS) and 10 mol% benzoyl peroxide in carbon tetrachloride 
for 5.5 h. After this time the starting material had been completely consumed and there 
were 2 overlapping new spots by TLC. 
1
H NMR of the crude product indicated that 
none of the desired side-chain bromination had occurred but that aromatic bromination 
had taken place instead. 
 
Scheme 3.1-5: a) NEt3, DCM, rt, 4.5 h, 85%; b) NBS, benzoyl peroxide, CCl4, reflux, 5.5 
h, 0%. 
If the benzyl chloride could be prepared then a Finkelstein reaction could be used to 
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generate the benzyl iodide in situ as Moradei et al. had done previously.
105
 Therefore the 
required 4-chloromethyl benzamide 43 was synthesised from 4-chloromethyl benzoyl 
chloride 42 and Boc-protected phenylene-1,2-diamine 39. Reaction of this benzyl 
chloride 43 with sodium iodide, potassium carbonate and a Boc-protected thiohydantoin 
gave the corresponding phenyl and benzyl substituted thioether analogues 44 and 45 in 
low yield, 28% and 30% respectively. The low yield reflects the formation of side 
products as opposed to incomplete reactions. One major side product (15-20% yield) 
was identified by 
1
H and 
13
C NMR as the product that had arisen from alkylation of the 
carbon atom of the thiohydantoins. TFA deprotection of the bis-Boc-protected 
compounds was not a clean reaction in either case; TLC indicated the formation of 
many products. Column chromatography enabled isolation of the products but only at a 
purity of ~85-90%, because impurities co-eluted from the column. The small amount of 
each product isolated meant that recrystallization was not attempted and no further 
efforts were made to synthesise the thioether-linked dihydroimidazolones.  
 
Scheme 3.1-6: a) NEt3, DCM, -10 °C – rt, 1 h, 91%; b) i) NaI, acetone, reflux, 2 h, ii) 
K2CO3, DCM, rt, 20 h, 28%; c) K2CO3, NaI, acetone, DCM, reflux, 25 h, 30%. 
3.2 Synthesis of reduced heterocycles 
Owing to racemisation of the dihydroimidazolone ring system and the low 
inhibitory activity of those compounds in cells (see section 3.3.3), a new series of 
compounds were targeted. It was anticipated that the cellular inactivity could have been 
caused by the highly polar nature of the heterocycle, giving the compounds poor 
membrane permeability. Heterocycles which didn’t contain a carbonyl group on the ring 
would be less polar ( 
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Figure 3.2-1), and furthermore the potential for racemisation would be greatly 
reduced in such ring systems. Accordingly further series of analogues without the 
carbonyl group on the heterocycle were synthesised. 
 
Figure 3.2-1: cLogP of heterocycle fragments as calculated by MarvinSketch 6.3. 
 
3.2.1 Thioether-linked dihydrothiazoles and dihydrooxazoles 
Reduction of L-phenylalanine with borane produced in situ from the reaction of 
sodium borohydride and iodine, gave L-phenylalaninol 46a in 74% yield. This amino 
alcohol was then reacted with carbon disulfide to give either the thiazolidine-2-thione 
47a or the oxazolidine-2-thione 48a, depending on the conditions, in 98% yield. The 
same procedures were applied to L-phenylglycine to make the phenyl substituted 
thiazolidine-2-thione 47b and oxazolidine-2-thione 48b, and to L-tryptophan for the 
thiazolidine-2-thione 47c (Scheme 3.2-1). 
 
Scheme 3.2-1: a) NaBH4, I2, THF, reflux, 16-18 h; b) CS2, KOH, H2O, reflux, 16 h;  
c) CS2, K2CO3, EtOH, 50 °C then H2O2, 5 min. 
The convergent approach developed above (Scheme 3.1-6) was applied; S-alkylation 
of both thiazolidine-2-thione 47a and oxazolidine-2-thione 48a was readily achieved in 
moderate yield (61% and 59% respectively) using the preassembled 4-
chloromethylbenzamide 43 and in situ Finkelstein conditions.
105
 Removal of the Boc-
protecting group using TFA was successful in the case of the dihydrothiazole 49a 
although it was not a clean reaction and gave moderate yield (56%). However the 
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attempt to remove the Boc-protecting group from dihydrooxazole 50a was 
unsuccessful; none of the desired product 52a was isolated, instead thiol 53 was isolated 
in 50% yield. 
 
Scheme 3.2-2: a) i) NaI, acetone, reflux, 2 h, ii) K2CO3, 47a or 48a, DCM, rt, 23 h, 
61% for 47a and 59% for 48a, b) TFA, DCM, rt, 2.5 h, 56% for 49a and 0% for 50a. 
It was thought that perhaps the dihydrooxazole ring was not stable to the 
conditions required for Boc removal. Since the Boc-protecting group in alkylating agent 
43 is not required for the alkylation reaction (the aryl amine is not very nucleophilic, 
owing to the delocalisation of its lone pair of electrons) removal of the Boc group prior 
to alkylation should provide an alternative route. Therefore benzyl chloride 43 was 
deprotected using TFA in dichloromethane to give the alkylating agent 54 in 73% yield. 
However the attempt to alkylate 47a with 54 using the Finkelstein conditions gave 
several spots by TLC; although the product 52a was isolated it was only 90% pure and 
obtained in low yield (30%). One minor side product (isolated in 7% yield) was 
identified by 
1
H NMR as the iodide ring opened product 55. Iodide’s high 
nucleophilicity, and formation of the strong C=O bond both contribute to the formation 
of this side product. 
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Scheme 3.2-3: a) TFA, DCM, rt, 2.5 h, 73%; b) 48a, K2CO3, NaI, acetone, reflux, 2.5 h, 
30% 52a (90% pure) and 7% 55. 
To overcome the problem of the dihydrooxazole ring being opened by iodide, 
the alkylation reaction was repeated without the sodium iodide, since the benzyl 
chloride itself could be an effective electrophile for the alkylation. This was the case; 
stirring 54 with 48a and potassium carbonate in acetone at reflux for 16.5 h gave the 
desired product 52a in 70% yield after purification. This procedure was also effective 
for alkylation of the phenyl substituted oxazolidine-2-thione 48b (Scheme 3.2-4) and 
the thiazoline-2-thiones 47b and 47c (Scheme 3.2-5). 
 
Scheme 3.2-4: a) 54, K2CO3, acetone, reflux, 16-18 h. 
 
Scheme 3.2-5: a) 54, K2CO3, acetone, reflux, 16-18 h. 
3.2.2 Amino-linked dihydrothiazoles and dihydrooxazoles  
By analogy with Scheme 3.1-1 and Scheme 3.1-2 the preparation of 59a was 
attempted using a reaction in which methanethiol is displaced from the heterocycle 
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(Scheme 3.2-6). First thiazolidine-2-thione 47a was readily methylated in quantitative 
yield following a literature procedure for methylation of the unsubstituted 
dihydrothiazolidine-2-thione.
106
 Heating 47a at reflux with iodomethane in acetone 
formed the hydroiodide salt from which the free base 56a was liberated using NaHCO3. 
Displacement of methanethiol by 4-(aminomethyl)benzoic acid failed; only starting 
material was recovered. 4-(aminomethyl)benzoic acid exists as a zwitterion and it is 
likely that the presence of the carboxylic acid group rendered the amine unreactive in 
this reaction. This displacement reaction did work well with the dihydroimidazolone 
compounds (Scheme 3.1-1, Scheme 3.1-2 and Scheme 3.1-3), however the carbonyl 
group on the heterocycle may increase the electrophilicity of the reacting carbon atom, 
thus activating the system. It was hoped that methyl 4-(aminomethyl)benzoate would 
displace methanethiol from 56a then the methyl ester could be hydrolysed to reveal the 
carboxylic acid. Because the hydrochloride salt of methyl-4-(aminomethyl)benzoate 
was available it was heated at reflux with dihydrothiazole 56a and potassium carbonate 
in ethanol; however, no reaction had occurred after 48 h and starting materials were 
recovered. It was believed that the heterogeneous base used may not have successfully 
deprotonated the hydrochloride salt of methyl-4-(aminomethyl)benzoate since the 
starting materials did not dissolve. The reaction was repeated using DIPEA in place of 
potassium carbonate and this gave the desired product 57a in 63% yield, after 24 h at 
reflux. Hydrolysis of the resulting methyl ester was achieved in 61% yield using lithium 
hydroxide in THF and water. BOP-mediated amide coupling of the acid 58a and 
phenylene-1,2-diamine was successful, but the reaction mixture contained many spots 
by TLC. Purification by column chromatography twice and trituration with hot diethyl 
ether gave a very low yield (7%) of the desired benzamide 59a (a significant amount of 
product was lost during purification). 
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Scheme 3.2-6: a) iodomethane, acetone, reflux, 3 h, then NaHCO3, 99%; b) 4-
(aminomethyl)benzoic acid, EtOH, reflux, 48 h; c) methyl 4-
(aminomethyl)benzoate.HCl, K2CO3, EtOH, reflux, 48 h, 0%; d) methyl 4-
(aminomethyl)benzoate.HCl, DIPEA, EtOH, reflux, 24 h, 63%; e) LiOH, H2O:THF, rt, 
26 h, 61%; f) phenylene-1,2-diamine, BOP, NEt3, DMF, rt, 4 h, 7%. 
A more convergent approach was sought because previously the amide couplings 
with phenylene-1,2-diamine had often been low yielding and purification of the 
products had been difficult. For this reason preassembled benzamide linker 61 was 
synthesised according to the procedure of Xian-Ping et al. (Scheme 3.2-7).
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 It was 
expected that this amine 61 could be used instead of using methyl 4-
(aminomethyl)benzoate in the displacement reaction that releases methanethiol. 
 
Scheme 3.2-7: a) EDC, NEt3, HOBt, phenylene-1,2-diamine, DMF, rt, 20 h, 56%; b) H2, 
10% Pd/C, H2SO4, MeOH, rt, 5.5 h, 62%. 
So dihydrothiazole 56b was stirred with 61 in ethanol at reflux for 24 h, but after 
this time no reaction had occurred, so heating was continued for a further 6 days after 
which time a small amount starting materials still remained. Purification of the crude 
product was attempted by column chromatography but the desired product (S)-59b was 
not isolated because of the complex mixture of products. Repeating the reaction at a 
higher temperature (120 °C) in n-butanol for 5 h gave the same result. The hydroiodide 
salt of 56b was reacted with 61 in ethanol at reflux overnight but this also gave a 
complicated mixture of products and starting materials. A neat melt of the two solids 
56b and 61 was also attempted at 180 °C for 1 h. This again gave a complicated mixture 
of products and starting materials, interestingly some liquid condensed around the neck 
of the flask in the melt reaction, which is presumed to be water formed from the 
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dehydration of the N-(2-aminophenyl)benzamide giving either 63 or 62 (Figure 3.2-2).  
 
Scheme 3.2-8: a) iodomethane, acetone, reflux, 3 h, then NaHCO3, 88%; b) 61, ethanol, 
reflux, 7 days; OR 61, n-butanol, reflux, 5 h; OR hydroiodide salt of 56b, 61, ethanol, 
reflux, 17 h; OR 61, 180 °C (melt), 1 h. 
 
Figure 3.2-2: Possible benzimidazole side products from the dehydration of N-(2-
aminophenyl)benzamides. 
Treating oxazolidine-2-thione 48a to the conditions used for methylation of 
thiazoline-2-thione 47a (Scheme 3.2-6) gave iodide 64a, which presumably arose from 
iodide ring opening of the desired product 65a in a similar manner to the formation of 
55 (Scheme 3.2-3). It had been expected that the dihydrooxazole ring would be 
inherently less stable than its thiazole equivalent, because of the stronger C=O bond 
formed from this ring opening compared to the C=S bond. Iodide 64a was obtained in 
high yield (93%) without purification and it was readily converted into the desired 2-
methylsulfanyl-4,5-dihydrooxazole 65a in 90% yield by stirring with potassium 
carbonate in acetonitrile at reflux. At this point it was anticipated that the previously 
low-yielding BOP coupling step would be a problem for the dihydrooxazole, as it had 
been for the dihydrothiazole. It was hoped that it could be avoided by employing a 
convergent route as attempted, albeit unsuccessfully, for the dihydrothiazole 56b above. 
Therefore dihydrooxazole 65a was heated at reflux with amine 61 for 4.5 hours in 
ethanol. TLC indicated that the starting materials had been consumed; however after 
column chromatography only a low yield (26%) of impure product 66a was isolated, 
which couldn’t be further purified. 
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Scheme 3.2-9: a) iodomethane, acetone, reflux, 2 h, 93%; b) K2CO3, MeCN, reflux, 5 h, 
90%; c) 61, EtOH, reflux, 4.5 h, 26% (~85% pure). 
It was thought that dehydration of the N-(2-aminophenyl)benzamide unit could 
be causing some of the impurities in the displacement reactions (Scheme 3.2-8 and 
Scheme 3.2-9) and so the Boc-protected preassembled linker unit 70 was prepared 
using a different route that was also previously published. First 4-(aminomethyl)benzoic 
acid was protected according to the solvent-free procedure of Chandra et al.
108
 as a 
trifluoroacetate 68 in 85% yield. This was then converted into the acid chloride and 
coupled to Boc-protected phenylene-1,2-diamine 39, to give benzamide 69 and finally 
the trifluoroacetate protecting group was removed with potassium carbonate to give 
amine 70 (Scheme 3.2-10).
109
 
 
Scheme 3.2-10: a) trifluoroacetic anhydride, 0 °C to rt, 2 h, 85%; b) Et3N, (COCl)2, 
DMF, DCM, 40 °C for 1 h; then 39, pyridine, rt for 20 h, 95%; c) K2CO3, H2O, MeOH, 
70 °C, 4 h, 88%. 
Phenyl substituted dihydrothiazole 56b was stirred with 70 in ethanol at reflux 
for 48 hours but starting materials remained, switching solvents to n-butanol allowed an 
increase in temperature to 120 °C, but after 48 h the reaction mixture still contained a 
substantial amount of 56b and many impurities had formed.  
 
Scheme 3.2-11: a) 70, ethanol, reflux, 48 h OR n-butanol, reflux, 48 h. 
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The reaction was also tested with benzyl substituted dihydrothiazole 56a; 
stirring at reflux with 70 in ethanol for 48 h gave a small amount of conversion but still 
56a remained. One equivalent of DIPEA was added to help facilitate proton transfers 
between the intermediates, but after stirring at reflux for 48 h the reaction was still 
incomplete and impurities were beginning to form. The product (S)-71a was isolated 
but only in low yield (19%), and purification was difficult (the product could not be 
purified to greater than ~80%) so an improved method was sought. 
 
Scheme 3.2-12: a) 70, ethanol, reflux, 48 h, then DIPEA, reflux, 48 h, 19% (~80% 
pure). 
Another approach was envisioned in which thiazolidine-2-imine 74 could 
undergo an alkylation reaction with benzyl chloride 43. The benzyl substituted 
thiazolidine-2-imine 74 was prepared using a similar procedure to the work of Carry et 
al.;
110
 reaction of amino alcohol 72 with tert-butyl isothiocyanate gave the tert-butyl 
thiourea 73 in quantitative yield. Stirring the thiourea with concentrated acid at reflux 
caused a dehydration cyclisation reaction and in situ removal of the tert-butyl group to 
give the imine 74 in 59% yield. 
 
Scheme 3.2-13: a) NaBH4, I2, THF, reflux, 16-18 h, 66%; b)tert-butyl isothiocyanate, 
ethanol, rt, 16 h, 98%; c) 6M aq. HCl, reflux, 8.5 h, 59%. 
Hirashima et al. reported that thiazolidine-2-imines could be alkylated using 
some benzyl bromides in pyridine,
111
 so 74 was stirred with benzyl chloride 43 in 
pyridine at room temperature, however none of the desired product (R)-71a was 
isolated. In another example from the literature Nagarajan et al. used an alkyl bromide 
and potassium carbonate to alkylate thiazolidine-2-imine.
112
 This suggested that the 
benzyl chloride 43 might not be reactive enough to alkylate the imine. Therefore an in 
situ Finkelstein reaction was carried out; imine 74 was stirred with benzyl chloride 43, 
potassium bromide and potassium carbonate at reflux. However the reaction gave a 
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complicated mixture of products and desired product (R)-71a was not identified in the 
mixture. 
 
Scheme 3.2-14: a) pyridine, rt, 16 h; b) KBr, K2CO3, dioxane, reflux, 24 h. 
Another option was a reductive amination reaction with the aldehyde 75. A 
similar reductive amination had been found in the patent literature using titanium 
isopropoxide then sodium borohydride to reductively alkylate a thiazolidine-2-imine 
with a benzyl ketone.
113
 Therefore the benzaldehyde 75 was prepared by a Kornblum 
oxidation using dimethyl sulfoxide and triethylamine N-oxide (Scheme 3.2-15-a), a 
procedure adapted from a patent by Sankyo Company.
114
 Subsequently a reductive 
amination reaction with the free base of 74 was attempted using titanium isopropoxide 
(Scheme 3.2-15-b); however the major product in the reaction was the alcohol 76 
(Figure 3.2-3). The two part nature of this procedure relies on the methanol added in the 
second step being completely anhydrous; otherwise the imine intermediate could just be 
hydrolysed back to the aldehyde by any water in the methanol. Since the desired 
amination is with an aldehyde which is more reactive than a ketone, the use of titanium 
isopropoxide might not be necessary. Therefore a standard reductive amination reaction 
was attempted; the free base of 74 was reacted with aldehyde 75 and sodium 
triacetoxyborohydride in dichloromethane, but the only product detected was the 
alcohol 76. 
 
Scheme 3.2-15: a) triethylamine N-oxide, DMSO, DCM, rt, 17 h, 45%; b) 74 (free 
base), titanium isopropoxide, DCM, rt , 17 h, then anh. MeOH and NaBH4, rt, 2 h; c) 74 
(free base), NaBH(OAc)3, DCM, rt 20 h. 
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Figure 3.2-3: Alcohol side product from the attempted reductive amination. 
To synthesise the amino-linked dihydrothiazoles an alternative approach was 
necessary. Instead of initially forming the heterocycle and appending the benzamide 
linker section, the chiral amino alcohol could first be joined to the benzamide linker and 
then the heterocycle could be formed in the final step. So by analogy to some previous 
work on 2-aminodihydrothiazoles by Yoshii et al.,
115
 a benzamide linker bearing an 
isothiocyanate 77, could be reacted with amino alcohols to give -hydroxythioureas, 
which could undergo cyclisation in concentrated acid in a similar manner to the 
formation of imine 74 (Scheme 3.2-13). 
Initially a modified procedure from Nasim et al.
116
 was used to prepare 
isothiocyanate 77 from amine 70 which had been made previously (Scheme 3.2-10). 
Reaction of 70 with carbon disulfide, then triethylamine followed by addition of tosyl 
chloride gave the isothiocyanate 77 in 68% yield (Scheme 3.2-16-a). An improved 
synthesis of 77 directly from 4-(aminomethyl)benzoic acid was subsequently 
developed. Using methodology from a patent by Nakano and Saito,
117
 4-
(aminomethyl)benzoic acid was converted quantitatively into the isothiocyanate 78, 
which without purification was then converted into the acid chloride and coupled with 
Boc-protected phenylene-1,2-diamine 39, to give 77 in 74% yield (2 steps). 
 
Scheme 3.2-16: a) i) DCM, rt, 1 min; ii) NEt3, rt, 10 min; iii) 0 °C, tosyl chloride, 10 
min, 68%; b) i) NEt3, THF, H2O, rt, 22 h; ii) 0 °C, I2, THF, 2 h; c) i) (COCl)2, DCM, 
DMF, rt then reflux, 2 h, 100%; ii) 39, DCM, pyridine, 0 °C, 1 h, then rt, 16 h, 74%. 
Reaction of isothiocyanate 77 with chiral amino alcohols 46 gave -
hydroxythioureas 79 in good yield. These thioureas were subsequently ring closed, and 
3. Chiral 5-membered heterocyclic capping groups 
Christopher Matthews  67 
deprotected in situ, by stirring at reflux in concentrated hydrochloric acid to give the 
desired amino-linked dihydrothiazoles 59. These final products were recrystallized to 
ensure maximum purity of the final compounds, however a substantial amount of 
material did not recrystallize and this is part of the reason for the low yield. The 
dehydration ring closure with concentrated hydrochloric acid failed in the case of 79e. 
Consequently, Mitsunobu conditions were applied to 79e and they afforded the desired 
thiazoline which was then deprotected to give 59e. 
 
Scheme 3.2-17: a) 77, MeCN, rt, 16 h; b) Conc. HCl, reflux, 10 min to 75 min (for all 
except 79e), c) diethyl azodicarboxylate, Ph3P, THF, rt, 75 min, then HCl in 
 Et2O, rt, 5 h (for 79e). See Table 3.2-1 below for substituents and yields. 
59 R
1
 R
2
 R
3
 R
4
 a) (%) b) (%) 
(S)-a PhCH2 H H H 87 10 
(R)-a H PhCH2 H H 94 22 
(S)-b Ph H H H 89 24 
(R)-b H Ph H H 96 23 
(R)-d H H Ph H 57 21 
(S)-d H H H Ph 100 49 
e p-HOC6H4 H H H 67 47 
(R,R)-f H Ph Ph H 99 36 
(S,S)-f Ph H H Ph 100 33 
Table 3.2-1: Substituents and yields for Scheme 3.2-17. 
With compounds 79d/f the stereochemistry of the acidic intramolecular ring 
closure becomes important. Initially it was thought that the reaction would proceed 
primarily through an SN1 type mechanism, since the water leaving group leaves behind 
a fairly stable benzylic carbocation. However in the case of 79d a truly SN1 mechanism 
would lead to racemisation which was not the case since the products have non-zero 
optical rotations that are approximately equal and opposite (+38.4 and -35.3 
respectively). In order to determine whether (R)-59d and (S)-59d had undergone partial 
racemisation they were sent to GSK and analysed using chiral HPLC by Eric Hortense. 
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This revealed that partial racemisation had taken place for each compound, (R)-59d had 
an enantiomeric excess of 58%, and (S)-59d had an enantiomeric excess of 46%. This 
suggests that in these cases the reaction was approximately 50% SN1 type (stepwise) and 
50% SN2 type (concerted). An SN1 mechanism might be expected to give a mixture of 
diastereomers for the two isomers of 59f, but these were not detected in either case. It is 
possible that the ~25% minor diastereomer was removed during recrystallization, or 
there may be diastereocontrol from the adjacent chiral centre. This would be likely to 
favour formation of trans-substituted diastereomer (the same isomer made by an SN2 
type mechanism) arising from ring closure of the least hindered conformation of the 
carbocation.
 
Figure 3.2-4: Mechanisms of acidic ring closure and the stereochemistry of products. 
The success of the convergent approach to make amino-linked dihydrothiazoles 
via -hydroxythiourea intermediates prompted the application of a similar methodology 
to make amino-linked dihydrooxazoles from the same -hydroxythiourea intermediates. 
A ring closure reaction in which sulfur is the leaving group, instead of oxygen, would 
afford the desired dihydrooxazole. Yellow mercuric oxide can activate sulfur as a 
leaving group, and it was used by Uchida et al.
118
 in an analogous reaction to convert a 
-hydroxythiourea into an amino-linked dihydrooxazole. Therefore thiourea (S)-79b 
was reacted with yellow mercuric oxide under those conditions (Scheme 3.2-18-a), 
however no conversion of (S)-79b was detected. Another literature procedure, by 
different authors, Hirashima et al.,
119
 used a different solvent mixture and a higher 
reaction temperature to carry out a similar reaction, so (S)-79b was subjected to these 
reaction conditions (Scheme 3.2-18-b). After extending the reaction time, and 
increasing the amount of yellow mercuric oxide added, complete conversion was 
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achieved; dihydrooxazole (S)-80b was isolated in 76% yield. The same reaction with 
(S)-79a proceeded very slowly with the same source of yellow mercuric oxide (an old 
commercial bottle) and after 6.5 h only a small amount of product was detected by TLC. 
However using freshly prepared yellow mercuric oxide
120
 the reaction was complete 
after 30 min and dihydrooxazole (S)-80a was isolated in 92% yield. Removal of the 
Boc-protecting groups from these two dihydrooxazoles using TFA in dichloromethane 
gave the final compounds 66a and (S)-66b in 47% and 74% yield respectively. 
 
Scheme 3.2-18: a) (for (S)-79b) yellow HgO, 1:2 ethanol:acetone, rt, 22 h, 0%; b) for 
(S)-79a: freshly prepared yellow HgO, 1:2 ethanol:toluene, reflux, 30 min, 92%; for 
(S)-79b: yellow HgO, 1:2 ethanol:toluene, reflux, 10 h, 76%; c) TFA, DCM, rt, 4 h, 47% 
for (S)-80a, 74% for (S)-80b. 
Mercury and its salts are very toxic, so preparing and using yellow mercuric 
oxide are hazardous procedures, for this reason an alternative, safer method of forming 
the dihydrooxazole ring was sought. Another method of activating the sulfur as a 
leaving group is to exploit its nucleophilicity by making the methyl thioether so that 
methanethiol (a good, volatile leaving group) can be lost upon formation of the 
dihydrooxazole, as in Scheme 3.1-1 and Scheme 3.1-2. This intra molecular approach 
has been used once before by Li et al. in 2011 to make a series of amino-linked 
dihydrooxazoles from amino alcohols and an isothiocyanate.
121
 They only reported the 
reaction using cyclic amino alcohols, and the thiourea intermediates were not isolated. 
Following their procedure, amino alcohol (R)-46b was stirred with isothiocyanate 77 in 
THF overnight, after this time the THF was evaporated, and then the residue was 
dissolved in acetone and stirred with iodomethane for 9 h before being quenched with 
sodium hydrogen carbonate (Scheme 3.2-19). The crude product was less pure than that 
from the reaction using yellow mercuric oxide, but after easy purification the 
dihydrooxazole (R)-80b was obtained in 41% yield. This procedure was then applied to 
a selection of amino alcohols that were either commercially available, or were made by 
reduction of the corresponding amino acid with sodium borohydride and iodine. When 
purification of the amino alcohol was difficult it was not purified before it was reacted 
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with isothiocyanate 77, but in those cases the -hydroxythiourea intermediate was 
purified. Removal of the Boc-protecting group using TFA in dichloromethane gave the 
desired final compounds in moderate to good yield. 
 
Scheme 3.2-19: a) 77, THF, rt, 16 h; b) iodomethane, acetone, rt, 4-9 h; c) TFA, DCM, 
rt, 4 h. 
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a) & b) 
(%) 
c) (%) 
(R)-b H Ph H H 41 32 
(S)-d H H Ph  H 71 34 
(R)-d H H H Ph  75 34 
e p-HOC6H4 H H H 67 70 
(R,S)-f H Ph  Ph  H  85 31 
(S,S)-f Ph  H Ph  H 56 98 
g Ph Ph H H 99 59 
(S)-h 
 
H H H 33 22 
(R)-h H 
 
H H 43 54 
i (±) p-FC6H4 / H H H 67 61 
j (±) m-FC6H4 / H H H 76 86 
k (±) p-F3CC6H4 / H H H 69 71 
m H H (±) p-HOC6H4 0 - 
Table 3.2-2: Substituents and yields for Scheme 3.2-19. 
This strategy was unsuccessful in the synthesis of the 4-hydroxyphenyl 
compound 66m derived from octopamine (Scheme 3.2-20), instead the methylsulfanyl 
substituted urea 81 was isolated. During the reaction thiourea 82 was not isolated, and 
because the urea 81 has a very similar Rf to thiourea 82 the reaction was left for longer 
than usual because it appeared by TLC that no reaction was taking place. The reaction 
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was repeated and the thiourea 82 intermediate was purified, then the ring closure step 
was carried out in an open flask (as opposed to under a nitrogen balloon) to encourage 
the methanethiol to evaporate. After only 4 h TLC showed that the urea 81 was the 
major product. Reverting to the use of freshly prepared yellow mercuric oxide also did 
not afford the desired dihydrooxazole 80m. It was envisioned that 81 might undergo an 
intramolecular cyclisation at elevated temperature, and so it was stirred at reflux in 
propan-2-ol (83 °C) for 48 h but no reaction was observed by TLC. 
 
Scheme 3.2-20: a) 77, K2CO3, THF, reflux, 90 h, then: iodomethane, acetone, rt, 40 h, 
30%; b) 77,K2CO3, THF, reflux, 96 h, 94%; c) iodomethane, acetone, rt, 4 h; d) freshly 
prepared yellow HgO, 1:2 ethanol:toluene, reflux, 6.5 h; e) 
i
PrOH, reflux, 48 h. 
The electron rich aromatic ring presumably provided an electronic ‘push’ to 
open the dihydrooxazole, once it had been made and protonated by the hydrogen iodide 
formed in the reaction, to give the stable urea group. The oxonium species 83 must then 
have then been trapped by methanethiol that was dissolved in the solvent (acetone). 
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Figure 3.2-5: Proposed mechanism for the formation of 81. 
3.2.3 Dihydroimidazoles 
Synthesis of chiral amino- and thioether-linked dihydroimidazole rings via the 
above convergent routes required access to chiral 1,2-diamines which are not 
commercially available. Based on the enzyme assay results of the compounds 
previously made (see Table 3.3-1 and Table 3.3-2) it was decided to make the phenyl 
substituted dihydroimidazoles only. The required diamine, (S)-1-phenylethane-1,2-
diamine 86 was prepared by either a lithium aluminium hydride, or sodium borohydride 
and iodine, reduction of (S)-phenylglycine amide 85. Both of these procedures afforded 
impure products that could not be easily purified, however purification after reaction 
with either carbon disulfide or isothiocyanate 77 was successful giving the 
imidazolindine-2-thione 87 (31%) or -aminothiourea 89 (57%) respectively (Scheme 
3.2-21). Alkylation of the thione 87 with benzyl chloride 54 afforded thioether-linked 
dihydroimidazole 88 in 66% yield after column chromatography but the mass return 
from recrystallization was very poor (3% final yield). Ring closure of the -
aminothiourea 89 using iodomethane gave the amino-linked dihydroimidazole 90 in 
near quantitative yield before purification. Attempts to purify this product using either a 
cationic ion exchange resin (Biotage, SCX-2 cartridge) or reverse phase HPLC (MDAP) 
resulted in very poor yield. Higher overall yield was obtained by not purifying 90 prior 
to removal of the Boc-protecting group; final compound 91 was then obtained in 47% 
yield after purification by reverse phase HPLC. 
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Scheme 3.2-21: a) SOCl2, MeOH, rt, 16 h, 100%; b) conc. aq. NH3, rt, 16 h, 58%; c) 
NaBH4, I2, anh. THF, reflux, 18 h; d) LiAlH4, anh. THF, reflux, 4 h; e) CS2, NEt3, EtOH, 
H2O, 60 °C, 5 h, then conc. HCl, reflux, 14 h, 31%, ; f) 54, K2CO3, acetone, reflux, 17 h, 
66%, g) 77, THF, rt, 18 h, 57%, h) iodomethane, acetone, rt, 18 h, 99% (crude); i) TFA, 
DCM, rt, 2 h, 47%. 
3.2.4 4-(3-Pyridyl)-dihydrooxazoles 
Despite being more potent than mocetinostat in the fluorometric assay against 
HDAC3, the phenyl-substituted amino-linked dihydrooxazole (S)-66b and amino-linked 
dihydrothiazole (S)-59b were less potent in the cancer cell line data (see Table 3.3-7). 
Whilst HDAC3 might not be the primary target in the cancer cell lines tested, 
mocetinostat seemed to have a cellular effect which was not accounted for by its 
enzyme inhibition data. The presence of the terminal pyridine ring in mocetinostat could 
be important in contributing to its inhibitory activity in cells, either by increasing 
aqueous solubility or by increasing cellular uptake via some sort of cell transport 
system. In order to establish whether a pyridine ring would impart increased enzymatic 
inhibition, or cellular activity, the 3-pyridyl substituted dihydrooxazoles were targeted. 
It was anticipated that if the 3-pyridyl substituted amino alcohol 94 could be prepared, 
the S- and amino-linked dihydrooxazoles would rapidly accessed using the convergent 
methodology developed above (Scheme 3.2-4 and Scheme 3.2-19). Synthesis of the 
chiral amino alcohol 94 was completed using a sulfinamide chiral auxiliary (Scheme 
3.2-22). Imine 92 was made from the condensation of (S)-2-methylpropane-2-
sulfinamide and 2-((tert-butyldimethylsilyl)oxy)acetaldehyde using copper(II) sulfate as 
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a dehydration reagent. Addition of 3-pyridyl lithium (prepared from the lithiation of 3-
bromopyridine) to the chiral imine 92 gave protected chiral amino alcohol 93 as a single 
diastereomer in 33% yield. Finally double deprotection using hydrochloric acid in 
dioxane afforded chiral amino alcohol 94 in 98% yield.  
Formation of the oxazolidine-2-thione 95 using carbon disulfide, and subsequent 
alkylation of this thione with 54 proceeded uneventfully, albeit with low yield (14% and 
45%), to give thioether-linked dihydrooxazole 96.
122
 
Reaction of chiral amino alcohol 94 with isothiocyanate 77 unexpectedly gave 
double addition product 99. This product formed as a result of there being excess 
isothiocyanate 77 present during the second step of the reaction, that is when 
iodomethane is added and the dihydrooxazole ring is formed. Usually, once the 2-
amino-4,5-dihydrooxazole ring is formed, it is immediately protonated by the hydrogen 
iodide produced in the reaction. However in this case the pyridine ring has a similar 
basicity to the 2-amino-4,5-dihydrooxazole ring which means that there will be some of 
the free base of the dihydrooxazole ring present. The excess isothiocyanate 77 then 
reacted with 97 formed in the reaction to give 99. This problem was solved by using 1.3 
equivalents of amino alcohol 94 to ensure all of the isothiocyanate had been consumed 
in the first step of the reaction. In this way the desired product 97 was obtained in low 
yield (21%), and subsequently the Boc-protecting group was removed to give 98 in 60% 
yield. 
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Scheme 3.2-22: a) CuSO4, DCM, rt, 90 h, 42%; b) 3-bromopyridine, BuLi, anh. toluene 
-78 °C, 1 h, then 92, -78 °C, 5 h, 38%; c) 4M HCl in dioxane, rt, 5 h, 98%; d) CS2, 
K2CO3, EtOH, H2O2, 50 °C, 1 min, 14%; e) 54, K2CO3, acetone, reflux, 17 h , 45%; f) 
77, THF, MeOH, rt, 17 h, then iodomethane, acetone, rt, 5 h, 21%; g) TFA, DCM, rt, 1.5 
h, 60%.
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3.3 Assay results 
3.3.1 In vitro enzyme assay 
All final compounds, those which contain the N-(2-aminophenyl)benzamide 
moiety, were evaluated for inhibition of HDAC activity. The results for the 
dihydroimidazolones are shown in Table 3.3-1; most of the compounds of this ring 
system showed slight selectivity for HDAC3-NCoR1. The Boc-protected compound 
29b is surprisingly potent; it had been thought that the t-butyl carbamate group would 
be too bulky to sit in the entrance to the tunnel. However presumably the group extends 
beyond the rim of the tunnel and forms a hydrophobic interaction with residues on the 
surface of the protein. The phenyl substituted compound 30c is the most potent 
compound of the series; it showed at least as great potency as did mocetinostat against 
HDAC3-NCoR1 and was more selective for this isoform. It is interesting to note that 
30c most closely resembles mocetinostat since it has a direct linkage from the 
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heterocycle to the terminal aromatic ring, indicating that this is the optimal overall 
length for HDAC3 inhibition. 
 
 
HDAC inhibitory activity IC50 (M) 
No. Structure  HDAC1 HDAC2 
HDAC3-
NCoR1 
HDAC6 HDAC8 
mocetinostat 
 
0.098±0.06 0.022±0.003 0.022±0.001 >20 35.0±4.4 
29b 
 
0.50±0.07 0.048±0.006 0.040±0.002 >20 27.2±1.0 
24b 
 
* 0.12±0.02 0.070±0.01 >20 24.3±2.0 
30b 
 
0.19±0.06 0.078±0.007 0.104±0.02 >20 >20 
24a 
 
* 0.26±0.02 0.083±0.01 >20 22.7±2.7 
30a 
 
* 0.066±0.003 0.030±0.006 >20 13.0±2.8 
30c 
 
0.35±0.2 0.056±0.01 0.014±0.007 >20 8.0±1.3 
Table 3.3-1: Inhibition of purified recombinant HDAC enzymes. * not determined, >20: 
less than 45% inhibition at 20 M. Data is from duplicate experiments and ± standard 
error measurement of the IC50 determination.
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The thioether-linked dihydrothiazoles were evaluated against HDAC2, HDAC3-
NCoR1, HDAC6 and HDAC8 (Table 3.3-2). Whilst none of the compounds were more 
potent than mocetinostat against any of these enzymes, once again the phenyl 
substituted analogue 51b was the most potent of the series against HDAC3-NCoR1. The 
results demonstrated that phenyl substituted thiazoline 51b has increased selectivity for 
HDAC3 over HDAC2, compared with the phenyl substituted dihydroimidazolone 30c 
(7 fold cf. 4 fold), which may be a result of testing the single enantiomer of 51b 
compared with the racemate of 30c. 
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HDAC inhibitory activity IC50 (M) 
No. Structure  HDAC2 HDAC3-NCoR1 HDAC6 HDAC8 
mocetinostat 
 
0.022±0.003 0.022±0.001 >20 35.0±4.4 
51c 
 
0.92±0.45 0.89±0.24 >20 >20 
51a 
 
0.58±0.12 0.509±0.02 >20 >20 
51b 
 
0.44±0.06 0.063±0.03 >20 >20 
Table 3.3-2: Inhibition of purified recombinant HDAC enzymes. >20: less than 45% 
inhibition at 20 M,. Data is from at least duplicate experiments and ± standard error 
measurement of the IC50 determination.
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Inhibition data for the thioether-linked dihydrooxazoles (Table 3.3-3) again 
revealed enhanced selectivity for HDAC3 compared with mocetinostat, although none 
showed greater potency than mocetinostat. In this ring system the phenyl substituent 
52b is not significantly more potent against HDAC3 than the benzyl compound 52a, 
although 52b is more selective for HDAC3. Replacing the phenyl ring with a 3-pyridyl 
ring (as is found in mocetinostat) slightly increases potency against HDAC3 and 
actually further increases selectivity for HDAC3 against HDAC2, 96 being almost 11 
fold selective for HDAC3. Having two nitrogen atoms in the heterocycle results in 
greater HDAC3 inhibition; thioether-linked dihydroimidazole 88 is the most potent 
thioether-linked compound prepared and is of comparable potency to mocetinostat. 
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HDAC inhibitory activity IC50 (M) 
No. Structure  HDAC1 HDAC2 
HDAC3-
NCoR2 
HDAC6 HDAC8 
mocetinostat 
 
0.098±0.06 0.022±0.003 0.045±0.01 
#
68% 35.0±4.4 
52a 
 
0.70±0.04 0.25±0.07 0.071±0.006 
#
60% 88.0±11 
52b 
 
1.2±0.6 0.36±0.05 0.066±0.008 
#
54% 9.5±2.2 
96 
 
◊
13% 0.61±0.13 0.056±0.003 
#
62% 112±14 
88 
 
0.38±0.005 0.18±0.006 0.038±0.002 
#
64% 14.3±1.8 
Table 3.3-3: Inhibition of purified recombinant HDAC enzymes. # percentage inhibition 
at 20 µM, ◊ percentage inhibition at 0.2 µM. Data is from at least duplicate experiments 
and ± standard error measurement of the IC50 determination.
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As expected the amino-linked dihydrothiazoles (Table 3.3-4) exhibited much 
more potent inhibition than the thioether-linked analogues above (Table 3.3-2). A few 
compounds (S)-59b, (S)-59d, and 59e) were at least as potent as mocetinostat against 
HDAC3-NCoR1 and all displayed enhanced selectivity towards that isoform. Although 
phenyl, 4-hydroxyphenyl, and benzyl mono-substitution at both the 4- and 5-positions 
of the heterocycle consistently gave compounds with good potency, bulkier 4,5-
diphenyl substitution of this ring system was detrimental to inhibition of all HDAC 
isoforms tested. This could be because of a general size requirement to fit in the 
entrance of the active site tunnel, although this seems unlikely given that bulky Boc-
protected dihydroimidazolone 29b is a potent HDAC3 inhibitor (Table 3.3-1). 
Alternatively it could be the trans-nature of the two phenyl rings causing loss of 
inhibition, because it is impossible for both rings to make contacts with the surface of 
the protein. Therefore one ring must be angled into the solvent which creates 
unfavourable ordering of water molecules around the hydrophobic ring. 
It is interesting to note that (S)-59b and its enantiomer (R)-59b have different 
selectivity profiles. The (S)-enantiomer (S)-59b is moderately HDAC3 selective 
whereas the (R)-enantiomer (R)-59b is slightly HDAC2 selective, although it has a 
greatly reduced selectivity. The two compounds exhibit the following HDAC1:2:3 
selectivity profiles (S)-59b; 77:7:1 and (R)-59b; 6:1:1.4. The 4-benzyl and 5-phenyl 
analogues do not show a similar switch in selectivity between enantiomers; in these 
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cases the selectivity profile within each pair of enantiomers is very similar. 
 
 
HDAC inhibitory activity IC50 (M) 
No. Structure  HDAC1 HDAC2 
HDAC3-
NCoR1 
HDAC6 HDAC8 
mocetinostat 
 
0.098±0.06 0.022±0.003 0.022±0.001 >20 35.0±4.4 
(S)-59a 
 
0.92±0.32 0.104±0.017 0.052±0.003 >20 34.9±7.1 
(R)-59a 
 
0.41±0.14 0.082±0.026 0.036±0.006 >20 12.7±2.5 
(S)-59b 
 
0.93±0.30 0.085±0.015 0.012±0.008 >20 4.1±0.85 
(R)-59b 
 
0.37±0.06 0.056±0.007 0.079±0.01 >20 10.7±1.1 
59e 
 
0.18±0.06 0.044±0.005 0.016±0.005 * 15.0±1.8 
(R)-59d 
 
* 0.111±0.008 0.023±0.009 * 1.4±0.1 
(S)-59d 
 
0.55±0.23 0.081±0.003 0.012±0.01 * 2.3±0.2 
(R,R)-59f 
 
* 0.425±0.074 0.287±0.123 * 14.9±0.5 
(S,S)-59f 
 
* 0.538±0.101 0.388±0.216 * 12.6±2.1 
Table 3.3-4: Inhibition of purified recombinant HDAC enzymes. >20: less than 45% 
inhibition at 20 M, * not determined. Data is from duplicate experiments and ± 
standard error measurement of the IC50 determination.
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Evaluation of amino-linked dihydrooxazoles against HDAC3-NCoR2 revealed 
that they were all at least as potent or more than mocetinostat with two exceptions, 4,4-
diphenyl and trans-4,5-diphenyl substituted compounds 66g and (R,R)-66f, which were 
less potent (Table 3.3-5). Trends similar to those seen for the thioether-linked 
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dihydrooxazoles can be seen again in these amino-linked analogues, although to a 
slightly lesser extent since the overall potency is greater with the amino-linked series. 
The phenyl substituted compound ((S)-66b) is slightly more potent and selective for 
HDAC3 than the benzyl substituted analogue (66a), and the 3-pyridyl version (98) is 
again slightly more potent and selective for HDAC3 than phenyl. Changes to either the 
nature or the stereochemistry of the terminal ring have a less significant impact on 
HDAC3 potency, and overall isoform selectivity, than they did in the corresponding 
dihydrothiazole series. Fluoro-substituents at either the para- or meta-position of the 4-
phenyl compound are tolerated (66i and 66j), as are para-trifluoromethyl and para-
hydroxy substituents, which means there is a capability to easily adjust physicochemical 
properties without greatly affecting enzyme inhibition. Indeed even the 
imidazoylmethyl compounds derived from L- and D-histidine ((S)-66h and (R)-66h) are 
potent, low nanomolar HDAC3 inhibitors, and show some of the same isoform 
selectivity. 
 Once again trans-4,5-diphenyl substitution ((R,R)-66f) was deleterious for 
inhibition of HDAC3, and in anticipation that this would be the case, cis-4,5-diphenyl 
amino-linked dihydrooxazole ((R,S)-66f) was also prepared in the hope that this might 
retain or improve potency. This was indeed the case (R,S)-66f is the most potent 
HDAC3 inhibitor of the series, and retains at least 12 fold selectivity over HDAC1 and 
HDAC2.  
Another point of particular note is that whereas in the analogous dihydrothiazole 
series the (S)-4-phenyl and (S)-5-phenyl compounds were the more potent enantiomers 
against HDAC3 ((S)-59b cf. (R)-59b, and (S)-59d cf. (R)-59d, Table 3.3-4), in the 
amino-linked dihydrooxazoles the opposite enantiomers of both the 4- and 5-phenyl 
substituted compounds were more potent against HDAC3 ((R)-66b cf. (S)-66b, and (R)-
66d cf. (S)-66d). This indicates that the dihydrooxazole ring might be orientated in a 
different conformation to the dihydrothiazole ring when bound to HDAC3. 
Alternatively the change from using HDAC3-NCoR1 to HDAC3-NCoR2 in the assay 
could be responsible for these differences, since the source of enzyme had to be 
changed between testing the two different series. 
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HDAC inhibitory activity IC50 (M) 
No. Structure  HDAC1 HDAC2 
HDAC3-
NCoR2 
HDAC6 HDAC8 
mocetinostat 
 
0.098±0.06 0.022±0.003 0.045±0.01 
#
68% 35.0±4.4 
(S)-66a 
 
0.20±0.02 0.13±0.04 0.041±0.001 
#
72% 63.0±5.4 
(S)-66b 
 
0.53±0.03 0.18±0.03 0.040±0.002 
#
66% 14.7±3.2 
(R)-66b 
 
0.082±0.002 0.18±0.03 0.033±0.002 
#
69% 80.7±19 
98 
 
0.26±0.01 0.43±0.07 0.031±0.002 
#
62% 111±15 
66e 
 
0.29±0.007 0.23±0.02 0.018±0.001 
#
13% 83.3±12 
(R)-66d 
 
0.076±0.005 0.192±0.007 0.011±0.003 
#
74% 173±38 
(S)-66d 
 
0.39±0.007 0.094±0.038 0.035±0.002 
#
72% 8.1±0.88 
(S)-66h 
 
0.078±0.002 0.16±0.01 0.021±0.001 
#
67% 179±29 
(R)-66h 
 
0.13±0.003 0.29±0.008 0.018±0.001 
#
61% 113±13 
(R,R)-66f 
 
◊
28% 0.28±0.03 0.118±0.02 
#
67% 29.2±2.9 
(R,S)-66f 
 
0.080±0.04 0.11±0.03 0.0063±0.005 
#
71% 25.2±3.2 
66g 
 
◊
21% 0.40±0.08 0.055±0.02 
#
61% 53.5±6.4 
66i 
 
0.19±0.009 0.15±0.008 0.034±0.004 
#
68% 33.9±6.1 
66j 
 
0.24±0.003 0.24±0.02 0.024±0.001 
#
70% 52.2±8.6 
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HDAC inhibitory activity IC50 (M) 
No. Structure  HDAC1 HDAC2 
HDAC3-
NCoR2 
HDAC6 HDAC8 
66k 
 
◊
20% 0.34±0.05 0.034±0.002 
#
67% 82.1±13 
91 
 
0.24±0.08 0.27±0.03 0.015±0.001 
#
78% 5.5±0.3 
Table 3.3-5: Inhibition of purified recombinant HDAC enzymes. # percentage inhibition 
at 20 M, ◊ percentage inhibition at 0.2 M. Data is from at least duplicate experiments 
and ± standard error measurement of the IC50 determination.
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3.3.2 Physicochemical properties 
A selection of the final compounds prepared in the project was sent to GSK, 
Stevenage in order to have some physicochemical properties measured. This data is 
shown below in Table 3.3-6 and it is useful to help identify compounds that are likely to 
be more potent in vivo. For example diphenyl-substituted compound (R,S)-66f which 
was the most potent compound in vitro might be less effective in vivo. This is because it 
has a high percentage human serum albumin (HSA) binding, which means that a large 
proportion of the compound will be bound to HSA. Other non-specific protein binding 
is also more likely, and so the concentration of free drug in circulation will effectively 
be reduced. This occurs when compounds are too lipophilic and is often accompanied 
by poor aqueous solubility, however (R,S)-66f has acceptable solubility. 
At the other end of the spectrum are analogues (S)-66h and (R)-66h, containing 
an imidazole ring; they show good solubility and low HSA binding, however in this 
case the artificial membrane permeability is very low. This suggests that these 
compounds will not rapidly cross cell membranes which would result in lower activities 
in cell based assays and in vivo since HDACs are intracellular targets. The cell 
membrane is a lipid membrane and because the imidazole ring is basic and protonated at 
pH 7.4, the charged species cannot easily cross the lipophilic interior of the membrane. 
This assay uses an artificial membrane to test permeability and sometimes in vivo cell 
permeability can actually be higher than this, possibly as a result of active transport 
systems. 
Several of the compounds tested showed good overall physicochemical 
properties, indicating that they might be suitable for progressing into cell based assays. 
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Compound 
Chrom 
log P 
Chrom 
log D7.4 
Solubility 
CLND (µg/mL) 
Permeablilty 
(pH 7.4, nm/s) 
%HSA 
binding 
Mocetinostat 2.96 2.96 107 350 92.5 
(S)-59b 4.65 4.24 108 510 
 
52a 5.67 5.41 31 440 96.5 
96 3.32 3.19 108 270 87.5 
88 4.31 3.49 116 300 91 
66a 4.15 2.86 ≥148 230 85.9 
(S)-66b 3.74 3.10 ≥153 330 85.3 
(R)-66b 3.76 3.09 ≥151 310 84.7 
98 1.78 1.71 ≥124 33 68.7 
66e 2.13 1.74 ≥130 13 74.4 
(R)-66d 3.58 2.79 98 180 84.9 
(S)-66d 3.84 2.99 77 162 89.9 
(S)-66h 0.95 0.90 ≥142 <3 46.8 
(R)-66h 0.93 0.89 ≥158 <3 46.5 
(R,R)-66f 5.41 5.01 6 410 96.9 
(R,S)-66f 5.01 4.54 73 410 94.9 
66g 5.59 5.29 7 390 96.6 
66i 3.97 3.39 147 270 88.1 
66j 3.84 3.42 ≥131 340 88.5 
66k 4.72 4.54 8 360 94.3 
91 3.46 1.92 ≥116 17 72.2 
Table 3.3-6: Table of physicochemical data measured by GSK, Stevenage.
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 Chrom log 
D and Chrom log P values
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 and permeability (artificial membrane permeability)
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were measured using procedures previously described. Solubility was measured using 
chemiluminescent nitrogen detection (CLND).
125
Human serum albumin (HSA) binding 
was measured using a fast gradient HPLC method with a chemically bonded protein 
stationary phase.
126
 Heat map indicates favourable numbers (green) through to 
unfavourable numbers (red).  
3.3.3 Cancer cell growth inhibition 
Initially some cancer cell line testing was carried out by Peter Soden at GSK, 
Stevenage. A selection of five compounds was tested for their ability to inhibit the 
growth of four cancer cell lines (Table 3.3-7). Mocetinostat and vorinostat were tested 
as controls in the assay. The results for dihydroimidazolones 30a and 30c are 
disappointing; they both weakly inhibited colon cancer cell line HCT116 but were 
inactive against the three other cell lines tested. Amino-linked dihydrothiazoles (S)-59b 
and (S)-59a were generally more potent than the thioether-linked dihydrothiazole 51c 
except against prostate cancer cell line DU145 which 51c inhibited almost as well as 
vorinostat. 
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 Cell growth inhibition IC50 (µM) 
Compound A549 DU145 HCT116 MCF-7 
mocetinostat 1.73±0.03 2.06±0.03 0.70±0.04 1.26±0.03 
vorinostat 2.27±0.04 2.58±0.02 1.39±0.03 2.29±0.06 
30a >50 >50 16.6±0.22 >50 
30c >50 >50 18.2±0.15 30.1±0.43 
(S)-59b 5.78±0.03 6.40±0.02 2.17±0.03 5.43±0.09 
(S)-59a 6.37±0.03 5.45±0.06 1.95±0.05 3.09±0.03 
51c 9.53±0.38 2.80±0.10 3.64±0.21 9.91±0.20 
Table 3.3-7: Cell growth inhibition data. Data from three independent experiments. 
 * not determined. Data were collected by Peter Soden at GSK, Stevenage.
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3.4 Conclusion 
Highly convergent methodology that enabled the rapid synthesis of chiral 
mocetinostat analogues was developed, whereby the pyrimidine ring is replaced by a 
non-aromatic 5-membered heterocyclic ring. Multiple series of compounds were 
prepared which contain a different chiral heterocycles, as well as different terminal 
aromatic capping groups. In vitro testing against individual isoforms revealed several 
compounds that are more potent and selective inhibitors than mocetinostat against 
HDAC3. In all ring systems, those compounds containing a 2-amino-linker are more 
potent than the thioether-linked equivalent. Of the heterocycles prepared both the 
dihydrooxazole and the dihydroimidazole showed the highest levels of inhibition. 
Additionally, many of the new HDAC inhibitors displayed higher solubility and lower 
binding to human serum albumin than that of mocetinostat. In an ex vivo cancer cell 
growth assay, some of the new compounds that were tested showed low micro molar 
inhibition of the cancer cell lines, but the level of inhibition was inferior to mocetinostat 
in all cases.  
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4 Search for novel zinc-binding groups 
4.1 Fragment screen 
Recently there have been several HDAC inhibitors discovered which contain 
novel zinc-binding groups (see section 1.4.1, p 19). Discovery of a new zinc-binding 
group for HDAC inhibitors would be an important discovery, especially if that zinc-
binding group had inherent isoform selectivity. A selection of fragments that were 
commercially available or easy to prepare was chosen from potential bi-dentate metal 
binding groups. The computational study by Chen et al.
55
 (discussed in section 1.4.1) 
was used to guide the choice of fragments tested. In particular those fragments which 
were amenable to further functionalisation were selected. The 8-hydroxyquinoline had 
shown steric clashes upon docking into the full structure of HDAC2 by Chen et al., but 
it was included in the set to be tested since it might not have steric clashes with another 
isoform which would achieve the desired aim of isoform selectivity. 
 
 
Figure 4.1-1: Commercially available fragments tested. 
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Only one fragment, 2-hydroxy-3-phenyl maleimide 100 was synthesised. 
Following a procedure from Xu et al.;
127
 diethyl oxalate was reacted with 2-
phenylacetamide and potassium tert-butoxide in THF to afford the phenyl maleimide 
100 in very poor yield (4%). This compound was actually a false positive in the assay; it 
appeared to be a potent inhibitor of HDAC8 but it was in fact interfering with the assay. 
This was confirmed by carrying out an experiment using deacetylated standard 130 (see 
section 5.1); the fluorescence was reduced to 10% of the control, when 100 (1 mM) was 
added before or after trypsin. This suggested 100 has significant UV absorption at the 
wavelength of detection (460 nM) and because of this there is no inhibition data shown 
for this compound. 
 
Scheme 4.1-1: a) t-BuOK, THF, 0 °C, 1.5 h, 4%. 
Fragment HDAC1 HDAC2 
HDAC3-
NCoR1 
HDAC8 
L-ascorbic acid 22 21 * 42 
mandelamide 20 20 * -3 
squaric acid 17 19 32 6 
2-hydroxymethyl imidazole 27 22 * 4 
8-aminoquinoline 43 60 66 76 
8-hydroxyquinoline 39 42 57 91 
L-methionine -4 2 -7 3 
L-cysteine -9 4 -10 79 
2-aminocyclohexan-1-ol * * 32 -5 
catechol * * 96 100 
salicylic acid * * 38 14 
thiosalicylic acid 48 17 35 69 
captopril 29 15 38 30 
2,4-dihydroxy-N-(2-
hydroxyethyl)benzamide 
20 21 29 6 
hippuric acid 32 12 33 6 
Table 4.1-1: Percentage inhibition at 1 mM. All data is averaged from duplicate 
experiments except HDAC3-NCor1 which is from a single experiment. * not determined. 
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From Table 4.1-1 it can be seen that of all the fragments tested only 8-
aminoquinoline, 8-hydroxyquinoline, catechol, L-cysteine and thiosalicylic acid had 
>50% inhibition against any isoform. Therefore a dose response curve was measured for 
these compounds against HDAC8 and the resulting IC50 values are shown below in 
Table 4.1-2. HDAC8 was chosen since that was shown to be the most sensitive of the 
isoforms tested of the initial fragment assay 
 
8-aminoquinoline 8-hydroxyquinoline catechol L-cysteine thiosalicylic acid 
436 96.3 214 265 223 
Table 4.1-2: IC50 values (M) against HDAC8 from a single experiment. 
4.2 Substituted 8-hydroxyquinolines 
The 8-hydroxyquinoline seemed to be the most promising fragment in terms of 
novelty, ability to be developed and it was the most potent HDAC8 fragment from the 
full dose-response experiment. A simple phenyl-substituted 8-hydroxyquinoline 101 
was prepared according to a literature procedure,
128
 in order to establish some very basic 
SAR of this novel zinc-binding group. The nature of the nitrogen atom is presumably 
vital for coordination to zinc because its lone pair is orthogonal to, and not delocalised 
around the aromatic ring, therefore the electrons are freely available to form a bond with 
the zinc ion. A nitrogen atom with similar electronics is found in an N-phenyl Schiff 
base 102 (Scheme 4.2-1). The delocalisation of electrons over the two aromatic rings 
effectively locks the conformation so that nitrogen’s lone pair is orientated in the same 
way as it is in the quinoline. Therefore the N-(2-hydroxyphenyl) Schiff base 102 was 
prepared according to a literature procedure,
129
 to test whether the quinoline could be 
replaced by a N-(2-hydroxyphenyl) Schiff base, since that would make analogue 
synthesis easier and faster than with the quinoline. 
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Scheme 4.2-1: a) Li, anh. Et2O, reflux, 1 h, then rt, air, 2 h, 70%; b) MeOH, reflux, 3 h, 
37%.  
Extension of the 8-hydroxyquinoline scaffold in this direction had failed to 
maintain inhibition, 101 and 102 do not inhibit HDAC8 (see 4.2.1, p 94), so it was 
decided to explore the opposite direction, that is 7-substitution instead of 2-substitution. 
It was decided to target substituents which had a SAHA like flexible linker and cap 
group. A route was devised that would give access to a selection of analogues (Figure 
4.2-1) including those with an unsaturated linker, and the corresponding 8-
methoxyquinolines. 
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Figure 4.2-1: Proposed route to SAHA like 8-hydroxyquinolines. 
 Synthesis of the SAHA like 8-hydroxyquinolines did not proceed as smoothly 
as planned. The allylation and Claisen rearrangement successfully installed the allyl 
group at the required 7-position and subsequent protection of the phenol as a methyl 
ether gave 104 in very good yield on a gram scale. Attempts to oxidatively cleave the 
alkene using osmium tetroxide and sodium metaperiodate gave aryl aldehyde 107 in 
87% yield instead of acetaldehyde 105. This was because the enol tautomer of desired 
product 105 was forming in the reaction and then undergoing a second dihydroxylation 
by osmium tetroxide to give a 1,2-diol intermediate which could then be oxidatively 
cleaved by excess sodium metaperiodate giving aldehyde 107. The desired aldehyde 
was obtained by separating the two steps; reaction of 104 with osmium tetroxide using 
potassium ferricyanide as a co-oxidant gave the 1,2-diol 118. The diol was subsequently 
oxidatively cleaved using sodium metaperiodate to give unstable acetaldehyde 105 in 
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66% yield over 2 steps. Aryl aldehyde 107 could also be accessed by rearrangement of 
the alkene, using potassium tert-butoxide, and then oxidative cleavage of the new 
olefin, using osmium tetroxide and sodium metaperiodate, in similar overall yield (89%) 
to the one step process. 
 
Scheme 4.2-2: a) i) allyl bromide, K2CO3, acetone, reflux, 24 h; ii) neat, 200 °C, 30 
min, 92%; b) iodomethane, NaOH, THF, rt, 18 h, 100%; c) OsO4, NaIO4, dioxane, H2O, 
rt, 16 h, 87% (107); d) OsO4, K3Fe(CN)6, t-BuOH, H2O, rt, 24 h, 81%; e) NaIO4, THF, 
H2O, rt, 5 min, 81%; f) t-BuOK, anh. THF, rt, 2 h, 94%; g) OsO4, NaIO4, dioxane, H2O, 
rt, 16 h, 95%. 
It was anticipated that a Horner-Wadsworth-Emmons reaction of phosphonate 
119 with both aldehydes 107 and 105 would give the desired (E, E) dienes.  
 
Scheme 4.2-3: a) P(OEt)3, 130 °C, 4 h, 84% (119); b) PPh3, toluene, rt, 16 h, 74% 
(120), c) AsPh3, toluene, reflux, 1.5 h, rt, 7 days, 75% (121). 
However reaction of 107 with 119 and sodium hydride in 1,2-dimethoxyethane 
gave only ~20% conversion by NMR and starting material aldehyde was still present. 
The product 113 could not be separated because it has the same Rf as the aldehyde 
starting materials. Therefore triphenylphosphonium bromide salt 120 was prepared 
(Scheme 4.2-3-b) then subsequently deprotonated using potassium, tert-butoxide and 
reacted with aldehyde 107 to give 113 (Scheme 4.2-4). However despite being a 
stabilised ylid which should give (E)-alkene, the product was roughly a 1:1 mixture of 
(E):(Z) isomers. Instead of purifying the ester the crude mixture was treated with 
lithium hydroxide to give the carboxylic acid 122 which was purified by a simple basic 
aqueous extraction procedure. Carboxylic acid 122 was converted into the acid chloride 
using oxalyl chloride, and coupled with aniline to afford the anilide 114 which was still 
a mixture of geometric isomers. Hydrogenation of the diene was attempted using a 
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hydrogen balloon and palladium on carbon, in a mixture of dichloromethane and 
methanol because 114 was insoluble in only dichloromethane. None of the desired 
quinoline 116 was isolated; instead the pyridine ring had also been reduced to give 
tetrahydroquinoline 123 in good yield (84%). It was not expected that the 8-
hydroxytetrahydroquinoline ring would be a good zinc-binding group, for the reasons 
discussed at the beginning of this section, but demethylation of 123 was attempted using 
boron tribromide. The reaction appeared to work by TLC however during column 
chromatography fractions containing the product became grey/black in colour which 
persisted after evaporation of the solvent. The proton NMR spectrum of the product was 
very broad and could not confirm that it was the desired compound 124; it appears that 
there may have been some sort of metal contaminant, unless the product is just very 
unstable.  
 
Scheme 4.2-4: a) 120, t-BuOK, anh. THF, rt, 1 h, then 107, rt, 1 h; b) LiOH, THF, H2O, 
reflux, 15 h, 59% (2 steps); c) i) oxalyl chloride, DCM, DMF, rt, 1 h, reflux, 1 h; ii) 
aniline, pyridine, DCM, rt, 16 h, 38%; d) H2, 10% Pd/C, DCM, MeOH, 48 h, 84%; e) 
BBr3, DCM, -78 °C, 4 h. 
It is known that stabilised triphenylarsonium ylids give good trans-selectivity in 
Wittig reactions and are more reactive than the corresponding phosphonium ylid,
130,131
 
so the corresponding triphenylarsonium salt 121 was prepared (Scheme 4.2-3-c). 
Reaction of this salt (using n-butyllithium to form the ylid) with aldehyde 107 gave 
ester 113 in 75% yield, also as an inseparable mixture of geometrical isomers. Since it 
was not possible to obtain the E,E diene selectively, only the saturated analogue would 
now be sought. Therefore reduction of the alkenes was attempted using a hydrogen 
balloon and palladium on carbon in ethyl acetate. It was expected that the over-
reduction experienced previously (Scheme 4.2-4-d) would not occur in a non-protic 
solvent. However, even when carrying out the hydrogenation in ethyl acetate some of 
the quinoline was reduced before the alkenes had been fully reduced, accounting for the 
low yield of 125 (24%). An alternative would be to carry out complete over-reduction 
followed by re-oxidation to the quinoline, which the literature suggested could be 
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accomplished using 2,3-dichloro-5,6-dicyano-1,4-benzoquinone (DDQ).
132
 In order to 
test this alternative route, complete reduction of 113 gave 126 in 93% yield, however re-
oxidation to the quinoline with DDQ was not a clean reaction and 125 was obtained in 
low yield (15%). The anilide 116 was prepared in good yield directly from ethyl ester 
125 using Weinreb conditions;
133
 that is initially treating aniline with 
trimethylaluminium to make the dimethylaluminium anilide and then addition of ester 
125. Demethylation of 116 was successfully completed using boron tribromide to afford 
the desired 8-hydroxyquinoline 117 in 49% yield. 
 
Scheme 4.2-5: a) 121, 
n
BuLi, anh. THF, rt, 16 h, 75%, b) H2, 10% Pd/C, EtOAc, rt, 5 h, 
24%, c) aniline, AlMe3, anh. toluene, rt, 17 h, 61%; d) BBr3, DCM, -10 °C to rt, 2 h, 
49%; e) H2,10% Pd/C, MeOH, rt, 20 h, 93%; f) DDQ, DCM, rt, 2.5 h, 15%. 
Reaction of diethyl phosphonate 119 with the more reactive aldehyde 105, did 
give the diene product 108 (Scheme 4.2-6), but as an inseparable mixture of 
geometrical isomers, and in low yield (19%). Using triphenylarsonium salt 121 the yield 
was improved (35%) but an E:Z mixture was still obtained. Complete reduction of diene 
108 using hydrogen and palladium on carbon, in methanol, gave tetrahydroquinoline 
127 in quantitative yield. However subsequent DDQ oxidation to the quinoline was 
unsuccessful. Due to time constraints no further attempts were made to prepare this 
compound. In order to access the unsaturated E,E-diene, olefin metathesis might be a 
more successful approach, however the problem of how to reduce the alkenes without 
reducing the quinoline remains.  
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Scheme 4.2-6: a) 119, NaH, anh. THF, rt, 12 h, 19%; b) 121, 
n
BuLi, anh.l THF, rt 16 h, 
35%; c) H2, 10% Pd/C, MeOH, rt, 20 h, 100%; d) DDQ, DCM, rt, 2 h. 
4.2.1 Enzyme assay results 
The substituted 8-hydroxyquinolines and 8-methoxyquinolines were tested for 
inhibition of HDAC8, however none of the compounds were potent inhibitors and so an 
IC50 value could not be generated for any of the compounds. Table 4.2-1 below shows 
the percentage inhibition of HDAC8 by each compound at 1 mM, the values are all 
significantly lower than the unsubstituted fragment 8-hydroxyquinoline (Table 4.1-2, 
91%). 
 
Compound Structure % inhibition 
101 
 
21 
102 
 
19 
123 
 
-6 
116 
 
34 
117 
 
3 
Table 4.2-1: Percentage inhibition of HDAC8 at 1 mM average values from duplicate 
experiments except 101 and 102 which are from a single experiment. 
No further exploration of the 8-hydroxyquinoline zinc-binding group was carried 
out; the question of whether the 8-hydroxyquinoline ring can be extended to give 
increased potency against HDAC8 remains unanswered, although the substitutions at 
the 2- and 7- positions made in this project were severely detrimental to activity. It 
seems unlikely therefore that any substitution at the 2- or 7- position will furnish 
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compounds with increased potency. Substitution at the 3- or 6- position might be more 
successful; however the synthesis of these compounds is less facile. 
4.3 Conclusion 
An investigation was carried out, to find novel zinc-binding groups that could 
give rise to new, more selective HDAC inhibitors. Initial screening of a targeted set of 
zinc-binding fragments, demonstrated that the 8-hydroxquinoline was the most 
promising of those tested, against HDAC8. Subsequently a set of substituted 8-
hydroxquinolines was synthesised, with substituents at the 2- or 7-positions of the 
quinoline ring. However all of the extended 8-hydroxquinolines that were made showed 
no significant inhibition of HDAC8. More work is needed to fully understand the SAR 
of the 8-hydroxquinoline fragment, including substituents at other positions around the 
ring system, to determine whether it could be useful as a new zinc-binding group with 
enhanced isoform selectivity.  
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5 In vitro deacetylation assays 
Initially, in vitro testing of compounds was carried out by Scottish Biomedical, 
UK. A selection of compounds, including vorinostat and mocetinostat as controls, was 
sent to be tested against HDAC11 to determine IC50 values. Vorinostat showed strong 
inhibition, yet the IC50 value calculated deviated significantly from literature values 
reported (26.6 nM cf. 100
53
-362
134,135
 nM). Furthermore mocetinostat was found to be 
completely inactive against HDAC11, which is in stark contrast with the literature 
report that it has an IC50 value of 0.59 µM.
68
 Since assay results from outsourcing did 
not agree with literature values, an enzyme assay was developed in order to evaluate the 
inhibition of compounds without the need for an external company.  
5.1 End-point assay 
Purified recombinant HDAC11 was purchased from Enzo Life Sciences, 
together with an assay kit containing fluorescent substrate for the deacetylation reaction, 
Fluor-de-lys
®
 SIRT1. This acetylated substrate is deacetylated by HDAC11 in the assay 
(Figure 5.1-1), deacetylation activates the substrate for a second step. A developer 
solution is added which selectively releases the fluorophore from the deacetylated 
substrate. The fluorescence of released fluorophore can be measured and it is directly 
proportional to enzyme activity, because the fluorescence is measured at the end of the 
reaction the assay is referred to as an end-point assay. 
 
 
Figure 5.1-1: Illustration of the Fluor-de-lys assay kit. The fluorophore (F*) is excited 
with 380 nm light and the emitted light (460 nm) is detected on a fluorometric plate 
reader. 
SAHA and mocetinostat were tested against HDAC11 at 6 concentrations each. 
The assay of SAHA gave a rough IC50 of ~50 nM, which is lower than literature values 
(albeit closer than the value from Scottish Biomedical), but more importantly the plot of 
percentage inhibition against log10(concentration) had a good sigmoidal shape. The 
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assay of mocetinostat did not give a correctly shaped sigmoidal plot; it showed ~25% 
inhibition at 1 nM yet only ~75% inhibition at 100 µM. The literature report of 
mocetinostat’s inhibition of HDAC11 was based on a similar assay which uses a slightly 
difference fluorescent substrate, MAL (Boc-Lys(Ac)-AMC).
68
 The second developer 
step in this assay contains a commercially available enzyme (trypsin) to cleave the 
fluorophore from the deacetylated substrate ML (Figure 5.1-2).  
 
Figure 5.1-2: Illustration of the HDAC assay with MAL and trypsin. 
In order to reproduce as closely as possible the assay from the literature, MAL 
was synthesised (Scheme 5.1-1)
85
, as was the deacetylated standard 130 which is 
needed to convert the fluorescence values from relative fluorescence units (RFU) to 
moles of substrate deacetylated, and 130 can also be used to check against false positive 
hits in the assay. If a compound inhibits trypsin, or if it absorbs radiation at the 
excitation or emission wavelength (380/460 nm), then it would appear to inhibit the 
HDAC enzyme in the assay. If the compound still appears to inhibit even when using 
the deacetylated standard 130 instead of using MAL, then it is a false positive.  
 
Scheme 5.1-2: a) POCl3, anh. pyridine, -10 °C, 30 min, 37%. 
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Scheme 5.1-3: a) 7-amino-4-methylcoumarin, anh. pyridine, POCl3, -10 °C, 1 h, 37%; 
b) H2 balloon, 10% Pd/C, MeOH, rt, 5 h, 42%. 
The experimental details describing mocetinostat’s IC50 for HDAC11 in the 
literature did not include the concentration of substrate used. Using the correct substrate 
concentration is vital for achieving a successful assay and an ideal concentration to use 
is in the range of the substrate’s Michaelis constant (Km) for that enzyme. Therefore a 
preliminary experiment was carried out using different concentrations of the substrate 
MAL and different reaction times in order to calculate the rate of reaction at different 
concentrations of MAL with a constant HDAC11 concentration (see Figure 5.1-4 for a 
representative graph against HDAC3-NCoR1). Then using the various reciprocal plots 
of the rate and substrate concentration data (see Figure 5.1-5 for a representative graph 
with HDAC3-NCoR1), an approximate Km value was determined to be 40 M for 
HDAC11 and MAL. Subsequently this value was used as the concentration of substrate 
in the assay, and mocetinostat was tested against HDAC11 in an assay with MAL. 
However again the plot of log10(concentration) against response was not a good fit to 
the expected sigmoidal curve. It was then reasoned that there could be some problem 
with the HDAC11 enzyme that was purchased, however Zhou et al. did not detail the 
source of their HDAC11. As the most recently identified HDAC, few inhibition data are 
available for this isoform and few commercial sources of the enzyme exist.  
In order to check whether the problem was with the enzyme and not with 
another aspect of assay, compounds were tested against another isoform. HDAC8 was 
chosen since it was readily available in large quantities (thanks to Simon Greenwood for 
providing HDAC8) because it can be expressed in Escherichia coli BL21 cells and the 
active protein successfully purified with a His-tag which was removed prior to final 
purification by size exclusion chromatography. Although it was expected that the 
compounds prepared in this project would be less potent against HDAC8, plots that 
fitted the expected sigmoidal curve would show that the assay was functioning 
correctly. The Km of MAL for HDAC8 was roughly calculated as being >1 mM (in 
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agreement with a literature value of >500 µM),
88
 this calculation was limited by the 
solubility of MAL, and so for use in assays 200 M was used (higher concentrations 
gave solubility problems). The assays with HDAC8 were successful, although as 
expected all benzamide compounds prepared had an IC50 value >1 M (see tables in 
section 3.3.1) the graph below in Figure 5.1-3 shows an example sigmoidal curve of 
mocetinostat against HDAC8, the points fit the curve well and the curve has limits at 0 
and 100% inhibition. 
 
Figure 5.1-3: Graph showing sigmoidal curve of percentage inhibition against 
log10(concentration) for mocetinostat against HDAC8. Points are the mean value from 
duplicate experiments and error bars are standard deviation from the mean. 
The other HDAC enzymes available from commercial sources are produced in 
insect cells (Sf9) because when made in E. coli cells they cannot be successfully 
purified or are enzymatically inactive. It is thought that there are post-translational 
modifications crucial for enzymatic activity that cannot occur in E. coli cells since these 
cells lack the necessary modifying enzymes. However HDAC8 does not have a flexible 
C-terminal tail known to contain some of the sites of post-translational modifications in 
other isoforms. Since HDAC11 is the smallest HDAC, it also lacks a C-terminal tail and 
it shares highest sequence homology with HDAC8 (see Figure 1.2-3, p 12) it was 
thought that expression of HDAC11 in E. coli might provide some active HDAC11 for 
use in assays. Several attempts were made to express and purify HDAC11 from E. coli 
cells using a similar expression system to that used for HDAC8; however HDAC11 
protein was not successfully obtained from these efforts. 
It was therefore decided to focus on the other isoforms that mocetinostat 
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inhibits: HDAC1, 2 and 3. These isoforms were also available commercially, and so 
they were purchased from Enzo Life Sciences, HDAC3 was supplied as a fusion protein 
with the deacetylase activation domain of the nuclear receptor co-repressor 1 complex 
(HDAC3-NCoR1). The Km values of MAL against HDAC2 and HDAC3-NCoR1 were 
roughly calculated as ~80 and ~14 M respectively using the procedure described above 
for HDAC11 (see representative graphs below), but for HDAC1 a Km value was found 
in the literature (58.9 M)136. 
 
Figure 5.1-4: Graph showing amount of deacetylated substrate at different time points 
for HDAC3-NCoR1 with different concentrations of MAL substrate. 
 
Figure 5.1-5: Graph of rate against rate/substrate concentration. Km = gradient × −1. 
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A selection of benzamide HDAC inhibitors have been shown to be slow binding 
for certain HDAC enzymes (see section 1.4.2, p 29). Therefore when assessing the 
inhibitory activity of these benzamide inhibitors in an end-point assay, the length of pre-
incubation of enzyme and inhibitor is crucial. An experiment was carried out with 
mocetinostat, against each isoform, comparing different lengths of pre-incubation. It 
was found that for HDAC3-NCoR1 even after 3 h pre-incubation the IC50 value had not 
reached equilibrium (Figure 5.1-6). However the longer the enzyme is left at room 
temperature, the more degradation and loss of activity occurs thereby reducing the 
resolution of the assay. So for HDAC3-NCoR1 three hours was decided as optimum, for 
HDAC1, 1 h was found to be optimum and for HDAC2, 3 h. The same process had been 
carried out for HDAC8 before testing against that isoform and pre-incubation made 
little difference in that case, so 15 min pre-incubation was used for the HDAC8 assays. 
 
Figure 5.1-6: Graph showing percentage inhibition against log10(concentration) for 
mocetinostat against HDAC3-NCoR1 with different pre-incubation times. Data points 
are mean values from duplicate experiments and error bars are SD from mean. Inset 
table shows IC50 values (nM) for each pre-incubation time. 
As the project progressed and more assays were carried out, new batches of 
HDAC enzymes were purchased. These new batches often behaved very differently in 
the assays to the original batches, sometimes having different activities and in some 
cases the inhibition of the new batch (by the same compounds) differed significantly. 
This can be seen for mocetinostat against HDAC6 comparing Table 3.3-4 with Table 
3.3-5, the percentage inhibition against the first batch of HDAC6 was <45% at 20 µM 
but against the second batch of enzyme, inhibition at the same concentration was 
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significantly higher (68%), these were the same HDAC6 kits both from Enzo Life 
Sciences, ordered approximately 18 months aparrt. Enzymes made by BPS Bioscience, 
US and distributed in the UK by TebuBio were found to be more active and consistent 
than those produced by Enzo Life Sciences.  
5.2 Progression method assay 
The endpoint assay discussed in the previous section, is a good assay for 
inhibitors that have fast on/off kinetics such as hydroxamic acids, however some 
benzamide HDAC inhibitors are known to be slow tight-binding inhibitors for certain 
isoforms (as discussed in section 1.4.2, p 29). The effect of introducing a longer pre-
incubation time in the assay partially accounts for the slow on rate, however the assay is 
non-optimal for evaluating slow on/off inhibitors. For this reason an alternative assay 
was investigated; the progression method assay described by Chou, Herman and 
Gottesfeld.
67
 
The assay follows the same basic principal as the end-point assay described in 
the previous section. Whereas that assay was carried out in two steps and a final 
fluorescence reading measured, the progression method assay contains both steps in 
‘one pot’ and measures the fluorescence in real time over the course of the reaction. One 
primary difference that enables both steps to be carried out in ‘one pot’ is the use of a 
more selective enzyme, endoproteinase Lys-C, which cleaves the fluorophore from the 
deacetylated intermediate. Lys-C selectively hydrolyses the amide bond on the C-
terminal side of a lysine residue, whereas trypsin which was used in the end-point assay 
above, cleaves on the C-terminal side of both lysine and arginine residues (except when 
followed by proline). The end result is that by using Lys-C in ‘one pot’ with the 
deacetylation reaction, the HDAC protein is degraded less quickly than it would be if 
trypsin were used. This means that the rate of a zero inhibitor control reaction is linear 
for enough time for the experiment to be useful, typically 45-60 mins. The assay also 
uses a slightly different substrate, Ac-Lys(Ac)-AMC (131) instead of MAL (Boc-
Lys(Ac)-AMC), and therefore the new substrate was synthesised. Starting from MAL, 
the Boc-protecting group was removed, and then the resulting amine was acetylated 
using acetic anhydride, to afford 131 in 59% yield. The assay also requires the substrate 
concentration to be greater than the Km, and according to the details in the literature 131 
was used at 50 µM with HDAC3-NCoR1 (5 times the Km). 
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Scheme 5.2-1: a) i) HCl in Et2O, DCM, rt, 2.5 h;  
ii) acetic anhydride, DIPEA, MeCN, -10 °C, 2 h, 59%. 
The fluorescence is measured every minute, and it is directly proportional to the 
amount of product produced in the assay. A non-linear regression of the integrated rate 
equation for slow binding inhibitors [𝐹 = 𝑣𝑠𝑡 + (𝑣0 − 𝑣𝑠)(1 − exp(−𝑘𝑜𝑏𝑠𝑡))/𝑘𝑜𝑏𝑠] is 
fit to the data to give a graph such as in Figure 5.2-1 below. 
 
Figure 5.2-1: Graph showing the time dependent inhibition of HDAC3-NCoR1 as a 
function of mocetinostat concentration. 
From this non-linear regression, an observed rate constant kobs can be calculated 
at each concentration of inhibitor. Subsequently a plot of these calculated kobs values 
against the inhibitor concentration (Figure 5.2-2) gives information on the mechanism 
of slow binding (for more details see Chou et al.
67
). 
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Figure 5.2-2: Graph showing hyperbolic relationship of kobs and mocetinostat 
concentration against HDAC3-NCoR1. The mean kobs value is from three independent 
experiments and error bars are standard deviation from the mean. 
As can be seen from the above graphs this assay was carried out with 
mocetinostat and HDAC3-NCoR1, and according to the hyperbolic shape of the graph 
in Figure 5.2-2, the slow binding mechanism is following a two-step process where the 
first initial fast binding of inhibitor and enzyme is followed by a slow second step such 
as a conformation change. According to Chou et al. the relationship between kobs and 
inhibitor concentration for this mechanism is described by the following equation:  
𝑘𝑜𝑏𝑠 = 𝑘−2 +
𝑘2[𝐼]
[𝐼]
+ 𝐾𝑖
∗(1 +
[𝑆]
𝐾𝑚
) 
Fitting this equation to the data can reveal the inhibition constant Ki and on and off rate 
constants for the slow step of binding. However using OriginPro to fit this equation to 
the data collected for mocetinostat against HDAC3-NCoR1, resulted in numbers being 
produced such as Ki=3.6 × 10
-21
, which is many orders of magnitude different from the 
Ki that can be calculated from the end-point assays even after considering a longer pre-
incuabtion time.  
The same problem was found whilst carrying out the assay against HDAC2; 
whilst the plots fit the correct general shape the final numbers calculated are not 
sensible. Again a hyperbolic relationship between kobs and mocetinostat concentration 
was observed and that indicates that again a two-step mechanism of inhibition is 
responsible for the slow binding. This is in contrast to the findings of Chou et al., 
because their benzamide inhibitor was reported as having a single step mechanism for 
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HDAC2 (but a two-step mechanism for HDAC3). 
Amino-linked thiazoline (S)-59b was also evaluated against HDAC2 and 
HDAC3-NCoR1 using this assay. Similarly to mocetinostat, (S)-59b demonstrates a 
two-step slow binding mechanism for both isoforms, however the final numbers 
generated (Ki, kon, and koff) are many orders of magnitude different to the results from 
the end-point assay. 
In order to verify that the benzamide zinc-binding group is responsible for the 
slow tight-binding kinetics, hydroxamic acid analogue of mocetinostat 20 was also 
evaluated against HDAC3-NCoR1. In this case, as expected the rate is independent of 
time, because inhibition is independent of time on the timescale of minutes, therefore 
the graph consists of straight lines (Figure 5.2-3). 
 
Figure 5.2-3: Graph showing the time independent inhibition of HDAC3-NCoR1 as a 
function of 20 concentration. 
This progression method assay was in theory better for evaluating slow tight-
binding inhibitors, and it was able to provide additional information about the binding 
events such as on and off rates for the slow step. However in practice when using it to 
calculate quantitative data such as Ki, the calculated values were many orders of 
magnitude different from the Ki calculated using the more widely recognised end point 
assay. This could be because of an intrinsic problem with the assay explained below.  
The fluorescence being measured in the assay is directly proportional to the 
amount of product from the second enzyme reaction. That second enzyme reaction is 
release of AMC from Ac-Lys-AMC, and at the start of the reaction the concentration of 
Ac-Lys-AMC (the substrate for the second step) is zero. During the first few minutes 
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the concentration of Ac-Lys-AMC increases which also means that the rate of the 
second step increases from zero at the start of the reaction. This means that the amount 
of product produced in the second reaction does not increase linearly at the start of the 
reaction, causing a lag period. Furthermore, since the length of lag period is dependent 
on the rate of production of Ac-Lys-AMC, it is different for different inhibitor 
concentrations and so it is not possible to easily adjust the equation for the fitting in 
order to account for this lag.  
Mathematically an equation that incorporates this lag period can be derived (for 
the reaction without inhibitor) by looking at the equations which govern the rates of the 
reactions. 
  
Figure 5.2-4: Progression method assay, showing abbreviated  
names used in the following equations below. 
The rate of production of fluorescence (F) is governed by the following 
equation: 
𝑑[F]
𝑑𝑡
= 𝑘2[S2]   eq. 1 
An expression for the concentration of S2 at a given time (t) can be derived by 
integrating the equation governing its rate of change and then rearranging: 
𝑑[𝑆2]
𝑑𝑡
= 𝑘1[S1] − 𝑘2[S2]  eq. 2 
[𝑆2] = 𝑘1[S1]𝑡 − 𝑘2[S2]𝑡   eq. 3 
[S2] =
𝑘1[S1]𝑡
(1+𝑘2𝑡)
    eq. 4 
Substituting eq. 4 into eq. 1 and integrating gives the expected equation that a 
plot of fluorescence against time should fit (for the reaction without inhibitor). 
𝑑[F]
𝑑𝑡
= 𝑘2
𝑘1[S1]𝑡
(1+𝑘2𝑡)
    eq. 5 
𝑑[F]
𝑑𝑡
= 𝑘1[S1] −
𝑘1[S1]
(1+𝑘2𝑡)
   eq. 6 
[𝐹] = 𝑘1[S1] (𝑡 −
ln⁡(𝑘2𝑡+1)
𝑘2
) eq. 7 
A plot of this equation roughly matches the observed shape of the reaction 
without inhibitor until the point that loss of activity can be seen because of enzyme 
degradation; an example plot of eq. 7 is shown below. 
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Figure 5.2-5: Example plot of eq. 7 (blue) and a straight line (red) to highlight the 
observed lag. Prepared using www.graphsketch.com. 
Another problem with this assay is that it is not applicable to all HDAC isoforms 
because of their sensitivity towards Lys-C degradation. Attempts were made to develop 
the assay for use with HDAC8; however this was not possible owing to the rapid loss of 
HDAC8 activity in the presence of Lys-C, even when using lower Lys-C concentrations 
than used with HDAC2/3. 
The problems associated with this progression method assay meant that it was 
not used extensively for testing compounds because the end point assay was more 
useful for providing reliable quantitative data. 
5.3 Conclusion 
Several problems were encountered during the in vitro testing of HDAC 
inhibitors, especially obtaining IC50 values that are consistent with literature values. In 
fact self-consistency was also sometimes a difficulty because of the variation between 
different batches of the purchased enzymes. Certain HDAC enzymes are known to 
function as homo- and hetero-dimers and this could be part of the reason for the 
observed differences in inhibition. Another reason could be the non-trivial, slow tight-
binding mechanism of benzamide HDAC inhibitors which make them highly sensitive 
to the conditions of the assay. These factors can also explain the large differences in 
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reported literature values for some benzamide HDAC inhibitors. For this reason an 
alternative type of in vitro assay was optimised to measure inhibition as a function of 
time, to account for the slow tight-binding nature of the inhibitors, however this assay 
also has its own limitations when attempting to use it to generate IC50 values. Whilst not 
perfect, the combination of these assays is at least able to give a rank order of inhibitor 
potency, determine isoform selectivity for the compounds prepared and demonstrate the 
time dependent nature of inhibition.  
6. Conclusion 
 
Christopher Matthews  109 
6 Conclusion 
In conclusion the project has been partially successful, the aims of the project 
were not fully achieved, but progress was made towards synthesising isoform selective 
HDAC inhibitors. 
The primary focus of the project was to develop inhibitors that are selective for 
inhibiting HDAC11; however this was not possible because of difficulties in setting up 
or outsourcing a reliable and reproducible fluorescent assay against HDAC11. Therefore 
there is some uncertainty about literature values for the inhibition of HDAC11 by 
mocetinostat and other inhibitors. The biological role of HDAC11 and the precise 
potential for HDAC11 selective inhibitors to treat various different diseases remains 
undetermined.  
Assays with other HDAC isoforms were far more consistent and IC50 values 
reported in the literature were largely reproduced. However it is worth noting that 
reproducibility of assay results was sometimes not as high as desired when testing 
compounds with different enzyme batches, or enzymes from different suppliers. It is 
also important to consider the exact set-up and protocol that is followed, especially in 
view of the slow-tight binding nature of certain benzamide HDAC inhibitors. 
It is important to reflect on the current options for in vitro testing of HDAC 
inhibitors, and the relevance of these assays when considering the use of inhibitors in an 
in vivo setting. Since the HDAC enzymes exist and function in multi-protein complexes, 
the inhibition of these complexes is likely to be different from the inhibition of the 
isolated purified recombinant proteins. Small changes to the isoform selectivity profile 
upon moving to an in vivo setting could change greatly the pharmacological result. It 
would be beneficial to the field if more work was done to establish robust ex vivo based 
assay techniques using the enzymes in their native multi-protein complexes, which can 
be used at a moderately high throughput scale and these assays must be well validated 
using a variety of different zinc-binding group inhibitors. Furthermore because of the 
complication of kinetic effects of slow binding inhibitors, an assay that can directly 
measure kinetics of inhibition would also be advantageous. There are some HDAC 
assays using Microfluidic Mobility Shift Assay systems
95
 and if these can incorporate 
HDAC enzymes in their native multi-protein complexes, yet provide information on 
isoform selectivity (perhaps using a proteomics based approach
96
) this would be of great 
benefit.  
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The different approaches to making isoform selective inhibitors had different 
levels of success. Attempts to find a new zinc-binding group with some inherent 
isoform selectivity were unsuccessful; however the potential number of zinc-binding 
fragments that could be prepared and tested is vast. So this is still an area which might 
prove successful in the future; L-cysteine and thiosalicylic acid are two fragments that 
could deserve some further attention based on the screening result of the fragment units; 
they showed some inhibition of HDAC8 but lower levels of inhibition against other 
isoforms. 
Development of a highly convergent synthetic route to make benzamide HDAC 
inhibitors containing a chiral heterocyclic capping group allowed the preparation of a 
large number of HDAC inhibitors to probe the effect of chirality on isoform selectivity. 
This has been shown to be a promising approach, increasing isoform selectivity within 
class I HDAC enzymes.  
The next steps for the chemistry of this work would be to further investigate 
different chiral heterocyclic rings, particularly different sized rings, since the orientation 
of the chiral substituent will have additional options. Likewise a more thorough study is 
needed into the effect that different capping substituents have on inhibition and 
selectivity. This may also allow the pharmacokinetic properties of the compounds to be 
adjusted. 
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7 Experimental 
General Experimental 
All chemicals were used as supplied, except phenylene-1,2-diamine which was 
recrystallized from ethanol prior to use. Column chromatography was carried out using 
(40-60 μm) silica gel and analytical TLC was carried out using Merck Keiselgel 
aluminium-backed plates coated with silica gel. Components were visualised using a 
combination of ultra-violet light and potassium permanganate. Melting points were 
determined using an Electrothermal melting point apparatus. Infrared (IR) spectra were 
recorded on a PerkinElmer spectrum 100 FT-IR spectrometer as neat powders or thin 
films. 
1
H NMR spectra were recorded at 300 MHz on a Bruker AMX300 spectrometer, 
at 400 MHz on a Bruker AMX400, at 500 MHz on a Bruker Avance 500 spectrometer, 
or at 600 MHz on a Bruker Avance 600 spectrometer in the stated solvent using residual 
protic solvent chloroform-d, methanol-d4, or DMSO-d6 as the internal standard. 
Chemical shifts are quoted in ppm. 13C NMR spectra were at 125 MHz on a Bruker 
Avance 500 spectrometer or at 150 MHz on a Bruker Avance 600 spectrometer in the 
stated solvent using the central reference of chloroform-d, methanol-d4, or DMSO-d6 as 
the internal standard. Mass spectra were performed at the Department of Chemistry, 
University College London. Optical rotations were measured using a PerkinElmer 343 
polarimeter.  
 
7.1 Experimental Procedures 
General procedure A (synthesis of thioureas):  
To a solution of the amino alcohol (1 - 1.2 eq) in acetonitrile (4 mL/mmol) was 
added 22 (1 eq) and the resulting suspension was stirred at rt for 16 h, then evaporated. 
 
General procedure B (cyclisation of thioureas into 2-aminothiazolines):  
A solution of the thiourea (1 mmol) in conc. hydrochloric acid (20 mL, 10M) 
was heated at 90 °C under reflux with stirring for the given length of time. Aqueous 
sodium hydroxide (5M) was then added to pH ~ 9; and the mixture was extracted with 
ethyl acetate (3 × 50 mL). The combined organic layers were washed with brine (2 × 
100 mL), dried Na2SO4, and evaporated.  
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N-(2-aminophenyl)-4-({[4-(pyridin-3-yl)pyrimidin-2-yl]amino}methyl)benzamide 
(mocetinostat)
97
 
 
To a solution of 9 (1.46 g, 4.77 mmol, 1.0 eq), BOP (2.43 g, 5.48 mmol, 1.15 eq) 
and phenylene-1,2-diamine (1.03 g, 9.53 mmol, 2.0 eq) in DMF (48 ml) was added 
triethylamine (1.33 ml, 9.53 mmol, 2.0 eq) and then stirred at rt for 24 h. Most of the 
DMF was evaporated. The resulting dark orange oil was purified by column 
chromatography on silica gel (ethyl acetate to 5% methanol:ethyl acetate) to give an 
orange sticky solid which was triturated with dichloromethane and filtered to give 
mocetinostat as a white powder (1.12 g, 2.83 mmol, 59%), mp 168-169 °C;
 1
H NMR 
(500 MHz, DMSO-d6) δ ppm 4.65 (2H, d, J=3.5 Hz, CH2), 4.87 (2H, br s, NH2), 6.58 
(1H, t, J=7.3 Hz, H(5)), 6.76 (1H, d, J=7.6 Hz, H(3)), 6.95 (1H, t, J=7.4 Hz, H(4)), 7.14 
(1H, d, J=7.3 Hz, H(6)), 7.25 (1H, d, J=5.0 Hz, H(20)), 7.41 - 7.58 (3H, m, H(25), H(11 
and 13)), 7.92 (2H, d, J=7.6 Hz, H(10 and 14)), 8.00 (1H, br t, J=5.2 Hz, CH2NH), 8.37 
- 8.43 (2H, m, H(24) and H(21)), 8.67 (1H, br s, H(26)), 9.24 (1H, br s, H(28)), 9.59 
(1H, br s, CONH); 
13
C NMR (125 MHz, DMSO-d6) δ ppm 44.0 (CH2), 106.1 (C(20)), 
116.1 (C(3)), 116.2 (C(5)), 123.4 (C(1)), 123.8 (C(25)), 126.4 (C(6)), 126.6 (C(4)), 
126.9 (C(11 and 13)), 127.8 (C(10 and 14)), 132.4 (C(23)), 133.0 (C(9)), 134.2 (C(24)), 
143.1 (C(2)), 144.1 (C(12)), 148.0 (C(28)), 151.3 (C(26)), 159.6 (C(19) and C(21)), 
162.4 (C(17)), 165.2 (C=O). 
Methyl 4-(guanidinomethyl)benzoate (6)
137
 
 
To a solution of methyl 4-(aminomethyl)benzoate hydrochloride (3.19 g, 15.8 
mmol, 1.0 eq) in abs. ethanol (15 ml) was added 1H-pyrazole-1-carboxamidine 
hydrochloride (2.80 g, 19.1 mmol, 1.2 eq) and N,N-diisopropylethylamine (8.25 ml, 
47.4 mmol, 3.0 eq). The mixture was stirred at reflux for 3 h. The solvent was 
evaporated and to the remaining oil was added 30 ml sat. aq. sodium hydrogen 
carbonate slowly under vigorous stirring followed by 190 ml water to achieve ~pH 9. A 
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white solid was formed and stirring continued for 1 h. The white precipitate was 
collected by filtration and washed with water and diethyl ether then triturated with 
diethyl ether to give 6 as a fine white powder (2.61 g, 12.6 mmol, 80 %), mp 158-159 ˚
C; 
1
H NMR (400 MHz, DMSO-d6) δ ppm 3.85 (3H, s, CO2CH3), 4.38 (2H, s, CH2Ar), 
7.40 (2H, d, J=8.3 Hz, ArH), 7.93 (2H, d, J=8.3 Hz, ArH); 
13
C NMR (125 MHz, 
DMSO-d6) δ ppm 43.4 (CH2), 52.1 (CH3), 127.1 (3, 5-aryl), 128.4 (1-aryl), 129.3 (2, 6-
aryl), 143.8 (4-aryl), 157.5 (C=N), 166.0 (C=O). 
(E)-3-(Dimethylamino)-1-(pyridin-3-yl)prop-2-en-1-one (7)
97
 
 
3-Acetylpyridine (1.96 ml, 17.8 mmol) was added to N,N-dimethylformamide 
dimethyl acetal (4.75 ml, 35.6 mmol) and the solution refluxed for 5 h. The reaction was 
then evaporated and the brown solid triturated with diethyl ether and filtered to give 7 as 
a yellow solid (2.62 g, 14.8 mmol, 83%), mp 84-85 °C (lit. 70-71)
138
; 
1
H NMR (400 
MHz, chloroform-d) δ ppm 2.94 (3H, s, CH3), 3.17 (3H, s, CH3), 5.67 (1H, d, J=12.0 
Hz, COCH), 7.35 (1H, dd, J=7.8, 4.8 Hz, 5-pyridyl), 7.84 (1H, d, J=12.0 Hz, CHNMe2), 
8.18 (1H, dt, J=7.8, 1.9 Hz, 4-pyridyl), 8.66 (1H, dd, J=4.8, 1.8 Hz, 6-pyridyl), 9.08 
(1H, d, J=1.8 Hz, 2-pyridyl); 
13
C NMR (75 MHz, chloroform-d) δ ppm 37.4 (NCH3), 
45.2 (NCH3), 91.8 (COCH), 123.3 (5-pyridyl), 135.1 (4-pyridyl), 135.7 (3-pyridiyl), 
148.9 (CHN), 151.4 (2-pyridyl), 154.7 (6-pyridyl), 186.3 (C=O). 
Methyl 4-((4-(pyridin-3-yl)pyrimidin-2-ylamino)methyl)benzoate (8)
97
 
 
A suspension of (E)-3-(dimethylamino)-1-(pyridin-3-yl)prop-2-en-1-one (7) 
(1.85 g, 10.5 mmol, 1.0 eq) and methyl 4-(guanidinomethyl)benzoate (6) (2.5 g, 12.1 
mmol, 1.15 eq) in propan-2-ol (25 ml) was stirred at reflux for 20 h. The orange 
solution was evaporated to dryness and the yellow residue triturated with cold ethyl 
acetate twice to give 8 as a cream powder (2.25 g, 67%), mp 149-50 ˚C. A portion was 
recrystallized from propan-2-ol to give a white solid, mp 153-154 °C; 
1
H NMR (500 
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MHz, DMSO-d6) δ ppm 3.80 (3H, s, OCH3), 4.64 (2H, d, J=5.7 Hz, H(12)), 7.24 (1H, d, 
J=5.0 Hz, H(7)), 7.43 - 7.55 (3H, m, H(14 and 18) and H(3)), 7.90 (2H, d, J=8.2 Hz, 
H(10 and 14)), 7.98 (1H, t, J=6.1 Hz, H(4)), 8.32 - 8.41 (2H, m, H(8) and H(11)), 8.66 
(1H, br s, H(5)), 9.19 (1H, br s, H(1)); 
13
C NMR (125 MHz, DMSO-d6) δ ppm 44.0 
(C(12)), 52.0 (OCH3), 106.2 (C(7)), 123.8 (C(4)), 127.2 (C(14 and 18), 127.9 (C(16)), 
129.2 (15 and 17), 132.3 (C(2)), 134.2 (C(3)), 146.4 (C(13)), 148.0 (C(1)), 151.3 (C(5)), 
159.3 (C(6) and C(8)), 162.4 (C(10)), 166.1 (C(19)). 
4-((4-(Pyridin-3-yl)pyrimidin-2-ylamino)methyl)benzoic acid (9)
97
 
 
To a solution of methyl 4-((4-(pyridin-3-yl)pyrimidin-2-
ylamino)methyl)benzoate (8) (1.60 g, 5.0 mmol) in THF (30 ml) was added a solution 
of lithium hydroxide monohydrate (0.525 g, 12.5 mmol, 2.5 eq) in water (15 ml) then 
stirred at room temperature for 24 h. THF was evaporated and then the resulting 
suspension was diluted with water (30 ml) and acidified with 1M aq. hydrochloric acid 
until pH 5-6, the precipitate was filtered and rinsed with water and dried to give 9 as a 
cream solid (1.49 g, 4.87 mmol, 97%), mp 210-211 °C; 
1
H NMR (400 MHz, DMSO-d6) 
δ ppm 4.66 (2H, d, J=5.8 Hz, H(12)), 7.26 (1H, d, J=5.0 Hz, H(7)), 7.44 - 7.58 (3H, m, 
H(14 and 18) and H(4)), 7.90 (2H, d, J=8.0 Hz, H(15 and 17)), 7.99 (1H, t, J=6.0 Hz, 
H(11)), 8.41 (2H, d, J=5.0 Hz, H(8) and H(3)), 8.69 (1H, br s, H(5)), 9.24 (1H, br s, 
H(1)), 12.85 (1H, br s, CO2H); 
13
C NMR (125 MHz, DMSO-d6) δ ppm 44.0 (C(12)), 
106.2 (C(7)), 123.9 (C(4)), 127.1 (C(14 and 18)), 129.1 (C(16)), 129.3 (C(15 and 17)), 
132.4 (C(2)), 134.2 (C(3)), 145.8 (C(13)), 147.9 (C(5)), 151.2 (C(1)), 159.3 (C(6) and 
C(8)), 162.4 (C(10)), 167.2 (C(19)). 
N-(3-aminonaphthalen-2-yl)-4-({[4-(pyridin-3-yl)pyrimidin-2-
yl]amino}methyl)benzamide (10) 
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Carboxylic acid 9 (0.238 g, 0.77 mmol) was stirred at reflux in SOCl2 (1 ml) and 
toluene (3 ml) for 3 h. The solution was evaporated and azeotroped with toluene to give 
a white solid which was dissolved in dichloromethane (5 ml) and triethylamine (0.11 
ml, 0.77 mmol). 
Naphthalene-2,3-diamine (0.134 g, 0.847 mmol, 1.1 eq) was dissolved in 
dichloromethane (5 ml) and triethylamine (0.11 ml, 0.77 mmol) and DMF (0.2 ml). The 
solution was cooled to 0 °C and to this stirring cooled solution was added the above 
solution of acid chloride dropwise over 10 min. Stirred at 0 °C for a further 30 min and 
then allowed to warm to rt whilst stirring for 1 h. Then sat. aq. sodium hydrogen 
carbonate (10 ml) was added and diluted with water (10 ml) and dichloromethane (15 
ml), the aqueous layer was extracted with dichloromethane (25 ml). The combined 
organics were washed with brine and dried Na2SO4 and evaporated. Purification by 
column chromatography (hexane to ethyl acetate) gave 10 as a tan solid (0.11 g, 0.246 
mmol, 32%), mp 185-187 °C; νmax (cm
-1
) 3411 (NH), 3332 (NH), 3224 (NH), 1640 
(C=O); 
1
H NMR (500 MHz, DMSO-d6) δ ppm 4.67 (2H, d, J=6.0 Hz, CH2N), 5.23 (2H, 
br s, NH2), 7.08 (1H, s, H(3)), 7.13 (1H, ddd, J=8.2, 6.8, 1.0 Hz, H(31)), 7.25 (1H, d, 
J=5.2 Hz, H(20)), 7.27 (1H, ddd, J=8.4, 6.8, 1.1 Hz, H(30)), 7.46 - 7.57 (4H, m, H(11), 
H(13), H(25) and H(29)), 7.65 (1H, d, J=8.2 Hz, H(32)), 7.85 (1H, s, H(6)), 7.97 (2H, d, 
J=8.4 Hz, H(10) and H(14)), 7.99 (1H, t, J=6.0 Hz, CH2NH), 8.38 - 8.42 (2H, m, H(24) 
and H(21)), 8.68 (1H, d, J=3.8 Hz, H(26)), 9.24 (1H, br s, H(28)), 9.72 (1H, s, CONH); 
13
C NMR (150 MHz, DMSO-d6) δ ppm 44.0 (CH2), 106.1 (C(20)), 108.7 (C(3)), 121.7 
(C(6)), 123.9 (C(25)), 124.1 (C(31)), 124.8 (C(30)), 125.5 (C(29)), 126.4 (C(1)), 126.5 
(C(5)), 127.0 (C(11 and 13)), 127.2 (C(32)), 127.9 (C(10 and 14)), 132.4 (C(23)), 132.8 
(C(4)), 133.0 (C(9)), 134.2 (C(24)), 142.2 (C(2)), 144.4 (C(12)), 148.1 (C(28)), 151.3 
(C(26)), 159.2 (C(21), 159.7 (C(19)), 162.4 (C(17)), 165.8 (C=O); m/z (ES
+
) 469 
([M+Na]
+
, 50%), 307 ([M-(C6H4NH2)+3H]
2+
, 100%); HRMS C27H22N6ONa
+
 requires: 
469.1753, found: 469.1774. 
2-nitro-4-phenylaniline (11)
139
 
 
To a solution of 4-bromo-2-nitroaniline (0.434 g, 2.0 mmol) and phenylboronic 
acid (0.293 g, 2.4 mmol, 1.2 eq) in 1,2-dimethoxyethane (17 ml) was added sodium 
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carbonate (2M aq., 2.1 ml, 4.0 mmol, 2 eq) and Pd(PPh3)4 (0.116 g, 0.1 mmol, 0.05 eq). 
The reaction mixture was stirred at 80 °C for 48 h (reaction may have been complete 
sooner but the product and bromo-aniline starting materials had exactly the same r.f. by 
TLC in a number of different solvent systems). After cooling, diluted with ethyl acetate 
(10 ml) and water (10 ml), aq. layer was extracted with ethyl acetate (20 ml), and the 
combined organics were washed with 10% sodium hydroxide (15 ml) and brine, dried 
Na2SO4 and evaporated to give an orange solid. Purification by column chromatography 
on silica gel (hexane:ethyl acetate, 3:1) gave an orange crystalline solid that was 
recrystallized from ethanol and water to give 11 as an orange crystalline solid (0.239 g, 
1.12 mmol, 56%), mp 169-170 °C (lit.
140
 169-171 °C); νmax (cm
-1
) 3476 (NH), 3344 
(NH), 1639 (NO); 
1
H NMR (400 MHz, chloroform-d) δ ppm 6.15 (2H, br s, NH2), 6.92 
(1H, d, J=8.8 Hz, H(5)), 7.36 (1H, t, J=7.3 Hz, H(10)), 7.46 (2H, t, J=7.5 Hz, H(9) and 
H(11)), 7.58 (2H, d, J=7.3 Hz, H(8) and H(12)), 7.67 (1H, dd, J=8.7, 2.1 Hz, H(6)), 8.40 
(1H, d, J=2.0 Hz, H(2)); 13C NMR (125 MHz, chloroform-d) δ ppm 119.4 (C(5)), 124.0 
(C(2)), 126.4 (C(8 and 12)), 127.4 (C(10)), 129.1 (C(9 and 11)), 130.5 (C(1)), 132.5 
(C(3)), 134.6 (C(6)), 138.9 (C(7)), 143.9 (C(4)). 
benzyl 4-amino-3-nitrobenzoate (12) 
 
To a stirred solution of 4-amino-3-nitrobenzoic acid (0.728 g, 4.0 mmol, 1.0 eq) 
in anhydrous DMF (20 ml) was added potassium carbonate (0.608 g, 4.4 mmol, 1.1 eq) 
followed by dropwise addition of benzyl bromide (0.476 ml, 4.0 mmol, 1.0 eq). The 
mixture was stirred at rt for 18 h then poured onto water (125 ml) and extracted with 
ethyl acetate (3 × 75 ml), the combined organics were washed with brine (4 × 50 ml) 
then dried MgSO4 and concentrated to give 12 as a yellow solid (1.04 g, 3.82 mmol, 
96%), mp 125-127 °C; νmax (cm
-1
) 3472 (NH), 3343 (NH), 1692 (C=O); 
1
H NMR (400 
MHz, chloroform-d) δ ppm 5.37 (2H, s, C(9)H2), 6.48 (2H, br s, NH2), 6.85 (1H, d, 
J=8.8 Hz, H(5)), 7.33 - 7.52 (5H, m, ArH), 8.03 (1H, dd, J=8.8, 2.0 Hz, H(6)), 8.89 (1H, 
d, J=2.0 Hz, H(2)); 
13
C NMR (125 MHz, chloroform-d) δ ppm 66.9 (C(9)), 118.6 
(C(5)), 119.1 (C(1)), 128.4 (C(11 and 15)), 128.5 (C(2)), 128.7 (C(12 and 14)), 129.2 
(C(13)), 131.6 (C(3)), 135.9 (C(10)), 136.0 (C(6)), 147.5 (C(4)), 164.9 (C(7)); m/z (EI
+
) 
272 (M
+
, 100%); HRMS C14H12N2O4
+
 requires: 272.0792, found: 272.0803. 
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methyl 4-amino-3-nitrobenzoate (13)
141
  
 
4-amino-3-nitrobenzoic acid (1.82 g, 10.0 mmol) suspended in methanol (20 ml) 
then cooled to 0 °C and SOCl2 (0.726 ml, 10.0 mmol) was added dropwise. After 
addition was complete stirred at reflux for 16 h, then cooled to 0 °C and filtered washed 
with cold methanol. The solid was dried under vacuum to give 13 as a yellow crystalline 
solid (1.84 g, 9.37 mmol, 94%), mp 199-200 °C (lit.
142
 198 °C); νmax (cm
-1
) 3473 (NH), 
3338 (NH), 1698 (C=O), 1627 (NO); 
1
H NMR (500 MHz, DMSO-d6) δ ppm 3.85 (3H, 
s, CH3), 7.04 - 7.15 (1H, m, H(6)), 7.89 (1H, d, J=6.9 Hz, H(5)), 8.00 (2H, br s, NH2), 
8.58 (1H, s, H(2)); 
13
C NMR (125 MHz, DMSO-d6) δ ppm 52.0 (CH3), 116.2 (C(1)), 
119.4 (C(5)), 128.1 (C(2)), 129.7 (C(3)), 134.9 (C(6)), 148.9 (C(4)), 165.0 (C=O). 
(4-amino-3-nitrophenyl)methanol (14) 
 
Methyl ester 13 (0.20 g, 1.02 mmol) and a stirrer bar were charged to a flask, the 
flask was then flushed with nitrogen, anhydrous THF (7 ml) was added, and the solution 
cooled to 0 °C. To this solution was added DIBAL (1M in dichloromethane, 2.6 ml, 2.6 
mmol, 2.5 eq) dropwise over 10 min keeping temperature below 5 °C. Stirred in ice 
bath for 1 h, then allowed to warm to rt and stirred for a further 3 h. Cooled to 0 °C and 
then methanol (3 ml) was added dropwise, followed by sat. aq. K/Na tartrate (10 ml) 
and ethyl acetate (20 ml). Stirred at rt for 2 h then separated and the aqueous layer 
extracted with ethyl acetate (50 ml and 25 ml). The combined organic layers were 
washed with brine, dried MgSO4 and concentrated to give 13 as a crystalline orange 
solid (0.169 g, 1.0 mmol, 98%) mp 102-104 °C (lit.
143
 100-101 °C). A small amount 
was recrystallized from ethanol and hexane to give a dark orange crystalline solid, mp 
106-107 °C; νmax (cm
-1
) 3437 (NH), 3328 (NH), 1641 (NO); 
1
H NMR (400 MHz, 
methanol-d4) δ ppm 4.50 (2H, s, CH2), 6.96 (1H, d, J=8.8 Hz, H(5)), 7.38 (1H, dd, 
J=8.8, 2.0 Hz, H(6)), 8.04 (1H, d, J=2.0 Hz, H(2)); 
13
C NMR (125 MHz, methanol-d4) δ 
ppm 64.1 (CH2O), 120.3 (C(5)), 124.9 (C(2)), 130.6 (C(1)), 132.0 (C(3)), 136.2 (C(6)), 
146.8 (C(4)). 
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4-{[(tert-butyldimethylsilyl)oxy]methyl}-2-nitroaniline (15) 
 
The alcohol 14 (0.5 g, 3.0 mmol, 1.0 eq), imidazole (0.612 g, 9.0 mmol, 3.0 eq) 
and tert-butyldimethylsilyl chloride (0.678 g, 4.5 mmol, 1.5 eq) were dissolved in 
anhydrous DMF (1.5 ml) and stirred at rt under a nitrogen balloon for 16 h. The solution 
was then diluted with water (40 ml) and extracted with diethyl ether (2 × 30 ml). The 
combined organic layers were washed with 5% aq. lithium chloride (3 × 20 ml) and 
brine (20 ml) then dried Na2SO4 and evaporated. Purification by column 
chromatography on silica gel (dichloromethane) gave 15 as a yellow crystalline solid 
(0.755 g, 2.67 mmol, 89%), mp 69-70 °C; νmax (cm
-1
) 3490 (NH), 3372 (NH), 1638 
(C=O);
 1
H NMR (400 MHz, chloroform-d) δ ppm 0.12 (6H, s, 2 × SiCH3), 0.95 (9H, s, 
C(CH3)3), 4.64 (2H, s, CH2O), 6.07 (2H, br s, NH2), 6.82 (1H, d, J=8.5 Hz, H(6)), 7.37 
(1H, dd, J=8.5, 2.0 Hz, H(5)), 8.07 (1H, d, J=2.0 Hz, H(3)); 
13
C NMR (125 MHz, 
chloroform-d) δ ppm -5.1 (2 × SiCH3), 18.4 (SiC(CH3)3), 26.0 (C(CH3)3), 64.0 (CH2O), 
119.0 (C(6)), 123.5 (C(3)), 130.6 (C(4)), 131.9 (C(2)), 134.4 (C(5)), 143.9 (C(1)); m/z 
(EI
+
) 282 (M
+
, 7%), 225 ([M-C(CH3)3]
+
, 100 %), 207 ([M-C(CH3)3-water]
+
, 67%); 
HRMS C13H22N2O3Si
+
 requires: 282.1394, found: 282.1403. 
N-(4-bromo-2-nitrophenyl)-4-({[4-(pyridin-3-yl)pyrimidin-2-
yl]amino}methyl)benzamide (16a) 
 
To a solution of 4-bromo-2-nitroaniline (0.217 g, 1.00 mmol, 1.0 eq), carboxylic 
acid 9 (0.367 g, 1.20 mmol, 1.2 eq) and BOP (0.522 g, 1.18 mmol, 1.18 eq) in pyridine 
(7 ml) was added sodium hydride (60% in mineral oil, 0.268 g, 6.7 mmol, 6.7 eq) 
portionwise under a stream of nitrogen. Stirred at rt for 2.5 h, then diluted with toluene 
(3 ml) and quenched with acetic acid (1 ml). The solvent was evaporated and then 
azeotroped with toluene. Dissolved in ethyl acetate (150 ml) and washed with sat. aq. 
sodium hydrogen carbonate (200 ml). The aqueous layer was extracted with ethyl 
acetate (100 ml), and the combined organics were washed with water (50 ml) and brine 
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(100 ml), then dried MgSO4 and evaporated to give an orange/yellow solid. Purification 
by column chromatography on silica gel (ethyl acetate) and recrystallization from acetic 
acid and water gave 16a as a yellow solid (0.354 g, 0.700 mmol, 70%), mp 197-198 °C; 
νmax (cm
-1
) 3351 (NH), 3248 (NH), 1689 (C=O);
 1
H NMR (400 MHz, DMSO-d6) δ ppm 
4.67 (2H, d, J=6.3 Hz, H(15)), 7.27 (1H, d, J=5.3 Hz, H(20)), 7.47 - 7.63 (3H, m, H(25) 
and H(11 and 13)), 7.72 (1H, d, J=8.8 Hz, H(6)), 7.90 (2H, d, J=8.3 Hz, H(10 and 14)), 
7.95 (1H, dd, J=8.7, 2.1 Hz, H(5)), 8.04 (1H, t, J=6.3 Hz, H(16)), 8.20 (1H, d, J=2.3 Hz, 
H(3)), 8.34 - 8.48 (2H, m, H(21) and H(24) ), 8.69 (1H, br s, H(26)), 9.24 (1H, br s, 
H(28)), 10.76 (1H, s, H(7)); 
13
C NMR (150 MHz, DMSO-d6) δ ppm 44.0 (CH2), 106.2 
(C(20)), 116.5 (C(4)), 123.9 (C(25)), 127.3 (C(10 and 14)), 127.5 (C(6)), 127.6 (C(3)), 
127.9 (C(11 and 13)), 131.0 (C(9)), 131.5 (C(1)), 132.4 (C(23)), 134.2 (C(24)), 136.7 
(C(5)), 143.3 (C(2)), 145.5 (C(12)), 148.1 (C(26)), 151.3 (C(28)), 159.7 (C(19)), 161.0 
(C(21)), 162.4 (C(17)), 165.2 (C=O); m/z (ES
+
) 505 (M
+
, 98%); HRMS C23H18N6O3Br
+
 
requires: 505.0624, found: 505.0604. 
N-(2-nitro-4-phenylphenyl)-4-({[4-(pyridin-3-yl)pyrimidin-2-
yl]amino}methyl)benzamide (16b) 
 
To a solution of 4-phenyl-2-nitroaniline 11 (0.215 g, 1.00 mmol, 1.0 eq), 
carboxylic acid 9 (0.361 g, 1.18 mmol, 1.18 eq) and BOP (0.522 g, 1.18 mmol, 1.18 eq) 
in pyridine (7 ml) was added sodium hydride (60% in mineral oil, 0.268 g, 6.7 mmol, 
6.7 eq) portionwise under a stream of nitrogen. Stirred at rt for 5 h then BOP (0.050 g, 
0.0113 mmol, 0.113 eq) was added and stirred at rt for 1 h, then sodium hydride (60% in 
mineral oil, 0.026 g, 0.67 mmol, 0.67 eq) added stirred at rt for 1 h. The mixture was 
diluted with toluene (2 ml) and quenched with acetic acid (2 ml). The solvent was 
evaporated and then azeotroped with toluene. Dissolved in ethyl acetate (150 ml) and 
washed with sat. aq. sodium hydrogen carbonate (100 ml). The aqueous layer was 
extracted with ethyl acetate (100 ml), and the combined organics were washed with 
brine (2 × 50 ml), then dried Na2SO4 and evaporated to give an orange/yellow solid. 
Purification by column chromatography on silica gel (hexane:ethyl acetate, 1:1 to 1:3) 
and recrystallization from acetic acid followed by stirring in sat. aq. sodium carbonate 
for 16 h then filtration gave 16b as a yellow solid (0.194 g, 0.387 mmol, 39%), mp 208-
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209 °C; νmax (cm
-1
) 3349 (NH), 3264 (NH), 1693 (C=O), 1675 (NO); 
1
H NMR (500 
MHz, DMSO-d6) δ ppm 4.67 (2H, d, J=5.8 Hz, CH2), 7.26 (1H, d, J=5.0 Hz, H(20)), 
7.42 (1H, t, J=7.3 Hz, 4-phenyl), 7.51 (5H, m, 3,5-phenyl, H(25), H(11) and H(13)), 
7.76 (2H, d, J=7.6 Hz, 2,6-phenyl), 7.87 (1H, d, J=8.2 Hz, H(5)), 7.92 (2H, d, J=7.9 Hz, 
H(10) and H(14)), 8.00 (1H, t, J=5.8 Hz, CH2NH), 8.06 (1H, d, J=8.2 Hz, H(6)), 8.23 
(1H, s, H(3)), 8.35 - 8.46 (2H, H(24) and H(21)), 8.67 (1H, br s, H(26)), 9.23 (1H, br s, 
H(28)), 10.73 (1H, br s, CONH); 
13
C NMR (125 MHz, DMSO-d6) δ ppm 44.0 (CH2), 
106.3 (C(20)), 122.6 (6)), 123.8 (C(25)), 126.2 (C(3)), 126.7 (C(10 and 14)), 127.3 
(C(11 and 13)), 127.8 (2,6-phenyl), 128.3 (C(1)), 129.2 (3,5-phenyl), 130.8 (C(9)), 
131.8 (C(5)), 131.8 (4-phenyl), 132.4 (C(23)), 134.2 (C(24)), 137.1 (C(4)), 137.5 (1-
phenyl), 143.0 (C(2)), 145.3 (C(12)), 148.0 (C(26)), 151.3 (C(28)), 159.5 (C(19) and 
C(21)), 162.4 (C(17)), 165.2 (C=O); m/z (ES
+
) 503 ([M+H]
+
, 100%); HRMS 
C29H23N6O3
+
 requires: 503.1832, found: 503.1818. 
benzyl 3-nitro-4-{[4-({[4-(pyridin-3-yl)pyrimidin-2-
yl]amino}methyl)benzene]amido}benzoate (16c) 
 
A suspension of benzoic acid 9 (0.452 g, 1.48 mmol, 1.2 eq) in SOCl2 (2 ml) and 
toluene (2 ml) was stirred at reflux for 3 h then evaporated to give the acid chloride as a 
cream solid. 
In a 2-neck oven-dried flask 12 (0.335 g, 1.23 mmol, 1.0 eq) was dissolved in 
anhydrous pyridine (5 ml) and the solution cooled to -10 °C (salt-ice bath) under a 
nitrogen balloon. To this solution was added 60% sodium hydride in mineral oil (0.148 
g, 3.69 mmol, 3.0 eq) and then stirred at -10 °C for 5 min (the yellow solution became a 
deep red colour). To this red solution at -10 °C was added the acid chloride prepared 
above portionwise as a cream solid under a nitrogen balloon over 5 min. Stirred at rt for 
2 h then quenched with acetic acid (2 ml), diluted with toluene (5 ml) and evaporated. 
The resulting oil was co-evaporated with toluene and then purified by column 
chromatography on silica gel (ethyl acetate) to give 16c as a pale yellow solid (0.353 g, 
0.629 mmol, 51%), mp 175-176 °C; νmax (cm
-1
) 3343 (NH), 3215 (NH), 1720 (C=O), 
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1683 (C=O); 
1
H NMR (600 MHz, DMSO-d6) δ ppm 4.67 (2H, br s, C(15)H2), 5.39 (2H, 
s, C(31)H2), 7.27 (1H, d, J=4.9 Hz, H(20)), 7.37 (1H, t, J=7.2 Hz, H(35)), 7.42 (2H, t, 
J=7.2 Hz, H(34 and 36)), 7.50 (2H, d, J=7.2 Hz, H(33 and 37)), 7.51 - 7.62 (3H, m, 
H(25) and H(11 and 13)), 7.92 (2H, d, J=8.3 Hz, H(10 and 14)), 8.02 (1H, d, J=8.5 Hz, 
H(6)), 8.04 (1H, t, J=6.2 Hz, H(16)), 8.29 (1H, dd, J=8.5, 1.7 Hz, H(5)), 8.35 - 8.45 
(2H, m, H(21) and H(24)), 8.48 (1H, d, J=1.7 Hz, H(3)), 8.68 (1H, br s, H(26)), 9.23 
(1H, br s, H(28)), 11.02 (1H, s, H(7)); 
13
C NMR (150 MHz, DMSO-d6) δ ppm 44.0 
(C(15)), 66.8 (C(31)), 106.2 (C(20)), 123.9 (C(25)), 125.3 (C(6)), 125.6 (C(4)), 126.1 
(C(3)), 127.3 (C(10 and 14)), 128.0 (C(11 and 13)), 128.2 (C(33 and 37)), 128.3 
(C(35)), 128.6 (C(34 and 36)), 131.4 (C(9)), 132.4 (C(23)), 134.2 (C(24)), 134.4 (C(5)), 
135.8 (C(2)), 136.1 (C(32)), 141.5 (C(1)), 145.8 (C(12)), 148.1 (C(26)), 151.3 (C(28)), 
159.2 (C(19)), 159.6 (C(21)), 162.4 (C(17)), 163.7 (C(29)), 165.3 (C(8)); m/z (ES
+
) 561 
([M+H]
+
, 100%); HRMS C31H25N6O5
+
 requires: 561.1886, found: 561.1877. 
N-(4-{[(tert-butyldimethylsilyl)oxy]methyl}-2-nitrophenyl)-4-({[4-(pyridin-3-
yl)pyrimidin-2-yl]amino}methyl)benzamide (16d) 
 
To a solution of arylamine 15 (0.700 g, 2.48 mmol, 1.2 eq), carboxylic acid 9 
(0.634 g, 2.07 mmol, 1.0 eq) and BOP (0.916 g, 2.07 mmol, 1.0 eq) in pyridine (15 ml) 
was added sodium hydride (60% in mineral oil, 0.580 g, 14.5 mmol, 7.0 eq) portionwise 
under a stream of nitrogen. Stirred at rt for 2.5 h, then the mixture was diluted with 
toluene (7 ml) and quenched with acetic acid (4 ml). The solvent was evaporated and 
then azeotroped with toluene. Dissolved in ethyl acetate (250 ml) and washed with 
water (150 ml), sat. aq. sodium hydrogen carbonate (150 ml) and brine (100 ml), then 
dried Na2SO4 and evaporated to give an orange/yellow solid. Purification by column 
chromatography on silica gel (hexane:ethyl acetate, 1:3) gave 16d as a yellow solid 
(0.490 g, 0.859 mmol, 41%), mp 144-146 °C; νmax (cm
-1
) 3356 (NH), 3228 (NH), 1684 
(C=O); 
1
H NMR (500 MHz, chloroform-d) δ ppm 0.12 (6H, s, 2 × SiCH3), 0.95 (9H, s, 
C(CH3)3), 4.76 (2H, s, CH2O), 4.82 (2H, d, J=6.1 Hz, CH2N), 5.97 (1H, br s, CH2NH), 
7.04 (1H, d, J=5.2 Hz, H(20)), 7.39 (1H, dd, J=7.9, 4.7 Hz, H(25)), 7.55 (2H, d, J=8.4 
Hz, H(11) and H(13)), 7.63 (1H, dd, J=8.8, 2.0 Hz, H(5)), 7.96 (2H, d, J=8.4 Hz, H(10) 
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and H(14)), 8.24 (1H, d, J=2.0 Hz, H(3)), 8.27 (1H, dt, J=7.9, 1.9 Hz, H(24)), 8.38 (1H, 
d, J=5.0 Hz, H(21)), 8.68 (1H, dd, J=4.7, 1.4 Hz, H(26)), 8.94 (1H, d, J=8.8 Hz, H(6)), 
9.19 (1H, d, J=1.6 Hz, H(28)), 11.29 (1H, s, CONH); 
13
C NMR (150 MHz, chloroform-
d) δ ppm -5.2 (2 × SiCH3), 18.5 (SiC(CH3)3), 26.0 (C(CH3)3), 45.2 (CH2N), 63.6 
(CH2O), 107.1 (C(20)), 122.2 (C(6)), 123.1 (C(3)), 123.7 (C(25)), 127.8 (C(10 and 14)), 
127.9 (C(11 and 13)), 132.9 (C(23)), 133.0 (C(9)), 133.9 (C(5)), 134.1 (C(1)), 134.6 
(C(24)), 136.4 (C(2)), 137.4 (C(4)), 144.7 (C(12)), 148.6 (C(28)), 151.4 (C(26)), 159.2 
(C(21)), 162.5 (C(19)), 162.6 (C(17)), 165.6 (C=O); m/z (ES
+
) 571 ([M+H]
+
, 100%); 
HRMS C30H35N6O4Si
+
 requires: 571.2489, found: 571.2483. 
N-(4-cyano-2-nitrophenyl)-4-({[4-(pyridin-3-yl)pyrimidin-2-
yl]amino}methyl)benzamide (16e) 
 
A suspension of benzoic acid 9 (0.225 g, 0.734 mmol, 1.0 eq) in SOCl2 (1 ml) 
and toluene (1 ml) was stirred at reflux for 2 h then evaporated and co-evaporated with 
toluene to give the acid chloride as a cream solid. 
In a 2-neck oven-dried flask 4-amino-3-nitro--benzonitrile (0.120 g, 0.734 
mmol, 1.0 eq) was dissolved in anhydrous pyridine (2 ml) and the solution cooled to -10 
°C (salt-ice bath) under a nitrogen balloon. To this solution was added 60% sodium 
hydride in mineral oil (88 mg, 2.20 mmol, 3.0 eq) and then stirred at -10 °C for 10 min 
(the yellow solution became a deep red colour). To this red solution at -10 °C was added 
the acid chloride prepared above portionwise as a cream solid under an nitrogen balloon 
over 10 min. Stirred at 0°C for 1 h then a further portion of 60% sodium hydride in 
mineral oil (44 mg, 1.10 mmol, 1.5 eq) was added and stirred at 0°C to rt for 4 h. Then 
quenched with acetic acid (1 ml), diluted with toluene (3 ml) and evaporated. The 
resulting oil was co-evaporated with toluene and then purified by column 
chromatography on silica gel (ethyl acetate) to give 16e as a white solid (0.146 g, 0.324 
mmol, 44%), mp 183-184 °C; νmax (cm
-1
) 3349 (NH), 3238 (NH), 1695 (C=O); 
1
H NMR 
(400 MHz, DMSO-d6) δ ppm 4.68 (2H, d, J=6.3 Hz, C(15)H2), 7.28 (1H, d, J=5.0 Hz, 
H(20)), 7.47 - 7.65 (3H, m, (H(11 and 13) and H25), 7.91 (2H, d, J=8.3 Hz, H(10 and 
14)), 7.99 (1H, d, J=8.5 Hz, H(6)), 8.04 (1H, t, J=6.3 Hz, H(16)), 8.19 (1H, dd, J=8.5, 
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2.0 Hz, H(5)), 8.36 - 8.46 (2H, m, H(21) and H(24)), 8.57 (1H, d, J=2.0 Hz, H(3)), 8.69 
(1H, d, J=3.5 Hz, H(26)), 9.24 (1H, br s, H(28)), 11.05 (1H, br s, H(7)); 
13
C NMR (150 
MHz, DMSO-d6) δ ppm 44.0 (C(15)), 106.2 (C(20)), 107.1 (C≡N), 117.2 (C(4)), 123.9 
(C(25)), 125.7 (C(6)), 127.3 (C(10 and 14)), 128.0 (C(11 and 13)), 129.7 (C(3)), 131.2 
(C(9)), 132.4 (C(23)), 134.2 (C(24)), 135.8 (C(2)), 137.3 (C(5)), 141.8 (C(1)), 145.9 
(C(12)), 148.1 (C(26)), 151.3 (C(28)), 159.2 (C(19)), 159.6 (C(21)), 162.4 (C(17)), 
165.4 (C(8)); m/z (ES
+
) 452 ([M+H]
+
, 71%); HRMS C24H18N7O3
+
 requires: 452.1471, 
found: 452.1454. 
N-(2-amino-4-bromophenyl)-4-({[4-(pyridin-3-yl)pyrimidin-2-
yl]amino}methyl)benzamide (17a) 
 
To a solution of FeSO4.7water (1.87 g, 6.74 mmol, 12 eq) in water (4 ml) and 
30% aq. ammonia (4 ml) heated to 60 °C was added a suspension of the nitro compound 
16a (0.28 g, 0.562 mmol, 1 eq) in ethanol (4 ml). Stirred at 60 °C for 4 h then cooled to 
rt and filtered through celite washing with 10% methanol/dichloromethane (100 ml) and 
DM 100 ml). The combined filtrate was washed with water (100 ml) and brine (100 ml), 
then dried MgSO4 and evaporated to give a pale yellow solid (0.24 g). Purified by 
column chromatography on silica gel (5% methanol/chloroform) to give 17a as a white 
solid (0.164 g, 0.345 mmol, 61%), mp 206-208 °C; νmax (cm
-1
) 3247 (NH), 1633 (C=O); 
1
H NMR (500 MHz, DMSO-d6) δ ppm 4.64 (2H, d, J=6.2 Hz, CH2N), 5.19 (2H, s, 
NH2), 6.69 (1H, dd, J=8.4, 2.0 Hz, H(5)), 6.93 (1H, d, J=2.0 Hz, H(3)), 7.09 (1H, d, 
J=8.4 Hz, H(6)), 7.24 (1H, d, J=5.2 Hz, H(20)), 7.44 - 7.55 (3H, m, H(11), H(13) and 
H(25)), 7.90 (2H, d, J=8.2 Hz, H(10) and H(14)), 7.97 (1H, t, J=6.2 Hz, CH2NH), 8.40 
(2H, d, J=5.2 Hz, H(24) and H(21)), 8.67 (1H, d, J=3.6 Hz, H(26)), 9.23 (1H, br s, 
H(28)), 9.53 (1H, s, CONH); 
13
C NMR (150 MHz, DMSO-d6) δ ppm 44.0 (CH2), 106.0 
(C(20)), 117.7 (C(3)), 118.3 (C(5)), 118.8 (C(4)), 122.5 (C(1)), 123.9 (C(25)), 126.9 
(C(11 and 13)), 127.9 (C(10 and 14)), 128.6 (C(6)), 132.4 (C(23)), 132.8 (C(9)), 134.2 
(C(24)), 144.3 (C(12)), 145.1 (C(2)), 148.1 (C(28)), 151.3 (C(26)), 159.1 (C(21)), 159.6 
(C(19)), 162.4 (C(17)), 165.4 (C=O); m/z (ES
+
) 475 ([M+H]
+
, 53%), 307 ([M-
(C6H3BrNH2)+3H]
2+
, 100%); HRMS C23H20N6OBr
+
 requires: 475.0882, found: 
475.0866. 
7. Experimental 
Christopher Matthews  124 
N-(2-amino-4-phenylphenyl)-4-({[4-(pyridin-3-yl)pyrimidin-2-
yl]amino}methyl)benzamide (17b) 
 
To a stirring suspension of 16b (0.557 g, 1.11 mmol) in methanol (10 ml) and 
dichloromethane (10 ml) was added 10% palladium on activated carbon (0.118 g). The 
flask was then evacuated and filled with nitrogen three times to remove oxygen, finally 
the flask was evacuated and then filled with hydrogen gas from a balloon. The mixture 
was stirred vigorously under a hydrogen balloon for 6 h, then filtered through a thin 
layer of celite and washed with methanol (100 ml) and a 1:1 mixture of methanol and 
dichloromethane (100 ml) the combined filtrates were evaporated. Purification by 
column chromatography on silica gel (4% methanol/chloroform) gave 17b as a white 
solid (0.165 g, 0.349 mmol, 31%), mp 207-209 °C; νmax (cm
-1
) 3338 (NH), 3239 (NH), 
1635 (C=O); 
1
H NMR (400 MHz, DMSO-d6) δ ppm 4.67 (2H, d, J=5.3 Hz, CH2), 5.04 
(2H, br s, NH2), 6.90 (1H, dd, J=8.0, 1.8 Hz, H(5)), 7.09 (1H, d, J=1.8 Hz, H(3)), 7.25 - 
7.30 (2H, m, H(20) and H(6)), 7.33 (1H, t, J=7.0 Hz, H(32)), 7.44 (2H, t, J=7.7 Hz, 
H(31 and 33), 7.48 - 7.61 (5H, m, H(11 and 13), H(30 and 34) and H(25)), 7.96 (2H, d, 
J=8.0 Hz, H(10 and 14)), 8.05 (1H, t, J=6.3 Hz, H(16)), 8.43 (2H, d, J=5.3 Hz, H(24) 
and H(21)), 8.69 (1H, d, J=3.8 Hz, H(26)), 9.26 (1H, br s, H(28)), 9.66 (1H, s, H(7)); 
13
C NMR (150 MHz, DMSO-d6) δ ppm 44.0 (C(15)), 106.1 (C(20)), 114.2 (C(3)), 114.8 
(C(5)), 123.0 (C(1)), 123.9 (C(25)), 126.4 (C(30 and 34)), 127.0 (C(11 and 13) and 
C(6)), 127.1 (C(32)), 127.9 (C(10 and 14)), 128.9 (C(31 and 33)), 132.4 (C(23)), 133.0 
(C(9)), 134.2 (C(24)), 138.3 (C(29)), 140.5 (C(4)), 143.3 (C(2)), 144.3 (C(12)), 148.1 
(C(28)), 151.3 (C(26)), 159.2 (C(19)), 159.7 (C(21)), 162.4 (C(17)), 165.3 (C(8)); m/z 
(ES
+
) 473 ([M+H]
+
, 47%), 307 ([M+H-water]
+
, 48%); HRMS C29H25N6O
+
 requires: 
473.2090, found: 473.2092. 
7. Experimental 
Christopher Matthews  125 
benzyl 3-amino-4-[4-({[4-(pyridin-3-yl)pyrimidin-2-
yl]amino}methyl)benzamido]benzoate (17c) 
 
To a suspension of 16c (147 mg, 0.262 mmol, 1.0 eq) in methanol (6 ml) and 
dichloromethane (4 ml) was added 10% palladium on activated carbon (28 mg). The 
flask was then evacuated and filled with nitrogen three times to remove oxygen, finally 
the flask was evacuated and then filled with hydrogen gas from a balloon. The mixture 
was stirred vigorously under a hydrogen balloon for 5.5 h, then filtered through a thin 
layer of celite and washed with methanol (3 × 20 ml) the combined filtrates were 
evaporated. Purification by column chromatography on silica gel (ethyl acetate) gave 
17c as a cream solid (25 mg, 0.0577 mmol, 22%), mp 149-151 °C; νmax (cm
-1
) 3431 
(NH), 3213 (NH), 1712 (C=O), 1631 (C=O); 
1
H NMR (600 MHz, DMSO-d6) δ ppm 
3.59 (2H, br s, NH2 (and H2O), 4.66 (2H, br s, C(16)H2), 5.32 (2H, s, C(31)H2), 7.22 - 
7.32 (2H, m, H(20) and H(5)), 7.36 (1H, t, J=7.2 Hz, H(35)), 7.39 - 7.56 (8H, m, H(3), 
H(6), H(11 and 13), H(33 and 37), H(34 and 36)), 7.62 (1H, br s, H(25)), 7.93 (2H, d, 
J=8.3 Hz, H(10 and 14)), 8.08 (1H, br s, H(16)), 8.43 (1H, br s, H(21)), 8.51 (1H, d, 
J=7.2 Hz, H(24)), 8.73 (1H, br s, H(26)), 9.27 (1H, br s, H(28)), 9.76 (1H, br s, H(7)); 
13
C NMR (150 MHz, DMSO-d6) δ ppm 44.0 (C(15)), 66.0 (C(31)), 106.2 (C(20)), 117.2 
(C(3)), 118.0 (C(5)), 124.3 (C(25)), 125.9 (C(6)), 127.0 (C(11 and 13)), 128.0 (C(10 
and 14)), 128.0 (C(33 and 37)), 128.1 (C(4) and C(35)), 128.5 (C(1)), 128.6 (C(34 and 
36)), 132.7 (C(23)), 132.8 (C(9)), 135.4 (C(24)), 136.3 (C(32)), 141.6 (C(2)), 144.5 
(C(12)), 147.1 (C(28)), 150.3 (C(26)), 159.3 (C(21)), 159.5 (C(19)), 162.2 (C(17)), 
165.4 (C(8)), 165.7 (C(29)); m/z (ES
+
) 531 ([M+H]
+
, 63%), 513 ([M+H-water]
+
, 45%); 
HRMS C31H27N6O3
+
 requires: 531.2145, found: 531.2123. 
7. Experimental 
Christopher Matthews  126 
N-(2-amino-4-{[(tert-butyldimethylsilyl)oxy]methyl}phenyl)-4-({[4-(pyridin-3-
yl)pyrimidin-2-yl]amino}methyl)benzamide (17d) 
 
To a stirring suspension of 16d (190 mg, 0.33 mmol) in methanol (8 ml) and 
chloroform (2 ml) was added 10% palladium on activated carbon (50 mg). The flask 
was then evacuated and filled with nitrogen three times to remove oxygen, finally the 
flask was evacuated and then filled with hydrogen gas from a balloon. The mixture was 
stirred vigorously under a hydrogen balloon for 7 h, then filtered through a thin layer of 
celite and washed with methanol (3 × 20 ml) the combined filtrates were evaporated. 
Purification by column chromatography on silica gel (ethyl acetate) gave 17d as a tan 
solid (0.064 g, 0.118 mmol, 36%), mp 89-90 °C; νmax (cm
-1
) 3300 (NH), 1641 (C=O); 
1
H NMR (400 MHz, methanol-d4) δ ppm 0.12 (6H, s, 2 × SiCH3), 0.96 (9H, s, 
C(CH3)3), 4.68 (2H, s, OCH2), 4.77 (2H, s, NCH2), 6.75 (1H, dd, J=8.0, 1.3 Hz, H(5)), 
6.90 (1H, d, J=1.3 Hz, H(3)), 7.16 (1H, d, J=8.0 Hz, H(6)), 7.20 (1H, d, J=5.3 Hz, 
H(20)), 7.54 - 7.58 (3H, m, H(25), H(11) and H(13)), 7.96 (2H, d, J=8.3 Hz, H(10) and 
H(14)), 8.39 (1H, d, J=5.3 Hz, H(21)), 8.46 (1H, d, J=7.3 Hz, H(24)), 8.64 (1H, dd, 
J=4.8, 1.5 Hz, H(26)), 9.19 (1H, br s, H(28)); 
13
C NMR (125 MHz, methanol-d4) δ ppm 
-4.7 (SiCH3), 19.4 (SiC(CH3)3), 26.7 (C(CH3)3), 45.9 (CH2N), 66.1 (CH2O), 107.6 
(C(20)), 116.8 (C(5)), 118.1 (C(3)), 124.4 (C(1)), 125.4 (C(6)), 127.5 (C(25)), 128.5 
(C(10 and 14)), 129.1 (C(11 and 13)), 134.1 (C(9)), 134.8 (C(23)), 136.6 (C(24)), 142.0 
(C(4)), 143.0 (C(2)), 145.7 (C(12)), 149.0 (C(26)), 151.7 (C(28)), 160.2 (C(21)), 163.5 
(C(19)), 163.8 (C(17)), 168.8 (C=O); m/z (ES
+
) 541 ([M+H]
+
, 100%), 523 ([M+H-
water]
+
, 38%); HRMS C30H37N6O2Si
+
 requires: 541.2747, found: 541.2756. 
3-amino-4-[4-({[4-(pyridin-3-yl)pyrimidin-2-yl]amino}methyl)benzamido]benzoic 
acid (17f) 
 
7. Experimental 
Christopher Matthews  127 
To a suspension of 16c (320 mg, 0.571 mmol, 1.0 eq) in methanol (6 ml) was 
added 10% palladium on activated carbon (120 mg). The flask was then evacuated and 
filled with nitrogen three times to remove oxygen, finally the flask was evacuated and 
then filled with hydrogen gas from a balloon. The mixture was stirred vigorously under 
a hydrogen balloon for 4 h. The methanol had evaporated so the residue was 
dissolved/suspended in methanol (10 ml) and dichloromethane (10 ml) and the flask 
was then evacuated and filled with nitrogen three times to remove oxygen, finally the 
flask was evacuated and then filled with hydrogen gas from a balloon, then stirred at rt 
for 16 h. A further portion of 10% palladium on activated carbon (60 mg) was added 
and the flask was then evacuated and filled with nitrogen three times to remove oxygen, 
finally the flask was evacuated and then filled with hydrogen gas from a balloon, then 
stirred at rt for 25 h then diluted with methanol (50 ml) filtered through a thin layer of 
celite and washed with warm methanol:chloroform (1:1, 50 ml) the combined filtrates 
were evaporated. The residue was partitioned between sodium hydrogen carbonate (sat. 
aq. 150 ml) and ethyl acetate (150 ml) an insoluble yellow solid was filtered, then the 
layers separated. The aq layer was acidified by dropwise addition of hydrochloric acid 
(5M aq.) until a brown precipitate appeared (pH~5) which was filtered and dried in a 
vacuum oven. Purification by column chromatography on silica gel (20% 
methanol/chloroform) gave 17f as a cream solid (60 mg, 0.136 mmol, 24%), mp 190-
193 °C; νmax (cm
-1
) 3230 (NH), 3051 (NH), 1712 (C=O), 1629 (C=O); 
1
H NMR (600 
MHz, DMSO-d6) δ ppm 4.64 (2H, br s, C(15)H2), 5.10 (2H, br s, NH2), 7.17 (1H, d, 
J=7.9 Hz, H(6)), 7.21 - 7.32 (2H, m, H(20) and H(5)), 7.40 (1H, s, H(3)), 7.43 - 7.58 
(3H, m, H(12 and 13) and H(25)), 7.95 (2H, d, J=7.9 Hz, H(10 and 14)), 8.05 (1H, t, 
J=5.3 Hz, N(16)H), 8.37 - 8.47 (2H, m, H(24) and H(21)), 8.68 (1H, br s, H(26)), 9.24 
(1H, br s, H(28)), 9.76 (1H, br s, N(7)H); 
13
C NMR (150 MHz, DMSO-d6) δ ppm 44.0 
(C(15)), 106.0 (C(20)), 117.1 (C(3)), 117.5 (C(5)), 123.9 (C(25)), 125.7 (C(6)), 126.9 
(C(11 and 13)), 127.2 (C(1)), 127.9 (C(10 and 14)), 129.1 (C(4)), 132.4 (C(23)), 132.8 
(C(9)), 134.2 (C(24)), 142.3 (C(2)), 144.4 (C(12)), 148.1 (C(28)), 151.3 (C(26)), 159.4 
(C(19)), 159.7 (C(21)), 162.4 (C(17)), 165.4 (C(8)), 168.0 (CO2H); m/z (ES
-
) 439 ([M-
H]
-
, 100%); HRMS C24H19N6O3
-
 requires: 439.1519, found: 439.1531. 
7. Experimental 
Christopher Matthews  128 
N-[2-amino-4-(hydroxymethyl)phenyl]-4-({[4-(pyridin-3-yl)pyrimidin-2-
yl]amino}methyl)benzamide (17g) 
 
To a suspension of the silyl protected nitro compound 16d (0.480 g, 0.841 mmol, 
1 eq) in THF, methanol and water (10 ml of each) was added ammonium acetate (0.648 
g, 8.41 mmol, 10 eq) and SnCl2.water (1.138 g, 5.05 mmol, 6 eq). Then stirred at rt for 
21 h, but TLC showed starting materials remained so the mixture was heated to 50 °C 
for 1 h. Tin salts were filtered and washed with ethyl acetate, and 10% methanol in 
dichloromethane. Then the filtrate was evaporated. Residue dissolved in ethyl acetate 
(200 ml) and washed with sat. aq. sodium hydrogen carbonate (100 ml) and brine (100 
ml), dried MgSO4 and evaporated to give a tan foamy solid which was purified by 
column chromatography on silica gel (10% to 20% methanol/dichloromethane) to give 
17g as a cream solid (0.165 g, 0.387 mmol, 46%), mp 127-129 °C; νmax (cm
-1
) 3265 
(NH), 1647 (C=O); 
1
H NMR (500 MHz, DMSO-d6) δ ppm 4.36 (2H, d, J=5.5 Hz, 
CH2O), 4.64 (2H, d, J=5.9 Hz, CH2N), 4.82 (2H, br s, NH2), 5.02 (1H, t, J=5.5 Hz, 
OH), 6.52 (1H, d, J=7.8 Hz, H(5)), 6.73 (1H, s, H(3)), 7.07 (1H, d, J=7.8 Hz, H(6)), 
7.25 (1H, d, J=4.9 Hz, H(20)), 7.42 - 7.56 (3H, m, H(11), H(13) and H(25)), 7.91 (2H, 
d, J=7.7 Hz, H(10) and H(14)), 7.98 (1H, t, J=5.9 Hz, CH2NH), 8.40 (2H, d, J=4.9 Hz, 
H(24) and H(21)), 8.67 (1H, br s, H(26)), 9.23 (1H, br s, H(28)), 9.54 (1H, br s, 
CONH); 
13
C NMR (150 MHz, DMSO-d6) δ ppm 44.0 (CH2N), 62.9 (CH2O), 106.1 
(C(20)), 114.2 (C(5)), 114.5 (C(3)), 121.9 (C(1)), 123.9 (C(25)), 126.4 (C(6)), 126.9 
(C(11 and 13)), 127.8 (C(10 and 14)), 132.4 (C(23)), 133.0 (C(9)), 134.2 (C(24)), 140.8 
(C(4)), 142.9 (C(2)), 144.1 (C(12)), 148.1 (C(28)), 151.3 (C(26)), 159.6 (C(21)), 161.0 
(C(19)), 162.4 (C(17)), 165.2 (C=O); m/z (ES
+
) 427 ([M+H]
+
, 70%), 409 ([M+H-
water]
+
, 100%); HRMS C24H23N6O2
+
 requires: 427.1882, found: 427.1872. 
7. Experimental 
Christopher Matthews  129 
N-(2-amino-4-methoxyphenyl)-4-({[4-(pyridin-3-yl)pyrimidin-2-
yl]amino}methyl)benzamide (18) 
 
To a solution of benzoic acid 9 (0.306 g, 1.0 mmol, 1.0 eq), 4-methoxy-1,2-
phenylene diamine (0.531 g, 1.1 mmol, 1.1 eq) and BOP (0.531 g, 1.2 mmol, 1.2 eq) in 
DMF (10 ml) was added triethylamine (0.28 ml,  2.0 mmol, 2.0 eq). The resulting 
solution was stirred at rt for 27 h under an nitrogen balloon, then diluted with ethyl 
acetate (50 ml), washed with brine (3 × 50 ml) and sodium hydrogen carbonate (sat. aq. 
2 × 25 ml). The combined aq layers were extracted with ethyl acetate (25 ml) and the 
combined organic layers were washed with brine (2 × 25 ml), dried Na2SO4 and 
concentrated. Purification by column chromatography on silica gel (ethyl acetate) gave 
18 as a cream solid (0.3 g, 0.70 mmol, 70%), mp 176-178 °C; νmax (cm
-1
) 3435 (NH), 
3249 (NH), 1628 (C=O); 
1
H NMR (400 MHz, DMSO-d6) δ ppm 3.67 (3H, s, OCH3), 
4.65 (2H, d, J=5.9 Hz, C(15)H2), 4.91 (2H, br s, NH2), 6.18 (1H, dd, J=8.5, 2.5 Hz, 
H(5)), 6.35 (1H, d, J=2.5 Hz, H(3)), 6.99 (1H, d, J=8.5 Hz, H(6)), 7.27 (1H, d, J=5.0 
Hz, H(20)), 7.41 - 7.60 (3H, m, H(11 and 13) and H(25)), 7.92 (2H, d, J=8.0 Hz, H(10 
and 14), 8.02 (1H, t, J=5.9 Hz, N(16)H), 8.42 (2H, d, J=5.3 Hz, H(24) and H(21)), 8.69 
(1H, d, J=3.3 Hz, H(26)), 9.25 (1H, br s, H(28)), 9.49 (1H, br s, N(7)H); 
13
C NMR (150 
MHz, DMSO-d6) δ ppm 44.0 (C(15)), 54.9 (OCH3), 100.7 (C(3)), 101.9 (C(5)), 106.1 
(C(20)), 116.6 (C(1)), 123.9 (C(25)), 126.9 (C(11 and 13)), 127.7 (C(10 and 14)), 127.9 
(C(6)), 132.4 (C(23)), 133.0 (C(9)), 134.2 (C(24)), 144.1 (C(12)), 144.6 (C(2)), 148.1 
(C(28)), 151.3 (C(26)), 158.2 (C(4)), 159.2 (C(21)), 159.6 (C(19)), 162.4 (C(17)), 165.3 
(C(8)); m/z (ES
-
) 425 ([M-H]
-
, 100%); HRMS C24H21N6O2
-
 requires: 425.1726, found: 
425.1732. 
7. Experimental 
Christopher Matthews  130 
N-(2-amino-4-hydroxyphenyl)-4-({[4-(pyridin-3-yl)pyrimidin-2-
yl]amino}methyl)benzamide (19) 
 
To a suspension of 18 (80 mg, 0.188 mmol, 1.0 eq) in dichloromethane (5 ml) at 
0 °C was added boron tribromide (1M in dichloromethane, 0.56 ml, 0.56 mmol, 3.0 eq) 
dropwise over 5 min. The resulting mixture was stirred for 1 h at 0 °C then boron 
tribromide (1M in dichloromethane, 0.56 ml, 3.0 eq) was added and the reaction stirred 
at rt for 16 h. Another portion of boron tribromide (1M in dichloromethane, 0.56 ml, 3.0 
eq) was added and the mixture stirred at rt for 7 h, then cooled to 0 °C and quenched 
with sodium hydrogen carbonate (sat. aq., 10 ml). A brown solid was filtered and 
washed with water (10 ml) and dichloromethane (10 ml) then dried. Purification by 
column chromatography on silica gel (7 to 10% methanol/dichloromethane) gave 19 as 
a beige solid (39 mg, 0.095 mmol, 50%), mp 223-225 °C; νmax (cm
-1
) 3325 (NH), 1640 
(C=O); 
1
H NMR (500 MHz, DMSO-d6) δ ppm 4.63 (2H, d, J=5.2 Hz, C(15)H2), 4.74 
(2H, br s, NH2), 6.00 (4H, dd, J=8.4, 2.5 Hz, H(5)), 6.19 (1H, d, J=2.5 Hz, H(3)), 6.84 
(1H, d, J=8.4 Hz, H(6)), 7.24 (1H, d, J=5.2 Hz, H(20)), 7.40 - 7.57 (3H, m, H(25) and 
H(11 and 13)), 7.89 (2H, d, J=8.2 Hz, H(10 and14)), 7.98 (1H, t, J=6.2 Hz, N(16)H), 
8.40 (2H, br. d, J=5.2 Hz, H(21) and H(24)), 8.67 (1H, br. d, J=3.5 Hz, H(26)), 8.95 
(1H, br s, OH), 9.23 (1H, br s, H(28)), 9.38 (1H, s, N(7)H); 
13
C NMR (150 MHz, 
DMSO-d6) δ ppm 44.0 (C(15)), 102.2 (C(3)), 103.7 (C(5)), 106.1 (C(20)), 115.2 (C(1)), 
123.9 (C(25)), 126.8 (C(11 and 13)), 127.7 (C(10 and 14)), 127.9 (C(6)), 132.4 (C(23)), 
133.1 (C(9)), 134.2 (C(24)), 144.0 (C(12)), 144.6 (C(2)), 148.1 (C(28)), 151.3 (C(26)), 
156.2 (C(4)), 159.2 (C(21)), 159.6 (C(19)), 162.4 (C(17)), 165.3 (C(8)); m/z (ES
-
) 411 
([M-H]
-
, 100%); HRMS C23H19N6O2
-
 requires: 411.1569, found: 411.1569.  
N-hydroxy-4-({[4-(pyridin-3-yl)pyrimidin-2-yl]amino}methyl)benzamide (20) 
 
7. Experimental 
Christopher Matthews  131 
To a stirring solution of sodium hydroxide (0.25 g, 6.24 mmol, 8 eq) in 50% 
aqueous hydroxylamine (2.4 ml, 39.2 mmol, 50 eq) at 0 °C was added a solution of 
methyl ester 8 (0.25 g, 0.781 mmol, 1 eq) in THF (10 ml) dropwise over 10 min. Then 
solution was warmed to rt and stirred for a further 5 min then evaporated. Diluted with 
water (10 ml), cooled to 0 °C and slowly neutralised to pH 8 by dropwise addition of 
2M hydrochloric acid. The precipitate was filtered, washed with water and dried. The 
resulting solid was purified by column chromatography on silica gel (8 to 20% 
methanol/dichloromethane) to give hydroxamic acid 20 as a cream solid (0.10 g, 0.332 
mmol, 42%), mp 186-187 °C; νmax (cm
-1
) 3248 (NH), 1628 (C=O); 
1
H NMR (400 MHz, 
DMSO-d6) δ ppm 4.62 (2H, d, J=6.0 Hz, H(12)), 7.26 (1H, d, J=5.0 Hz, H(7)), 7.43 
(2H, d, J=7.3 Hz, H(14 and 18)), 7.53 (1H, dd, J=7.0, 5.0 Hz, H(4)), 7.70 (2H, d, J=8.3 
Hz, H(15 and 17)), 7.96 (1H, t, J=6.0 Hz, H(11)), 8.41 (2H, m, H(3) and H(8)), 8.68 
(1H, d, J=3.8 Hz, H(5)), 8.97 (1H, br s, ONH), 9.23 (1H, br s, H(1)), 11.13 (1H, br s, 
OH); 
13
C NMR (125 MHz, DMSO-d6) δ ppm 43.9 (C(12)), 106.1 (C(7)), 123.8 (C(4)), 
126.9 (C(14 and 18)), 127.0 (C(15 and 17)), 131.1 (C(2)), 132.4 (C(16)), 134.2 (C(3)), 
143.8 (C(13)), 148.0 (C(1)), 151.3 (C(5)), 159.5 (C(6) and C(8)), 162.4 (C(10)), 164.2 
(C(19)); m/z (ES
+
) 322 ([M+H]
+
, 25%); HRMS C24H24N3OS2
+
 requires: 322.1304, 
found: 322.1306. 
 (5S)-1-acetyl-5-benzyl-2-thiohydantoin ((S)-21a)
99
 
 
L-phenylalanine (1.65 g, 10 mmol) and ammonium thiocyanate (0.761 g, 10 
mmol) were ground together with a mortar and pestle then transferred to a round 
bottomed flask and suspended in acetic anhydride (7.5 ml, 79.5 mmol). The mixture 
was stirred at 100 °C for 1 h then poured onto ice water (20 ml) and stored in a freezer 
overnight. The mixture was filtered and washed with cold water (30 ml) and the solid 
dried in a desiccator with phosphorus pentoxide as a drying agent to yield a cream solid. 
Recrystallization from ethanol and water gave (S)-21a as a white crystalline solid (1.17 
g, 4.7 mmol, 47%), mp 167-169 °C (lit.
99
 170 °C); νmax (cm
-1
) 3083 (NH), 1732 (C=O), 
1701 (C=O); 
1
H NMR (300 MHz, DMSO-d6) δ ppm 2.68 (3H, s, NCOCH3), 3.10 (1H, 
dd, J=13.9, 2.7 Hz, C(6)H), 3.37 - 3.42 (1H, m, C(6)H`), 4.98 (1H, dd, J=5.6, 2.7 Hz, 
C(5)H), 6.85 - 7.08 (2H, m, ArH), 7.2 – 7.3 (3H, m, ArH), 12.42 (1H, br s, NH). 
7. Experimental 
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(5R)-1-acetyl-5-benzyl-2-thiohydantoin ((R)-21a) 
 
D-phenylalanine (1.65 g, 10 mmol) was reacted according to the above 
procedure for (S)-21a after recrystallization from ethanol and water gave (R)-21a as a 
white crystalline solid (0.777 g, 3.13 mmol, 31%), mp 163-165 °C; νmax (cm
-1
) 3083 
(NH), 1744 (C=O), 1701 (C=O); 
1
H NMR (300 MHz, DMSO-d6) δ ppm 2.68 (3H, s, 
NCOCH3), 3.10 (1H, dd, J=13.9, 2.7 Hz, C(6)H), 3.35 - 3.41 (1H, m, C(6)H`), 4.98 
(1H, dd, J=5.8, 2.5 Hz, C(5)H), 6.89 - 7.05 (2H, m, ArH), 7.13 - 7.39 (3H, m, ArH), 
12.42 (1H, br s, NH); 
13
C NMR (125 MHz, DMSO-d6) δ ppm 27.3 (NCOCH3), 34.4 
(C(6)), 63.5 (C(5), 127.3 (1-aryl), 128.4 (2,6-aryl), 129.2 (3,5-aryl), 134.2 (4-aryl), 
170.0, 172.6, 182.3 (2 C=O and C=S); m/z (EI
+
) 248 (M
+
, 69%); HRMS C12H12N2O2S 
requires 248.0614, found 248.0607. 
(5R)-1-acetyl-5-(1H-indol-3-ylmethyl)-2-thiohydantoin ((R)-21b) 
 
D-tryptophan (1.02 g, 4.97 mmol) and ammonium thiocyanate (0.378 g, 4.97 
mmol) were ground together with a mortar and pestle then transferred to a round 
bottomed flask and suspended in acetic anhydride (3.3 ml, 35 mmol). The mixture was 
stirred at 100 °C for 10 min then poured onto ice water (20 ml) and stored in a freezer 
overnight. The mixture was triturated then filtered and washed with cold water (20 ml) 
and the solid dried in a desiccator with phosphorus pentoxide as a drying agent to yield 
an orange solid. Recrystallization from ethanol and water gave (R)-21b as a yellow 
solid (1.00 g, 3.51 mmol, 70%), mp 156-159 °C; νmax (cm
-1
) 3394 (NH), 1755 (C=O), 
1675 (C=O); 
1
H NMR (400 MHz, DMSO-d6) δ ppm 2.68 (3H, s, NCOCH3), 3.31 (1H, 
dd, J=14.8, 2.3 Hz, C(6)H), 3.55 (1H, dd, J=14.8, 5.5 Hz, C(6)H`), 4.99 (1H, dd, J=5.5, 
2.3 Hz, C(5)H), 6.93 - 7.01 (2H, m, ArH), 7.06 (1H, t, J=7.4 Hz, ArH), 7.32 (1H, d, 
J=8.0 Hz, ArH), 7.36 (1H, d, J=8.0 Hz, ArH), 10.96 (1H, br s, indole NH), 12.30 (1H, s, 
N(3)H); 
13
C NMR (125 MHz, DMSO-d6) δ ppm 24.7 (NCOCH3), 27.5 (C(6)), 63.7 
(C(5), 106.3, 111.4, 118.0, 118.6, 121.0, 124.1, 127.3, 135.8 (8 ArC), 170.1, 173.2, 
182.5 (2 C=O and C=S); m/z (EI
+
) 287 (M
+
, 5%), 130 ([indole-CH2]
+
, 100%); HRMS 
C14H13O2N3S requires: 287.0723, found: 287.0725. 
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 (5S)-1-acetyl-5-(1H-indol-3-ylmethyl)-2-thiohydantoin ((S)-21b)
99
 
 
L-tryptophan (1.02 g, 4.97 mmol) and ammonium thiocyanate (0.378 g, 4.97 
mmol) were ground together with a mortar and pestle then transferred to a round 
bottomed flask and suspended in acetic anhydride (3.3 ml, 35 mmol). The mixture was 
stirred at 100 °C for 25 min then poured onto ice water (20 ml) and stored in a freezer 
overnight. The mixture was filtered and washed with cold water (20 ml) and the solid 
dried in a desiccator with phosphorus pentoxide as a drying agent to yield an orange 
solid. Recrystallization from ethanol and water gave (S)-21b as a yellow solid (1.12 g, 
3.91 mmol, 79%), mp 157-160 °C (lit.
99
 183-185 °C); νmax (cm
-1
) 3392 (NH), 1754 
(C=O), 1673 (C=O); 
1
H NMR (500 MHz, DMSO-d6) δ ppm 2.66 (3H, s, NCOCH3), 
3.29 (1H, dd, J=15.1, 2.2 Hz, C(6)H), 3.52 (1H, dd, J=14.8, 5.4 Hz, C(6)H`), 4.96 (1H, 
dd, J=5.7, 2.5 Hz, C(5)H), 6.91 - 6.97 (2H, m, ArH), 7.03 (1H, t, J=7.3 Hz, ArH), 7.30 
(2H, d, J=7.9 Hz, ArH), 7.34 (1H, d, J=7.9 Hz, ArH), 10.94 (1H, br s, indole NH), 
12.28 (1H, br s, N(3)H). 
1-Acetyl-5-benzyl-2-(methylsulfanyl)-4,5-dihydro-1H-imidazol-4-one (22a) 
 
To a stirring mixture of thiohydantoin (R)-21a (0.70 g, 2.82 mmol) and 
anhydrous potassium carbonate (0.468 g, 3.38 mmol) in acetonitrile (35 ml) at rt was 
added iodomethane (0.263 ml, 4.23 mmol) dropwise. The resulting mixture was stirred 
at rt for 3.5 h under nitrogen, then filtered and then filtrate evaporated. The resulting 
cream solid was purified by column chromatography (ethyl acetate:hexane, 1:9 to 2:1) 
to give 22a as a white solid (0.203 g, 0.774 mmol, 27%), mp 142-143 °C; νmax (cm
-1
) 
1725 (C=O), 1698 (C=O); 
1
H NMR (500 MHz, DMSO-d6) δ ppm 2.24 (3H, s, SCH3), 
2.39 (3H, s, NCOCH3), 3.17 (1H, dd, J=14.3, 2.7 Hz, C(6)H), 3.35 (1H, dd, J=14.3, 6.0 
Hz, C(6)H`), 4.96 (1H, dd, J=6.0, 2.8 Hz, C(5)H), 6.97 - 7.06 (2H, m, ArH), 7.22 (3H, 
s, ArH); 
13
C NMR (125 MHz, DMSO-d6) δ ppm 15.7 (SCH3), 23.6 (NCOCH3), 36.1 
(C(6)), 64.1 (C(5), 127.1 (1-aryl), 128.2 (2,6-aryl), 129.4 (3,5-aryl), 134.0 (4-aryl), 
168.5, 184.5, 185.4 (2 C=O and C=N); m/z (EI
+
) 262 (M
+
, 12%); HRMS C13H14O2N2S 
requires: 262.0771, found: 262.0765. 
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1-Acetyl-5-(1H-indol-3-ylmethyl)-2-(methylsulfanyl)-4,5-dihydro-1H-imidazol-4-
one (22b) 
 
Thiohydantoin (R)-21b (0.907 g, 3.38 mmol) was reacted according to the above 
procedure for 22a, purification by column chromatography (ethyl acetate:hexane, 1:1 to 
2:1) gave 22b as a cream solid (0.610 g, 2.03 mmol, 60%), mp 187-190 °C; νmax (cm
-1
) 
3234 (NH), 1725 (C=O), 1698 (C=O); 
1
H NMR (500 MHz, DMSO-d6) δ ppm 2.22 (3H, 
s, SCH3), 2.39 (3H, s, NCOCH3), 3.35 (1H, dd, J=15.4, 2.9 Hz, C(6)H), 3.47 (1H, dd, 
J=15.4, 5.8 Hz, C(6)H`), 4.94 (1H, dd, J=5.8, 3.0 Hz, C(5)H), 6.93 (1H, t, J=7.5 Hz, 
ArH), 6.96 (1H, d, J=2.4 Hz, ArH), 7.03 (1H, t, J=7.5 Hz, ArH), 7.29 (1H, d, J=8.0 Hz, 
ArH), 7.40 (1H, d, J=8.0 Hz, ArH), 10.90 (1H, br s, NH); 
13
C NMR (125 MHz, DMSO-
d6) δ ppm 15.6 (SCH3), 23.6 (NCOCH3), 26.4 (C(6)), 64.1 (C(5), 106.4, 111.3, 118.3, 
118.5, 121.0, 124.1, 127.2, 135.7 (8 ArC), 168.5, 185.1, 185.3 (2 C=O and C=N); m/z 
(EI
+
) 301 (M
+
, 10%), 130 ([indole-CH2]
+
, 100%); HRMS C15H15N3O2S requires: 
301.0880, found: 301.0878. 
4-({[1-acetyl-5-benzyl-4-oxo-4,5-dihydro-1H-imidazol-2-yl]amino}methyl)benzoic 
acid (23a) 
 
To a solution of 22a (179 mg, 0.682 mmol) in ethanol (8 ml) was added 4-
(methylamino)benzoic acid (103 mg, 0.682 mmol). The resulting mixture was stirred at 
reflux under nitrogen for 18 h. The solution was cooled to rt, then cooled in a 
refrigerator before being filtered and the solid dried under vacuum to give 23a as a 
cream solid (122 mg, 0.335 mmol, 49%), mp 232-234 °C; νmax (cm
-1
) 3263 (NH/CO2H), 
1688 (C=O); 
1
H NMR (500 MHz, DMSO-d6) δ ppm 2.42 (9H, s, NCOCH3), 3.14 (1H, 
dd, J=14.2, 1.9 Hz, C(6)H), 3.30 (1H, dd, J=14.2, 5.7 Hz, C(6)H`), 4.37 (1H, dd, 
J=15.8, 6.0 Hz, C(8)H), 4.52 (1H, dd, J=15.8, 6.6 Hz, C(8)H`), 4.77 (1H, dd, J=5.7, 1.9 
Hz, C(5)H), 6.91 (2H, d, J=8.2 Hz, ArH), 6.99 - 7.08 (2H, m, ArH), 7.18 - 7.32 (3H, m, 
ArH), 7.77 (2H, d, J=8.2 Hz, ArH), 9.28 (1H, t, J=6.3 Hz, NH); 
13
C NMR (125 MHz, 
DMSO-d6) δ ppm 24.2 (NCOCH3), 35.7 (C(6)), 45.4 (C(8)), 63.1 (C(5), 126.6, 126.8, 
128.1, 129.2, 129.6, 134.4, 142.9 (7 ArC), 167.2, 167.6, 171.2, 183.4 (3 C=O and C=N); 
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m/z (ES
+
) 366 ([M+H]
+
, 100%); HRMS C20H20N3O4 requires: 366.1454, found: 
366.1448. 
4-({[1-acetyl-5-(1H-indol-3-ylmethyl)-4-oxo-4,5-dihydro-1H-imidazol-2-
yl]amino}methyl)benzoic acid (23b) 
 
22b (0.60 g, 1.99 mmol) was reacted according to the above procedure for 23a, 
filtration gave 23b as a tan solid (0.295 g, 0.729 mmol, 37%) and the mother liquor was 
evaporated and the residue re-crystallised from ethanol to give further 23b as a tan solid 
(0.129 g, 0.320 mmol, 16%) overall yield 53%, mp163-166 °C; νmax (cm
-1
) 3315 (NH), 
1728 (C=O), 1674 (C=O), 1663 (C=O);
1
H NMR (500 MHz, DMSO-d6) δ ppm 2.46 
(3H, s, NCOCH3), 3.31 (1H, dd, J=15.1, 2.2 Hz, C(6)H), 3.45 (6H, dd, J=15.1, 5.4 Hz, 
C(6)H`), 4.32 (1H, dd, J=15.8, 5.7 Hz, C(8)H), 4.49 (1H, dd, J=15.8, 6.9 Hz, C(8)H`), 
4.75 (1H, dd, J=5.4, 2.2 Hz, C(5)H), 6.74 (2H, d, J=8.0 Hz, ArH), 6.92 (1H, t, J=7.3 
Hz, ArH), 6.99 (1H, d, J=2.0 Hz, ArH), 7.04 (1H, t, J=7.4 Hz, ArH), 7.36 (1H, d, J=8.2 
Hz, ArH), 7.41 (1H, d, J=7.9 Hz, ArH), 7.74 (2H, d, J=8.2 Hz, ArH), 9.20 (1H, t, J=6.3 
Hz, N(7)H), 11.00 (1H, br s, indole NH); 
13
C NMR (125 MHz, DMSO-d6) δ ppm 24.2 
(NCOCH3), 26.2 (C(6)), 45.3 (C(8)), 63.3 (C(5), 106.6, 111.3, 118.3, 118.5, 120.8, 
124.3, 126.2, 127.5, 129.3, 129.3, 135.9, 142.9 (12 ArC), 167.2, 167.8, 171.2, 184.1 (3 
C=O and C=N); m/z (ES
-
) 403 ([M-H]
-
, 95%); HRMS C22H19N4O4 requires: 403.1406, 
found: 403.1412. 
4-({[1-acetyl-5-benzyl-4-oxo-4,5-dihydro-1H-imidazol-2-yl]amino}methyl)-N-(2-
aminophenyl)benzamide (24a) 
 
To a solution of the acid 23a (114 mg, 0.312 mmol) and BOP (165 mg, 0.374 
mmol) in anhydrous DMF (1.4 ml) was added triethylamine (174 μl, 1.25 mmol) and 
then stirred at rt for 15 min under nitrogen. To this solution was added phenylene-1,2-
diamine (40 mg, 0.374 mmol) and then the solution stirred at rt under nitrogen for 3.5 h. 
The reaction mixture was then diluted with ethyl acetate (50 ml) and washed with water 
(25 ml), sodium hydrogen carbonate (25 ml), and brine (25 ml). Dried MgSO4 and 
evaporated to give an orange solid. (If an oil was isolated at this point the oil was 
7. Experimental 
Christopher Matthews  136 
dissolved in ethyl acetate and washed with sat. aq. lithium chloride, or triturated with 
diethyl ether to remove DMF.) Purification by column chromatography (4% 
methanol/dichloromethane) gave benzamide 24a as a white solid (21 mg, 0.0464 mmol, 
15%), mp 235-236 °C; νmax (cm
-1
) 3283 (NH), 1720 (C=O), 1671 (C=O); 
1
H NMR (600 
MHz, DMSO-d6) δ ppm 2.44 (3H, s, COCH3), 3.16 (1H, dd, J=14.0, 2.3 Hz, H(21)), 
3.31 (1H, dd, J=14.0, 5.6 Hz, H(21)’), 4.40 (1H, dd, J=15.6, 5.6 Hz, H(15)), 4.54 (1H, 
dd, J=15.6, 6.6 Hz, H(15)’), 4.80 (1H, dd, J=5.6, 2.3 Hz, H(19)), 4.91 (2H, br s, NH2), 
6.61 (1H, t, J=7.3 Hz, H(5)), 6.79 (1H, d, J=7.2 Hz, H(3)), 6.94 - 7.00 (3H, m, H(11 and 
13) and H(4)), 7.07 (2H, d, J=7.2 Hz, H(23 and 27)), 7.17 (1H, d, J=7.5 Hz, H(6)), 7.28 
(2H, t, J=7.5 Hz, H(24 and 26)), 7.32 (1H, t, J=7.2 Hz, H(24)), 7.84 (2H, d, J=7.5 Hz, 
H(10 and 14)), 9.30 (1H, t, J=6.4 Hz, H(16)), 9.64 (1H, s, H(7)); 
13
C NMR (150 MHz, 
DMSO-d6) δ ppm 24.3 (CH3), 35.8 (C(21)), 45.4 (C(15)), 63.1 (C(19)), 116.1 (C(3)), 
116.3 (C(5)), 123.3 (C(1)), 126.5 (C(11 and 13)), 126.6 (C(4)), 126.8 (C(6)), 127.0 
(C(25)), 127.7 (C(10 and 14)), 128.3 (C(23 and 27)), 129.6 (C(24 and 26)), 133.2 
(C(9)), 134.4 (C(22)), 141.4 (C(12)), 143.2 (C(2)), 165.1 (C(17)), 167.6 (C(8)), 171.3 
(NAc), 183.5 (C(20)); m/z (ES
+
) 456 ([M+H]
+
, 80%); HRMS C26H26N5O3, requires: 
456.2036, found: 456.2017. 
4-({[1-acetyl-5-(1H-indol-3-ylmethyl)-4-oxo-4,5-dihydro-1H-imidazol-2-
yl]amino}methyl)-N-(2-aminophenyl)benzamide (24b) 
 
Acid 23b (240 mg, 0.593 mmol) was reacted according to the above procedure 
for 24a, purification by column chromatography (6% methanol/dichloromethane) gave a 
cream solid (260 mg), recrystallization from methanol and dichloromethane then gave 
benzamide 24b as a cream crystalline solid (182 mg, 0.367 mmol, 62%), mp 168-170 
°C; νmax (cm
-1
) 3267 (NH), 1720 (C=O), 1676 (C=O); 
1
H NMR (500 MHz, DMSO-d6) δ 
ppm 2.45 (3H, s, COCH3), 3.31 (1H, dd, J=15.1, 2.4 Hz, H(21)), 3.46 (1H, dd, J=15.1, 
5.4 Hz, H(21)’), 4.36 (1H, dd, J=15.6, 6.0 Hz, H(15)), 4.49 (1H, dd, J=15.6, 6.8 Hz, 
H(15)’), 4.76 (1H, dd, J=5.4, 2.4 Hz, H(19)), 4.90 (2H, br s, NH2), 6.61 (1H, t, J=8.0 
Hz, H(5)), 6.79 (1H, dd, J=8.0, 1.1 Hz, H(3)), 6.84 (2H, d, J=8.0 Hz, H(11 and 13)), 
6.92 - 7.00 (3H, m, H(27), H(28) and H(23)), 7.05 (1H, t, J=8.0 Hz, H(4)), 7.19 (1H, d, 
J=7.7 Hz, H(6)), 7.38 (1H, d, J=8.0 Hz, H(26)), 7.43 (1H, d, J=8.0 Hz, H(29)), 7.79 
(2H, d, J=8.0 Hz, H(10 and 14)), 9.22 (1H, t, J=6.4 Hz, H(16)), 9.55 (1H, s, H(7)), 
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10.96 (1H, br. d, J=1.6 Hz, H(24)); 
13
C NMR (125 MHz, DMSO-d6) δ ppm 24.2 (CH3), 
26.2 (C(21)), 45.3 (C(15)), 63.3 (C(19)), 106.6 (C(22)), 111.4 (C(26)), 116.1 (C(3)), 
116.3 (C(5)), 118.3 (C(29)), 118.5 (C(28)), 120.9 (C(27)), 123.4 (C(1)), 124.2 (C(23)), 
126.2 (C(11 and 13), 126.5 (C(4)), 126.6 (C(6)), 127.5 (C(30)), 127.7 (C(10 and 14)), 
133.2 (C(9)), 135.8 (C(25)), 141.3 (C(12)), 143.1 (C(2)), 165.2 (C(17)), 167.7 (C(8)), 
171.2 (NAc), 184.1 (C(20)); m/z (ES
+
) 495 ([M+H]
+
, 100%); HRMS C28H27N6O3, 
requires: 495.2145, found: 495.2129. 
N-(tert-butoxycarbonyl)-L-phenylalanine (25a)
102
 
 
To a solution of L-phenylalanine (1.6 g, 9.69 mmol) in THF:water (1:1, 40 ml), 
was added di-tert-butyl dicarbonate (2.33 g, 10.7 mmol), then sodium hydroxide (0.853 
g, 21.3 mmol) was added and the reaction was stirred at rt for 16 h under nitrogen. The 
THF was evaporated and dichloromethane (60 ml) was added then 10% aq. 
hydrochloric acid was added dropwise whilst stirring vigorously until the precipitate 
ceased forming (~pH 4). The organic layer was separated, dried MgSO4, and evaporated 
to give a colourless oil which was then dissolved in sat. aq. sodium hydrogen carbonate 
(50 ml) and washed with dichloromethane (50 ml). The aqueous layer was then 
acidified by dropwise addition of 2M hydrochloric acid to ~pH 4 and extracted with 
dichloromethane (50 ml), dried, MgSO4 to yield 25a as a clear oil (2.53 g, 9.54 mmol, 
98%); νmax (cm
-1
) 3200-2800 br. (NH and OH), 1714 (C=O); 
1
H NMR (1:2 mixture of 
rotamers) (500 MHz, chloroform-d) δ ppm 1.29 (3H, s, C(CH3)3), 1.44 (6H, s, 
C(CH3)3), 2.93 (m) and 3.08 (dd, J=13.7, 6.1 Hz) (1H, PhCHH`), 3.20 (1H, m, 
PhCHH`), 4.41 (m) and 4.62 (m) (1H, CH(N)CO), 4.95 (d, J=7.4 Hz) and 6.41 ( m) 
(1H, NH), 7.12 - 7.37 (5H, m, ArH), 9.57 (1H, br s, CO2H); m/z (CI
+
) 266 ([M+H]
+
, 
32%). 
N-(tert-butoxycarbonyl)-L-tryptophan (25b)
103
 
 
L-tryptophan (1.6 g, 7.84 mmol) was suspended in methanol (60 ml) and 
triethylamine (2.23 ml, 16.0 mmol) was added followed by di-tert-butyl dicarbonate 
(2.27 g, 10.4 mmol) then stirred at rt for 16 h under nitrogen by which time all solids 
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had dissolved. Solvents were evaporated, and then the residue was dissolved in sat. aq. 
sodium hydrogen carbonate (200 ml) and washed with dichloromethane (100 ml). The 
aqueous layer was acidified by dropwise addition of 5M hydrochloric acid to pH 4 and 
extracted with dichloromethane (200 ml). This dichloromethane was dried MgSO4 and 
evaporated to give 25b as a white solid (2.13 g, 7.0 mmol, 89%), mp 130-131 °C (lit.
103
 
138-139 °C); 
1
H NMR (500 MHz, DMSO-d6) δ ppm 1.32 (9H, s, C(CH3)3), 2.96 (1H, 
dd, J=14.5, 9.5 Hz, PhCHH`), 3.12 (1H, dd, J=14.5, 4.6 Hz, PhCHH`), 4.13 (1H, app. 
td, J=8.5, 4.6 Hz, CH(N)CO), 6.94 (1H, d, J=8.2 Hz, BocNH), 6.97 (1H, t, J=7.5 Hz, 
ArH), 7.05 (1H, t, J=7.5 Hz, ArH), 7.13 (1H, br s, ArH), 7.32 (1H, d, J=8.0 Hz, ArH), 
7.51 (1H, d, J=8.0 Hz, ArH), 10.81 (1H, br s, indole NH), 12.51 (1H, br s, CO2H); 
13
C 
NMR (125 MHz, DMSO-d6) δ ppm 26.8 C(CH3)3), 28.2 (CH2), 54.5 (CHN), 78.0 
(OC(CH3)3), 110.2, 111.4, 118.1, 118.3, 120.9, 123.6, 127.2, 136.1 (8 AcC), 155.4 
(CO2N), 173.9 (CO2H). 
N-(tertbutoxycarbonyl) D-phenylglycine (25c)
144
 
 
To a mixture of D-phenylglycine (1.6 g, 10.6 mmol) and sodium hydrogen 
carbonate (1.33 g, 15.9 mmol) was added THF:water (1:1, 60 ml) then di-tert-butyl 
dicarbonate and stirred at rt for 17 h. The THF was evaporated, then diluted with 200 ml 
water, washed with 100 ml diethyl ether. The aqueous layer was acidified with 3M 
hydrochloric acid to pH 3 then extracted with diethyl ether (3 × 80 ml). These three 
were combined washed with brine, dried over MgSO4 and evaporated to give 25c as a 
white solid (2.54 g, 10.0 mmol, 95%), mp 87-88 °C (lit. 87-89.5 °C)
145
; 
1
H NMR (400 
MHz, chloroform-d) 2:1 ratio of rotamers δ ppm 1.24 (6H, s, (C(CH3)3)) 1.46 (3H, s, 
(C(CH3)3)), 5.16 (0.66H, d, J=4.5 Hz, NCH) 5.32 - 5.42 (0.33H, m, NCH), 5.53 - 5.64 
(0.33H, m, NH) 8.11 (0.66H, d, J=4.5 Hz, NH), 7.29 - 7.52 (5H, m, Ph), 9.94 (1H, br s, 
CO2H); 
13
C NMR (125 MHz, chloroform-d) δ ppm 28.0 (C(CH3)3), 58.9 (CH), 81.7 
(OC(CH3)3), 127.3, 128.0, 128.5, 138.4 (4 ArC), 157.1 (NCOO), 173.5 (CO2H). 
 (5S)-1-(tert-butoxycarbonyl)-5-benzyl-2-thiohydantoin (26a)
101
 
 
To a solution of N-(tert-butoxycarbonyl)-L-phenylalanine 25a (100 mg, 0.377 
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mmol, 1.0 eq) in acetonitrile (10 ml) was added ethoxycarbonyl isothiocyanate (53 µl, 
0.452 mmol, 1.2 eq) and pyridine (37 µl, 0.452 mmol, 1.2 eq). The resulting solution 
was stirred at rt for 18 h, then the solvent was evaporated and the residue was purified 
by column chromatography (ethyl acetate:hexane, 1:1) to give 26a as a white solid (104 
mg, 0.338 mmol, 90%), mp 113-115 °C; νmax (cm
-1
) 3239 (NH), 1745 ( C=O); 
1
H NMR 
(500 MHz, chloroform-d) δ ppm 1.63 (9H, s, C(CH3)3), 3.29 (1H, dd, J=14.2, 2.5 Hz, 
C(6)H), 3.49 (1H, dd, J=13.9, 5.7 Hz, C(6)H`), 4.81 (1H, dd, J=5.4, 2.8 Hz, C(5)H), 
7.08 (2H, dd, J=6.5, 2.7 Hz, ArH), 7.19 - 7.33 (3H, m, ArH), 8.54 (1H, br s, NH); 
13
C 
NMR (125 MHz, chloroform-d) δ ppm 28.2 (C(CH3)3), 36.0(C(6)), 64.5(C(5), 85.6 
(OC(CH3)3), 127.9 (1-aryl), 128.9 (2,6-aryl), 129.6 (3,5-aryl), 133.0 (4-aryl), 148.6 
(CO2N), 171.0, 178.2 (C=O and C=S); m/z (EI
+
) 306 (M
+
, 7%), 206 ([M-Boc]
+
, 95%); 
HRMS C15H18N2O3S requires: 306.1033, found: 306.1038. 
(5S)-1-(tert-butoxycarbonyl)-5-(1H-indol-3-ylmethyl)-2-thiohydantoin (26b) 
 
N-(tert-butoxycarbonyl)-L-tryptophan 25b (2.11 g, 6.93 mmol) was reacted 
according to the above procedure for 26a. Purification by column chromatography 
(ethyl acetate:hexane, 1:2) gave 26b as a white solid (1.98 g, 5.72 mmol, 82%), mp 85-
87 °C; νmax (cm
-1
) 3354 (NH), 1736 (C=O); 
1
H NMR (400 MHz, chloroform-d) δ ppm 
1.64 (9H, s, C(CH3)3), 3.53 (1H, dd, J=15.0, 2.8 Hz, C(6)H), 3.63 (1H, dd, J=15.1, 5.3 
Hz, C(6)H`), 4.81 (1H, dd, J=5.3, 2.9 Hz, C(5)H), 6.93 (1H, d, J=2.0 Hz, ArH), 7.10 
(1H, t, J=7.2 Hz, ArH), 7.17 (1H, t, J=7.2 Hz, ArH), 7.31 (1H, d, J=8.0 Hz, ArH), 7.56 
(1H, d, J=8.0 Hz, ArH), 8.12 (1H, br s, indole NH), 8.35 (1H, br s, N(3)H); 
13
C NMR 
(125 MHz, chloroform-d) δ ppm 26.1 (C(CH3)3), 28.2 (C(6)), 64.4 (C(5), 85.5 
(OC(CH3)3), 107.1, 111.3, 118.7, 120.0, 122.4, 123.7, 127.4, 135.9 (8 ArC), 148.8 
(CO2N), 171.5, 178.6 (C=O and C=S); m/z (EI
+
) 345 (M
+
, 12%), 130 ([indole-CH2]
+
, 
97%); HRMS C17H19O3N3S requires: 345.1142, found: 345.1144. 
(5R)-1-(tert-butoxycarbonyl)-5-phenyl-2-thiohydantoin (26c) 
 
N-Boc D-Phenylglycine 25c (2.5 g, 9.95 mmol, 1.0 eq) was reacted according to 
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the procedure for 26a. Purification by column chromatography (hexane:ethyl acetate, 
3:1 to ethyl acetate) gave a sticky white solid (some pyridine) which was recrystallized 
from chloroform to give 26c as a white solid (1.71 g, 5.84 mmol, 59%), mp 172-173 °C; 
νmax (cm
-1
) 3111 (NH), 1740 (C=O); 
1
H NMR (500 MHz, DMSO-d6) δ ppm 1.17 (9H, s, 
C(CH3)3), 5.62 (1H, s, CH), 7.23 (2H, d, J=6.9 Hz, ArH), 7.34 - 7.47 (3H, m, ArH), 
12.63 (1H, br s, NH); 
13
C NMR (125 MHz, DMSO-d6) δ ppm 27.2 (C(CH3)3), 66.6 
(CH), 83.3 (C(CH3)3), 126.4 (1-aryl), 128.7 (2,6-aryl), 129.0 (3,5-aryl), 134.9 (4-aryl), 
147.5 (NC=OO), 171.3 (C=S), 180.9 (HNC=O); m/z (EI
+
) 292 (M
+
, 3%), 192 ([M-
Boc]
+
, 100%); HRMS C14H16N2O3S
+
 requires: 292.0876, found: 292.0870. 
1-(tert-butoxycarbonyl)-5-benzyl-2-(methylsulfanyl)-4,5-dihydro-1H-imidazol-4-
one (27a) 
 
Thiohydantoin 26a (0.90 g, 2.90 mmol) was reacted according to the procedure 
for 22a, purification by column chromatography (ethyl acetate:hexane, 1:2) gave 27a as 
a white solid (0.586 g, 1.83 mmol, 63%), mp 105-107 °C; νmax (cm
-1
) 1722 (C=O); 
1
H 
NMR (500 MHz, chloroform-d) δ ppm 1.61 (9H, s, C(CH3)3), 2.37 (3H, s, SCH3), 3.32 
(1H, dd, J=13.9, 2.5 Hz, C(6)H), 3.42 (1H, dd, J=13.9, 6.0 Hz, C(6)H), 4.52 (1H, dd, 
J=6.0, 2.5 Hz, C(5)H), 7.02 - 7.10 (2H, m, ArH), 7.18 - 7.25 (3H, m, ArH); 
13
C NMR 
(125 MHz, chloroform-d) δ ppm 16.2 (SCH3), 28.2 (C(CH3)3), 36.1 (C(6)), 64.5 (C(5), 
85.7 (OC(CH3)3), 127.4 (1-aryl), 128.6 (2,6-aryl), 129.5 (3,5-aryl), 133.8 (4-aryl), 148.4 
(CO2N), 184.7, 186.0 (C=O and C=N); m/z (ES
+
) 321 ([M+H]
+
, 100%); HRMS 
C16H21N2O3S requires: 321.1264, found: 321.1273. 
1-(tert-butoxycarbonyl)-5-(1H-indol-3-ylmethyl)-2-(methylsulfanyl)-4,5-dihydro-
1H-imidazol-4-one (27b) 
 
Thiohydantoin 26b (1.85 g, 5.36 mmol) was reacted according to the procedure 
for 22a, purification by column chromatography (ethyl acetate:hexane, 2:3 to 1:1) gave 
27b as a cream solid (1.35 g, 3.76 mmol, 70%), mp 96-98 °C; νmax (cm
-1
) 3312 (NH), 
1720 (C=O); 
1
H NMR (500 MHz, chloroform-d) δ ppm 1.60 (9H, s, C(CH3)3), 2.33 
(3H, s, SCH3), 3.49 (1H, dd, J=15.1, 3.0 Hz, C(6)H), 3.64 (1H, dd, J=15.0, 5.5 Hz, 
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C(6)H`), 4.60 (1H, dd, J=5.5, 3.0 Hz, C(5)H), 6.95 (1H, d, J=2.4 Hz, ArH), 7.07 (1H, t, 
J=7.5 Hz, ArH), 7.14 (1H, t, J=7.6 Hz, ArH), 7.30 (1H, d, J=8.0 Hz, ArH), 7.53 (1H, d, 
J=8.0 Hz, ArH), 8.26 (1H, br s, NH); 
13
C NMR (125 MHz, chloroform-d) δ ppm 16.2 
(SCH3), 26.0 (C(CH3)3), 28.2 (C(6)), 64.8 (C(5)), 85.8 (OC(CH3)3), 107.9, 111.2, 118.5, 
119.6, 122.0, 123.5, 127.8, 135.9 (8 ArC), 148.5 (CO2N), 185.4 and 186.1 (C=O and 
C=N); m/z (ES
+
) 382 ([M+Na]
+
, 90%); HRMS C18H21N3O3NaS requires: 382.1201, 
found: 382.1188. 
1-(tert-butoxycarbonyl)-5-phenyl-2-(methylsulfanyl)-4,5-dihydro-1H-imidazol-4-
one (27c) 
 
To a stirring mixture of thiohydantoin 26c (0.25 g, 0.855 mmol, 1.0 eq) and 
anhydrous potassium carbonate (0.141 g, 1.03 mmol, 1.2 eq) in acetonitrile (10 ml) at rt 
was added iodomethane (80 µL, 1.28 mmol, 1.5 eq) dropwise. The resulting mixture 
was stirred vigorously at rt for 2.5 h under nitrogen, then evaporated. The resulting 
residue was dissolved/suspended in ethyl acetate (20 ml) and filtered then the filtrate 
was evaporated to give 27c as a white solid (0.259 g, 0.845 mmol, 99%), mp 145-147 
°C; νmax (cm
-1
) 1737 (C=O), 1713 (C=O); 
1
H NMR (500 MHz, chloroform-d) δ ppm 
1.26 (9H, s, C(CH3)3), 2.67 (3H, s, SCH3), 5.18 (1H, s, CH), 7.15 - 7.23 (2H, m, ArH), 
7.30 - 7.39 (3H, m, ArH); 
13
C NMR (125 MHz, chloroform-d) δ ppm 16.4 (CH3), 27.7 
(C(CH3)3), 67.6 (CH2), 85.4 (OC(CH3)3), 126.4 (1-aryl), 128.7 (2,6-aryl), 129.0 (3,5-
aryl), 134.5 (4-aryl), 148.4 (NC=OO), 183.0 (C=N), 186.6 (NC=OC); m/z (EI
+
) 306 
(M
+
, 3%), 205 ([M-Boc]
+
, 100%); HRMS C15H18O3N2S
+
 requires: 306.1033, found: 
306.1036. 
4-({[1-(tert-butoxycarbonyl)-5-benzyl-4-oxo-4,5-dihydro-1H-imidazol-2-
yl]amino}methyl)benzoic acid (28a) 
 
To a solution of 27a (0.550 g, 1.72 mmol) in ethanol (15 ml) was added 4-
(methylamino)benzoic acid (0.260 g, 1.72 mmol). The resulting mixture was stirred at 
reflux under nitrogen for 18 h. The solvent was evaporated and the residue dissolved in 
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ethyl acetate (50 ml) then washed with water (50 ml) and brine (50 ml). The organic 
layer was dried MgSO4 and evaporated. Purification by column chromatography (ethyl 
acetate) gave 28a as a cream solid (0.238 g, 0.562 mmol, 33%), mp 137-140 °C; νmax 
(cm
-1
) 3386 (NH/CO2H), 1702 (C=O); 
1
H NMR (500 MHz, chloroform-d) δ ppm 1.62 
(9H, br s, C(CH3)3), 3.22 - 3.40 (2H, m, , C(6)H2), 4.28 - 4.44 (1H, m, C(8)H), 4.49 
(1H, br s, C(8)H`), 4.77 (1H, dd, J=14.8, 6.6 Hz, C(5)H), 6.96 (2H, d, J=7.3 Hz, ArH), 
7.10 (2H, d, J=6.3 Hz, ArH), 7.15 - 7.34 (3H, m, ArH), 7.94 (2H, d, J=7.3 Hz, ArH), 
8.43 (1H, br s, NH), 8.95 (1H, br s, CO2H);
 13
C NMR (125 MHz, chloroform-d) δ ppm 
28.3 (C(CH3)3), 35.8 (C(6)), 46.4 (C(8)), 63.5 (C(5)), 85.7 (OC(CH3)3), 127.2, 127.4, 
128.6, 128.9, 129.7, 130.6, 134.1, 142.2 (8 ArC), 167.8, 170.5, 174.1, 184.3 (3 C=O and 
C=N); m/z (ES
-
) 422 ([M-H]
-
, 100%); HRMS C23H24N3O5 requires: 422.1716, found: 
422.1707. 
4-({[1-(tert-butoxycarbonyl)-5-(1H-indol-3-ylmethyl)-4-oxo-4,5-dihydro-1H-
imidazol-2-yl]amino}methyl)benzoic acid (28b) 
 
To a solution of 27b (1.30 g, 3.62 mmol) in ethanol (30 ml) was added 4-
(methylamino)benzoic acid (0.547 g, 3.62 mmol). The resulting mixture was stirred at 
reflux under nitrogen for 4 h. The solvent was evaporated and the resulting yellow solid 
purified by column chromatography (6% methanol/dichloromethane) to give 28b as a 
cream solid (0.997 g, 2.16 mmol, 60%), mp 187-190 °C; νmax (cm
-1
) 3271 (NH), 1746 
(C=O), 1697 (C=O), 1693 (C=O); 
1
H NMR (500 MHz, DMSO-d6) δ ppm 1.58 (9H, s, 
C(CH3)3), 3.23 (1H, dd, J=14.7, 2.3 Hz, C(6)H), 3.44 (1H, dd, J=14.7, 5.3 Hz, C(6)H`), 
4.31 (1H, dd, J=15.8, 5.8 Hz, C(8)H), 4.45 - 4.52 (2H, m, C(8)H` and C(5)H), 6.76 (2H, 
d, J=8.2 Hz, ArH), 6.88 (1H, d, J=2.2 Hz, ArH), 6.92 (1H, t, J=7.5 Hz, ArH), 7.04 (1H, 
t, J=7.5 Hz, ArH), 7.36 (1H, d, J=8.0 Hz, ArH), 7.44 (1H, d, J=8.0 Hz, ArH), 7.74 (2H, 
d, J=8.2 Hz, ArH), 8.72 (1H, br. t, J=5.7, 5.7 Hz, N(7)H), 10.97 (1H, br. d, J=2.2 Hz, 
indole NH), CO2H not observed; 
13
C NMR (125 MHz, DMSO-d6) δ ppm 25.2 
(C(CH3)3), 27.7 C(6), 45.3 (C(8)), 63.2 (C(5)), 84.0 (OC(CH3)3), 107.0, 111.3, 118.2, 
118.4, 120.8, 123.8, 126.2, 127.6, 129.2, 135.8 (10 ArC), 150.2 (CO2N), 167.2, 184.0 (2 
C=O and C=N); m/z (ES
+
) 463 ([M+H]
+
, 10%); HRMS C25H27N4O5 requires: 463.1981, 
found: 463.1993. 
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4-(([1-(tert-butoxycarbonyl)-5-phenyl-4-oxo-4,5-dihydro-1H-imidazol-2-
yl]amino)methyl)benzoic acid (28c) 
 
To a solution of 27c (0.25 g, 0.817 mmol) in ethanol (5 ml) was added 4-
(aminomethyl)benzoic acid (0.124 g, 0.817 mmol), then stirred at reflux for 4 h. Cooled 
in a refrigerator and filtered to give a cream solid (30 mg). The filtrate was evaporated 
to give a white solid which was purified by column chromatography (hexane:ethyl 
acetate, 1:4) to give 28c as a white solid (0.131 g, 0.319 mmol, 39%), mp 166-168 °C; 
νmax (cm
-1
) 3315 (NH/CO2H), 1702 (C=O); 
1
H NMR (500 MHz, methanol-d4) δ ppm 
1.24 (9H, s, C(CH3)3), 4.76 - 4.84 (2H, m, H(8)), 5.28 (1H, s, H(5)), 7.24 (2H, d, J=7.3 
Hz, ArH), 7.32 - 7.43 (3H, m, ArH), 7.52 (2H, d, J=8.2 Hz, ArH), 8.03 (2H, d, J=8.5 
Hz, ArH); 
13
C NMR (125 MHz, methanol-d4) δ ppm 27.9 (C(CH3)3), 47.5 (CH2), 68.1 
(CHPh), 86.1 (OC(CH3)3), 127.8, 128.5, 129.5, 129.9, 131.2, 131.4, 137.2, 143.9 (8 
ArC), 151.7 (NC=OO), 169.4, 169.5 (C=N and C=O), 185.7 (C=O); m/z (ES
+
) 410 
([M+H]
+
, 8%); HRMS C22H24N3O5
+
 requires: 410.1716, found: 410.1704. 
tert-butyl 2-[({4-[(2-aminophenyl)carbamoyl]phenyl}methyl)amino]-5-benzyl-4-
oxo-4,5-dihydro-1H-imidazole-1-carboxylate (29a) 
 
Acid 28a (230 mg, 0.543 mmol) was reacted according to the above procedure 
for 24a, purification by column chromatography (2% methanol/dichloromethane) gave 
benzamide 29a as a cream solid (154 mg, 0.299 mmol, 55%), mp 121-124 °C; νmax (cm
-
1
) 3304 (NH), 1699 (C=O); 
1
H NMR (400 MHz, chloroform-d) δ ppm 1.65 (9H, s, 
C(CH3)3), 3.29 - 3.39 (2H, m, H(21) and H(21)’), 3.92 (2H, br s, NH2), 4.40 (1H, dd, 
J=15.4, 5.4 Hz, H(15)), 4.44 - 4.50 (1H, m, H(15)’), 4.73 (1H, dd, J=15.4, 7.2 Hz, 
H(19)), 6.81 - 6.89 (2H, m, H(5) and H(3)), 7.02 (2H, d, J=8.0 Hz, H(11 and 13)), 7.07 - 
7.14 (3H, m, H(4) and H(23 and 27)), 7.17 - 7.40 (4H, m, H(6), H(24 and 26) and 
H(25)), 7.81 (2H, d, J=8.0 Hz, H(10 and 14)), 8.15 (1H, br s, H(16)), 8.41 (1H, br s, 
H(8)); 
13
C NMR (125 MHz, chloroform-d) δ ppm 28.3 (C(CH3)3), 35.8 (C(21)), 46.2 
(C(15)), 63.4 (C(19)), 85.6 (OC(CH3)3), 118.4 (C(3)), 119.8 (C(5)), 124.7 (C(1)), 125.4 
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(C(4)), 127.3 (C(6)), 127.3 (C(25)), 127.6 (C(11 and 13)), 127.9 (C(10 and 14)), 128.6 
(C(23 and 27)), 129.7 (C(24 and 26)), 133.6 (C(9)), 134.2 (C(22)), 140.6 (C(12)), 140.8 
(C(2)), 151.1 (CO2N), 165.5 (C(17)), 167.8 (C(8)), 184.1 (C(20)); m/z (ES
+
) 514 
([M+H]
+
, 10%), 536 ([M+Na]
+
, 19%); HRMS C29H3Boc1N5O4Na, requires: 536.2274, 
found: 536.2277. 
tert-butyl 2-[({4-[(2-aminophenyl)carbamoyl]phenyl}methyl)amino]-5-(1H-indol-3-
ylmethyl)-4-oxo-4,5-dihydro-1H-imidazole-1-carboxylate (29b) 
 
Acid 28b (0.970 g, 2.10 mmol) was reacted according to the above procedure for 
24a, purification by column chromatography (6% methanol:chloroform) gave 
benzamide 29b as a cream solid (0.398 g, 0.721 mmol, 34%), mp 185-186 °C; νmax (cm
-
1
) 3288 (NH), 1732 (C=O), 1699 (C=O); 
1
H NMR (500 MHz, chloroform-d) δ ppm 1.66 
(9H, s, C(CH3)3), 3.30 (1H, dd, J=14.8, 2.4 Hz, H(21)), 3.49 (1H, dd, J=14.8, 3.7 Hz, 
H(21)’), 3.98 (2H, br s, NH2), 4.12 (1H, dd, J=15.8, 5.2 Hz, H(15)), 4.41 - 4.45 (1H, m, 
H(15)’), 4.58 (1H, dd, J=15.8, 7.7 Hz, H(19)), 6.52 (2H, d, J=8.0 Hz, H(11 and 13)), 
6.67 (1H, d, J=1.7 Hz, H(28)), 6.75 - 6.82 (2H, m, H(5) and H(3)), 6.99 (1H, t, J=7.5 
Hz, H(4)), 7.03 - 7.12 (2H, m, H(23) and H(27)), 7.34 (1H, d, J=7.7 Hz, H(6)), 7.41 
(1H, d, J=8.4 Hz, H(26)), 7.44 (1H, d, J=8.2 Hz, H(29)), 7.66 (2H, d, J=7.7 Hz, H(10 
and 14)), 8.31 (1H, br s, H(16)), 8.71 (1H, br s, H(7)), 9.11 (1H, br s, H(24)); 
13
C NMR 
(125 MHz, chloroform-d) δ ppm 25.7 (C(21)), 28.3 (C(CH3)3), 45.9 (C(15)), 64.2 
(C(19)), 85.7 (OC(CH3)3), 107.1 (C(22)), 111.8 (C(26)), 117.8 (C(3)), 118.1 (C(5)), 
119.3 (C(29)), 119.4 (C(28)), 121.7 (C(27)), 124.2 (C(23)), 124.6 (C(1)), 125.8 (C(4)), 
126.5 (C(11 and 13)), 127.2 (C(6)), 127.9 (C(10 and 14)), 128.0 (C(30)), 133.2 (C(9)), 
136.0 (C(25)), 140.3 (C(12)), 141.2 (C(2)), 151.0 (CO2N), 166.0 (C(17)), 168.0 (C(8)), 
185.4 (C(20)); m/z (ES
+
) 553 ([M+H]
+
, 15%), 575 ([M+Na]
+
, 8%); HRMS 
C31H32N6O4Na, requires: 575.2383, found: 575.2389. 
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tert-butyl 2-[({4-[(2-aminophenyl)carbamoyl]phenyl}methyl)amino]-5-phenyl-4-
oxo-4,5-dihydro-1H-imidazole-1-carboxylate (29c) 
 
To a solution of benzoic acid 28c (0.115 g, 0.281 mmol, 1 eq), BOP reagent 
(0.143 g, 0.323 mmol, 1.15 eq) and phenylene-1,2-diamine (0.061 g, 0.562 mmol, 2 eq) 
in DMF (3 ml) was added triethylamine (0.075 ml, 0.562 mmol, 2 eq) and stirred at rt 
for 4 h. Some DMF was evaporated then diluted with ethyl acetate (50 ml) and washed 
with sat. aq. lithium chloride (20 ml) and brine (2 × 20 ml). The crude product was 
purified by column chromatography on silica gel (ethyl acetate) to give the benzamide 
29c as a cream solid (0.139 g, 0.277 mmol, 98%), mp 178-180 °C; νmax (cm
-1
) 3318 
(NH), 1736 (C=O), 1700 (C=O); 
1
H NMR (500 MHz, chloroform-d) δ ppm 1.22 (9H, s, 
C(CH3)3), 4.02 (2H, br s, NH2), 4.71 (1H, d, J=15.1 Hz, H(15)), 4.76 (1H, d, J=15.1 Hz, 
H(15)’), 5.10 (1H, s, H(19)), 6.78 (2H, d, J=7.3 Hz, H(11 and 13)), 7.03 (1H, t, J=7.6 
Hz, H(5)), 7.17 (2H, d, J=7.3 Hz, H(22 and 26)), 7.24 (1H, d, J=7.6 Hz, H(3)), 7.27 - 
7.39 (5H, m, H(23 and 25), H(24), H(4) and H(6))), 7.82 (2H, d, J=7.3 Hz, ArH, H(10 
and 14)), 8.44 (1H, br s, H(16)), 8.79 (1H, br s, H(7)); 
13
C NMR (125 MHz, 
chloroform-d) δ ppm 27.7 (C(CH3)3), 46.8 (C(15)), 66.7 (C(19)), 85.5 (OC(CH3)3), 
118.5 (C(3)), 119.9 (C(5)), 124.6 (C(1)), 125.7 (C(4)), 126.5 (C(11 and 13)), 127.3 
(C(6)), 128.0 (C(10 and 14)), 128.2 (C(23 and 25)), 128.6 (C(24)), 128.9 (C(22 and 
26)), 133.8 (C(9)), 135.2 (C(22)), 140.4 (C(12)), 140.5 (C(2)), 150.8 (CO2N), 165.8 
(C(17)), 168.0 (C(8)), 183.1 (C(20)); m/z (ES
+
) 522 ([M+Na]
+
, 45%); HRMS 
C28H29N5O4Na
+
 requires: 522.2117, found: 522.2103. 
N-(2-aminophenyl)-4-({[5-benzyl-4-oxo-4,5-dihydro-1H-imidazol-2-
yl]amino}methyl)benzamide (30a) 
 
To a solution of Boc-protected benzamide 29a (100 mg, 0.195 mmol) in 
dichloromethane (1 ml) was added trifluoroacetic acid (1 ml). The resulting solution 
was stirred at rt for 3 h then solvents were evaporated, and the resulting oil was 
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azeotroped with toluene to give a pink solid. This solid was partitioned between sat. aq. 
sodium hydrogen carbonate (50 ml) and ethyl acetate (50 ml) then the organic layer was 
washed with brine, dried MgSO4 and evaporated to give a yellow solid. Purification by 
column chromatography (10% methanol/dichloromethane) gave deprotected benzamide 
30a as a pale yellow solid (58 mg, 0.140 mmol, 72%), mp 157-160 °C; νmax (cm
-1
) 3197 
(NH), 1699 (C=O); 
1
H NMR (2:1 mix of tautomers)
 
(600 MHz, DMSO-d6) δ ppm 2.76 
(1H, dd, J=13.6, 6.4 Hz, H(21)), 2.94 - 2.99 (0.33H, m, H(21)’), 3.03 (0.66H, dd, 
J=13.4, 3.2 Hz, H(21)’), 4.06 (1H, app. t, J=5.1 Hz, H(19)), 4.28 - 4.52 (2H, m, H(15) 
and H(15)’), 4.91 (2H, br s, NH2), 6.60 (1H, t, J=7.3 Hz, H(5)), 6.79 (1H, d, J=7.9 Hz, 
H(3)), 6.97 (1H, t, J=7.5 Hz, H(4)), 7.10 - 7.31 (8H, m, ArH), 7.63 (0.66H, br s, H(18)), 
7.74 (0.66H, br s,H(16)), 7.89 (1.32H, d, J=7.2 Hz, H(10 and 14)), 7.95 (0.66H, br. d., 
J=7.2 Hz, H(10 and 14)), 8.23 (0.33H, br s, H(28)), 8.35 (0.33H, br s, H(16)), 9.64 
(0.66H, br s, H(7)), 9.69 (0.33H, br s, H(7)); 
13
C NMR (150 MHz, DMSO-d6) δ ppm 
37.2, 43.7, 44.7, 61.2, 116.1, 116.3, 123.3, 126.3, 126.5, 126.7, 126.7, 126.9, 127.8, 
128.0, 128.1, 129.5, 129.6, 133.2, 133.3, 136.9, 137.3, 141.8, 142.8, 143.2, 165.1, 
170.8, 171.5, 187.6, 188.1 (complicated mixture of tautomers); m/z (CI
+
) 414 ([M+H]
+
, 
15%); HRMS C24H24N5O2, requires: 414.1930, found: 414.1935. 
N-(2-aminophenyl)-4-({[5-(1H-indol-3-ylmethyl)-4-oxo-4,5-dihydro-1H-imidazol-2-
yl]amino}methyl)benzamide (30b) 
 
To a solution of Boc-protected benzamide 29b (300 mg, 0.543 mmol) in 
dichloromethane (3 ml) was added trifluoroacetic acid (1.5 ml). The resulting solution 
was stirred at rt for 3 h then solvents were evaporated, and the resulting oil was 
azeotroped with toluene to give an orange solid. This solid was partitioned between sat. 
aq. sodium hydrogen carbonate (100 ml) and ethyl acetate (150 ml) then the organic 
layer was washed with brine, dried MgSO4 and evaporated to give 30b as a pale yellow 
solid (240 mg, 0.530 mmol, 98%), mp 205-207 °C. Recrystallisation of 50 mg from 
dichloromethane:methanol gave 30 mg of 30b as a cream solid, mp 214-215 °C; νmax 
(cm
-1
) 3216 (NH), 1689 (C=O), 1662 (C=O); 
1
H NMR (2:1 mixture of tautomers) (400 
MHz, DMSO-d6) δ ppm 2.86 (1H, dd, J=14.8, 7.0 Hz, H(21)), 3.16 (1H, br. dd, J=14.8, 
5.3 Hz, H(21)), 4.03 - 4.15 (1H, m, H(19)), 4.34 - 4.50 (2H, m, H(15) and H(15)’), 4.91 
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(2H, br s, NH2), 6.61 (1H, t, J=7.4 Hz, H(5)), 6.79 (1H, d, J=7.5 Hz, H(3)), 6.90 - 7.39 
(8H, m, ArH), 7.57 (1.66H, br s, 1 × ArH and H(18)), 7.68 (0.66H, br s, H(16)), 7.86 - 
7.96 (2H, m, H(10 and 14)), 8.18 (0.33H, br s, H(31)), 8.33 (1H, br s, H(16)), 9.62 (1H, 
br s, H(7)), 10.83 - 10.92 (1H, m, H(24)); 
13
C NMR (125 MHz, DMSO-d6) δ ppm 27.4, 
43.7, 44.7, 48.6, 54.9, 61.1, 76.6, 106.8, 109.9, 111.2, 116.1, 116.3, 118.2, 118.6, 120.8, 
123.3, 126.5, 126.6, 127.5, 127.8, 133.2, 136.0, 142.8, 143.1, 165.1, 171.7, 178.1, 
184.9, 188.6 (complicated mixture of tautomers); m/z (ES
+
) 453 ([M+H]
+
, 100%); 
HRMS C26H25N6O2, requires: 453.2039, found: 453.2023. 
N-(2-aminophenyl)-4-(([4-oxo-5-phenyl-4,5-dihydro-1H-imidazol-2-
yl]amino)methyl)benzamide (30c) 
 
To a solution of Boc protected compound 29c (0.135 g, 0.270 mmol) in 
dichloromethane (1.5 ml) was added trifluoroacetic acid (0.75 ml) and stirred at rt for 3 
h. The solution was evaporated and azeotroped with toluene × 4. Then dissolved in 
methanol (10 ml) and sat. aq. sodium hydrogen carbonate (10 ml) was added and the 
methanol was evaporated, diluted with 10 ml water and the suspension was sonicated to 
break up big particles. Then filtered, washed with water and diethyl ether and dried 
under vacuum to give 30c as a cream solid (0.075 g, 0.188 mmol, 70%), mp 221-223 
°C; νmax (cm
-1
) 3263 (NH), 3062 (NH), 1706 (C=O), 1654 (C=O); (A mixture of NH 
tautomers was observed by NMR) 
1
H NMR (500 MHz, DMSO-d6) δ ppm 4.47 - 4.63 
(2H, m, H(15) and H(15)’), 4.85 (1H, s, H(19)), 4.89 (2H, br s, NH2), 6.59 (1H, t, J=7.1 
Hz, H(5)), 6.77 (1H, d, J=7.9 Hz, H(3)), 6.96 (1H, t, J=7.1 Hz, H(4)), 7.12 - 7.20 (2H, 
m, ArH), 7.20 - 7.30 (2H, m, ArH), 7.30 - 7.39 (2H, m, ArH), 7.41 - 7.49 (2H, m, ArH), 
7.92 - 8.02 (2H, m, H(10 and 14)), 8.12 - 8.24 (1H, m, major tautomer H(16) and 
H(18)), 8.72 (1H, br s, minor tautomer H(16) and H(27)), 9.63 (1H, br s, H(7)); 
13
C 
NMR (150 MHz, DMSO-d6) δ ppm 43.4, 43.8, 45.0, 45.1, 63.8, 116.2, 116.5, 123.2, 
123.3, 125.6, 125.8, 126.5, 126.6, 126.7, 127.0, 127.1, 127.2, 127.4, 127.5, 127.5, 
127.7, 128.0, 128.2, 128.3, 128.4, 128.6, 133.3, 133.4, 137.7, 141.6, 142.7, 143.0, 
143.1, 165.2, 171.7, 186.7 (complicated mixture of tautomers); m/z (ES
+
) 400 ([M+H]
+
, 
100%); HRMS C23H22N5O2
+
 requires: 400.1774, found: 400.1755. 
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tert-butyl 4-(bromomethyl)benzoate (31)
146
 
 
4-(bromomethyl)benzoic acid (1.00 g, 4.65 mmol) was dissolved in SOCl2 (2.5 
ml) and then stirred at reflux under nitrogen for 3 h. Then excess SOCl2 was evaporated 
to give a cream solid. This solid was dissolved in anhydrous diethyl ether (70 ml) and to 
this stirring solution under nitrogen was added potassium tert-butoxide (0.522 g, 4.65 
mmol) portionwise over 1.5 h and then stirred for a further 1.5 h at rt under nitrogen. 
The mixture was filtered washing with diethyl ether and then the filtrate was evaporated 
to give 31 as a white solid (0.802 g, 2.96 mmol, 64%), mp 55-56 °C (lit.
146
 58-59); 
1
H 
NMR (500 MHz, chloroform-d) δ ppm 1.59 (9H, s, C(CH3)3), 4.49 (2H, s, CH2Br), 7.43 
(2H, d, J=8.2 Hz, ArH), 7.96 (2H, d, J=8.2 Hz, ArH); 
13
C NMR (125 MHz, chloroform-
d) δ ppm 28.2 (C(CH3)3), 32.5 (CH2Br), 81.3 (OC(CH3)3), 128.9 (4-aryl), 130.0 (2,6-
aryl), 132.0 (3,5-aryl), 142.1 (1-aryl), 165.2 (C=O); m/z (EI
+
) 270 (M
+
, 2%), 135 ([M-
Br-C(CH3)3+H
+
]
+
, 100%). 
tert-butyl 4-({[1-acetyl-5-benzyl-4-oxo-4,5-dihydro-1H-imidazol-2-
yl]sulfanyl}methyl)benzoate (32a) 
 
To a solution of thiohydantoin (S)-21a (0.298 g, 1.20 mmol) in acetonitrile (20 
ml) was added tert-butyl 4-(bromomethyl)benzoate 31 (0.358 g, 1.32 mmol) and 
triethylamine (0.184 ml, 1.32 mmol). The resulting solution was stirred at 40 °C for 5.5 
hours, then evaporated to give a cream solid. Purification by column chromatography 
(ethyl acetate:hexane, 1:1) gave 32a as a white solid (0.385 g, 0.877 mmol, 73%), mp 
143-144 °C; νmax (cm
-1
) 3447 (NH), 1702 (C=O), 1662 (C=O); 
1
H NMR (500 MHz, 
DMSO-d6) δ ppm 1.54 (9H, s, C(CH3)3), 2.41 (3H, s, COCH3), 3.16 (1H, dd, J=14.3, 
2.6 Hz, C(6)H), 3.36 (1H, dd, J=14.3, 5.8 Hz, C(6)H`), 4.15 (2H, d, J=14.0 Hz, C(8)H), 
4.28 (1H, d, J=14.0 Hz, C(8)H`), 4.98 (2H, dd, J=5.8, 2.6 Hz, C(5)H), 6.96 - 7.01 (2H, 
m, ArH), 7.17 - 7.21 (3H, m, ArH), 7.22 (2H, d, J=8.2 Hz, ArH), 7.75 (2H, d, J=8.2 Hz, 
2,6-aryl); 
13
C NMR (125 MHz, DMSO-d6) δ ppm 23.6 (COCH3), 27.8 (C(CH3)3), 35.5 
(C(6)), 36.0 (C(8)), 64.2 (C(5)), 80.7 (OC(CH3)3), 127.0, 128.2, 128.9, 129.1, 129.4, 
130.1, 133.8, 141.8 (8 ArC), 164.7, 168.6, 184.1, 184.5 (3 C=O and C=N); m/z (EI
+
) 
438 (M
+
, 67%); HRMS C24H26O4N2S requires: 438.1608, found: 438.1612. 
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tert-butyl 4-({[1-acetyl-5-(1H-indol-3-ylmethyl)-4-oxo-4,5-dihydro-1H-imidazol-2-
yl]sulfanyl}methyl)benzoate (32b) 
 
To a solution of thiohydantoin (S)-21b (0.752 g, 2.62 mmol) in acetonitrile (45 
ml) was added tert-butyl 4-(bromomethyl)benzoate 31 (0.780 g, 2.88 mmol) and 
triethylamine (0.40 ml, 2.88 mmol). The resulting solution was stirred at 40 °C for 2.5 
hours, then evaporated to give a cream solid. Purification by column chromatography 
(ethyl acetate:hexane, 1:1) gave 32b as a white solid (0.708 g, 1.48 mmol, 56%), mp 
183-185 °C; νmax (cm
-1
) 3320 (NH), 1738 (C=O), 1690 (C=O); 
1
H NMR (500 MHz, 
DMSO-d6) δ ppm 1.55 (9H, s, C(CH3)3), 2.43 (3H, s, COCH3), 3.38 (1H, dd, J=15.1, 
2.3 Hz, C(6)H), 3.50 (3H, dd, J=15.1, 5.5 Hz, C(6)H`), 4.09 (1H, d, J=14.0 Hz, C(8)H), 
4.30 (1H, d, J=14.0 Hz, C(8)H`), 4.97 (1H, dd, J=5.6, 2.3 Hz, C(5)H), 6.91 - 6.96 (1H, 
m, ArH), 6.99 (1H, d, J=2.4 Hz, ArH), 7.02 - 7.08 (3H, m, ArH), 7.32 (1H, d, J=8.0 Hz, 
ArH), 7.39 (1H, d, J=7.9 Hz, ArH), 7.69 (2H, d, J=8.4 Hz, ArH), 10.96 (1H, br. d, J=2.4 
Hz, NH); 
13
C NMR (125 MHz, DMSO-d6) δ ppm 23.6 (COCH3), 26.6 (C(6)), 27.8 
(C(CH3)3), 35.3 (C(8)), 64.3 (C(5)), 80.6 (OC(CH3)3), 106.1, 111.3, 118.4, 118.6, 120.9, 
124.4, 127.1, 128.7, 129.1, 130.1, 135.8, 141.8 (12 ArC), 164.7, 168.6, 184.1, 185.1 (3 
C=O and C=N); m/z (ES
-
) 476 (M
-
, 100%); HRMS C26H26O4N3S requires: 476.1634, 
found: 476.1644. 
4-({[1-acetyl-5-benzyl-4-oxo-4,5-dihydro-1H-imidazol-2-yl]sulfanyl}methyl)benzoic 
acid (33a) 
 
To a solution of 32a (0.318 g, 0.725 mmol) in dichloromethane (3 ml) was added 
trifluoroacetic acid (3 ml) and the solution stirred at rt for 2 h. The solvent was 
evaporated and then azeotroped with toluene to give 33a as a white solid (0.272 g, 0.711 
mmol) which contained an unidentified impurity (~30%) however TLC indicated that 
column chromatography was unsuitable for the separation of the impurity. Therefore the 
material was used impure. 
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4-({[1-acetyl-5-(1H-indol-3-ylmethyl)-4-oxo-4,5-dihydro-1H-imidazol-2-
yl]sulfanyl}methyl)benzoic acid (33b) 
 
To a solution of 32b (0.689 g, 1.44 mmol) in dichloromethane (6 ml) was added 
trifluoroacetic acid (3 ml) and the solution stirred at rt for 45 min. The solvent was 
evaporated and then azeotroped with toluene to give a pale yellow solid which was 
triturated with diethyl ether and filtered to give 33b as a white solid (0.498 g, 1.18 
mmol, 82%), mp 139-141 °C; νmax (cm
-1
) 3452 (NH), 1720 (C=O), 1698 (C=O); 
1
H 
NMR (500 MHz, DMSO-d6) δ ppm 2.42 (3H, s, COCH3), 3.34 - 3.41 (1H, m, C(6)H), 
3.50 (1H, dd, J=15.4, 5.6 Hz, C(6)H`), 4.13 (1H, d, J=14.0 Hz, C(8)H), 4.27 (1H, d, 
J=14.0 Hz, C(8)H`), 4.97 (1H, dd, J=5.5, 2.8 Hz, C(5)H), 6.93 (1H, t, J=7.2 Hz, ArH), 
6.99 (1H, d, J=2.2 Hz, ArH), 7.04 (1H, t, J=7.2 Hz, ArH), 7.12 (2H, d, J=8.2 Hz, ArH), 
7.31 (1H, d, J=8.0 Hz, ArH), 7.39 (1H, d, J=7.9 Hz, ArH), 7.77 (2H, d, J=8.2 Hz, ArH), 
10.96 (1H, br s, NH), 12.90 (1H, br s, CO2H); 
13
C NMR (125 MHz, DMSO-d6) δ ppm 
23.6 (COCH3), 26.6 (C(6)), 35.4 (C(8)), 64.3 (C(5)), 106.2, 111.3, 118.3, 118.6, 120.9, 
124.3, 127.1, 128.8, 129.4, 129.6, 135.8, 141.7 (12 ArC), 167.0, 168.6, 184.0, 185.2 (3 
C=O and C=N); m/z (ES
+
) 422 ([M+H]
+
, 32%), 444 ([M+Na]
+
, 25%); HRMS 
C22H19O4N3S requires: 444.0994, found: 444.1003. 
tert-butyl (2-aminophenyl)carbamate (39)
147
 
 
To a solution of phenylene-1,2-diamine (1.63 g, 15.1 mmol) in THF (25 ml) was 
added a solution of di-tert-butyl dicarbonate in THF (5 ml) dropwise at rt. Then stirred 
for a further 2 h at rt and the solvent was evaporated. Purification by column 
chromatography (hexane:ethyl acetate, 4:1) gave 39 as a white solid (2.56 g, 12.3 mmol, 
81%), mp 112-114 °C (lit. 114 °C)
148
; 
1
H NMR (500 MHz, chloroform-d) δ ppm 1.51 
(9H, s, C(CH3)3), 3.70 (2H, br s, NH2), 6.29 (1H, br s, NH), 6.70 - 6.83 (2H, m, ArH), 
6.99 (1H, td, J=7.6, 1.3 Hz, ArH), 7.23 - 7.32 (1H, m, ArH); 
13
C NMR (125 MHz, 
chloroform-d) δ ppm 28.4 (C(CH3)3), 80.6 (OC(CH3)3), 117.7, 119.7, 124.9, 126.2, 
140.0 (5 ArC), 153.9 (C=O). 
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tert-butyl (2-(4-methylbenzamido)phenyl)carbamate (40) 
 
To a solution of aryl amine 39 (200 mg, 0.96 mmol) and triethylamine (0.268 
mL, 1.92 mmol) in dichloromethane (3 mL) was added para-toluoyl chloride (0.127 
mL, 0.96 mmol) then the mixture was stirred at rt for 4.5 h under a nitrogen atmosphere. 
Diluted with dichloromethane (20 mL) and washed with sodium hydrogen carbonate 
(sat. aq., 2 × 20 mL), brine (20 mL) and dried MgSO4 then evaporated. The resulting 
beige solid was triturated with hexane and filtered to give 40 as a white solid (0.267 g, 
0.817 mmol, 85%), mp 124-126 °C; νmax (cm
-1
) 3246 (NH), 1687 (C=O), 1651 (C=O); 
1
H NMR (400 MHz, chloroform-d) δ ppm 1.53 (9H, s, C(CH3)3), 2.44 (3H, s, CH3), 
6.98 (1H, br s, BocNH), 7.09 - 7.23 (2H, m, ArH), 7.24 - 7.35 (3H, m, H(11 and 13) and 
ArH), 7.73 (1H, d, J=7.8 Hz, ArH), 7.88 (2H, d, J=8.0 Hz, H(10 and 14)), 9.14 (1H, br 
s, H(7)); 
13
C NMR (125 MHz, chloroform-d) δ ppm 21.6 (CH3), 28.4 (C(CH3)3), 81.3 
(OC(CH3)3), 124.6 (C(3)), 125.8 (C(5)), 125.9 (C(4)), 125.9 (C(6)), 127.5 (C(10 and 
14)), 129.3 (C(11 and 13)), 130.1 (C(2)), 131.0 (C(9)), 131.5 (C(1)), 142.5 (C(12)), 
154.7 (NCOO), 165.8 (C(8)); m/z (ESI
+
) 327 ([M+H]
+
, 100%); HRMS C19H23N2O3
+
 
requires: 327.1703, found: 327.1710. 
tert-butyl (2-([4-(chloromethyl)benzoyl]amino)phenyl)carbamate (43) 
 
To a solution of 39 (2.55 g, 12.2 mmol, 1.0 eq) in dichloromethane (50 ml) 
cooled to -10 °C, was added triethylamine (1.86 ml, 13.4 mmol, 1.1 eq) then a solution 
of 4-(chloromethyl)benzoyl chloride (2.54 g, 13.4 mmol, 1.1 eq) in dichloromethane (20 
ml)dropwise. The stirred solution was allowed to warm to rt and stirred for 1 h. Then 
evaporated and suspended/dissolved in diethyl ether and filtered. The solid was 
dissolved in dichloromethane (200 ml) and washed successively with sat. aq. 
ammonium chloride (200 ml), sat. aq. sodium hydrogen carbonate (200 ml), brine, then 
dried over MgSO4 and evaporated to give 43 as a white powdery solid (4.02 g, 11.2 
mmol, 91%), mp 172-173 °C; νmax (cm
-1
) 3277 (NH), 1682 (C=O), 1655 (C=O); 
1
H 
NMR (500 MHz, chloroform-d) δ ppm 1.51 (9H, s, C(CH3)3), 4.63 (2H, s, CH2Cl), 6.83 
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(1H, br s, BocNH), 7.14 (1H, t, J=7.6 Hz, H(5)), 7.21 (2H, m, H(4) and H(6)), 7.48 (2H, 
d, J=8.2 Hz, H(11 and 13)), 7.77 (1H, d, J=7.9 Hz, H(3)), 7.96 (2H, d, J=8.2 Hz, H(10 
and 14), 9.27 (1H, br s, H(7)); 
13
C NMR (125 MHz, chloroform-d) δ ppm 28.4 
(C(CH3)3), 45.5 (CH2Cl), 81.6 (OC(CH3)3), 124.6 (C(3)), 125.9 (C(6)), 126.1 (C(4)), 
126.1 (C(5)), 127.9 (C(10 and 14)), 128.8 (C(11 and 13)), 129.9 (C(9)), 130.9 (C(2)), 
134.3 (C(1)), 141.3 (C(12)), 154.8 (CO2N), 165.1 (C(8)); m/z (ES
+
) 383 ([M+Na]
+
, 
90%); HRMS C19H21N2O3ClNa
+
 requires: 383.1138, found: 383.1136. 
4-({[1-(tert-butoxycarbonyl)-5-benzyl-4-oxo-4,5-dihydro-1H-imidazol-2-
yl]sulfanyl}methyl)-N-(2-aminophenyl)benzamide (44) 
 
To a solution of the benzyl chloride 43 (0.7 g, 1.94 mmol, 1.1 eq) in acetone (15 
ml) was added sodium iodide (0.582 g, 3.88 mmol, 2.2 eq) then stirred at reflux for 2 h 
(the round bottomed flask, oil bath and condenser were wrapped in foil to keep the 
benzyl iodide in the dark). After 2 h the mixture was cooled to rt and a solution of 
thiohydantoin 44 (0.539 g, 1.76 mmol, 1.0 eq) in dichloromethane (5 ml) was added 
followed by potassium carbonate (0.365 g, 2.64 mmol, 1.5 eq). The resulting mixture 
was stirred at rt for 20 h (in the dark). The mixture was then filtered then evaporated. 
The residue was purified by column chromatography (hexane:ethyl acetate, 2:1 to 1:1) 
to give 44 as a white solid (0.137 g, 0.217 mmol, 12%), mp 104-106 °C; νmax (cm
-1
) 
3287 (NH), 1722 (C=O); 
1
H NMR (400 MHz, chloroform-d) δ ppm 1.53 (9H, s, 
C(CH3)3)), 1.64 (9H, s, C(CH3)3)), 3.35 (1H, dd, J=13.8, 2.5 Hz, H(21)), 3.45 (1H, dd, 
J=13.8, 5.8 Hz, H(21)’), 4.22 (1H, d, J=13.8 Hz, H(15)), 4.37 (1H, d, J=13.8 Hz, 
H(15)’), 4.54 - 4.59 (1H, m, H(19)), 6.87 (1H, br s, BocNH), 7.04 - 7.08 (2H, m, ArH), 
7.16 - 7.31 (8H, m, ArH), 7.80 (1H, d, J=7.5 Hz, H(6)), 7.86 (2H, d, J=8.3 Hz, H(10 and 
14)), 9.23 (1H, br s, H(7)); 
13
C NMR (125 MHz, DMSO-d6) δ ppm 28.1 (C(CH3)3), 28.3 
(C(CH3)3), 36.0 (C(15)), 36.7 (C(21)), 64.5 (C(19)), 81.4 (OC(CH3)3), 85.9 (OC(CH3)3), 
124.5 (C(3)), 125.7 (C(6)), 125.9 (C(4)), 126.0 (C(5)), 127.5 (C(24)), 127.7 (11 and 13), 
128.5 (C(22 and 26)), 129.3 (10 and 14), 129.3 (23 and 25), 130.0 (C(9)), 130.8 (C(2)), 
133.4 (C(1) and C(21)), 139.8 (C(12)), 148.3 (CO2 CO2N), 154.6 (CO2N), 165.1 
(C(17)), 184.6 (C(8)); m/z (ES
+
) 653 ([M+Na]
+
, 100%); HRMS C34H38N4O6SNa
+
 
requires: 653.2410, found: 653.2408. 
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4-({[1-(tert-butoxycarbonyl)-5-phenyl-4-oxo-4,5-dihydro-1H-imidazol-2-
yl]sulfanyl}methyl)-N-(2-aminophenyl)benzamide (45) 
 
To a solution of the benzyl chloride 43 (253 mg, 0.70 mmol, 1.0 eq) in 
dichloromethane (7 ml) was added thiohydantoin 26c, potassium carbonate (290 mg, 
2.1 mmol, 3.0 eq), sodium iodide (105 mg, 0.7 mmol, 1.0 eq) and acetone (3 ml), the 
mixture was then heated to reflux for 25 h. Then evaporated, the residue was portioned 
between ethyl acetate and water (10 ml each) then separated, then organic layer was 
washed with brine, dried MgSO4 and concentrated to give an orange foam which was 
purified by column chromatography (dichloromethane:ethyl acetate, 4:1) to give 45 as a 
white solid (130 mg, 0.21 mmol, 30%), mp 133-135 °C; νmax (cm
-1
) 3296 (NH), 1724 
(C=O); 
1
H NMR (500 MHz, chloroform-d) δ ppm 1.25 (9H, s, C(CH3)3), 1.50 (9H, s, 
C(CH3)3), 4.54 (1H, d, J=13.6 Hz, H(15)), 4.59 (1H, d, J=13.6 Hz, H(15)’), 5.18 (1H, s, 
H(19)), 6.90 (1H, br s, BocNH), 7.11 - 7.25 (5H, H(5), H(3), H(22 and 26) and H(24)), 
7.31 - 7.40 (3H, m, H(23 and 25) and H(4)), 7.54 (2H, d, J=8.2 Hz, H(11 and 13)), 7.75 
(1H, d, J=7.6 Hz, H(6)), 7.93 (2H, d, J=8.2 Hz, H(10 and 14)), 9.26 (1H, br s, H(7)); 
13
C NMR (125 MHz, chloroform-d) δ ppm 27.7 (C(CH3)3), 28.4 (C(CH3)3), 37.4 
(C(15)), 67.5 (C(19)), 81.5 (OC(CH3)3), 85.6 (OC(CH3)3), 124.6 (C(3)), 125.9 (C(6)), 
126.0 (C(4)), 126.1 (C(5)), 126.4 (C(10 and 14)), 128.0 (C(11 and 13)), 128.9 (C(24)), 
129.1 (C(23 and 25)), 129.7 (C(22 and 26)), 130.1 (C(9)), 130.9 (C(2)), 133.9 (C(1)), 
134.3 (C(21)), 139.6 (C(12)), 148.4 (CO2N), 154.7 (CO2N), 165.2 (C(17)), 183.0 
(C(20)), 185.2 (C(8)); m/z (ES
+
) 639 ([M+Na]
+
, 100%); HRMS C33H36N4O6SNa
+
 
requires: 639.2253, found: 639.2264. 
L-Phenylalinol (46a)
149
 
 
A 2-neck flask (oven-dried) was fitted with a magnetic stirrer and a reflux 
condenser and then NaBH4 (1.36 g, 36.1 mmol, 2.4 eq) and L-Phenylalanine (2.48 g, 
15.0 mmol, 1.0 eq) were added, followed by dry THF (40 ml). Then a dropping funnel 
was fitted and the mixture cooled to 0 °C in an ice bath. A solution of iodine (3.80 g, 
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15.0 mmol, 1.0 eq) in THF (10 ml) was added dropwise over 30 min, vigorous gas 
evolution was observed, after gas evolution had stopped the mixture was heated to 
reflux for 18 h. Then cooled to rt and methanol added slowly until solution became 
clear. Stirred for 30 min and then the solvent was evaporated. The resulting white paste 
was dissolved in 30 ml of 20% aq. potassium hydroxide and stirred for 4 h then 
extracted with dichloromethane (3 × 30 ml). The combined organics were washed with 
brine, and dried Na2SO4 and evaporated to give a crystalline solid which was 
recrystallized from toluene to give 46a as a white solid (1.19 g, 7.87 mmol, 52%), mp 
88-90 °C (lit. 90-92 °C)
149
; 
1
H NMR (500 MHz, chloroform-d) δ ppm 2.04 (3H, br s, 
NH2 and OH), 2.52 (1H, dd, J=13.5, 8.7 Hz, CHH`Ph), 2.79 (1H, dd, J=13.5, 5.0 Hz, 
CHH`Ph), 3.07 - 3.17 (1H, m, NCH), 3.39 (1H, dd, J=10.7, 7.3 Hz, CHH`OH), 3.63 
(1H, dd, J=10.7, 3.8 Hz, CHH`OH), 7.16 - 7.27 (3H, m, ArH), 7.28 - 7.34 (2H, m, ArH); 
13
C NMR (125 MHz, chloroform-d) δ ppm 40.9 (CH2Ph), 54.3 (CHN), 66.3 (CwaterH), 
126.5 (p-Ph), 128.7 (o-Ph), 129.3 (m-Ph), 138.7 (i-Ph). 
(2R)-2-amino-2-phenylethan-1-ol ((R)-46b) 
 
A 3-neck flask (oven-dried) was fitted with a magnetic stirrer and a reflux 
condenser and then NaBH4 (0.756 g, 20 mmol, 2.0 eq) was added followed by dry THF 
(20 ml). Then a dropping funnel was fitted and the mixture cooled to 0 °C in an ice bath. 
A solution of iodine (2.54 g, 10.0 mmol, 1.0 eq) in THF (10 ml) was added dropwise 
over 20 min, vigorous gas evolution was observed, after gas evolution had stopped D-
phenylglycine (1.51 g, 10.0 mmol, 1.0 eq) was added and the mixture was heated to 
reflux for 16.5 h. Then cooled to rt and methanol added slowly until solution became 
clear. Stirred for 30 min and then the solvent was evaporated. The resulting white paste 
was dissolved in 30 ml of 20% aq. potassium hydroxide and stirred for 4 h then 
extracted with dichloromethane (3 × 30 ml). The combined organics were washed with 
brine (20 mL then 75 mL), dried Na2SO4 and then evaporated to give a white semi-solid 
which was recrystallized from toluene to give (R)-46b as a white crystalline solid (0.68 
g, 4.78 mmol, 48%), mp 73-75 °C (lit. 69-71 °C)
149
; 
1
H NMR (500 MHz, chloroform-d) 
δ ppm 2.38 (3H, br s, NH2 and OH), 3.58 (1H, dd, J=10.8, 8.5 Hz, H(1)), 3.75 (1H, dd, 
J=10.8, 4.2 Hz, H(1)`), 4.06 (1H, dd, J=8.2, 4.2 Hz, H(2)), 7.23 - 7.45 (5H, m, ArH); 
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13
C NMR (125 MHz, chloroform-d) δ ppm 57.8 (C(1)), 68.4 (C(2)), 126.9 (C(4 and 8)), 
127.9 (C(6)), 129.0 (C(5 and 7)), 143.0 (C(3)). 
 (2S)-2-amino-2-phenylethan-1-ol ((S)-46b)
149
 
 
A 3-neck flask (oven-dried) was fitted with a magnetic stirrer and a reflux 
condenser and then NaBH4 (0.756 g, 20 mmol, 2.0 eq) was added followed by dry THF 
(20 ml). Then a dropping funnel was fitted and the mixture cooled to 0 °C in an ice bath. 
A solution of iodine (2.54 g, 10.0 mmol, 1.0 eq) in THF (10 ml) was added dropwise 
over 20 min, vigorous gas evolution was observed, after gas evolution had stopped L-
phenylglycine (1.51 g, 10.0 mmol, 1.0 eq) was added and the mixture was heated to 
reflux for 16 h. Then cooled to rt and methanol added slowly until solution became 
clear. Stirred for 30 min and then the solvent was evaporated. The resulting white paste 
was dissolved in 30 ml of 20% aq. potassium hydroxide and stirred for 4 h then 
extracted with dichloromethane (3 × 30 ml). The combined organics were washed with 
brine (20 mL then 75 mL), dried Na2SO4 and then evaporated to give a white semi-solid 
which was recrystallized from toluene to give (S)-46b as a white crystalline solid (0.68 
g, 4.69 mmol, 50%), mp 76-77 °C (lit. 76-78 °C)
150
; 
1
H NMR (500 MHz, chloroform-d) 
δ ppm 2.25 (3H, br s, NH2 and OH), 3.55 (1H, dd, J=10.9, 8.3 Hz, H(1)), 3.73 (1H, dd, 
J=10.9, 4.3 Hz, H(1)`), 4.04 (1H, dd, J=8.3, 4.3 Hz, H(2)), 7.24 - 7.29 (1H, m, H(6)), 
7.30 - 7.38 (4H, m, H(4 and 8) and H(5 and7)); 
13
C NMR (125 MHz, chloroform-d) δ 
ppm 57.4 (C(1)), 68.1 (C(2)), 126.6 (C(4 and 8)), 127.6 (C(6)), 128.7 (C(5 and 7)), 
142.7 (C(3)).  
(2S)-2-amino-3-(1H-indol-3-yl)propan-1-ol (46c)
151
 
 
A 3-neck flask (oven-dried) was fitted with a magnetic stirrer and a reflux 
condenser and then NaBH4 (0.756 g, 20.0 mmol, 2.0 eq) and L-tryptophan (2.04 g, 10.0 
mmol, 1.0 eq) were added, followed by dry THF (20 ml). Then a dropping funnel was 
fitted and the mixture cooled to 0 °C in an ice bath. A solution of iodine (2.54 g, 10.0 
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mmol, 1.0 eq) in THF (10 ml) was added dropwise over 20 min, vigorous gas evolution 
was observed, after gas evolution had stopped the mixture was heated to reflux for 17 h. 
Then cooled to rt and methanol added slowly until solution became clear. Stirred for 30 
min and then the solvent was evaporated. The resulting white paste was dissolved in 20 
ml of 20% aq. potassium hydroxide and stirred for 20 h then neutralised slightly with 
hydrochloric acid (2M aq. to ~ pH 11) and extracted with dichloromethane (3 × 20 ml) 
then 20% ethanol/chloroform (4 × 25 ml). The combined organics were washed with 
brine, and dried Na2SO4 and evaporated to give 46c as a yellow oil (1.38 g, 7.27 mmol, 
73%); νmax (cm
-1
) 3401 (OH), 3251 (NH); 
1
H NMR (400 MHz, chloroform-d) δ ppm 
1.73 (3H, br s, NH2 and OH), 2.74 (1H, dd, J=14.4, 8.4 Hz, H(10)), 2.97 (1H, dd, 
J=14.4, 5.1 Hz, H(10)`), 3.25 - 3.33 (1H, m, H(11)), 3.46 (1H, dd, J=10.5, 7.2 Hz, 
H(12)), 3.72 (1H, dd, J=10.5, 4.0 Hz, H(12)), 7.08 (1H, d, J=2.0 Hz, H(2)), 7.15 (1H, 
app. t, J=7.3 Hz, H(6)), 7.24 (1H, app. t, J=7.2 Hz, H(7)), 7.40 (1H, d, J=8.0 Hz, H(5)), 
7.64 (1H, d, J=8.0 Hz, H(8)), 8.09 (1H, br s, H(1)); 
13
C NMR (150 MHz, chloroform-d) 
δ ppm 30.5 (C(10)), 53.0 (C(11)), 66.9 (C(12)), 111.3 (C(8)), 112.8 (C(3)), 119.0 
(C(7)), 119.6 (C(5)), 122.3 (C(6)), 122.7 (C(2)), 127.7 (C(4)), 136.5 (C(9)). 
(S)-4-(1-amino-2-hydroxyethyl)phenol (46e)  
 
An oven-dried three-neck flask was charged with a stirrer bar, NaBH4 (0.756 g, 
20.0 mmol) and anh. THF (20 mL) then cooled in an ice bath. To this stirring 
suspension was added a solution of iodine (2.54 g, 10.0 mmol) in anh. THF (10 mL) 
dropwise over 15 min [Caution hydrogen gas produced!]. After addition had finished 
and gas formation had ceased, 4-hydroxy-L-phenylglycine (1.67 g, 10.0 mmol) was 
added and the mixture heated to reflux for 14 h. The mixture was then cooled to rt and 
methanol added cautiously until a clear solution formed (~ 5 mL), stirred for 30 min and 
then evaporated. The resulting white paste was dissolved in aqueous potassium 
hydroxide (20%, 20 mL), stirred at rt for 4 h then neutralised to pH ~ 8 – 9. The product 
could not be extracted into an organic solvent and so the water was removed with a 
freeze drier. The resulting hygroscopic white solid was dissolved/suspended in 
ethanol:chloroform (1:1, 200 mL), stirred for 1 h then filtered and the solvent 
evaporated. The white solid was dissolved /suspended in ethanol:chloroform (1:9, 200 
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mL), stirred for 1 h then filtered. The filtrate was dried with MgSO4 and evaporated to 
give 46e as a hygroscopic white solid (1.5 g, 98%) which was used without any further 
purification. 
2-amino-2,2-diphenylethanol (46g)
152
  
 
To a suspension of 2-amino-2,2-diphenylacetic acid (1 g, 4.40 mmol) in 
anhydrous THF (10 mL) at rt was added borane-THF complex 1M in THF (11.00 mL, 
11.00 mmol) dropwise over 5 min, then the suspension was stirred at 70 °C for 16.5 h. 
The solution was cooled to rt and then a further 10 mL of borane-THF complex 1M in 
THF was added and stirred at 70 °C for 6 h. After cooling to 20 ºC methanol (10 mL) 
was added cautiously then stirred for 30 min at rt. The solvent was then evaporated and 
the resulting white paste stirred with potassium hydroxide (20% aq w/w, 30 mL) for 16 
h at 20 ºC, the solution was then extracted with ethyl acetate (3 × 25 mL), the combined 
organics were washed with brine, dried Na2SO4 and evaporated to give 46g (0.863 g, 
4.05 mmol, 92%) as a white solid, mp 118-120 °C; 
1
H NMR (400 MHz, chloroform-d) 
δ ppm 2.35 (3H, br s, NH2 and OH), 4.12 (2H, s, CH2), 7.23 - 7.42 (10H, m, ArH); 
13
C 
NMR (100 MHz, chloroform-d) δ ppm 62.4 (CNH2), 70.2 (COH), 126.8 (o-Ph), 126.9 
(p-Ph), 128.4 (m-Ph), 145.9 (i-Ph). 
2-amino-2-(4-fluorophenyl)ethan-1-ol (46i)  
 
A 3-neck flask was fitted with a magnetic stirrer and a reflux condenser and then 
flame dried. Under a nitrogen atmosphere NaBH4 (0.224 g, 5.92 mmol, 2.0 eq) was 
added followed by anhydrous THF (10 ml). Then a dropping funnel was fitted and the 
mixture cooled to 0 °C in an ice bath. A solution of iodine (1.05 g, 2.96 mmol, 1.0 eq) in 
THF (10 ml) was added dropwise over 30 min, vigorous gas evolution was observed, 
after gas evolution had stopped 4-fluoro-DL-phenylglycine (0.5 g, 2.96 mmol, 1.0 eq) 
was added and the mixture was heated to reflux for 17 h. Then cooled to rt and 
methanol added slowly until the solution became clear. Stirred for 30 min and then the 
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solvent was evaporated. The resulting white paste was dissolved in 30 ml of 20% aq. 
potassium hydroxide and stirred for 6 h then extracted with dichloromethane (3 × 30 
ml). The combined organics were washed with brine (20 mL then 75 mL), dried Na2SO4 
and then evaporated to give a white solid which was impure but used without further 
purification (0.22 g, 1.42 mmol, 48%); 
1
H NMR (400 MHz, chloroform-d) δ ppm 2.51 
(3H, br s, NH2 and OH), 3.54 (1H, dd, J=10.8, 8.3 Hz, OCHH’), 3.72 (1H, dd, J=10.8, 
4.3 Hz, OCHH’), 4.07 (1H, dd, J=8.3, 4.3 Hz, PhCH), 7.05 (2H, t, J=8.8 Hz, ArH), 7.32 
(2H, dd, J=8.5, 5.5 Hz, ArH). 
2-amino-2-(3-fluorophenyl)ethanol (46j)
153
 
 
To a suspension of 2-amino-2-(3-fluorophenyl)acetic acid (1 g, 5.91 mmol) in 
anhydrous THF (10 mL) at rt was added borane-THF complex (1M in THF, 14.78 mL, 
14.78 mmol) dropwise over 5 min, then the solution was stirred at 70 °C for 15.5 h. 
After cooling to 20 ºC, methanol (10 mL) was added cautiously, then stirred for 30 min. 
The solvent was then evaporated and the resulting white paste stirred with potassium 
hydroxide (20% aq w/w, 30 mL) for 4 h at 20 ºC, then extracted with ethyl acetate (2 × 
30 mL). The combined organic layers were dried Na2SO4, and evaporated to give a 
yellow oil (0.9 g) which was purified by flash column chromatography on silica gel (2-
10% (2M ammonia/methanol) in dichloromethane) to give a colourless oil (390 mg), 
which was purified again by MDAP to give 46j (177 mg, 1.141 mmol, 19%) as a white 
solid, mp 86-88 °C; 
1
H NMR (400 MHz, chloroform-d) δ ppm 2.17 (3H, br s, NH2 and 
OH), 3.55 (1H, dd, J=10.9, 8.0 Hz, H(2)), 3.75 (1H, dd, J=10.9, 4.3 Hz, H(1)), 4.07 
(1H, dd, J=8.0, 4.3 Hz, H(1)’), 6.88 - 7.02 (1H, m, ArH), 7.04 - 7.15 (2H, m, ArH), 7.26 
- 7.36 (1H, m, ArH); 
13
C NMR (100 MHz, chloroform-d) δ ppm 57.0 (s, C(2)), 67.8 (s, 
C(1)), 113.5 (d, J=21.6 Hz, C(4)), 114.3 (d, J=21.6 Hz, C(6)), 122.1 (d, J=3.2 Hz, 
C(8)), 130.1 (d, J=8.0 Hz, C(7)), 145.4 (d, J=6.4 Hz, C(3)), 163.0 (d, J=246.1 Hz, 
C(5)). 
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2-amino-2-(4-(trifluoromethyl)phenyl)ethanol (46k)
154
 
 
To a suspension of 2-amino-2-(4-(trifluoromethyl)phenyl)acetic acid (1.5 g, 6.84 
mmol) in anhydrous THF (15 mL) at rt was added borane-THF complex (1M in THF, 
17.11 mL, 17.11 mmol) dropwise over 5 min, then the solution was stirred at 70 °C for 
16.5 h. After cooling to 20 ºC methanol (10 mL) was added cautiously, then stirred for 
30 min. The solvent was evaporated and the resulting yellow paste stirred with 
potassium hydroxide (20% aq w/w, 30 mL) for 4 h at 20 ºC, then extracted with ethyl 
acetate (3 × 30 mL), the combined organic layers were washed with brine, dried Na2SO4 
and evaporated to give a yellow semi-solid (1.3 g). Purification by flash column 
chromatography on silica gel (2-10% (2M ammonia/methanol) in dichloromethane) 
gave 46k (0.646 g, 3.15 mmol, 46%) as a white solid, mp 110-116 °C; 
1
H NMR (500 
MHz, chloroform-d) δ ppm 2.14 (3H, br s, NH2 and OH), 3.58 (1H, dd, J=10.7, 8.0 Hz, 
H(2)), 3.78 (1H, dd, J=10.7, 4.1 Hz, H(1)), 4.16 (1H, dd, J=8.0, 4.1 Hz, H(1)’), 7.49 
(2H, d, J=8.1 Hz, H(4 and 8)), 7.63 (2H, d, J=8.1 Hz, H(5 and 7)); 
13
C NMR (125 MHz, 
chloroform-d) δ ppm 57.0 (s, C(2)), 67.8 (s, C(1)), 124.1 (q, J=271.9 Hz, CF3), 125.5 (q, 
J=3.7 Hz, C(5 and 7)), 126.9 (s, C(4 and 8)), 129.8 (q, J=32.5 Hz, C(6)), 146.6 (s, 
C(3)); m/z (ESI
+
) 206 ([M+H]
+
, 100%); HRMS C9H11NOF3
+
 requires: 206.0787, found: 
206.0790. 
 (4S)-4-benzyl-1,3-thiazolidine-2-thione (47a)
155
 
 
To a mix of L-Phenylalinol 46a (1.16 g, 7.67 mmol, 1.0 eq) in 1M aq. potassium 
hydroxide (38 ml) was added carbon disulfide (2.32 ml, 38.4 mmol, 5.0 eq). The 
resulting solution was stirred at reflux for 18 h then cooled to rt and extracted with 
dichloromethane (3 × 25 ml). The combined organic layers were dried MgSO4 and 
evaporated to give 47a as a white solid (1.5 g, 7.17 mmol, 93%), mp 72-74 °C (lit. 93-
94 °C)
155
; 
1
H NMR (300 MHz, chloroform-d) δ ppm 2.90 - 3.11 (2H, m, CH2Ph), 3.31 
(1H, dd, J=11.1, 6.7 Hz, CHH`S), 3.57 (1H, dd, J=11.1, 7.6 Hz, CHH`S), 4.38 - 4.55 
(1H, m, CHN), 7.12 - 7.44 (5H, m, ArH), 7.81 (1H, br s, NH); 
13
C NMR (75 MHz, 
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chloroform-d) δ ppm 38.2 (CH2Ph), 40.1 (CH2S), 65.1 (CHN), 127.5, 129.1, 129.2, 
135.9 (4 ArC), 201.0 (C=S). 
(4S)-4-phenyl-1,3-thiazolidine-2-thione (47b)
155
 
 
To a mix of impure (S)-46b (0.80 g, 5.8 mmol, 1.0 eq) in 1M aq. potassium 
hydroxide (30 ml) was added carbon disulfide (1.75 ml, 29 mmol, 5.0 eq). The resulting 
solution was stirred at 80 °C (should have been at 100 °C) for 18 h then cooled to rt and 
extracted with dichloromethane (3 × 30 ml). The combined organic layers were washed 
with water (30 ml), dried MgSO4 and evaporated. Purification by column 
chromatography on silica gel (hexane:ethyl acetate, 4:1) gave 47b as a white solid 
(0.293 g, 1.50 mmol, 26%), mp 125-126 °C (lit. 125-127 °C)
156; νmax (cm
-1
) 3125 (NH); 
1
H NMR (500 MHz, chloroform-d) δ ppm 3.50 (1H, dd, J=11.3, 8.3 Hz, H(8)), 3.85 
(1H, dd, J=11.3, 8.0 Hz, H(8)`), 5.32 (1H, t, J=8.2 Hz, H(7)), 7.32 - 7.49 (5H, m, ArH), 
7.77 (1H, br s, NH); 
13
C NMR (125 MHz, chloroform-d) δ ppm 41.6 (C(8)), 67.5 
(C(7)), 126.3 (C(2 and 6)), 129.3 (C(4)), 129.4 (C(3 and 5)), 138.0 (C(4)), 201.7 (C=S). 
(4S)-4-(1H-indol-3-ylmethyl)-1,3-thiazolidine-2-thione (47c) 
 
To a mix of impure 46c (0.34 g, 1.79 mmol, 1.0 eq) in 1M aq. potassium 
hydroxide (9 ml) was added carbon disulfide (0.54 ml, 8.95 mmol, 5.0 eq). The 
resulting solution was stirred at reflux for 18 h then cooled to rt and extracted with 
dichloromethane (3 × 10 ml). The combined organic layers were washed with brine, 
dried MgSO4 and evaporated. Purification by column chromatography on silica gel 
(hexane:ethyl acetate, 1:1) gave 47c as a white solid (0.161 g, 0.65 mmol, 36%), mp 73-
75 °C; νmax (cm
-1
) 3310 (NH), 3146 (NH); 
1
H NMR (500 MHz, chloroform-d) δ ppm 
3.12 (1H, dd, J=14.3, 6.1 Hz, H(10)), 3.16 (1H, dd, J=14.3, 7.7 Hz, H(10)`), 3.35 (1H, 
dd, J=11.1, 6.6 Hz, H(12)), 3.61 (1H, dd, J=11.1, 7.8 Hz, H(12) `), 4.51 - 4.60 (1H, m, 
H(11)), 7.08 (1H, d, J=2.4 Hz, (H(2)), 7.16 (1H, td, J=7.4, 0.9 Hz, H(6)), 7.24 (1H, td, 
J=7.7, 0.9 Hz, H(7)), 7.41 (1H, d, J=8.2 Hz, H(5)), 7.52 - 7.61 (2H, m, H(8) and 
CSNH), 8.22 (1H, br s, indole NH); 
13
C NMR (125 MHz, chloroform-d) δ ppm 30.1 
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(C(10)), 38.5 (C(12)), 64.4 (C(11)), 110.3 (C(3)), 111.7 (C(8)), 118.4 (C(7)), 120.1 
(C(5)), 122.7 (C(6)), 123.1 (C(2)), 126.9 (C(4)), 136.4 (C(9)), 200.9 (C=S); m/z (EI
+
) 
248 (M
+
, 100%); HRMS C12H12N2S2
+
 requires: 248.0436, found: 248.0439. 
 (4S)-4-benzyl-1,3-oxazolidine-2-thione (48a) 
157
 
 
To a mixture of L-phenylalinol 46a (1.64 g, 10.9 mmol, 1 eq), potassium 
carbonate (0.753 g, 5.55 mmol, 0.5 eq) and CS2 (1.32 ml, 21.8 mmol, 2 eq) in absolute 
ethanol (11 ml) stirred and heated to 50 °C was added 30% aq. hydrogen peroxide (1.85 
ml, 16.4 mmol, 1.5 eq) dropwise [Caution: Exotherm!]. After completion of addition the 
mixture was cooled to rt and filtered. The filtrate was diluted with ethyl acetate (75 ml) 
washed with water (acidified with 2M hydrochloric acid as layers were not separating) 
(3 × 15 ml) and brine, then dried Na2SO4 and evaporated to give oxazolidine-2-thione 
48a as a colourless viscous oil (2.07 g, 10.7 mmol, 98%); νmax (cm
-1
) 3179 (NH), 1494 
(C=S); 
1
H NMR (400 MHz, chloroform-d) δ ppm 2.87 - 3.04 (2H, m, CH2Ph), 4.28 - 
4.38 (1H, m, CH), 4.42 (1H, dd, J=8.9, 6.4 Hz, CHH’O), 4.70 (1H, app. t, J=8.8 Hz, 
CHH’O), 7.20 (2H, d, J=7.0 Hz ArH), 7.26 - 7.40 (3H, m, ArH), 7.88 (1H, br s, NH); 
13
C NMR (125 MHz, chloroform-d) δ ppm 40.6 (CH2Ph), 57.9 (CH), 74.9 (CH2O), 
127.6, 129.1, 129.3, 135.3 (4 ArC), 189.7 (C=S). 
(S)-4-phenyloxazolidine-2-thione (48b)
157
 
 
To a mixture of L-phenylglycinol (S)-46b (0.2 g, 1.46 mmol, 1 eq), potassium 
carbonate (0.101 g, 0.729 mmol, 0.5 eq) and CS2 (0.176 ml, 2.92 mmol, 2 eq) in 
absolute ethanol (1.5 ml) stirred and heated to 50 °C was added 30% aq. hydrogen 
peroxide (0.248 ml, 2.19 mmol, 1.5 eq) dropwise [Caution: Exotherm!]. After 
completion of addition the mixture was cooled to rt and filtered. The filtrate was diluted 
with ethyl acetate (10 ml) washed with water (acidified with 2M hydrochloric acid as 
layers were not separating) (2 × 5 ml) and brine, then dried MgSO4 and evaporated to 
give oxazolidine-2-thione 48b as a white solid (0.21 g, 1.17 mmol, 80%), mp 117-118 
°C (lit.
157
 120-121 °C); νmax (cm
-1
) 3172 (NH); 
1
H NMR (400 MHz, chloroform-d) δ 
ppm 4.48 (1H, dd, J=9.0, 7.0 Hz, CHH’O), 5.00 (1H, t, J=9.0 Hz, CHH’O), 5.15 (1H, 
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dd, J=9.0, 7.0 Hz, CHPh), 7.26 - 7.48 (5H, m, ArH), 8.15 (1H, br s, NH); 
13
C NMR 
(125 MHz, chloroform-d) δ ppm 60.6 (CH2O), 78.1 (CHPh), 126.6 (m-Ph), 129.6 (p-
Ph), 129.8 (o-Ph), 138.3 (i-Ph), 190.3 (C=S). 
tert-butyl N-(2-{[4-({[(4S)-4-benzyl-4,5-dihydro-1,3-thiazol-2-
yl]sulfanyl}methyl)benzene]amido}phenyl)carbamate (49a) 
 
To a solution of the benzyl chloride 43 (0.92 g, 2.55 mmol, 1.1 eq) in acetone 
(15 ml) was added sodium iodide (0.765 g, 5.1 mmol, 2.2 eq) then stirred at reflux for 2 
h (the round bottomed flask, oil bath and condenser were wrapped in foil to keep the 
benzyl iodide in the dark). After 2 h the mixture was cooled to rt and a solution of 
thiazolidine-2-thione 47a (0.485 g, 2.32 mmol, 1.0 eq) in dichloromethane (10 ml) was 
added followed by potassium carbonate (0.481 g, 3.48 mmol, 1.5 eq). The resulting 
mixture was stirred at rt for 28 h (in the dark). The mixture was then evaporated then 
dissolved/suspended in ethyl acetate and filtered then evaporated. The residue was 
purified by column chromatography (dichloromethane to 5% EtOAC:dichloromethane) 
to give 49a as a white solid (0.751 g, 1.4 mmol, 61%), mp 67-69 °C; νmax (cm
-1
) 3275 
(NH), 1693 (C=O), 1656 (C=O); 
1
H NMR (500 MHz, chloroform-d) δ ppm 1.50 (9H, s, 
C(CH3)3), 2.77 (1H, dd, J=13.6, 8.5 Hz, H(21)), 3.12 - 3.19 (2H, m, H(21)’ and H(20)), 
3.35 (1H, dd, J=10.7, 7.9 Hz, H(20)’), 4.36 (1H, d, J=13.6 Hz, H(15)), 4.43 (1H, d, 
J=13.6 Hz, H(15)’), 4.65 - 4.75 (1H, m, NCH, H(19)), 6.88 (1H, br s, BocNH), 7.10 - 
7.28 (6H, m, ArH), 7.32 (2H, t, J=7.3 Hz, H(24 and 26)), 7.45 (2H, d, J=8.2 Hz, H(11 
and 13)), 7.74 (1H, d, J=7.9 Hz, H(6)), 7.90 (2H, d, J=8.2 Hz, H(10 and 14)), 9.18 (1H, 
br s, H(7)); 
13
C NMR (125 MHz, chloroform-d) δ ppm 28.4 (C(CH3)3), 36.6 (C(15)), 
39.4 (C(20)), 40.2 (C(21)), 77.5 (C(19)), 81.5 (OC(CH3)3), 124.6 (C(3)), 125.9 (C(6)), 
126.0 (C(4)), 126.1 (C(5)), 126.7 (C(24)), 127.7 (C(10 and 14)), 128.6 (C(11 and 13)), 
129.4 (C(22 and 26)), 129.4 (C(23 and 25)), 130.1 (C(9)), 130.9 (C(2)), 133.4 (C(1)), 
138.3 (C(21)), 141.2 (C(12)), 154.7 (CO2N), 165.3 (C(17) and C(8)); m/z (EI
+
) 533 (M
+
, 
35%); HRMS C29H31N3O3S2
+
 requires: 533.1801, found: 533.1804. 
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tert-butyl N-(2-{[4-({[(4S)-4-benzyl-4,5-dihydro-1,3-oxazol-2-
yl]sulfanyl}methyl)benzene]amido}phenyl)carbamate (50a) 
 
To a solution of benzyl chloride 43 (0.512 g, 1.42 mmol, 1.1 eq) in acetone (10 
ml) was added sodium iodide (0.427 g, 2.85 mmol, 2.2 eq) then stirred at reflux for 2 h 
(wrapped in foil to block out light). Cooled to rt and a solution of oxazolidine-2-thione 
48a (0.25 g, 1.29 mmol, 1 eq) in acetone (5 ml)
 
was added and potassium carbonate 
(0.268 g, 1.94 mmol, 1.5 eq) was added then stirred at rt for 23 h. The solvent was 
evaporated then the residue was dissolved in ethyl acetate and filtered. The filtrate was 
evaporated and the resulting yellow oil was purified by column chromatography on 
silica gel (5 to 10% ethyl acetate/dichloromethane) to give benzamide 50a as a white 
solid (0.434 g, 0.839 mmol, 59%), mp 59-61 °C; νmax (cm
-1
) 3280 (NH), 1696 (C=O), 
1656 (C=O); 
1
H NMR (500 MHz, chloroform-d) δ ppm 1.50 (9H, s, C(CH3)3), 2.67 
(1H, td, J=13.8, 8.4 Hz, CHH’Ph), 3.09 (1H, td, J=13.8, 6.1 Hz, CHH’Ph), 4.08 (1H, 
app. t, J=8.0 Hz, CHH’O), 4.22 - 4.35 (3H, m, SCH2 and CHH’O), 4.39 - 4.47 (1H, m, 
CH), 6.89 (1H, br s, ArCONH), 7.10 - 7.16 (1H, m, ArH), 7.17 - 7.27 (5H, m, ArH), 
7.27 - 7.33 (2H, m, ArH), 7.48 (2H, d, J=8.0 Hz, ArH), 7.75 (1H, t, J=5.6 Hz, ArH), 
7.91 (2H, d, J=8.0 Hz, ArH), 9.20 (1H, br s, OCONH); 
13
C NMR (125 MHz, 
chloroform-d) δ ppm 28.4 (C(CH3)3), 35.9 (CH2Ar), 41.7 (CH2Ph), 67.8 (CH2O), 73.7 
(CH), 81.5 (OC(CH3)3), 124.6, 125.9, 126.1, 126.7, 127.8, 128.6, 129.3, 130.0, 130.9, 
133.5, 137.7, 141.2 (12 ArC), 154.7 (ONC=O), 165.1 (C=N), 165.3 (ArNC=O) [2 
aromatic carbons overlapping with other aromatic carbons]; m/z (ES
+
) 518 ([M+H]
+
, 
33%), 462 ([M+2H-C(CH3)3]
+
, 100%); HRMS C29H32N3O4S
+
 requires: 518.2114, 
found: 518.2093. 
N-(2-aminophenyl)-4-(([(4S)-4-benzyl-4,5-dihydro-1,3-thiazol-2-
yl]sulfanyl)methyl)benzamide (51a) 
 
To a solution of 49a (0.30 g, 0.562 mmol) in dichloromethane (2.5 ml) was 
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added trifluoroacetic acid (0.5 ml) the solution was stirred at rt for 2.5 h, then 
evaporated and azeotroped with toluene four times. The residue was dissolved in 
dichloromethane (15 ml) and washed with sat. aq. sodium hydrogen carbonate (15 ml) 
then the aqueous layer was extracted with dichloromethane (10 ml), the combined 
organic layers were dried MgSO4 and concentrated to give a cream solid that was 
purified by column chromatography on silica gel (hexane:ethyl acetate, 3:2) and then 
recrystallized from dichloromethane and hexane to give 51a as a white solid (0.135 g, 
0.311 mmol, 55%), mp 135-137 °C; [α]D
20 -20.6 (c 1.0, methanol); νmax (cm
-1
) 3274 
(NH), 1635 (C=O), 1603 (C=N); 
1
H NMR (400 MHz, chloroform-d) δ ppm 2.79 (1H, 
dd, J=13.6, 8.8 Hz, H(21)), 3.11 - 3.23 (2H, m, H(21)’ and H(20)), 3.36 (1H, dd, J=10.9, 
7.9 Hz, H(20)’), 3.84 (2H, br s, NH2), 4.37 (1H, d, J=13.6 Hz, H(15)), 4.42 (1H, d, 
J=13.6 Hz, H(15)), 4.65 - 4.76 (1H, m, H(19)), 6.78 - 6.91 (2H, m, H(5) and H(3)), 7.09 
(1H, t, J=7.4 Hz, H(4)), 7.19 - 7.39 (6H, m, ArH), 7.46 (2H, d, J=7.7 Hz, H(11 and 13)), 
7.83 (2H, d, J=7.7 Hz, H(10 and 14)), 8.06 (1H, br s, H(7)); 
13
C NMR (125 MHz, 
chloroform-d) δ ppm 36.5 (ArCH2S), 39.5 (CH2S), 40.2 (CH2Ph), 77.8 (CH), 118.6, 
120.0, 124.7, 125.4, 126.7, 127.4, 127.7, 128.6, 129.4, 129.5, 133.2, 138.5, 140.5, 141.5 
(14 ArC), 163.9 C=N, 165.6 (C=O); m/z (ES
+
) 434 ([M+H]
+
, 100%); HRMS 
C24H24N3OS2
+
 requires: 434.1361, found: 434.1360. 
N-(2-aminophenyl)-4-({[(4S)-4-phenyl-4,5-dihydro-1,3-thiazol-2-
yl]sulfanyl}methyl)benzamide (51b) 
 
To a solution of 47b (83 mg, 0.425 mmol, 1.0 eq) and benzyl chloride 54 (110 
mg, 0.422 mmol, 1.0 eq) in acetone (4 ml) was added potassium carbonate (88 mg, 
0.638 mmol, 1.5 eq) and then stirred at reflux for 17 h. Cooled to rt and evaporated and 
then partitioned between water (15 ml) and ethyl acetate (15 ml), the aq. layer was 
extracted with ethyl acetate (10 ml) then the combined organics were washed with brine 
(10 ml), dried Na2SO4, and evaporated to give a beige solid. Purification by column 
chromatography on silica gel (dichloromethane:ethyl acetate, 7:1) and then again 
(hexane:ethyl acetate, 3:2) gave 51b as a white solid (114 mg, 0.262 mmol, 62%), mp 
113-114 °C; [α]D
20 +75.5 (c 1.0, methanol); νmax (cm
-1
) 3276 (NH), 1647 (C=O), 1614 
(C=N); 
1
H NMR (500 MHz, chloroform-d) δ ppm 3.30 (1H, dd, J=10.9, 9.0 Hz, 
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C(20)HH`), 3.63 (2H, br s, NH2), 3.78 (1H, dd, J=10.9, 8.3 Hz, C(20)HH`), 4.40 (1H, d, 
J=13.7 Hz, C(15)HH`), 4.46 (1H, d, J=13.7 Hz, C(15)HH`), 5.49 (1H, t, J=8.6 Hz, 
C(19)H), 6.74 - 6.85 (2H, m, H(5) and H(3)), 7.08 (1H, t, J=7.3 Hz, H(4)), 7.24 - 7.32 
(4H, m, ArH), 7.32 - 7.38 (2H, m, ArH), 7.46 (2H, d, J=7.9 Hz, H(11 and 13)), 7.79 
(2H, d, J=7.9 Hz, (H(10 and 14)), 8.01 (1H, br s, NH); 
13
C NMR (125 MHz, 
chloroform-d) δ ppm 36.5 (C(20)), 43.1 (C(15)), 79.6 (C(19)), 118.5 (C(3)), 119.9 
(C(5)), 124.6 (C(1)), 125.4 (C(6)), 126.6 (C(10 and 14)), 127.4 (C(4)), 127.7 (C(22 and 
26)), 127.9 (C(24)), 128.7 (C(11 and 13)), 129.6 (C(23 and 25)), 133.3 (C(9)), 140.8 
(C(2)), 141.5 (C(21)), 141.6 (C(12)), 165.2 (C(17)), 165.6 (C(8)); m/z (EI
+
) 419 (M
+
, 
100%); HRMS C23H21N3OS2
+
 requires: 419.1121, found: 419.1125. 
N-(2-aminophenyl)-4-({[(4S)-4-(1H-indol-3-ylmethyl)-4,5-dihydro-1,3-thiazol-2-
yl]sulfanyl}methyl)benzamide (51c) 
 
To a solution of 47c (0.229 g, 0.920 mmol, 1.2 eq) and benzyl chloride 54 (0.2 g, 
0.767 mmol, 1.0 eq) in acetone (4 ml) was added potassium carbonate (0.159 g, 1.15 
mmol, 1.5 eq) and then stirred at reflux for 16.5 h. Cooled to rt and evaporated and then 
partitioned between water (25 ml) and ethyl acetate (25 ml), the aq. layer was extracted 
with ethyl acetate (10 ml) then the combined organics were washed with brine (10 ml), 
dried MgSO4, and evaporated to give a beige solid. Purification by column 
chromatography on silica gel (hexane:ethyl acetate, 1:1) gave 51c as a white solid 
(0.311 g, 0.658 mmol, 86%), mp 138-140 °C; [α]D
20 -16.5 (c 1.0, methanol); νmax (cm
-1
) 
3379 (NH), 3324 (NH), 1638 (C=O); 
1
H NMR (500 MHz, chloroform-d) δ ppm 2.96 
(1H, dd, J=14.6, 8.3 Hz, C(21)HH`), 3.13 - 3.27 (2H, m, C(20)HH` and C(21)HH`), 
3.34 (1H, dd, J=10.8, 8.0 Hz, C(20)HH`), 3.81 (2H, br s, NH2), 4.30 (1H, d, J=13.6 Hz, 
C(15)HH`), 4.40 (1H, d, J=13.6 Hz, C(15)HH`), 4.82 (1H, app. quin, J=7.1 Hz, H(19)), 
6.76 - 6.87 (2H, m, H(5) and H(3)), 6.91 (1H, s, H(23)), 7.03 - 7.15 (2H, m, H(4) and 
H(28)), 7.18 (1H, t, J=7.5 Hz, H(27)), 7.26 (1H, d, J=7.9 Hz, H(6)), 7.33 (1H, d, J=8.0 
Hz, H(26)), 7.39 (2H, d, J=8.0 Hz, H(11 and 13)), 7.64 (1H, d, J=7.9 Hz, H(29)), 7.72 
(2H, d, J=8.0 Hz, H(10 and 14)), 7.98 (1H, br s, NH), 8.36 (1H, br s, NH); 
13
C NMR 
(125 MHz, chloroform-d) δ ppm 29.8 (C(21)), 36.4 (C(20)), 39.8 (C(15)), 77.1 (C(19)), 
111.4 (C(26)), 112.4 (C(22)), 118.4 (C(3)), 118.9 (C(29)), 119.4 (C(27)), 119.8 (C(5)), 
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122.1 (C(28)), 122.9 (C(23)), 124.4 (C(1)), 125.6 (C(4)), 127.5 (C(6)), 127.6 (C(11 and 
13)), 127.7 (C(30)), 129.5 (C(10 and 14)), 133.1 (C(9)), 136.3 (C(25)), 141.0 (C(2)), 
141.6 (C(12)), 163.5 C((17)), 165.9 C((8)); m/z (EI
+
) 472 (M
+
, 10%), 208 ([M+H-
(indoleCH2)-(CONHC6H5NH2)]
+
, 100%), 130 ([indole-CH2]
+
, 100%); HRMS 
C26H24N4OS2
+
 requires: 472.1386, found: 472.1393. 
(S)-N-(2-aminophenyl)-4-(((4-benzyl-4,5-dihydrooxazol-2-
yl)thio)methyl)benzamide (52a) 
 
To a solution of thione 48a (84 mg, 0.437 mmol, 1.2 eq) and benzyl chloride 54 
(95 mg, 0.364 mmol, 1.0 eq) in acetone (4 mL) was added potassium carbonate (75 mg, 
0.543 mmol, 1.5 eq), then mixture was then stirred at reflux for 16.5 h and evaporated. 
The residue was partitioned between water (15 mL) and ethyl acetate (20 mL) the layers 
were separated, and the aqueous layer was extracted with ethyl acetate (15 mL). The 
combined organic layers were washed with brine, dried MgSO4 and evaporated to give 
an orange solid (175 mg) that was purified by column chromatography on silica gel 
(ethyl acetate:hexane, 1:1) to give 52a as a cream solid (106 mg, 0.254 mmol, 70%), mp 
137-140 °C; [α]D
25 -32.0 (c 0.5, methanol); νmax (cm
-1
) 3274 (NH), 1649 (C=O); 
1
H 
NMR (300 MHz, chloroform-d) δ ppm 2.66 (1H, dd, J=13.8, 8.3 Hz, H(21)), 3.08 (1H, 
dd, J=13.8, 5.5 Hz, H(21)’), 3.86 (2H, br s, NH2), 4.03 - 4.12 (1H, m, H(20)), 4.19 - 
4.35 (3H, m, H(20)’, H(15) and H(15)’), 4.36 - 4.50 (1H, m, H(19)), 6.75 - 6.89 (2H, m, 
H(5) and H(3)), 7.02 - 7.13 (1H, m, H(4)), 7.14 - 7.35 (6H, m, ), 7.48 (2H, d, J=8.0 Hz, 
H(11 and 13)), 7.83 (2H, d, J=8.0 Hz, H(10 and 14)), 7.96 (1H, br s, H(7)); 
13
C NMR 
(125 MHz, chloroform-d) δ ppm 36.2 (C(21)), 42.0 (C(15)), 68.2 (C(20)), 74.0 (C(19)), 
118.8 (C(3)), 120.2 (C(6)), 125.0 (C(1)), 125.6 (C(4)), 127.0 (C(5)), 127.7 (C(24)), 
128.0 (C(11 and 13)), 129.0 (C(10 and 14)), 129.6 (C(22 and 26)), 129.8 (C(23 ad 25)), 
133.7 (C(9)), 138.0 (C(2)), 141.1 (C(21)), 141.7 (C(12)), 165.3 (C(17)), 165.8 (C(8)); 
m/z (ESI
-
) 416 ([M-H]
-
, 100%); HRMS C24H22N3O2S
-
 requires: 416.1438, 
found:416.1433. 
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(S)-N-(2-aminophenyl)-4-(((4-phenyl-4,5-dihydrooxazol-2-
yl)thio)methyl)benzamide (52b) 
 
To a solution of thione 48b (185 mg, 1.03 mmol, 1.0 eq) and benzyl chloride 54 
(269 mg, 1.03 mmol, 1.0 eq) in acetone (10 mL) was added potassium carbonate (213 
mg, 1.56 mmol, 1.5 eq), then mixture was then stirred at reflux for 18 h and evaporated. 
The residue was partitioned between water (40 mL) and ethyl acetate (40 mL) the layers 
were separated, and the organic layer was washed with brine, dried MgSO4 and 
evaporated to give an orange solid (420 mg) that was purified by column 
chromatography on silica gel (ethyl acetate:hexane, 1:1), and then purified again by 
column chromatography on silica gel (dichloromethane:ethyl acetate, 4:1 to 3:1) to give 
52b as a cream solid (66 mg, 0.163 mmol, 16%), mp 64-65 °C; [α]D
25 -14.0 (c 0.5, 
methanol); νmax (cm
-1
) 3292 (NH), 1653 (C=O); 
1
H NMR (400 MHz, chloroform-d) δ 
ppm 3.91 (2H, br s, NH2), 4.22 (1H, t, J=8.0 Hz, H(20), 4.31 - 4.46 (2H, m, H(15) and 
H(15)’), 4.75 (1H, t, J=8.9 Hz, H(20)’), 5.25 (6H, dd, J=9.5, 8.0 Hz, H(19)), 6.83 - 6.93 
(2H, m, H(5) and H(3)), 7.13 (1H, t, J=7.3 Hz, H(4)), 7.21 (2H, d, J=7.0 Hz, ArH), 7.26 
- 7.41 (6H, m, ArH), 7.56 (2H, d, J=8.0 Hz, ArH), 7.87 (3H, d, J=7.5 Hz, H(10 and 14) 
and H(7)); 
13
C NMR (125 MHz, chloroform-d) δ ppm 35.9 (C(15)), 69.9 (C(19)), 76.6 
(C(20)), 118.5 (C(3)), 119.8 (C(5)), 124.6 (C(1)), 125.4 (C(4)), 126.6 (C(11 and 13)), 
127.4 (C(6)), 127.7 (C(22 and 26)), 127.9 (C(24)), 128.8 (C(23 and 25)), 129.5 (C(10 
and 14)), 133.4 (C(9)), 140.8 (C(21)), 141.4 (C(21)), 141.9 (C(12)), 165.6 (C(17)), 
166.0 (C(8)); m/z (CI) 404 ([M+H]
+
, 100%); HRMS C23H22N3O2S
+
 requires: 404.1427, 
found: 404.1426. 
N-(2-aminophenyl)-4-(chloromethyl)benzamide (54) 
 
To a solution of Boc-protected benzylchloride 43 (0.361 g, 1.0 mmol) in 
dichloromethane (2.5 ml) was added trifluoroacetic acid (0.5 ml) and the resulting 
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solution stirred at rt for 2.5 h. The solution was azeotroped with toluene two times, and 
the resulting yellow solid triturated with diethyl ether three times to give a white solid. 
Partitioned between ethyl acetate (30 ml) and sat. aq. sodium hydrogen carbonate (20 
ml), organic layer washed with brine, dried Na2SO4 and evaporated to give 54 as a 
white solid (0.190 g, 0.727 mmol, 73%), mp 132-133 °C; νmax (cm
-1
) 3370 (NH), 3279 
(NH), 1645 (C=O); 
1
H NMR (500 MHz, DMSO-d6) δ ppm 4.83 (2H, s, CH2), 4.90 (2H, 
br s, NH2), 6.59 (1H, t, J=7.4 Hz, H(5)), 6.77 (1H, d, J=7.3 Hz, H(3)), 6.97 (1H, t, J=7.6 
Hz, H(4)), 7.16 (1H, d, J=7.6 Hz, H(6)), 7.56 (2H, d, J=7.9 Hz, H(11 and 13)), 7.97 
(2H, d, J=7.9 Hz, H(10 and 14)), 9.67 (1H, s, H(7)); 
13
C NMR (125 MHz, DMSO-d6) δ 
ppm 45.5 (CH2), 116.1 (C(3)), 116.2 (C(5)), 123.2 (C(6)), 126.6 (C(1)), 126.7 (C(4)), 
128.1 (C(11 and 13)), 128.7 (C(10 and 14)), 134.5 (C(9)), 140.8 (C(12)), 143.1 (C(2)), 
164.9 (C(8)); m/z (EI
+
) 260 (M
+
, 11%), 153 ([M-PhNH2NH]
+
, 30%); HRMS 
C14H13N2OCl
+
 requires: 260.0711, found: 260.0708. 
 (4S)-4-benzyl-2-(methylsulfanyl)-4,5-dihydro-1,3-thiazole (56a) 
 
To a solution of 47a (1.00 g, 4.78 mmol, 1.0 eq) in acetone (10 ml) was added 
iodomethane (0.36 ml, 5.73 mmol, 1.2 eq) and then stirred at reflux for 3 h. TLC 
indicated that some starting material remained so iodomethane (0.1 ml, 1.6 mmol, 0.3 
eq) and stirred at reflux for a further 2 h. Then evaporated and partitioned between sat. 
aq. sodium hydrogen carbonate and dichloromethane, the organic layer was dried 
MgSO4 and evaporated to give 56a as a colourless oil (1.06 g, 4.73 mmol, 99%); νmax 
(cm
-1
) 1561 (C=N); 
1
H NMR (500 MHz, chloroform-d) δ ppm 2.56 (3H, s, SCH3), 2.74 
(1H, dd, J=13.6, 9.1 Hz, CHH`Ph), 3.14 (1H, dd, J=10.8, 6.6 Hz, CHH`S), 3.19 (1H, dd, 
J=13.6, 5.0 Hz, CHH`Ph), 3.32 (1H, dd, J=10.8, 7.9 Hz, CHH`S), 4.64 - 4.73 (1H, m, 
CHN), 7.21 - 7.27 (3H, m, ArH), 7.29 - 7.34 (2H, m, ArH); 
13
C NMR (125 MHz, 
chloroform-d) δ ppm 15.5 (CH3), 39.3 (CH2Ph), 40.2 (CH2S), 77.9 (CHN), 126.6, 
128.6, 129.4, 138.5 (4 ArC), 165.7 (C=N); m/z (CI
+
)
 
224 ([M+H]
+
, 100%); HRMS 
C11H14NS2
+
 requires 224.0568, found: 224.0569. 
 (4S)-2-(methylsulfanyl)-4-phenyl-4,5-dihydro-1,3-thiazole (56b) 
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To a suspension of 47b (0.20 g, 1.02 mmol, 1.0 eq) in acetone (2 ml) was added 
iodomethane (0.097 ml, 1.54 mmol, 1.5 eq). The mixture was stirred at reflux for 4 h 
under a nitrogen balloon then evaporated and the resulting white solid partitioned 
between sodium hydrogen carbonate (sat. aq., 15 ml) and dichloromethane (15 ml). The 
aqueous layer was extracted with dichloromethane (10 ml) and the combined organics 
were washed with brine (10 ml) dried MgSO4 and concentrated to give 56b as an orange 
oil (0.188 g, 0.898 mmol, 88%); νmax (cm
-1
) 1561 (C=N); 
1
H NMR (500 MHz, 
chloroform-d) δ ppm 2.61 (3H, s, SCH3), 3.30 (1H, dd, J=10.9, 9.0 Hz, H(8)H), 3.79 
(1H, dd, J=10.9, 8.2 Hz, H(8)`), 5.49 (1H, app. t, J=8.6 Hz, H(7)), 7.23 - 7.40 (5H, m, 
ArH); 
13
C NMR (125 MHz, chloroform-d) δ ppm 15.6 (SCH3), 43.1 (C(8)), 79.7 (C(7)), 
126.6 (C(3 and 5)), 127.8 (C(4)), 128.7 (C(2 and 6), 141.7 (C(1)), 167.0 (C=N); m/z 
(EI
+
) 209 (M
+
, 34%); HRMS C10H11NS2
+
 requires: 209.0327, found: 209.0333. 
methyl 4-(([(4S)-4-benzyl-4,5-dihydro-1,3-thiazol-2-yl]amino)methyl)benzoate 
(57a) 
 
To a solution of dihydro-1,3-thiazole 56a (0.24 g, 1.07 mmol, 1 eq) in ethanol 
(2.5 ml) was added methyl 4-(aminomethyl)benzoate hydrochloride (0.22 g, 1.07 mmol, 
1 eq) and N,N-diisopropylethylamine (186 µl, 1.07 mmol, 1 eq). The resulting mixture 
was stirred at reflux for 24 h. Then concentrated and partitioned between ethyl acetate 
(25 ml) and sat. aq. sodium hydrogen carbonate (25 ml), the organic layer was washed 
with sat. aq. sodium hydrogen carbonate, dried with Na2SO4, and concentrated to give 
an orange oil that was purified by column chromatography on silica gel (4% 
methanol/dichloromethane) to give 57a as a colourless oil (0.23 g, 0.676 mmol, 63%); 
νmax (cm
-1
) 1716 (C=O), 1610 (C=N); 
1
H NMR (500 MHz, chloroform-d) δ ppm 2.74 
(1H, dd, J=13.4, 8.7 Hz, CHH’Ph), 3.02 - 3.11 (2H, m, CHH’S and CHH’Ph), 3.26 (1H, 
dd, J=10.7, 6.9 Hz, CHH’S), 3.91 (3H, s, CO2CH3), 4.39 - 4.46 (2H, CHN and NH), 
4.49 (1H, d, J=15.4 Hz, ArCHH’N), 4.54 (1H, d, J=15.4 Hz, ArCHH’N), 7.17 - 7.24 
(3H, m, 3 ArH), 7.25 - 7.32 (2H, m, 2 ArH), 7.38 (2H, d, J=8.2 Hz, Ar-3,5 H), 8.00 (2H, 
d, J=8.2 Hz, Ar-2,6 H); 
13
C NMR (125 MHz, chloroform-d) δ ppm 38.3 (CH2S), 41.2 
(CHPh), 49.6 (CO2CH3), 52.2 (CH2N), 71.9 (CH), 126.5, 127.4, 128.6, 129.3, 129.3, 
130.0, 138.6, 144.0 (8 ArC), 161.4 (C=N), 167.0 (C=O); m/z (ES
+
) 341 ([M+H]
+
, 
100%); HRMS C19H21N2O2S
+
 requires: 341.1324, found: 341.1324. 
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4-(([(4S)-4-benzyl-4,5-dihydro-1,3-thiazol-2-yl]amino)methyl)benzoic acid (58a) 
 
To a solution of methyl ester 57a (0.210, 0.617 mmol, 1 eq) in THF (3.5 ml) was 
added a solution of lithium hydroxide monohydrate (0.065 g, 1.54 mmol, 2.5 eq) in 
water (1.5 ml), then stirred at rt for 26 h. The THF was evaporated then diluted with 
water (25 ml) and extracted with ethyl acetate (25 ml) and 5% methanol in 
dichloromethane (2 × 25 ml). The combined organics were washed with brine, dried 
Na2SO4 and evaporated. The crude product was purified by column chromatography on 
silica gel (10% methanol/dichloromethane) to give the benzoic acid 58a as a white solid 
(0.122 g, 0.375 mmol, 61%), mp 70-72 °C; νmax (cm
-1
) 1706 (C=O), 1633 (C=N); 
1
H 
NMR (400 MHz, DMSO-d6) δ ppm 2.91 (1H, dd, J=13.6, 7.8 Hz, CHH’Ph), 3.03 (1H, 
dd, J=13.6, 4.8 Hz, CHH’Ph), 3.25 (1H, dd, J=11.3, 5.8 Hz, CHH’S), 3.37 (1H, br s, 
NH), 3.52 (1H, dd, J=11.3, 7.8 Hz, (CHH’S), 4.50 - 4.61 (1H, m, CH), 4.65 - 4.80 (2H, 
m, NCH2Ar), 7.15 - 7.34 (5H, m, ArH), 7.48 (2H, d, J=8.0 Hz, ArH), 7.97 (2H, d, J=8.0 
Hz, ArH), 10.60 (1H, br s, CO2H); 
13
C NMR (125 MHz, DMSO-d6) δ ppm 34.6 (CH2S), 
38.7 (CH2Ph), 47.9 (NCH2Ar), 63.3 (CH), 126.7, 127.7, 128.4, 129.5, 129.6, 130.2, 
136.3, 141.3 (8 ArC), 167.0 (C=O); m/z (ES
+
) 327 ([M+H]
+
, 100%); HRMS 
C18H19N2O2S
+
 requires: 327.1167, found: 327.1170. 
 (R)-N-(2-aminophenyl)-4-(((4-benzyl-4,5-dihydrothiazol-2-
yl)amino)methyl)benzamide ((R)-59a) 
 
The thiourea (R)-79a (0.355 g, 0.664 mmol) was reacted according to general 
procedure B for 15 min. Purification of the residue by column chromatography on silica 
gel (ethyl acetate:hexane, 3:2 to 2:1) gave a cream solid (117 mg) which was 
recrystallized from chloroform to give (R)-59a as a white solid (62 mg, 22%), mp 
143−144 °C; [α]D
20 +9.7 (c 1.0, methanol); νmax (cm
−1
) 3164 (NH), 1662 (C=O), 1615 
(C=N); 
1
H NMR (400 MHz, chloroform-d) δ 2.75 (1H, dd, J = 13.3, 8.8 Hz, H(20)), 
2.98−3.17 (2H, m, H(20)’ and H(21)), 3.28 (1H, dd, J = 10.7, 7.2 Hz, H(21)’), 3.90 (2H, 
br s, NH2), 4.38−4.47 (1H, m, H(19)), 4.47−4.59 (2H, m, H(15) and H(15)’), 5.16 (1H, 
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br s, H(16)), 6.76−6.93 (2H, m, H(5) and H(3)), 7.11 (1H, td, J = 7.7, 1.0 Hz, H(4)), 
7.17−7.35 (6H, m, H(24 and 27), H(6), H(24 and 26) and H(25)), 7.40 (2H, d, J = 8.0 
Hz, H(11 and 13)), 7.85 (2H, d, J = 8.0 Hz, H(10 and 14)), 8.05 (1H, br s, H(7));
 13
C 
NMR (150 MHz, chloroform-d) δ ppm 38.5 (C(20)), 41.3 (C(21)), 49.6 (C(15)), 72.1 
(C(19)), 118.5 (C(3)), 119.8 (C(5)), 124.7 (C(1)), 125.3 (C(4)), 126.5 (C(25)), 127.3 
(C(6)), 127.7 (C(24 and 26)), 127.8 (C(11 and 13)), 128.6 (C(10 and 14)), 129.4 (C(23 
and 27)), 133.2 (C(9)), 138.8 (C(2)), 140.8 (C(22)), 143.3 (C(12)), 161.0 (C(17)), 165.7 
(C(8)); m/z (ES, %) 417 ([M+H]
+
, 100); HRMS (CI) calcd for C24H25N4OS [M+H]
+
 
417.1744, found 417.1723. 
(S)-N-(2-aminophenyl)-4-(((4-benzyl-4,5-dihydrothiazol-2-
yl)amino)methyl)benzamide ((S)-59a) 
 
A solution of (S)-79a (0.135 g, 0.252 mmol) in conc. hydrochloric acid (5 ml) 
was heated at 90 °C under a reflux condenser and stirred for 15 min. Then sodium 
hydroxide (5M, aq) was added to pH ~ 9, and the product extracted with ethyl acetate (3 
× 30 ml). The combined organics were washed with brine, dried Na2SO4, and 
evaporated. Purification by column chromatography on silica gel (1% methanol/ethyl 
acetate) gave a cream solid (68 mg) which was further purified by recrystallization from 
chloroform to give (S)-59a as a white solid (10 mg, 0.024 mmol, 10%), mp 144-145 °C; 
[α]D
20 -9.2 (c 1.0, methanol); νmax (cm
-1
) 3162 (NH), 1636 (C=O), 1614 (C=N); 
1
H NMR 
(500 MHz, chloroform-d) δ ppm 2.72 (1H, dd, J=13.4, 8.8 Hz, H(20)), 3.00 - 3.10 (2H, 
m, H(20)` and H(21)), 3.24 (1H, dd, J=10.6, 7.2 Hz, H(21)`), 3.94 (3H, br s, NH2 and 
H(16)), 4.34 - 4.42 (1H, m, H(19)), 4.47 (2H, m, H(15) and H(15)’), 6.74 - 6.86 (2H, m, 
H(5) and H(3)), 7.07 (1H, app. t, J=7.5 Hz, H(4)), 7.19 (2H, d, J=7.4 Hz, H(24 and 27)), 
7.22 (1H, d, J=7.1 Hz, H(6)), 7.25 - 7.31 (3H, m, H(24 and 26) and H(25)), 7.34 (2H, d, 
J=7.7 Hz, H(11 and 13)), 7.80 (2H, d, J=7.7 Hz, H(10 and 14)), 8.13 (1H, br s, H(7)); 
13
C NMR (150 MHz, chloroform-d) δ ppm 38.3 (C(20)), 41.3 (C(21)), 49.6 (C(15)), 
71.9 (C(19)), 118.5 (C(3)), 119.8 (C(5)), 124.6 (C(1)), 125.5 (C(4)), 126.6 (C(25)), 
127.3 (C(6)), 127.7 (C(24 and 26)), 127.8 (C(11 and 13)), 128.6 (C(10 and 14)), 129.4 
(C(23 and 27)), 133.2 (C(9)), 138.8 (C(2)), 140.9 (C(22)), 143.2 (C(12)), 161.5 (C(17)), 
165.8 (C(8)); m/z (ES
+
) 417 ([M+H]
+
, 100%); HRMS C24H25N4OS
+
 requires: 417.1749, 
7. Experimental 
Christopher Matthews  172 
found: 417.1738. 
 (R)-N-(2-aminophenyl)-4-(((4-phenyl-4,5-dihydrothiazol-2-
yl)amino)methyl)benzamide ((R)-59b) 
 
The thiourea (R)-79b (0.345 g, 0.663 mmol) was reacted according to general 
procedure B for 45 min. Purification of the residue by column chromatography on silica 
gel (ethyl acetate:hexane, 8:1) afforded a cream solid (149 mg) which was recrystallized 
from chloroform to give (R)-59b as a white solid (62 mg, 23%), mp 155−156 °C; 
[α]D
20⁡−62.0 (c 1.0, methanol); νmax (cm
−1
) 3281 (NH), 1612 (C=O); 
1
H NMR (400 MHz, 
chloroform-d) δ 3.23 (1H, dd, J = 10.5, 8.3 Hz, H(20)), 3.70 (1H, dd, J = 10.5, 7.5 Hz, 
H(20)’), 3.90 (2H, br s, NH2), 4.47−4.60 (2H, m, H(15) and H(15)`), 5.28 (1H, t, J = 7.9 
Hz, H(19)), 5.71 (1H, br s, H(16)), 6.78−6.91 (2H, m, H(5) and H(3)), 7.11 (1H, td, J = 
7.6, 1.0 Hz, H(4)), 7.20−7.36 (6H, m, H(22 and 26), H(23 and 25), H(24) and H(6)), 
7.40 (2H, d, J = 8.0 Hz, H(11 and 13)), 7.85 (2H, d, J = 7.8 Hz, H(10 and 14)), 8.05 
(1H, br s, H(7));
 13
C NMR (150 MHz, chloroform-d) δ ppm 42.5 (C(20)), 49.3 (C(15)), 
74.5 (C(19)), 118.5 (C(3)), 119.9 (C(6)), 124.7 (C(1)), 125.4 (C(4)), 126.5 (C(22 and 
26)), 127.3 (C(24)), 127.6 (C(5)), 127.7 (C(23 and 25)), 127.8 (C(11 and 13)), 128.6 
(C(10 and 14)), 133.2 (C(9)), 140.8 (C(2)), 143.1 (C(21)), 143.3 (C(12)), 162.2 (C(17)), 
165.7 (C(8)); m/z (ES, %) 403 ([M+H]
+
, 100); HRMS (CI) calcd for C23H23N4OS 
[M+H]
+
 403.1587, found 403.1570. 
(S)-N-(2-aminophenyl)-4-(((4-phenyl-4,5-dihydrothiazol-2-
yl)amino)methyl)benzamide ((S)-59b) 
 
A solution of (S)-79b (0.460 g, 0.883 mmol) in conc. hydrochloric acid (15 ml) 
was heated at 90 °C under a reflux condenser and stirred for 75 min. Then sodium 
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hydroxide (5M, aq) was added to pH ~ 9, and the product extracted with ethyl acetate 
(100 mL + 2 × 50 ml). The combined organics were washed with brine, dried Na2SO4, 
and evaporated. Purification by column chromatography on silica gel (ethyl 
acetate:hexane, 7:1 to 8:1) gave a cream solid (257 mg) which was further purified by 
recrystallization from chloroform to give (S)-59b as a white solid (85 mg, 0.211 mmol, 
24%), mp 150-151 °C; [α]D
20 +67.7 (c 1.0, methanol); νmax (cm
-1
) 3190 (NH), 1622 
(C=O); 
1
H NMR (400 MHz, chloroform-d) δ ppm 3.23 (1H, dd, J=10.6, 8.3 Hz, H(20)), 
3.70 (1H, dd, J=10.6, 7.7 Hz, H(20)`), 3.89 (2H, br s, NH2), 4.54 (2H, s, H(15) and 
H(15)`), 5.28 (1H, app. t, J=8.0 Hz, H(19)), 5.66 (1H, br s, H(16)), 6.79 - 6.90 (2H, m, 
H(5) and H(3)), 7.11 (1H, td, J=7.7, 1.5 Hz, H(4)), 7.22 - 7.36 (6H, m, H(22 and 26), 
H(23 and 25), H(24) and H(6)), 7.40 (2H, d, J=8.0 Hz, H(11 and 13)), 7.84 (2H, d, 
J=8.0 Hz, H(10 and 14)), 8.04 (1H, br s, H(7)); 
13
C NMR (150 MHz, chloroform-d) δ 
ppm 42.5 (C(20)), 49.4 (C(15)), 74.4 (C(19)), 118.5 (C(3)), 119.9 (C(6)), 124.7 (C(1)), 
125.4 (C(4)), 126.5 (C(22 and 26)), 127.3 (C(24)), 127.6 (C(5)), 127.7 (C(23 and 25)), 
127.8 (C(11 and 13)), 128.6 (C(10 and 14)), 133.2 (C(9)), 140.9 (C(2)), 143.1 (C(21)), 
143.3 (C(12)), 162.3 (C(17)), 165.8 (C(8)); m/z (CI
+
) 403 ([M+H]
+
, 21%), 385 ([M+H-
water]
+
, 100%); HRMS C23H22N4OS
+
 requires: 403.1593, found: 403.1585. 
 (S)-N-(2-aminophenyl)-4-(((5-phenyl-4,5-dihydrothiazol-2-
yl)amino)methyl)benzamide ((S)-59d) 
 
Thiourea (R)-79d (0.50 g, 0.96 mmol) was reacted according to general 
procedure B for 30 min. The residue was purified by column chromatography on silica 
gel (7% methanol/dichloromethane) and then recrystallized from ethanol and water 
twice to give (S)-59d as a white solid (0.190 g, 49%), mp 159-164 °C; [α]D
20 -35.3 (c 
1.0, MeOH); νmax (cm
-1
) 3328 (NH), 1633 (C=O), 1620 (C=N);
 1
H NMR (600 MHz, 
methanol-d4) δ ppm 3.98 (1H, dd, J=13.2, 5.3 Hz, H(19)), 4.25 (1H, dd, J=13.2, 7.7 Hz, 
H(19)’), 4.55 (2H, s, H(15) and H(15)’), 4.99 - 5.06 (1H, m, H(20)), 6.78 (1H, t, J=7.5 
Hz, H(5)), 6.91 (1H, d, J=7.9 Hz, H(3)), 7.08 (1H, t, J=7.5 Hz, H(4)), 7.19 (1H, d, J=7.5 
Hz, H(6)), 7.22 - 7.27 (1H, m, H(24)), 7.28 - 7.40 (4H, m, H(23 and 25) and H(22 and 
26)), 7.48 (2H, d, J=7.9 Hz, H(11 and 13)), 7.97 (2H, d, J=7.9 Hz, H(10 and 14)); 
13
C 
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NMR (150 MHz, methanol-d4) δ ppm 48.6 (C(15)), 56.3 (C(19)), 68.0 (C(20)), 118.9 
(C(3)), 119.9 (C(6)), 125.5 (C(1)), 127.8 (C(4)), 128.3 (C(11 and 13)), 128.6 (C(10 and 
14)), 128.7 (C(5)), 128.9 (C(24)), 129.2 (C(22 and 26)), 129.9 (C(23 and 25)), 134.5 
(C(9)), 143.0 (C(2)), 143.9 (C(21)), 144.6 (C(12)), 164.9 (C(17)), 168.8 (C(8)); m/z (ES, 
%) 401 ([M-H]
-
, 100); HRMS calcd. for C23H21N4OS
 
[M-H]
-
 401.1436, found: 
401.1446. 
(R)-N-(2-aminophenyl)-4-(((5-phenyl-4,5-dihydrothiazol-2-
yl)amino)methyl)benzamide ((R)-59d) 
 
Thiourea (S)-79d (0.25 g, 0.480 mmol) was reacted according to general 
procedure B for 45 min. The residue was purified by column chromatography on silica 
gel (5% methanol/dichloromethane) and then recrystallized from ethanol and water to 
give (R)-59d as a white solid (41 mg, 21%), mp 161-163 °C; [α]D
20 +38.4 (c 1.0, 
MeOH); νmax (cm
-1
) 3250 (NH), 1610 (C=O); 1H NMR (400 MHz, methanol-d4) δ ppm 
4.00 (1H, dd, J=13.2, 5.3 Hz, H(19)), 4.27 (1H, dd, J=13.2, 7.6 Hz, H(19)’), 4.57 (2H, s, 
H(15) and H(15)’), 5.04 (1H, dd, J=7.6, 5.3 Hz, H(20)), 6.80 (1H, td, J=7.7, 1.3 Hz, 
H(5)), 6.93 (1H, dd, J=8.0, 1.3 Hz, H(3)), 7.07 - 7.14 (1H, m, H(4)), 7.21 (1H, dd, 
J=7.9, 1.1 Hz, H(6)), 7.24 - 7.30 (1H, m, H(24)), 7.30 - 7.36 (2H, m, H(23 and 25)), 
7.37 - 7.42 (2H, m, H(22 and 26)), 7.51 (2H, d, J=8.2 Hz, H(11 and 13)), 7.99 (2H, d, 
J=8.2 Hz, H(10 and 14)); 
13
C NMR (150 MHz, methanol-d4) δ ppm 48.5 (C(15)), 56.3 
(C(19)), 68.3 (C(20)), 118.8 (C(3)), 119.7 (C(6)), 125.4 (C(1)), 127.7 (C(4)), 128.1 
(C(11 and 13)), 128.4 (C(10 and 14)), 128.5 (C(5)), 128.7 (C(24)), 129.0 (C(22 and 
26)), 129.7 (C(23 and 25)), 134.3 (C(9)), 143.1 (C(2)), 143.8 (C(21)), 144.7 (C(12)), 
164.4 (C(17)), 168.7 (C(8)); m/z (CI) 403 ([M+H]
+
, 100%); HRMS calcd. for 
C23H23N4OS
 
[M+H]
+
 403.1587, found: 403.1566. 
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(S)-N-(2-aminophenyl)-4-(((4-(4-hydroxyphenyl)-4,5-dihydrothiazol-2-
yl)amino)methyl)benzamide (59e) 
 
A modified procedure from Kim and Cha was followed.
158
 To a solution of 
thiourea (79e) (0.35 g, 0.652 mmol) in anh. THF (10 mL) was added 
triphenylphosphine (0.257 g, 0.978 mmol) and then a solution of diethyl 
azodicarboxylate (0.154 ml, 0.978 mmol) in anh. THF (5 mL) dropwise by syringe over 
5 min. The solution was stirred for 75 min at rt then HCl in diethylether (2M, 5 mL) was 
added and stirred for 5 h at rt. The suspension was placed in a refrigerator for 3 days, 
then filtered and the hygroscopic white solid was partitioned between 5% 
methanol/dichloromethane (25 mL) and sat. aq. sodium hydrogen carbonate (20 mL). 
The aqueous layer was extracted with 5% methanol/dichloromethane (2 × 25 mL), then 
the combined organics were washed with brine (20 mL), dried Na2SO4 and evaporated. 
Purification by column chromatography on silica gel (8% methanol/dichloromethane) 
gave 59e as a white solid (0.128 g, 47%), mp 128-131 °C; [α]D
20 -63.8 (c 1.0, MeOH); 
νmax (cm
-1
) 3250 (NH), 1607 (C=O); 
1
H NMR (400 MHz, methanol-d4) δ ppm 3.15 (1H, 
dd, J=10.5, 7.5 Hz, H(20)), 3.66 (1H, dd, J=10.7, 7.7 Hz, H(20)’), 4.49 - 4.56 (1H, m, 
H(15)), 4.56 - 4.66 (1H, m, H(15)’), 5.21 (1H, t, J=7.4 Hz, H(19)), 6.74 (2H, d, J=8.5 
Hz, H(23 and 25)), 6.80 (1H, t, J=7.5 Hz, H(5)), 6.93 (1H, d, J=7.8 Hz, H(3)), 7.03 - 
7.16 (3H, m, H(4) and H(22 and 26)), 7.21 (1H, d, J=7.8 Hz, H(6)), 7.50 (2H, d, J=8.2 
Hz, H(11 and 13)), 7.98 (2H, d, J=8.2 Hz, H(10 and 14)); 
13
C NMR (150 MHz, DMSO-
d6) δ ppm 42.0 (C(15)), 47.1 (C(20)), 74.0 (C(19)), 114.8 (C(23 and 25)), 116.2 (C(3)), 
116.4 (C(5)), 123.3 (C(1)), 126.5 (C(4)), 126.8 (C(6)), 127.1 (C(11 and 13)), 127.3 
(C(10 and 14)), 127.8 (C(22 and 26)), 133.0 (C(9)), 134.2 (C(21)), 143.2 (C(2)), 143.5 
(C(12)), 156.3 (C(24)), 159.8 (C(17)), 165.2 (C(8)); m/z (CI) 419 ([M+H]
+
, 85%); 
HRMS calcd. for C23H23N4O2S [M+H]
+
 419.1536, found: 419.1525. 
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N-(2-aminophenyl)-4-((((4S,5S)-4,5-diphenyl-4,5-dihydrothiazol-2-
yl)amino)methyl)benzamide ((S,S)-59f) 
 
Thiourea (R,S)-79f (0.572 g, 0.96 mmol) was reacted according to general 
procedure B for 10 min. The resulting cream solid was recrystallized twice from ethyl 
acetate and hexane to give (S,S)-59f as a white solid (0.151 g, 33%), mp 162-164 °C; 
[α]D
20 -79.3 (c 1.0, MeOH); νmax (cm
-1
) 3239 (NH), 1610 (C=O); 
1
H NMR (600 MHz, 
chloroform-d) δ ppm 4.31 (2H, br s, NH2), 4.50 (2H, s, H(15) and H(15)’), 4.75 (1H, d, 
J=6.8 Hz, H(20)), 5.25 (1H, d, J=6.8 Hz, H(19)), 6.77 - 6.85 (2H, m, ArH), 7.08 (1H, t, 
J=7.7 Hz, ArH), 7.10 - 7.16 (2H, m, ArH), 7.20 - 7.34 (9H, m, ArH), 7.36 (2H, d, J=7.9 
Hz, H(11 and 13)), 7.82 (2H, d, J=7.9 Hz, H(10 and 14)), 8.17 (1H, br s, H(7)); 
13
C 
NMR (150 MHz, chloroform-d) δ ppm 49.3 (C(15)), 64.0 (C(19)), 82.6 (C(20)), 118.5 
(C(3)), 119.8 (C(6)), 124.6 (C(1)), 125.5 (C(4)), 126.5 (C(28 and 32)), 127.4 (C(5)), 
127.8 (C(30) and C(29 and 31), 127.8 (C(11 and 13)), 127.9 (C(22 and 26)), 128.1 
(C(24)), 128.6 (C(10 and 14)), 128.9 (C(23 and 25)), 133.2 (C(9)), 140.1 (C(27)), 140.9 
(C(2)), 142.0 (C(21)), 143.2 (C(12)), 161.5 (C(17)), 165.8 (C(8)); m/z (ES, %) 477 ([M-
H]
-
, 100); HRMS calcd. for C29H26N4OS
 
[M-H]
-
 477.1749, found: 477.1761. 
N-(2-aminophenyl)-4-((((4R,5R)-4,5-diphenyl-4,5-dihydrothiazol-2-
yl)amino)methyl)benzamide ((R,R)-59f) 
 
Thiourea (S,R)-79f (0.570 g, 0.96 mmol) was reacted according to general 
procedure B for 10 min. The resulting cream solid was recrystallized from ethyl acetate 
and hexane to give (S,S)-59f as a white solid (0.165 g, 36%), mp 166-168 °C; [α]D
20 
+80.3 (c 1.0, MeOH); νmax (cm
-1
) 3272 (NH), 1610 (C=O); 
1
H NMR (600 MHz, 
chloroform-d) δ ppm 3.87 (2H, br s, NH2), 4.49 (2H, s, H(15) and H(15)’), 4.75 (1H, d, 
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J=6.7 Hz, H(20)), 5.24 (1H, d, J=6.7 Hz, H(19)), 6.77 - 6.85 (2H, m, ArH), 7.08 (1H, t, 
J=7.7 Hz, ArH), 7.10 - 7.17 (2H, m, ArH), 7.18 - 7.40 (11H, m, ArH), 7.80 (2H, d, 
J=7.5 Hz, H(10 and 14)), 8.20 (1H, br s, H(7)); 
13
C NMR (150 MHz, chloroform-d) δ 
ppm 49.2 (C(15)), 64.0 (C(19)), 82.7 (C(20)), 118.4 (C(3)), 119.8 (C(6)), 124.7 (C(1)), 
125.5 (C(4)), 126.5 (C(28 and 32)), 127.3 (C(5)), 127.7 (C(30)), 127.7 (C(29 and 31)), 
127.8 (C(11 and 13)), 127.9 (C(22 and 26)), 128.0 (C(24)), 128.5 (C(10 and 14)), 128.9 
(C(23 and 25)), 133.2 (C(9)), 140.2 (C(27)), 140.9 (C(2)), 142.1 (C(21)), 143.3 (C(12)), 
161.3 (C(17)), 165.9 (C(8)); m/z (ES, %) 477 ([M-H]
-
, 100); HRMS calcd. for 
C29H26N4OS [M-H]
-
 477.1749, found: 477.1770.  
4-cyano-N-(2-aminophenyl)benzamide (60)
107
 
 
To a solution of 4-cyanobenzoic acid (0.294 g, 2.0 mmol, 1 eq) in DMF (8 ml) 
was added EDC (0.767 g, 4.0 mmol, 2 eq), HOBT (0.324 g, 2.4 mmol, 1.2 eq), 
triethylamine (1.12 ml, 8.0 mmol, 4 eq) and phenylene-1,2-diamine (0.432 g, 4.0 mmol, 
2 eq). The resulting solution was stirred at rt for 20 hours. Then diluted with brine (400 
ml) and filtered, the solids were washed with water and then dried in vacuo to give a 60 
as a beige solid (0.272 g, 1.12 mmol, 56%), mp 204-205 °C; νmax (cm
-1
) 3411 (NH), 
3355 (NH), 3270 (NH), 2238 (C≡N), 1642 (C=O); 1H NMR (500 MHz, DMSO-d6) δ 
ppm 4.95 (2H, br s, NH2), 6.58 (1H, t, J=7.4 Hz, H(14)), 6.77 (1H, d, J=7.9 Hz, H(12)), 
6.98 (1H, t, J=7.4 Hz, H(13)), 7.14 (1H, d, J=7.6 Hz, H(15)), 7.99 (2H, d, J=8.0 Hz, 
H(4 and 6)), 8.12 (2H, d, J=8.0 Hz, H(3 and 7)), 9.86 (1H, br s, H(9)); 
13
C NMR (125 
MHz, DMSO-d6) δ ppm 113.6 (C(2)), 116.0 (C(12)), 116.1 (C(14)), 118.4 (C(1)), 122.5 
(C(10)), 126.9 (C(7)), 126.9 (C(13)), 128.7 (C(4 and 6)), 132.3 (C(3 and 7)), 138.7 
(C(5)), 143.4 (C(11)), 164.1 (C(8)); m/z (EI
+
) 237 (M
+
, 38%), 130 ([CNC6H4CO]
+
, 
38%), 107 ([C6H4NH2NH]
+
, 100%); HRMS C14H11N3O
+
 requires: 237.0897, found: 
237.0905.  
4-(aminomethyl)-N-(2-aminophenyl)benzamide (61) 
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To a solution of 4-cyano-N-(2-aminophenyl)benzamide 60 (0.25 g, 1.05 mmol) 
in methanol (40 ml) was added H2SO4 (0.114 ml, 2.1 mmol, 2 eq) and 10% activated Pd 
on carbon (0.2 g). The flask was evacuated and filled with nitrogen three times to ensure 
there was no oxygen in the flask, then evacuated and filled with hydrogen. Stirred at rt 
for 5.5 h under a hydrogen balloon. Then filtered through celite washing with methanol 
[caution do not let the celite with Pd become dry fire hazard!]. The filtrate was 
neutralised with 1M sodium hydroxide in methanol (2 ml). The resulting mixture was 
filtered and the filtrate evaporated to give a pink oil (0.23 g) which was purified by 
column chromatography on silica gel (1% ammonia (30% aq.), 14% methanol, 85% 
chloroform) to give 61 as a white solid (0.156 g, 0.65 mmol, 62 %), mp 189-190 °C; 
νmax (cm
-1
) 3260 (NH), 3224 (NH), 1635 (C=O); 
1
H NMR (300 MHz, DMSO-d6) δ ppm 
1.90 (2H, br s, CH2NH2), 3.77 (2H, s, CH2), 4.88 (2H, br s, ArNH2), 6.59 (3H, t, J=7.5 
Hz, 5-anilyl), 6.77 (1H, d, J=7.2 Hz, 3-anilyl), 6.96 (1H, t, J=7.5 Hz, 4-anilyl), 7.15 
(1H, d, J=7.5 Hz, 6-anilyl), 7.44 (2H, d, J=8.3 Hz, 3,5-aryl), 7.91 (2H, d, J=8.3 Hz, 2,6-
aryl), 9.61 (1H, br s, CONH); 
13
C NMR (125 MHz, DMSO-d6) δ ppm 45.4 (C(1)), 
116.2 (C(12)), 116.3 (C(14)), 123.5 (C(10)), 126.4 (C(15)), 126.7 (C(13)), 126.7 (C(4 
and 6)), 127.6 (C(3 and 7)), 132.5 (C(5)), 143.1 (C(11)), 148.0 (C(2)), 165.2 (C=O); m/z 
(EI
+
) 241 (M
+
, 51%), 134 ([M-C6H4NH2NH]
+
, 100%); HRMS C14H15N3O
+
 requires: 
241.1210, found: 241.1213. 
N-[(2S)-1-iodo-3-phenylpropan-2-yl](methylsulfanyl)formamide (64a) 
 
 
To a solution of oxazolidine-2-thione 48a (1.5 g, 7.76 mmol, 1 eq) in acetone 
(22 ml) was added iodomethane (0.72 ml, 11.6 mmol, 1.5 eq). The solution was stirred 
at reflux for 2 h then evaporated and partitioned between sat. aq. sodium hydrogen 
carbonate (30 ml) and dichloromethane (50 ml), the aqueous layer was extracted with 
dichloromethane (50 ml) then the combined organics were washed with brine, dried 
MgSO4, and filtered and evaporated to give iodide 64a as a white solid (2.41 g, 7.19 
mmol, 93%), mp 91-93 °C; νmax (cm
-1
) 3284 (NH), 1640 (C=O);
 1
H NMR (500 MHz, 
chloroform-d) δ ppm 2.35 (3H, s, SCH3), 2.81 (1H, dd, J=13.7, 8.0 Hz, CHH’Ph), 2.95 
(1H, dd, J=13.7, 5.7 Hz, CHH’Ph), 3.17 (1H, dd, J=10.3, 4.1 Hz, CHH’I), 3.39 (1H, dd, 
J=10.2, 4.6 Hz, CHH’I), 3.93 (1H, br s, NCH), 5.50 (1H, br s, NH), 7.22 - 7.29 (3H, m, 
ArH), 7.29 - 7.35 (2H, m, ArH); 
13
C NMR (125 MHz, chloroform-d) δ ppm 12.5 
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(SCH3), 12.8 (ICH2), 40.4 (CH2Ph), 51.8 (CH), 127.2, 128.9, 129.3, 136.6 (4 ArC), 
167.6 (C=O); m/z (CI
+
) 336 ([M+H]
+
, 10%), 244 ([M-PhCH2]
-
, 70%); HRMS 
C11H15NOSI
+
 requires: 335.9919, found: 335.9911. 
 (4S)-4-benzyl-2-(methylsulfanyl)-4,5-dihydro-1,3-oxazole (65a) 
 
To a solution of iodide 64a (1.8 g, 5.37 mmol) in acetonitrile (20 ml) was added 
potassium carbonate ( 1.33 g, 9.62 mmol, 1.8 eq) and stirred at reflux for 5 h. The 
mixture was then evaporated, dissolved/suspended in EtOAC (30 ml) and washed with 
water (20 ml), the aqueous layer was extracted with EtOAC (20 ml). The combined 
organics were washed with brine and dried Na2SO4 and evaporated to give a yellow oil 
(1.12 g). Purification by column chromatography on silica gel (hexane:ethyl acetate, 
4:1) gave 65a as a pale yellow oil (1.00 g, 4.82 mmol, 90%); νmax (cm
-1
) 1747 (C=N); 
1
H NMR (500 MHz, chloroform-d) δ ppm 2.48 (3H, s, CH3), 2.66 (1H, dd, J=13.6, 8.8 
Hz, CHH’Ph), 3.14 (1H, dd, J=13.7, 4.9 Hz, CHH’Ph), 4.09 (1H, dd, J=8.0, 7.1 Hz, 
CHH’O), 4.28 (1H, t, J=8.7 Hz, CHH’O), 4.36 - 4.46 (1H, m, CHN), 7.18 - 7.25 (3H, 
m, ArH), 7.30 (15H, t, J=7.6 Hz, ArH); 
13
C NMR (125 MHz, chloroform-d) δ ppm 14.6 
(SCH3), 41.8 (CH2Ph), 67.8 (CHN), 73.7 (CH2O), 126.7, 128.6, 129.3, 137.8 (4 ArC), 
166.7 (C=N); m/z (EI
+
) 207 (M
+
, 12%), 116 ([M-CH2Ph]
+
, 100%); HRMS C11H13NOS
+
 
requires: 207.0712, found: 207.0716.  
(S)-N-(2-aminophenyl)-4-(((4-benzyl-4,5-dihydrooxazol-2-
yl)amino)methyl)benzamide (66a) 
 
To a solution of (S)-80a (0.44 g, 0.88 mmol) in dichloromethane (3.4 mL) was 
added trifluoroacetic acid (0.6 mL). The solution was stirred at rt for 5 h, then 
trifluoroacetic acid (0.2 mL) was added and the solution stirred at rt for a further 30 
min. The reaction was diluted with dichloromethane (50 mL) and sodium bicarbonate 
(sat. aq., 30 mL) then stirred vigorously for 5 min. The mixture was separated and the 
organic layer washed with brine (30 mL), dried Na2SO4 and evaporated. Purification by 
column chromatography on silica gel (1% ammonia (30% aq.), 1% methanol, 98% ethyl 
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acetate) gave 66a as a white solid (0.167 g, 0.416 mmol, 47%), mp 146-147 °C; [α]D
25 
+8.8 (c 0.5, methanol); νmax (cm
-1
) 3202 (NH), 1674 (C=N), 1647 (C=O); 
1
H NMR (500 
MHz, chloroform-d) δ ppm 2.62 (1H, dd, J=13.5, 8.3 Hz, H(21)), 3.00 (1H, dd, J=13.5, 
5.0 Hz, H(21)’), 3.87 (2H, br s, NH2), 3.98 (1H, t, J=7.7 Hz, H(20), 4.18 (1H, t, J=8.1 
Hz, H(20)’), 4.22 - 4.30 (1H, m, H(19)), 4.32 - 4.44 (2H, m, H(15) and H(15)’), 6.74 - 
6.85 (2H, m, H(5) and H(3)), 7.07 (1H, t, J=7.3 Hz, H(4)), 7.15 (2H, d, J=7.1 Hz, ArH), 
7.20 (1H, t, J=6.9 Hz, ArH), 7.23 - 7.36 (5H, m, ArH), 7.81 (2H, d, J=7.4 Hz, H(10 and 
14)), 8.22 (1H, br s, H(7)); m/z (CI) 401 ([M+H]
+
, 100%); HRMS C24H25N4O2
+
 
requires: 401.1972, found: 401.1963. 
 (R)-N-(2-aminophenyl)-4-(((4-phenyl-4,5-dihydrooxazol-2-
yl)amino)methyl)benzamide ((R)-66b) 
 
To a solution of (R)-80b (150 mg, 0.308 mmol) in dichloromethane (5 mL) was 
added TFA (0.47 mL, 6.16 mmol) dropwise then stirred at rt for 3 h. Quenched with 
sodium bicarbonate (sat. aq., 20 mL) and extracted with ethyl acetate (2 × 30 mL), the 
combined organic layers were washed with brine (30 mL), dried Na2SO4 and evaporated 
to give a white solid that was purified by column chromatography on silica gel (1% 
ammonia (30% aq.), 1% methanol, 98% ethyl acetate) to give (R)-66b as a white solid 
(38 mg, 0.098 mmol, 32%), mp 115-118 °C; [α]D
25 -14.0 (c 1.0, methanol); νmax (cm
-1
) 
3287 (NH), 1649 (C=O); 
1
H NMR (300 MHz, chloroform-d) δ ppm 4.04 (1H, t, J=7.5 
Hz, H(20)), 4.11 (1H, br s, NH2), 4.33 (2H, s, H(15) and H(15)’), 4.56 (1H, t, J=8.6 Hz, 
H(20)’), 5.02 (1H, dd, J=8.8, 7.3 Hz, H(19)), 6.68 – 6.61 (2H, m, H(5) and H(3)), 7.04 
(1H, td, J=7.6, 1.0 Hz, H(4)), 7.12 - 7.36 (8H, m, ArH), 7.73 (2H, d, J=7.9 Hz, H(10 
and 14)), 8.52 (1H, br s, H(7)); 
13
C NMR (75 MHz, chloroform-d) δ ppm 46.5 (C(15)), 
67.4 (C(19)), 75.5 (C(20)), 118.3 (C(3)), 119.6 (C(5)), 124.6 (C(1)), 125.8 (C(4)), 126.6 
(C(11 and 13)), 127.4 (C(6) and C(22 and 26), 127.6 (C(24)), 127.9 (C(23 and 25)), 
128.8 (C(10 and 14)), 133.1 (C(9)), 141.2 (C(21)), 143.2 (C(12)), 143.6 (C(2)), 161.9 
(C(17)), 166.1 (C(8)); m/z (ESI
+
) 387 ([M+H]
+
, 100%); HRMS C23H23N4O2
+
 requires: 
387.1816, found: 387.1808.  
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(S)-N-(2-aminophenyl)-4-(((4-phenyl-4,5-dihydrooxazol-2-
yl)amino)methyl)benzamide ((S)-66b) 
 
To a solution of (S)-80b (103 mg, 0.21 mmol) in dichloromethane (0.9 mL) was added 
trifluoroacetic acid (0.1 mL). The solution was stirred at rt for 1.5 h, then trifluoroacetic 
acid (0.05 mL) was added and the solution stirred at rt for a further 2.5 h. The reaction 
was diluted with dichloromethane (10 mL) and sodium bicarbonate (sat. aq., 10 mL) 
then stirred vigorously for 5 min. The mixture was separated and the organic layer 
washed with sodium bicarbonate (sat. aq., 10 mL), dried Na2SO4 and evaporated. 
Purification by column chromatography on silica gel (1% ammonia (30% aq.), 1% 
methanol, 98% ethyl acetate) gave (S)-66b as a white solid (60 mg, 0.155 mmol, 74%), 
mp 85-86 °C; [α]D
25 +12.2 (c 0.5, methanol); νmax (cm
-1
) 3254 (NH), 1649 (C=O); 
1
H 
NMR (500 MHz, chloroform-d) δ ppm 3.91 (2H, br s, NH2), 4.09 (1H, t, J=7.6 Hz, 
H(20)), 4.42 (2H, br s, H(15) and H(15)’), 4.62 (1H, t, J=8.5 Hz, H(20)’), 5.09 (1H, t, 
J=7.9 Hz, H(19)), 6.75 - 6.88 (2H, m, H(5) and H(3)), 7.09 (1H, t, J=7.6 Hz, H(4)), 7.20 
- 7.38 (8H, m, ArH), 7.80 (2H, d, J=6.3 Hz, H(10 and 14)), 8.32 (1H, br s, H(7)); 
13
C 
NMR (125 MHz, chloroform-d) δ ppm 46.9 (C(15)), 67.9 (C(19)), 75.7 (C(20)), 118.7 
(C(3)), 120.0 (C(5)), 125.0 (C(1)), 125.8 (C(4)), 126.8 (C(11 and 13)), 127.6 (C(6)), 
127.7 (C(22 and 26)), 127.8 (C(24)), 128.1 (C(23 and 25)), 129.0 (C(10 and 14)), 133.5 
(C(9)), 141.3 (C(21)), 143.6 (C(12)), 144.0 (C(2)), 162.1 (C(17)), 166.2 (C(8)); m/z 
(ESI
-
) 385 ([M-H]
-
, 100%); HRMS C23H21N4O2
-
 requires: 385.1670, found:385.1673. 
(R)-N-(2-aminophenyl)-4-(((5-phenyl-4,5-dihydrooxazol-2-
yl)amino)methyl)benzamide ((R)-66d) 
 
To a solution of (R)-80d (280 mg, 0.575 mmol) in dichloromethane (4 mL) was 
added trifluoroacetic acid (0.6 mL, 7.79 mmol) dropwise. The resulting solution was 
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stirred at rt for 3.5 h then a further 0.4 mL of trifluoroacetic acid was added and stirred 
for another 1 h. The reaction was quenched with sodium bicarbonate (sat. aq., 15 mL) 
and then extracted with ethyl acetate (3 × 20 mL). The combined organics were washed 
with brine, dried Na2SO4 and evaporated to give a white solid (195 mg) which was 
purified by flash column chromatography on silica gel (1.6-8% (2M 
ammonia/methanol) in dichloromethane) to give a white solid (140 mg). Further 
purification by MDAP gave (R)-66d (75 mg, 0.194 mmol, 34%) as a white solid, mp 
196-197 °C; [α]D
25 -23.0 (c 1.0, methanol); νmax (cm
-1
) 3398 (NH), 3238 (NH), 3340 
(NH), 1668 (C=N), 1641 (C=O); 
1
H NMR (400 MHz, DMSO-d6) δ ppm 3.44 (1H, dd, 
J=12.2, 6.6 Hz, H(19), 4.04 (1H, dd, J=12.2, 9.2 Hz, H(19)’), 4.38 (2H, s, H(15) and 
H(15)’), 4.90 (2H, br s, NH2), 5.51 (1H, dd, J=9.2, 6.6 Hz, H(20)), 6.62 (1H, t, J=7.3 
Hz, H(5)), 6.80 (1H, d, J=7.8 Hz, H(3)), 6.98 (1H, t, J=7.3 Hz, H(4), 7.10 - 7.24 (2H, m, 
H(6) and H(16)), 7.26 - 7.36 (3H, m, H(22 and 26) and H(24)),7.40 (2H, t, J=7.1 Hz, 
H(23 and 25)), 7.46 (2H, d, J=8.0 Hz, H(11 and 13)), 7.96 (2H, d, J=8.0 Hz, H(10 and 
14)), 9.64 (1H, s, H(7)); 
13
C NMR (100 MHz, DMSO-d6) δ ppm 46.1 (C(15)), 61.2 
(C(19)), 80.3 (C(20)), 116.6 (C(3)), 116.8 (C(5)), 123.9 (C(1)), 125.9 (C(22 and 26)), 
126.9 (C(4)), 127.1 (C(6)), 127.3 (C(11 and 13)), 128.2 (C(10 and 14)), 128.3 (C(24)), 
129.1 (C(23 and 25)), 133.5 (C(9)), 142.2 (C(21)), 143.6 (C(12)), 144.2 (C(2)), 160.5 
(C(17)), 165.7 (C(8)); m/z (ESI
+
) 387 ([M+H]
+
, 100%); HRMS C23H23N4O2
+
 requires: 
387.1816, found: 387.1813. 
(S)-N-(2-aminophenyl)-4-(((5-phenyl-4,5-dihydrooxazol-2-
yl)amino)methyl)benzamide ((S)-66d) 
 
To a solution of (S)-80d (0.275 g, 0.565 mmol) in dichloromethane (6 mL) was 
added trifluoroacetic acid (0.871 mL, 11.30 mmol). The resulting solution was stirred at 
rt for 3 h, then quenched by pouring onto sodium bicarbonate (sat. aq., 15 mL) and 
extracted with ethyl acetate (3 × 30 mL). The combined organics were washed with 
brine, dried Na2SO4, and evaporated to give a white solid (240 mg) which was purified 
by MDAP to give (S)-66d (75 mg, 0.194 mmol, 34%) as a cream solid, mp 214-215 °C; 
[α]D
25 +22.0 (c 0.5, methanol); νmax (cm
-1
) 3338, (NH), 3237 (NH), 1668 (C=N), 1641 
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(C=O); 
1
H NMR (500 MHz, DMSO-d6) δ ppm 3.49 (1H, dd, J=11.8, 7.0 Hz, H(19)), 
4.08 (1H, dd, J=11.8, 9.1 Hz, H(19)’), 4.41 (2H, s, H(15) and H(15)’), 4.91 (2H, br s, 
NH2), 5.61 (1H, t, J=8.0 Hz, H(20)), 6.62 (1H, t, J=7.3 Hz, H(5)), 6.80 (1H, d, J=7.7 
Hz, H(3)), 6.99 (1H, t, J=7.0 Hz, H(4)), 7.19 (1H, d, J=7.4 Hz, H(6)), 7.31 - 7.38 (3H, 
m, H(22 and 26) and H(24)), 7.39 - 7.44 (2H, m, H(23 and 25)), 7.46 (2H, d, J=8.0 Hz, 
H(11 and 13)), 7.97 (2H, d, J=7.7 Hz, H(10 and 14)), 9.67 (1H, s, H(7)); 
13
C NMR (125 
MHz, DMSO-d6) δ ppm 46.0 (C(15)), 59.5 (C(29)), 80.9 (C(20)), 116.6 (C(3)), 116.7 
(C(5)), 123.8 (C(1)), 126.1 (C(22 and 26)), 126.9 (C(4)), 127.2 (C(6)), 127.3 (C(11 and 
13)), 128.3 (C(10 and 14)), 128.6 (C(24)), 129.1 (C(23 and 25)), 133.7 (C(9)), 141.3 
(C(21)), 143.6 (C(12)), 143.6 (C(2)), 160.7 (C(17)), 165.6 (C(8)); m/z (ESI
+
) 387 
([M+H]
+
, 100%); HRMS C23H23N4O2
+
 requires: 387.1816 , found: 387.1822. 
(S)-N-(2-aminophenyl)-4-(((4-(4-hydroxyphenyl)-4,5-dihydrooxazol-2-
yl)amino)methyl)benzamide (66e) 
 
To a solution of 80e (250 mg, 0.497 mmol) in dichloromethane (6 mL) was 
added trifluoroacetic acid (0.767 mL, 9.95 mmol). The resulting solution was stirred at 
rt for 2.5 h, then quenched by pouring onto sodium bicarbonate (sat. aq., 15 mL) and 
extracted with ethyl acetate (3 × 30 mL). The combined organics were washed with 
brine, dried Na2SO4, and evaporated to give a white solid which was purified by flash 
column chromatography on silica gel (1-10% (2M ammonia/methanol) in 
dichloromethane) to give 66e (141 mg, 0.350 mmol, 70%) as a white solid, mp 158-160 
°C; [α]D
25 +17.6 (c 0.5, methanol); νmax (cm
-1
) 3262 (NH), 1646 (C=O); 
1
H NMR (400 
MHz, methanol-d4) δ ppm 4.03 (1H, dd, J=8.0, 6.8 Hz, H(20)), 4.39 - 4.54 (2H, m, 
H(15) and H(15)’), 4.62 (1H, dd, J=9.0, 8.0 Hz, H(20)’), 4.99 (1H, dd, J=9.0, 6.8 Hz, 
H(19)), 6.74 (2H, d, J=8.6 Hz, H(23 and 25)), 6.79 (1H, td, J=7.6, 1.0 Hz, H(5)), 6.92 
(1H, dd, J=7.8, 1.2 Hz, H(3)), 7.02 - 7.14 (3H, m, H(22 and 26) and H(4)), 7.22 (1H, d, 
J=7.8 Hz, H(6)), 7.52 (2H, d, J=8.1 Hz, H(11 and 13)), 7.98 (2H, d, J=8.3 Hz, H(10 and 
14)); 
13
C NMR (100 MHz, methanol-d4) δ ppm 45.6 (C(15)), 66.3 (C(19)), 75.3 (C(20)), 
114.9 (C(23 and 25)), 117.4 (C(3)), 118.3 (C(5)), 124.0 (C(1)), 126.3 (C(6)), 127.0 
(C(10 and 14)), 127.1 (C(4)), 127.2 (C(11 and 13)), 127.6 (C(22 and 26)), 132.9 
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(C(21)), 134.4 (C(9)), 142.3 (C(2)), 143.6 (C(12)), 156.5 (C(24)), 162.5 (C(17)), 167.3 
(C(8)); m/z (ESI
+
) 403 ([M+H]
+
, 100%); HRMS C23H23N4O3
+
 requires: 403.1765, 
found: 403.1765. 
N-(2-aminophenyl)-4-((((4S,5S)-4,5-diphenyl-4,5-dihydrooxazol-2-
yl)amino)methyl)benzamide ((R,R)-66f) 
 
To a solution of (R,R)-80f (155 mg, 0.275 mmol) in dichloromethane (2 mL) 
was added trifluoroacetic acid (0.424 mL, 5.51 mmol) dropwise. The resulting solution 
was stirred at rt for 2 h, then quenched with sodium bicarbonate (sat. aq., 10 mL) and 
extracted with ethyl acetate (2 × 15 mL), the combined organics were dried with 
Na2SO4 and evaporated to give a white solid (140 mg) which was purified by flash 
column chromatography on silica gel (1-6% (2M ammonia/methanol) in 
dichloromethane) to give (R,R)-66f (125 mg, 0.270 mmol, 98%) as a white solid, mp 
110-113 °C; [α]D
25 -33.2 (c 1.0, methanol); νmax (cm
-1
) 3264 (NH), 1657 (C=O); m/z 
(ESI
+
) 463 ([M+H]
+
, 100%); 
1
H NMR (400 MHz, methanol-d4) δ ppm 4.46 - 4.63 (2H, 
m, H(15) and H(15)’), 4.89 (1H, m, H(19)), 5.23 (1H, d, J=6.6 Hz, H(20)), 6.79 (1H, t, 
J=7.5 Hz, H(5)), 6.92 (1H, dd, J=8.1, 1.3 Hz, H(3)), 7.10 (1H, td, J=7.7, 1.5 Hz, H(4)), 
7.19 - 7.44 (11H, m, ArH), 7.57 (2H, d, J=8.3 Hz, H(11 and 13)), 8.02 (2H, d, J=8.1 Hz, 
H(10 and 14)); 
13
C NMR (100 MHz, methanol-d4) δ ppm 45.6 (C(15)), 75.9 (C(19)), 
89.3 (C(20)), 117.4 (C(3)), 118.3 (C(5)), 124.0 (C(1)), 125.3 (C(11 and 13)), 126.2 
(C(28 and 32)), 126.3 (C(4)), 127.1 (C(22 and 26)), 127.2 (C(6)), 127.4 (C(30)), 127.7 
(C(29 and 31)), 128.2 (C(24)), 128.4 (C(23 and 25)), 128.5 (C(10 and 14)), 133.0 
(C(9)), 139.9 (C(27)), 142.4 (C(21)), 142.8 (C(12)), 143.4 (C(2)), 162.0 (C(17)), 167.3 
(C(8)); HRMS C29H27N4O2
+
 requires: 463.2129, found: 463.2128; 94% purity by 
LCMS. 
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N-(2-aminophenyl)-4-((((4R,5S)-4,5-diphenyl-4,5-dihydrooxazol-2-
yl)amino)methyl)benzamide ((R,S)-66f) 
 
To a solution of (R,S)-80f (414 mg, 0.736 mmol) in dichloromethane (6 mL) 
was added trifluoroacetic acid (1.134 mL, 14.72 mmol) dropwise. The resulting solution 
was stirred at rt for 5 h. The reaction was quenched by adding to sodium bicarbonate 
(sat. aq., 20 mL) and ethyl acetate (50 mL), the layers were separated and the aqueous 
layer was extracted with another portion of ethyl acetate (20 mL). The combined 
organics were washed with brine, dried Na2SO4 and evaporated to give a white solid 
(300 mg). Purification by flash column chromatography on silica gel (3-6% (2M 
ammonia/methanol) in dichloromethane) followed by MDAP gave (R,S)-66f (107 mg, 
0.231 mmol, 31%) as a white solid, mp 112-113 °C; [α]D
25 +51.6 (c 0.5, methanol); νmax 
(cm
-1
) 3270 (NH), 1652 (C=O); 
1
H NMR (400 MHz, chloroform-d) δ ppm 3.90 (2H, br 
s, NH2), 4.39 - 4.63 (2H, m, H(15) and H(15)’), 5.38 (1H, d, J=8.8 Hz, H(19)), 5.81 
(1H, d, J=8.8 Hz, H(20)), 6.73 - 6.94 (6H, m, ArH), 6.94 - 7.17 (7H, m, ArH), 7.26 - 
7.35 (1H, m, ArH), 7.40 (2H, d, J=7.8 Hz, ArH), 7.84 (2H, d, J=7.8 Hz, ArH), 8.30 (1H, 
br s, N(7)); 
13
C NMR (100 MHz, chloroform-d) δ ppm 46.5 (C(15)), 72.0 (C(19)), 85.7 
(C(20)), 118.3 (C(3)), 119.7 (C(5)), 124.6 (C(1)), 125.4 (C(4)), 126.2 (C(11 and 13)), 
126.8 (C(6)), 127.2 (C(30)), 127.4 (C(24)), 127.5 (C(28 and 32)), 127.5 (C(22 and 26)), 
127.6 (C(29 and 31)), 127.6 (C(23 and 25)), 127.7 (C(10 and 14)), 133.2 (C(9)), 136.4 
(C(27)), 139.2 (C(21)), 140.9 (C(12)), 143.3 (C(2)), 161.5 (C(17)), 165.8 (C(8)); m/z 
(ESI
+
) 463 ([M+H]
+
, 100%); HRMS C29H27N4O2
+
 requires: 463.2129, found: 463.2128. 
N-(2-aminophenyl)-4-(((4,4-diphenyl-4,5-dihydrooxazol-2-
yl)amino)methyl)benzamide (66g) 
 
To a solution of 80g (280 mg, 0.498 mmol) in dichloromethane (6 mL) was 
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added trifluoroacetic acid (0.767 mL, 9.95 mmol). The resulting solution was stirred at 
rt for 2.5 h, then quenched by pouring onto sodium bicarbonate (sat. aq., 15 mL) and 
extracted with ethyl acetate (3 × 30 mL). The combined organics were washed with 
brine, dried Na2SO4, and evaporated to give a white solid (210 mg) which was purified 
by flash column chromatography on silica gel (1-6% (2M ammonia/methanol) in 
dichloromethane) to give 66g (135 mg, 0.292 mmol, 59%) as a white solid, mp 176-177 
°C; νmax (cm
-1
) 3194 (NH), 1670 (C=N), 1649 (C=O); 
1
H NMR (400 MHz, methanol-d4) 
δ ppm 4.54 (2H, s, H(15) and H(15)’), 4.79 (2H, s, H(20)), 6.79 (1H, td, J=7.6, 0.8 Hz, 
H(5)), 6.92 (1H, dd, J=8.1, 1.2 Hz, H(3)), 7.10 (1H, td, J=7.7, 1.3 Hz, H(4)), 7.17 - 7.37 
(11H, m, ArH), 7.49 (2H, d, J=8.2 Hz, H(11 and 13)), 7.96 (2H, d, J=8.2 Hz, H(10 and 
14)); 
13
C NMR (100 MHz, methanol-d4) δ ppm 45.4 (C(15)), 76.4 (C(19)), 80.0 (C(20)), 
117.4 (C(3)), 118.3 (C(5)), 124.0 (C(1)), 126.3 (C(6)), 126.6 (C(2 × Ph-ortho)), 126.6 
(C(2 × Ph-para)), 127.0 (C(10 and 14)), 127.1 (C(4)), 127.6 (C(11 and 13)), 127.8 (C(2 
× Ph-meta)), 132.9 (C(9)), 142.4 (C(2)), 143.6 (C(12)), 146.4 (C(2 × Ph-ipso)), 161.4 
(C(17)), 167.2 (C(8)); m/z (ESI
+
) 463 ([M+H]
+
, 100%); HRMS C29H27N4O2
+
 requires: 
463.2129, found: 463.2118. 
(R)-4-(((4-((1H-imidazol-4-yl)methyl)-4,5-dihydrooxazol-2-yl)amino)methyl)-N-(2-
aminophenyl)benzamide ((R)-66h) 
 
To a suspension of (R)-80h (100 mg, 0.204 mmol) in dichloromethane (2 mL) 
was added trifluoroacetic acid (0.314 mL, 4.08 mmol) dropwise. The resulting solution 
was stirred at rt for 2 h. Then evaporated and the resulting white solid purified by 
MDAP to (R)-66h (43 mg, 0.110 mmol, 54%) as a white solid, mp 191-193 °C; [α]D
25 
+6.3 (c 1.0, methanol); νmax (cm
-1
) 3227 (NH), 1673 (C=N), 1627 (C=O); 
1
H NMR (500 
MHz, methanol-d4) δ ppm 2.74 (1H, dd, J=15.5, 5.4 Hz, H(21)), 3.24 (1H, dd, J=15.5, 
7.3 Hz, H(21)’), 3.88 (1H, dd, J=11.3, 5.2 Hz, H(20)), 4.36 (1H, dd, J=11.1, 6.7 Hz, 
H(20)’), 4.43 (2H, s, H(15) and H(15)’), 4.92 - 4.99 (1H, m, H(19)), 6.70 (1H, s, 
H(23)), 6.79 (1H, t, J=7.3 Hz, H(5)), 6.93 (1H, d, J=7.7 Hz, H(3)), 7.06 - 7.13 (1H, m, 
H(4)), 7.21 (1H, d, J=7.4 Hz, H(6)), 7.45 (2H, d, J=7.7 Hz, H(11 and 13)), 7.59 (1H, s, 
H25)), 7.97 (2H, d, J=8.0 Hz, H(10 and 14)); 
13
C NMR (125 MHz, methanol-d4) δ ppm 
28.8 (C(21)), 42.9 (C(15)), 50.6 (C(19)), 54.7 (C(20)), 117.3 (C(3)), 118.3 (C(5)), 118.8 
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(C(23)), 123.9 (C(1)), 126.2 (C(6)), 126.8 (C(10 and 14)), 127.1 (C(4)), 127.6 (C(11 
and 13)), 130.9 (C(25)), 132.8 (C(9)), 134.6 (C(23)), 142.4 (C(12)), 144.2 (C(2)), 158.8 
(C(17)), 167.3 (C(8)); m/z (ESI
+
) 391 ([M+H]
+
, 100%); HRMS C21H23N6O2
+
 requires: 
391.1877, found: 391.1881. 
(S)-4-(((4-((1H-imidazol-4-yl)methyl)-4,5-dihydrooxazol-2-yl)amino)methyl)-N-(2-
aminophenyl)benzamide ((S)-66h) 
 
To a suspension of (S)-80h (130 mg, 0.265 mmol) in dichloromethane (2 mL) 
was added trifluoroacetic acid (0.2 mL, 2.60 mmol) dropwise. The resulting solution 
was stirred at rt for 3 h, then a further 0.2 mL trifluoroacetic acid was added, and stirred 
at rt for 2 h. Quenched with sodium bicarbonate (sat. aq., 15 mL) and then ethyl acetate 
(20 mL) was added, but an insoluble white precipitate remained in the aqueous layer. 
Ethyl acetate was separated and the aqueous layer was basified with 2M NaOH to pH 
10/11 then extracted with 20% ethanol/chloroform (4 × 25 mL). The combined organics 
were washed with brine, dried Na2SO4 and evaporated to give a grey solid (40 mg), 
LCMS showed the product was dissolved in the aqueous layer. The aqueous layer was 
passed over a 10 g SCX-2 cartridge, then washed with methanol (100 mL), and eluted 
with 2M ammonia/methanol (100 mL), but LCMS showed the product to be in the flow 
though and methanol wash fraction. The methanol and water were evaporated to give a 
white solid which was stirred with 10% methanol/dichloromethane for 30 min, then the 
inorganics were filtered and the filtrate was evaporated to give a white solid (60 mg) 
which was purified by MDAP to give (S)-66h (23 mg, 0.059 mmol, 22%) as a white 
solid, mp 192-194 ºC; [α]D
25 -18.0 (c 0.1, methanol); νmax (cm
-1
) 3241 (NH), 1655 
(C=O);
 1
H NMR (400 MHz, methanol-d4) δ ppm 2.74 (1H, ddd, J=15.5, 5.5, 1.0 Hz, 
H(21)), 3.24 (1H, ddd, J=15.5, 7.4, 1.0 Hz, H(21)’), 3.87 (1H, dd, J=11.3, 5.1 Hz, 
H(20)), 4.35 (1H, dd, J=11.3, 6.8 Hz, H(20)’), 4.43 (2H, s, H(15) and H(15)’), 4.89 - 
5.00 (1H, m, H(19)), 6.69 (1H, s, H(23)), 6.79 (1H, t, J=7.2 Hz, H(5)), 6.92 (1H, dd, 
J=8.1, 1.2 Hz, H(3)), 7.05 - 7.13 (1H, m, H(4)), 7.20 (1H, d, J=7.6 Hz, H(6)), 7.44 (2H, 
d, J=8.3 Hz, H(11 and 13)), 7.57 (1H, s, H(25)), 7.96 (2H, d, J=8.1 Hz, H(10 and 14)); 
13
C NMR (125 MHz, DMSO-d6) δ ppm 29.5 (C(21)), 43.1 (C(15)), 50.7 (C(19)), 55.0 
(C(20)), 116.6 (C(3)), 116.7 (C(5)), 119.9 (C(23)), 123.8 (C(1)), 126.9 (C(4)), 127.1 
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(C(6)), 127.2 (C(11 and 13)), 128.2 (C(10 and 14)), 131.4 (C(25)), 133.4 (C(22)), 134.6 
(C(9)), 143.6 (C(2)), 144.9 (C(12)), 157.9 (C(17)), 165.6 (C(8)); m/z (ESI
+
) 391 
([M+H]
+
, 100%); HRMS C21H23N6O2
+
 requires: 391.1877, found: 391.1878. 
N-(2-aminophenyl)-4-(((4-(4-fluorophenyl)-4,5-dihydrooxazol-2-
yl)amino)methyl)benzamide (66i) 
 
To a solution of 80i (220 mg, 0.436 mmol) in dichloromethane (6 mL) was 
added TFA (0.67 mL, 8.72 mmol) dropwise then stirred at rt for 3 h. Quenched with 
sodium bicarbonate (sat. aq., 10 mL) and extracted with ethyl acetate (2 × 30 mL), the 
combined organic layers were washed with brine (40 mL), dried Na2SO4 and evaporated 
to give a cream solid (200 mg) that was purified by column chromatography on silica 
gel (1% ammonia (30% aq.), 1% methanol, 98% ethyl acetate) and again (1% ammonia 
(30% aq.), 6% methanol, 93% ethyl acetate) to give 66i as a white solid (108 mg, 0.267 
mmol, 61%), mp 104-108 °C; νmax (cm
-1
) 3245 (NH), 1649 (C=O); 
1
H NMR (500 MHz, 
chloroform-d) δ ppm 3.98 - 4.06 (1H, m, H(20)), 4.09 (2H, br s, NH2), 4.39 (2H, s, 
H(15) and H(15)’), 4.54 - 4.67 (1H, m, H(20)), 4.97 - 5.14 (1H, m, H(19)), 6.71 - 6.86 
(2H, m, ArH), 6.93 - 7.03 (2H, m, ArH), 7.03 - 7.12 (1H, m, ArH), 7.12 - 7.22 (2H, m, 
ArH), 7.22 - 7.36 (3H, m, ArH), 7.70 - 7.87 (2H, m, ArH), 8.44 (1H, br s, H(7)); 
13
C 
NMR (125 MHz, chloroform-d) δ ppm 46.4 (C(15)), 66.7 (C(19)), 75.3 (C(20)), 115.3 
(d, J=22.1 Hz, H(23 and 25), 118.1 (C(3)), 119.5 (C(5)), 124.4 (C(1)), 125.5 (C(4)), 
127.2 (C(6) and C(11 and 13)), 127.6 (C(10 and 14)), 127.9 (d, J=8.6 Hz, C(22 and 26), 
133.0 (C(9)), 139.2 (C(21)), 140.9 (C(12)), 142.9 (C(2)), 162.0 (d, J=245.7 Hz, C(24)), 
161.7 (C(17)), 165.7 (C(8)); m/z (ESI
+
) 405 ([M+H]
+
, 100%); HRMS C23H22FN4O2
+
 
requires: 405.1721, found: 405.1710. 
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N-(2-aminophenyl)-4-(((4-(3-fluorophenyl)-4,5-dihydrooxazol-2-
yl)amino)methyl)benzamide (66j) 
 
To a solution of 80j (190 mg, 0.377 mmol) in dichloromethane (3 mL) was 
added trifluoroacetic acid (0.580 mL, 7.53 mmol) dropwise. The resulting solution was 
stirred at rt for 2 h, then quenched with sodium bicarbonate (sat. aq., 10 mL) and 
extracted with ethyl acetate (2 × 20 mL), the combined organics were washed with brine 
(20 mL) then dried with Na2SO4 and evaporated to give a white solid (150 mg) which 
was purified by flash column chromatography on silica gel (1-6% (2M 
ammonia/methanol) in dichloromethane) to give 66j (131 mg, 0.324 mmol, 86%) as a 
white solid, mp 84-86 °C; νmax (cm
-1
) 3276 (NH), 1652 (C=O); 
1
H NMR (400 MHz, 
methanol-d4) δ ppm 4.05 (1H, dd, J=8.2, 6.4 Hz, H(20)), 4.41 - 4.56 (2H, m, H(15) and 
H(15)’), 4.68 (1H, dd, J=9.1, 8.3 Hz, H(20)’), 5.09 (1H, dd, J=9.0, 6.4 Hz, H(19)), 6.79 
(1H, td, J=7.6, 1.0 Hz, H(5)), 6.88 - 7.02 (3H, m, H(3), H(24) and H(26), 7.03 - 7.14 
(2H, m, H(4) and H(22)), 7.21 (1H, d, J=7.8 Hz, H(6)), 7.33 (1H, td, J=7.9, 5.9 Hz, 
H(23)), 7.53 (2H, d, J=8.1 Hz, H(11 and 13)), 8.00 (2H, d, J=8.1 Hz, H(10 and 14)); 
13
C 
NMR (100 MHz, methanol-d4) δ ppm 45.6 (15), 66.2 (19), 74.9 (20), 112.7 (d, J=22.4 
Hz, C(24)), 113.7 (d, J=20.8 Hz, C(26)), 117.3 (C(3)), 118.3 (C(5)), 121.9 (d, J=3.2 Hz, 
C(22)), 124.0 (C(1)), 126.3 (C(6)), 127.0 (C(11 and 13)), 127.2 (C(4)), 127.7 (C(10 and 
14)), 130.0 (d, J=8.0 Hz, C(23)), 133.0 (C(9)), 142.4 (C(2)), 143.4 (C(12)), 146.8 (d, 
J=7.2 Hz, C(21)), 163.0 (d, J=245.3 Hz, C(25)), 163.0 (C(17)), 167.2 (C(8)); m/z (ESI
+
) 
405 ([M+H]
+
, 100%); HRMS C23H22FN4O2
+
 requires: 405.1721, found: 405.1723; 94% 
purity by LCMS. 
N-(2-aminophenyl)-4-(((4-(4-(trifluoromethyl)phenyl)-4,5-dihydrooxazol-2-
yl)amino)methyl)benzamide (66k) 
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To a solution of 80k (190 mg, 0.343 mmol) in dichloromethane (4 mL) was 
added trifluoroacetic acid (0.528 mL, 6.85 mmol). The resulting solution was stirred at 
rt for 2.5 h, then quenched by pouring onto sodium bicarbonate (sat. aq., 15 mL) and 
extracted with ethyl acetate (3 × 30 mL). The combined organics were washed with 
brine, dried Na2SO4, and evaporated to give a white solid (130 mg) which was purified 
by flash column chromatography on silica gel (1-6% (2M ammonia/methanol) in 
dichloromethane) to give 66k (110 mg, 0.242 mmol, 71%) as a white solid, mp 198-199 
°C; νmax (cm
-1
) 3265 (NH), 1653 (C=O); 
1
H NMR (500 MHz, methanol-d4) δ ppm 4.08 
(1H, dd, J=8.2, 6.6 Hz, H(20)), 4.44 - 4.58 (2H, m, H(15) and H(15)’), 4.73 (1H, dd, 
J=9.2, 8.2 Hz, H(20)’), 5.18 (1H, dd, J=9.2, 6.6 Hz, H(19)), 6.80 (1H, t, J=7.4 Hz, 
H(5)), 6.93 (1H, d, J=8.0 Hz, H(3)), 7.11 (1H, t, J=7.1 Hz, H(4)), 7.22 (1H, d, J=7.7 Hz, 
H(6)), 7.43 (2H, d, J=8.0 Hz, H(22 and 26), 7.54 (2H, d, J=8.0 Hz, H(11 and 13)), 7.64 
(2H, d, J=8.0 Hz, H(23 and 25)), 8.01 (2H, d, J=8.0 Hz, H(10 and 14)); 
13
C NMR (125 
MHz, methanol-d4) δ ppm 45.6 (C(15)), 66.3 (C(19)), 74.8 (C(20)), 117.4 (C(3)), 118.3 
(C(5)), 124.3 (q, J=271.0 Hz, CF3), 124.0 (C(23)), 125.1 (q, J=3.9 Hz, C(23 and 25)), 
126.3 (C(6)), 126.7 (C(22 and 26)), 127.0 (C(10 and 14)), 127.2 (C(4)), 127.7 (C(11 and 
13)), 129.2 (q, J=32.4 Hz, C(24)), 133.0 (C(9)), 142.4 (C(2)), 143.4 (C(12)), 148.3 
(C(21)), 163.2 (C(17)), 167.2 (C(8)); m/z (ESI
+
) 455 ([M+H]
+
, 100%); HRMS 
C24H22F3N4O2
+
 requires: 455.1689, found: 455.1686; 92% purity by LCMS. 
4-[(trifluoroacetamido)methyl]benzoic acid (68)
108
  
 
Trifluoracetic anhydride (1.74 ml, 12.5 mmol, 2.5 eq) was added dropwise to 4-
(aminomethyl)benzoic acid (0.756 g, 5.0 mmol, 1.0 eq) at 0 °C. Upon completion of 
addition the mixture was homogeneous. Stirring continued for 2 h at rt, then ice-water 
was added to precipitate the product which was filtered, washed with water and dried to 
give 68 as a white powder (1.06 g, 4.25 mmol, 85%), mp 212-213 °C (lit. 199-203 
°C)
108; νmax (cm
-1
) 3291 (NH), 1708 (C=O), 1684 (C=O); 
1
H NMR (500 MHz, DMSO-
d6) δ ppm 4.45 (2H, d, J=6.0 Hz, C(7)H2), 7.38 (2H, d, J=8.4 Hz, H(3 and 5)), 7.92 (2H, 
d, J=8.4 Hz, H(2 and 6)), 10.07 (1H, t, J=6.0 Hz, H(8)), 12.93 (1H, br s, CO2H); 
13
C 
NMR (125 MHz, DMSO-d6) δ ppm 42.3 (C(7)), 116.0 (q, J=288.0 Hz, C(10)), 127.4 
(C(3 and 5)), 129.6 (C(2 and 6)), 129.8 (C(1)), 142.4 (C(4)), 156.5 (q, J=36.2 Hz, C(9)), 
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167.1 (CO2H). 
tert-butyl N-(2-{4-[(trifluoroacetamido)methyl]benzamido}phenyl)carbamate 
(69)
109
 
 
To a suspension of benzoic acid 68 (1.0 g, 4.05 mmol, 1.1 eq) in 
dichloromethane (7 ml) was added dropwise oxalyl chloride (0.467 ml, 5.52 mmol, 1.5 
eq), followed by two drops of DMF. Stirred at rt until bubbles stopped forming, and 
then at 40 °C for 1 h. Solvent evaporated and then co-evaporated with toluene. Then 
dissolved in dichloromethane (3 ml) and added dropwise to a solution of 39 in 
dichloromethane (3 ml) and pyridine (6 ml) at 0 °C. Stirred at 0 °C for 30 min then 
warmed to rt and stirred for a further 20 h. To the reaction mixture was added sodium 
hydrogen carbonate (sat. aq. 15 ml) and then extracted with chloroform (2 × 30 ml), the 
combined organic layer was washed with brine (10 ml), dried MgSO4 and evaporated to 
give 69 as a pale yellow solid (1.522 g, 3.48 mmol, 95%), mp 157-158 °C; νmax (cm
-1
) 
3334 (NH), 1722 (C=O), 1672 (C=O), 1663 (C=O); 
1
H NMR (500 MHz, DMSO-d6) δ 
ppm 1.43 (9H, s, (3 × C(23)H3), 4.47 (2H, br s, C(15)H2), 7.09 - 7.23 (2H, m, H(4) and 
H(5)), 7.43 (2H, d, J=8.0 Hz, H(11 and 13), 7.48 - 7.56 (2H, m, H(3) and H(6)), 7.93 
(2H, d, J=8.0 Hz, H(10 and 14)), 8.66 (1H, br s, H(19)), 9.82 (1H, br s, H(7)), 10.10 
(1H, br s, H(16)); 
13
C NMR (125 MHz, DMSO-d6) δ ppm 28.0 (C(23)), 42.3 (C(15)), 
79.6 (C(22)), 116.0 (q, J=288.0 Hz, C(17)), 123.8 (C(3)), 124.1 (C(6)), 125.6 (C(4)), 
126.0 (C(5)), 127.4 (C(11 and 13)), 127.9 (C(10 and 14)), 129.7 (C(8)), 131.7 (C(2)), 
133.3 (C(1)), 141.4 (C(12)), 153.5 (C(20)), 156.5 (q, J=36.3 Hz, C(16)), 165.1 (C(7)); 
m/z (ES
+
) 460 ([M+Na]
+
, 85%), 401 ([M+Na+MeCN-Boc]
+
, 100%), 360 ([M+Na-
Boc]
+
, 30%); HRMS C21H22N3O4NaF3
+
 requires: 460.1460, found: 460.1442. 
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tert-butyl N-{2-[4-(aminomethyl)benzamido]phenyl}carbamate (70)
109
 
 
To a suspension of 69 (1.45 g, 3.32 mmol, 1.0 eq) in methanol (13 ml) and water 
(20 ml) was added potassium carbonate (0.518 g, 3.75 mmol, 1.13 eq) the mixture was 
stirred at 70 °C for 4 h, then cooled to rt, diluted with water (50 ml) and extracted with 
chloroform (75 ml). The organic layer was washed with brine (75 ml), dried Na2SO4 
and evaporated to give 70 as a cream solid (0.994 g, 2.91 mmol, 88%), mp 80-83 °C; 
νmax (cm
-1
) 3278 (NH), 1693 (C=O), 1653 (C=O); 
1
H NMR (400 MHz, chloroform-d) δ 
ppm 1.53 (9H, s, (3 × C(20)H3), 3.97 (2H, br s, NH2), 7.10 (1H, br s, H(17)), 7.15 (1H, 
td, J=7.7, 1.5 Hz, H(5)), 7.21 (1H, td, J=7.7, 1.3 Hz, H(4)), 7.27 (1H, dd, J=7.7, 1.5 Hz, 
H(6)), 7.41 (2H, d, J=8.3 Hz, H(11 and 13)), 7.76 (1H, dd, J=7.7, 1.3 Hz, H(3)), 7.94 
(2H, d, J=8.3 Hz, H(10 and 14)), 9.23 (1H, br s, H(7)); 
13
C NMR (125 MHz, 
chloroform-d) δ ppm 28.4 (C(20)), 46.1 (C(15)), 81.3 (C(20)), 124.6 (C(3)), 125.8 
(C(6)), 125.9 (C(4)), 126.0 (C(5)), 127.2 (C(11 and 13)), 127.8 (C(10 and 14)), 130.1 
(C(9)), 131.0 (C(2)), 132.8 (C(1)), 147.2 (C(12)), 154.7 (C(18)), 165.6 (C(8)); m/z (EI
+
) 
341 (M
+
, 23%), 241 ([M+H-Boc]
+
, 15%); HRMS C19H23N3O3
+
 requires: 341.1734, 
found: 341.1737. 
3-tert-butyl-1-[(2R)-1-hydroxy-3-phenylpropan-2-yl]thiourea (73)  
 
The procedure by Carry et al. for a similar reaction was used.
110
 To a solution of 
72 (0.302 g, 2.0 mmol, 1.0 eq) in ethanol (3 ml) was added tert-butyl isothiocyanate 
(0.38 ml, 3.0 mmol, 1.5 eq), and then stirred at rt for 16 h. The solvent was evaporated 
then the colourless oil was dissolved in ethyl acetate (20 ml) and washed with brine (2 × 
20 ml). Dried over Na2SO4 and then concentrated to give 73 as a sticky oil (0.521 g, 
1.96 mmol, 98%); νmax (cm
-1
) 3414 (NH), 3286 (NH), 1532 (C=S); 
1
H NMR (400 MHz, 
chloroform-d) δ ppm 1.34 (9H, s, C(CH3)3), 2.50 (1H, br s, OH), 2.95 (1H, dd, J=13.6, 
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8.3 Hz, C(6)H), 3.09 (1H, dd, J=13.6, 6.0 Hz, C(6)H`), 3.68 (1H, dd, J=11.0, 4.0 Hz, 
C(4)H), 3.77 (1H, dd, J=10.8, 4.0 Hz, C(4)H`), 4.70 (1H, br s, H(5)), 6.11 (1H, d, J=7.8 
Hz, N(1)H), 6.15 (1H, br s, N(3)H), 7.18 - 7.40 (5H, m, ArH); 
13
C NMR (75 MHz, 
chloroform-d) δ ppm 29.4 (C(CH3)3), 37.0 (C(6)), 52.8 (NC(CH3)3), 57.6 (C(5)), 63.2 
(C(4)), 126.8 (C(10)), 128.7 (C(8 and 12)), 129.4 (C(9 and 11)), 137.6 (C(7)), 180.5 
(C(2)); m/z (EI
+
) 266 (M
+
, 34%), 248 ([M-water]
+
, 32%); HRMS C14H22N2OS
+
 
requires: 266.1447, found: 266.1452. 
(4R)-4-benzyl-1,3-thiazolidin-2-iminium chloride (74)  
 
The procedure by Carry et al. for a similar reaction was used.
110
 To 73 (0.5 g, 
1.88 mmol) was added hydrochloric acid (6M, aq., 5 ml) and the resulting mixture was 
stirred at 100 °C under reflux for 8.5 h (the mixture became homogeneous upon 
heating). Then cooled to rt and stored in a refrigerator O/N (because the rotary 
evaporator for removing water was unavailable). The solution was evaporated to give a 
pale yellow oil which was triturated with diethyl ether, decanting the diethyl ether and 
adding fresh diethyl ether several times to give a white solid. The solid was suspended 
in dichloromethane (25 ml) and stirred at rt for 3 h, then filtered and washed with 
dichloromethane to give 74 as a white solid (0.252 g, 1.10 mmol, 59 %). Some of the 
free base was also liberated: a portion of the solid was suspended in dichloromethane 
and washed with sodium hydrogen carbonate (sat. aq.), brine and then dried with 
Na2SO4 and concentrated. 
HCl salt, mp 166-167 °C; νmax (cm
-1
) 3443 (NH), 3302 (NH), 3025 (NH), 1636 
(C=N); 
1
H NMR (500 MHz, DMSO-d6) δ ppm 2.89 (1H, dd, J=13.7, 7.6 Hz, H(6)), 
2.99 (1H, dd, J=13.7, 5.6 Hz, H(6)`), 3.24 (1H, dd, J=11.3, 5.8 Hz, H(5)), 3.52 (1H, dd, 
J=11.3, 7.6 Hz, H(5)`), 4.50 (1H, tdd, J=7.6, 7.6, 5.8, 5.6 Hz, H(4)), 7.22 - 7.36 (5H, m, 
Ph), 8.92 - 10.38 (3H, m, 3 × NH); 
13
C NMR (125 MHz, DMSO-d6) δ ppm 34.4 (C(5)), 
38.6 (C(6)), 61.6 (C(4)), 126.8 (C(7)), 128.6 (C(8 and 12)), 129.4 (C(9 and 11)), 136.3 
(C(10)), 172.1 (C(2)); m/z (CI
+
) 193 ([M-Cl]
+
, 35%); HRMS C10H13N2S
+
 requires: 
193.0799, found: 193.0806.  
Free base: mp 69-70 °C; 
1
H NMR (300 MHz, chloroform-d) δ ppm 2.76 (1H, dd, 
J=13.5, 7.9 Hz, H(5), 2.94 - 3.12 (2H, m, H(5)` and H(6)), 3.28 (1H, dd, J=10.7, 7.2 Hz, 
H(6)`), 4.45 (1H, app. quin, J=7.2 Hz, H(4)), 5.03 (2H, br s, NH2), 7.15 - 7.35 (5H, m, 
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Ph); 
13
C NMR (75 MHz, chloroform-d) δ ppm 39.9 (C(5)), 41.5 (C(6)), 73.8 (C(4)), 
126.3 (C(7)), 128.5 (C(8 and 12)), 129.2 (C(9 and 11)), 139.2 (C(10)), 160.9 (C(2)). 
tert-butyl N-[2-(4-formylbenzamido)phenyl]carbamate (75)
114
 
 
To a solution of 43 (0.20 g, 0.55 mmol, 1.0 eq) in dichloromethane (3 ml) and 
DMSO (1 ml) at 0 °C was added trimethylamine N-oxide dehydrate (0.244 g, 2.2 mmol, 
4.0 eq) then the resulting solution was allowed to warm to rt and stirred for 17 h. 
Diluted with ethyl acetate (30 ml) and washed with water (10 ml) then brine (10 ml), 
dried MgSO4 and evaporated. Purification by column chromatography on silica gel 
(ethyl acetate:hexane, 1:2) gave 75 as a white solid (0.084 g, 0.247 mmol, 45%), mp 
131-132 °C; νmax (cm
-1
) 3285 (NH), 1703 (C=O), 1662 (C=O); 
1
H NMR (300 MHz, 
chloroform-d) δ ppm 1.50 (9H, s, H(20)), 7.02 (1H, s, H(16)), 7.06 - 7.21 (3H, m, H(4), 
H(5) and H(6), 7.71 - 7.80 (1H, m, H(3)), 7.95 (2H, d, J=8.4 Hz, H(11 and 13)), 8.10 
(2H, d, J=8.4 Hz, H(10 and 14)), 9.62 (1H, br s, H(7)), 10.08 (1H, s, H(15)); 
13
C NMR 
(75 MHz, chloroform-d) δ ppm 28.3 (C(20)), 81.6 (C(19)), 124.5 (C(3)), 125.8 (C(6)), 
126.0 (C(4)), 126.2 (C(5)), 128.1 (C(10 and 14)), 129.8 (C(11 and 13)), 129.9 (C(2)), 
130.5 (C(1)), 138.4 (C(9)), 139.5 (C(12)), 154.8 (C(17)), 164.5 (C(8)), 191.6 (C(15)); 
m/z (ES
-
) 339 ([M-H]
-
, 34%); HRMS C19H19N2O4
-
 requires: 339.1345, found: 339.1347. 
tert-butyl N-{2-[4-(isothiocyanatomethyl)benzamido]phenyl}carbamate (77)  
 
According to a literature procedure,
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 carbon disulfide (3.48 mL, 57.5 mmol, 
3.2 eq) was added to a mixture of 4-(aminomethyl)benzoic acid (3.0 g, 19.8 mmol, 1.1 
eq) and triethylamine (6.62 mL, 47.5 mmol, 2.6 eq) in THF (13 mL) and water (13 mL). 
The reaction mixture was stirred vigorously for 22 h, then the resulting solution was 
cooled to 0 °C and a solution of iodine (5.38 g, 21.2 mmol, 1.18 eq) in THF( 13 mL) 
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was added dropwise over 10 min. The mixture was stirred at 0 °C for 2 h, then 1M 
hydrochloric acid (20 mL) and sodium sulphite (0.49 g, 3.9 mmol) were added and 
mixed. The mixture was then extracted with ethyl acetate (100 mL and 50 mL), the 
combined organics were washed with 1M hydrochloric acid (2 × 50 mL) and brine (50 
mL) then dried MgSO4 and evaporated to give 4-(isothiocyanatomethyl)benzoic acid as 
a cream  
solid (4.07 g, 21.1 mmol, 106%). To a suspension of this cream solid in 
dichloromethane (35 mL) was added oxalyl chloride (2.28 mL, 27 mmol, 1.5 eq) 
dropwise, followed by a few drops of DMF. The resulting mixture was stirred at rt for 1 
h (until bubble formation had ceased) and the resulting solution stirred at reflux for 1 h. 
The solution was evaporated and then co-evaporated with toluene (20 mL) to ensure 
complete removal of excess oxalyl chloride. The remaining oil was dissolved in 
dichloromethane (25 mL) and added dropwise over 10 min to a solution of 39 (3.748 g, 
18 mmol, 1 eq) in dichloromethane (25 mL) and pyridine (25 mL) at 0 °C. The reaction 
was stirred at 0 °C for 1 h then warmed to rt and stirred for a further 16.5 h. Then 
sodium hydrogen carbonate (sat. aq., 150 mL) was added and the mixture extracted with 
chloroform (2 × 100 mL). The combined organics were washed with 1M hydrochloric 
acid (2 × 150 mL) and brine (150 mL), then dried MgSO4 and evaporated to give an 
orange oil that was purified by column chromatography (3% ethyl 
acetate/dichloromethane) to give 77 as a cream solid (5.11 g, 13.3 mmol, 74%).  
tert-butyl (R)-(2-(4-((3-(1-hydroxy-3-phenylpropan-2-
yl)thioureido)methyl)benzamido)phenyl)carbamate ((R)-79a) 
 
D-Phenylalaninol (0.126 g, 0.83 mmol) was reacted according to general 
procedure A and the product purified by column chromatography on silica gel (ethyl 
acetate:hexane, 2:1) to give (R)-79a as a white solid (0.382 g, 94%), mp 101−103 °C; 
νmax (cm
-1
) 3279 (NH), 1692 (C=O), 1648 (C=O); 1H NMR (400 MHz, chloroform-d) δ 
1.49 (9H, s, H(32)), 1.88 (1H, s, H(16/18)), 2.72 (1H, dd, J = 13.6, 8.0 Hz, H(21)), 2.84 
(1H, dd, J = 13.6, 5.8 Hz, H(21)’), 3.37 (2H, br s, OH and H(20)), 3.60 (1H, d, J = 10.5 
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Hz, H(20)’), 4.28−5.00 (3H, m, H(15), H(15)’ and H(19)), 6.65 (1H, br s, H(28)), 
7.06−7.37 (10H, m, ArH), 7.60 (1H, d, J = 7.3 Hz, H(6)), 7.67 (2H, d, J = 7.8 Hz, H(10 
and 14)), 9.38 (1H, br s, H(7));
 13
C NMR (150 MHz, chloroform-d) δ ppm 28.4 (C(32)), 
37.3 (C(21)), 48.0 (C(15)), 57.2 (C(20)), 64.1 (C(19)), 81.8 (C(31)), 124.9 (C(3)), 125.9 
(C(6)), 126.1 (C(4)), 126.6 (C(5)), 126.8 (C(25)), 127.5 (C(10 and 14)), 127.8 (C(11 
and 13)), 128.8 (C(23 and 27)), 129.3 (C(24 and 26)), 130.4 (C(9)), 130.7 (C(2)), 132.6 
(C(1)), 137.5 (C(22)), 142.5 (C(12)), 154.9 (C(28)), 166.3 (C(8)), 182.8 (C(17)); m/z 
(ES, %) 557 ([M+Na]
+
, 100); HRMS (CI) calcd for C29H35N4O4S [M+H]
+
 535.2374, 
found 535.2378. 
tert-butyl (S)-(2-(4-((3-(1-hydroxy-3-phenylpropan-2-
yl)thioureido)methyl)benzamido)phenyl)carbamate ((S)-79a)  
 
Using a method from.
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 To a suspension of 77 (0.240 g, 0.626 mmol, 1.0 eq) in 
toluene (5 ml) was added L-phenylalinol 46a (0.095 g, 0.626 mmol, 1.0 eq) and the 
mixture was stirred at rt under an nitrogen balloon for 63 h. The resulting solution was 
evaporated and then azeotroped with dichloromethane to give a white solid, which was 
purified by column chromatography on silica gel (ethyl acetate:hexane, 2:1) to give (S)-
79a as a white solid (0.290 g, 0.543 mmol, 87%), mp 103-106 °C; νmax (cm
-1
) 3287 
(NH), 1693 (C=O), 1648 (C=O); 
1
H NMR (400 MHz, chloroform-d) δ ppm 1.49 (9H, s, 
H(32)), 1.81 (1H, br s, H(16/18)), 2.73 (1H, dd, J=13.7, 7.8 Hz, H(21)), 2.85 (1H, dd, 
J=13.7, 6.0 Hz, H(21)`), 3.20 (1H, br s, OH), 3.35 - 3.45 (1H, m, H(20)), 3.62 (1H, br. 
d, J=8.3 Hz, H(20)`), 4.36 - 4.84 (3H, m, H(15), H(15)’ and H(19)), 6.61 (1H, br s, 
H(28)), 7.06 - 7.35 (11H, m, 10 ArH and H(16/18)), 7.59 - 7.66 (1H, m, H(6)), 7.69 
(2H, d, J=8.0 Hz, H(10 and 14)), 9.35 (1H, br s, H(7)); 
13
C NMR (150 MHz, 
chloroform-d) δ ppm 28.4 (C(32)), 37.3 (C(21)), 48.0 (C(15)), 57.2 (C(20)), 64.2 
(C(19)), 81.8 (C(31)), 124.9 (C(3)), 125.9 (C(6)), 126.1 (C(4)), 126.6 (C(5)), 126.8 
(C(25)), 127.5 (C(10 and 14)), 127.8 (C(11 and 13)), 128.8 (C(23 and 27)), 129.3 (C(24 
and 26)), 130.4 (C(9)), 130.7 (C(2)), 132.6 (C(1)), 137.5 (C(22)), 142.5 (C(12)), 154.9 
(C(28)), 166.3 (C(8)), 182.8 (C(17)); m/z (ES
+
) 557 ([M+Na]
+
, 36%), 435 ([M+H-
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Boc]
+
, 100%); HRMS C29H34N4O4SNa
+
 requires: 557.2198, found: 557.2192. 
tert-butyl (R)-(2-(4-((3-(2-hydroxy-1-
phenylethyl)thioureido)methyl)benzamido)phenyl)carbamate ((R)-79b) 
 
(R)-2-Phenylglycinol (R)-46b (0.112 g, 0.82 mmol) was reacted according to 
general procedure A and the product purified by column chromatography on silica gel 
(ethyl acetate/hexane, 3:2 to 2:1) to give (R)-79b as a white solid (0.37 g, 96%), mp 
107.109 °C; νmax (cm
-1
) 3278 (NH), 1692 (C=O), 1648 (C=O); 
1
H NMR (400 MHz, 
chloroform-d) δ 1.49 (9H, s, C(CH3)3), 1.88 (1H, br s, H(16/18)), 3.49 (1H, br s, OH), 
3.66 (1H, m, H(20), 3.79 (1H, d, J = 8.8 Hz, H(20)’), 4.69 (2H, d, J = 2.8 Hz, H(15) and 
H(15)’), 5.20 (1H, br s, H(19)), 6.97.7.39 (11H, m, ArH), 7.59 (1H, d, J = 6.8 Hz, H(3)), 
7.69 (2H, d, J = 8.0 Hz, H(10 and 14)), 9.35 (1H, br s, H(7));
 13
C NMR (150 MHz, 
chloroform-d) δ ppm 28.4 (C(31)), 48.4 (C(15)), 60.2 (C(19)), 66.5 (C(20), 81.7 
(C(30)), 124.9 (C(3)), 125.9 (C(6)), 126.0 (C(4)), 126.5 (C(5)), 126.9 (C(22 and 26)), 
127.4 (C(10 and 14)), 127.8 (C(11 and 13)), 128.3 (C(24)), 129.1 (C(23 and 25)), 130.4 
(C(9)), 130.7 (C(2)), 132.7 (C(1)), 138.2 (C(21)), 142.3 (C(12)), 154.9 (C(28)), 166.2 
(C(8)), 182.7 (C(17)); m/z (ES, %) 521 ([M+H]
+
, 80%), 421 ([M+H-(Boc)]
+
, 100%); 
HRMS calcd for C28H33N4O4S [M+H]
+
 521.2217, found 521.2195. 
tert-butyl (S)-(2-(4-((3-(2-hydroxy-1-
phenylethyl)thioureido)methyl)benzamido)phenyl)carbamate ((S)-79b) 
 
7. Experimental 
Christopher Matthews  198 
To a solution of (S)-2-phenylglycinol, (S)-46b (0.165 g, 1.2 mmol, 1.2 eq) in 
acetonitrile (4 ml) was added isothiocyanate 77 (0.384 g, 1.0 mmol, 1.0 eq) and the 
resulting suspension stirred at rt for 16.5 h. The resulting solution was evaporated, then 
dissolved in ethyl acetate (20 ml) and washed with hydrochloric acid (1M aq., 20 ml), 
sodium hydrogen carbonate (sat. aq., 20 ml) and brine (20 ml). The organic was dried 
with MgSO4 and evaporated then purified by column chromatography on silica gel 
(ethyl acetate:hexane, 3:2 to 2:1) to give (S)-79b as a white solid (0.464 g, 0.891 mmol, 
89%), mp 108-111 °C; νmax (cm
-1
) 3285 (NH), 1691 (C=O), 1646 (C=O); 
1
H NMR (600 
MHz, chloroform-d) δ ppm 1.46 (9H, s, H(31)), 1.84 (1H, s, H(16/18), 3.45 (1H, br s, 
OH), 3.61 - 3.69 (1H, m, H(20)), 3.73 - 3.81 (1H, m, H(20)`), 4.53 - 4.81 (2H, m, H(15) 
and H(15)’), 5.19 (1H, br s, H(19)), 7.08 (2H, br s, ArH and H(27)), 7.11 - 7.18 (3H, m, 
ArH), 7.20 (2H, d, J=7.2 Hz, ArH), 7.24 - 7.32 (5H, m, 4 ArH and H(16/18)), 7.59 (1H, 
d, J=6.8 Hz, H(3)), 7.67 (2H, d, J=7.5 Hz, H(10 and 14)), 9.33 (1H, br s, H(7)); 
13
C 
NMR (150 MHz, chloroform-d) δ ppm 28.4 (C(31)), 48.4 (C(15)), 60.2 (C(19)), 66.5 
(C(20), 81.7 (C(30)), 124.9 (C(3)), 125.9 (C(6)), 126.0 (C(4)), 126.5 (C(5)), 126.9 
(C(22 and 26)), 127.4 (C(10 and 14)), 127.8 (C(11 and 13)), 128.3 (C(24)), 129.1 (C(23 
and 25)), 130.4 (C(9)), 130.7 (C(2)), 132.7 (C(1)), 138.2 (C(21)), 142.3 (C(12)), 154.9 
(C(28)), 166.2 (C(8)), 182.7 (C(17)); m/z (ES
+
) 521 ([M+H]
+
, 20%), 543 ([M+Na]
+
, 
50%); HRMS C28H33N4O4S
+
 requires: 521.2223, found: 521.2180. 
 (R)-tert-butyl (2-(4-((3-(2-hydroxy-2-
phenylethyl)thioureido)methyl)benzamido)phenyl)carbamate ((R)-79d) 
 
(R)-(-)-2-amino-1-phenylethanol (0.137 g, 1.0 mmol, 1 eq) was reacted 
according to general procedure A to give (R)-79d as a pale yellow solid (0.519 g, 100%) 
which was used without purification, mp 153-156 °C; νmax (cm
-1
) 3287 (NH), 1682 
(C=O), 1660 (C=O); 
1
H NMR (600 MHz, chloroform-d) δ ppm 1.48 (9H, s, C(CH3)3), 
3.29 - 4.08 (3H, br. m, OH and 2 × H(19)), 4.57 - 5.01 (3H, m, H(15), H(15)’ and 
H(20)), 6.64 (1H, br s, BocNH), 7.06 (1H, br s, ArH), 7.15 - 7.23 (2H, m, ArH), 7.24 - 
7.36 (7H, m, ArH), 7.66 (1H, d, J=7.2 Hz, H(6)), 7.73 (2H, d, J=7.2 Hz, H(10 and 14)), 
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9.36 (1H, br s, H(7)); 
13
C NMR (150 MHz, chloroform-d) δ ppm 28.4 (C(CH3)3), 48.5 
(C(15)), 52.0 (C(19)), 74.2 (C(20)), 81.9 (OC(CH3)3), 125.0 (C(3)), 125.9 (C(22 and 
26)), 126.2 (C(6) and C(4)), 126.5 (C(5)), 127.7 (C(10 and 14)), 127.9 (C(11 and 13)), 
128.1 (C(24)), 128.7 (C(23 and 25)), 130.4 (C(9)), 130.7 (C(2)), 132.9 (C(1)), 141.6 
(C(21)), 142.2 (C(12)), 154.9 (NCOO), 166.0 (C(8)), 183.8 (C(17)); m/z (EI) 519 ([M-
H]
-
, 50%); HRMS (CI) calcd. for C28H33N4O4S [M+H]
+
 521.2217, found: 521.2195. 
 (S)-tert-butyl (2-(4-((3-(2-hydroxy-2-
phenylethyl)thioureido)methyl)benzamido)phenyl)carbamate ((S)-79d) 
 
(S)-(+)-2-amino-1-phenylethanol (0.125 g, 0.911 mmol, 1 eq) was reacted 
according to general procedure A and purified by column chromatography on silica gel 
(ethyl acetate:hexane, 3:2), then purified again by column chromatography on silica gel 
(ethyl acetate:hexane, 1:1) to give (S)-79d as a white solid (0.272 g, 57%), mp 150-154 
°C; νmax (cm
-1
) 3284 (NH), 1682 (C=O), 1661 (C=O); 
1
H NMR (400 MHz, chloroform-
d) δ ppm 1.48 (9H, s, C(CH3)3), 3.48 (1H, br s, OH), 3.58 - 4.35 (2H, m, 2 × H(19)), 
4.69 (3H, br s, H(15), H(15)’ and H(20)), 6.88 (1H, br s, BocNH), 7.10 - 7.20 (2H, m, 
ArH), 7.20 - 7.40 (8H, m, ArH), 7.53 - 7.62 (1H, m, ArH), 7.68 (2H, d, J=8.0 Hz, H(10 
and 14)), 9.41 (1H, br s, H(7)); 
13
C NMR (150 MHz, chloroform-d) δ ppm 28.4 
(C(CH3)3), 48.3 (C(15)), 52.0 (C(19)), 74.0 (C(20)), 81.8 (OC(CH3)3), 124.9 (C(3)), 
125.9 (C(22 and 26)), 126.0 (C(6)), 126.1 (C(4)), 126.6 (C(5)), 127.7 (C(10 and 14)), 
127.8 (C(11 and 13)), 128.0 (C(24)), 128.6 (C(23 and 25)), 130.4 (C(9)), 130.6 (C(2)), 
132.7 (C(1)), 141.6 (C(21)), 142.4 (C(12)), 154.9 (NCOO), 166.2 (C(8)), 183.7 (C(17)); 
m/z (EI) 519 ([M-H]
-
, 35%); HRMS (CI) calcd. for C28H33N4O4S [M+H]
+
 521.2217, 
found: 521.2208. 
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(S)-tert-butyl (2-(4-((3-(2-hydroxy-1-(4-
hydroxyphenyl)ethyl)thioureido)methyl)benzamido)phenyl)carbamate (79e) 
 
To a suspension of impure amino alcohol (46e) (0.536 g, 3.5 mmol) in 
acetonitrile (12 mL) was added 22 (0.384 g, 1.0 mmol). The resulting mixture was 
stirred vigorously at rt for 17.5 h before being evaporated and the residue partitioned 
between ethyl acetate (100 mL) and aqueous hydrochloric acid (1M, 50 mL). The 
organic layer was washed with water (50 mL), brine (50 mL), dried MgSO4 and 
evaporated. Purification of the yellow solid by column chromatography on silica gel 
(ethyl acetate:hexane, 3:1) gave 79e as a white solid (0.359 g, 67%), mp 128-132 °C; 
νmax (cm
-1
) 3250 (NH), 1685 (C=O), 1646 (C=O);
 1
H NMR (400 MHz, methanol-d4) δ 
ppm 1.51 (9H, s, C(CH3)3), 3.79 (2H, app. d, J=5.8 Hz, 2 × H(20)), 4.62 - 4.82 (1H, m, 
H(15)), 4.86 - 5.00 (1H, m, H(15)’), 5.27 (1H, br s, H(19)), 6.79 (2H, d, J=8.5 Hz, H(23 
and 25)), 7.12 - 7.29 (4H, m, ArH), 7.30 - 7.41 (2H, m, ArH), 7.42 - 7.50 (1H, m, ArH), 
7.58 - 7.66 (1H, m, ArH), 7.90 (2H, d, J=8.0 Hz, H(10 and 14)); 
13
C NMR (150 MHz, 
methanol-d4) δ ppm 28.7 (C(CH3)3), 60.4 (C(15)), 66.4 (C(20)), 79.5 (C(19)), 81.8 
(OC(CH3)3), 116.3 (C(23 and 25)), 125.6 (C(3)), 126.3 (C(6)), 127.2 (C(4)), 127.5 
(C(5)), 128.5 (C(11 and 13)), 128.7 (C(10 and 14)), 129.3 (C(22 and 26)), 131.6 (C(9) 
and C(2)), 133.0 (C(1)), 134.0 (C(21)), 144.9 (C(12)), 156.3 (NCOO), 158.0 (C(24)), 
168.2 (C(8)), 183.9 (C(17)); m/z (ES) 535 ([M-H]
-
, 100%); HRMS calcd. for 
C28H31N4O5S
 
[M-H]
-
 535.2015, found: 535.2017. 
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tert-butyl (2-(4-((3-((1S,2R)-2-hydroxy-1,2-
diphenylethyl)thioureido)methyl)benzamido)phenyl)carbamate ((R,S)-79f)  
 
(1R,2S)-(-)-2-amino-1,2-diphenyl ethanol (0.213 g, 1.0 mmol, 1 eq) was reacted 
according to general procedure A to give (R,S)-79f as a pale yellow solid (0.596 g, 
100%) which was used without purification, mp 135-140 °C; νmax (cm
-1
) 3273 (NH), 
1693 (C=O), 1651 (C=O); 
1
H NMR (600 MHz, chloroform-d) δ ppm 1.46 (9H, s, 
C(CH3)3), 3.21 (1H, br s, OH), 4.54 (1H, dd, J=15.1, 4.1 Hz, H(15)), 4.73 (1H, br. d, 
J=15.0 Hz, H(15)’), 5.06 (1H, d, J=3.4 Hz, H(19)), 5.51 (1H, br s, H(20)), 6.87 - 7.10 
(8H, m, BocNH and ArH), 7.12 - 7.25 (8H, m, ArH), 7.58 - 7.70 (3H, m, ArH), 9.33 
(1H, br s, H(7)); 
13
C NMR (150 MHz, chloroform-d) δ ppm 28.4 (C(CH3)3), 48.3 
(C(15)), 63.8 (C(19)), 76.6 (C(20)), 81.7 (OC(CH3)3), 124.8 (C(3)), 125.9 (C(6)), 126.0 
(C(4)), 126.4 (C(5)), 126.6 (C(28 and 32)), 127.5 (C(10 and 14)), 127.8 (C(11 and 13)), 
128.0 (C(24) and C(30)), 128.2 (C(22 and 26)), 128.2 (C(29 and 31)), 128.3 (C(23 and 
25)), 130.3 (C(9)), 130.5 (C(2)), 133.0 (C(1)), 136.4 (C(27)), 139.6 (C(21)), 142.1 
(C(12)), 154.8 (NCOO), 166.1 (C(8)), 182.4 (C(17)); m/z (EI) 595 ([M-H]
-
, 60%); 
HRMS (CI) calcd. for C34H37N4O4S [M+H]
+
 597.2530, found: 597.2524. 
tert-butyl (2-(4-((3-((1R,2S)-2-hydroxy-1,2-
diphenylethyl)thioureido)methyl)benzamido)phenyl)carbamate ((S,R)-79f)  
 
(1S,2R)-(+)-2-amino-1,2-diphenyl ethanol (0.213 g, 1.0 mmol, 1 eq) was reacted 
according to general procedure A to give (S,R)-79f as a pale yellow solid (0.590 g, 
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99%) which was used without purification, mp 130-133 °C; νmax (cm
-1
) 3275 (NH), 
1693 (C=O), 1650 (C=O); 
1
H NMR (400 MHz, chloroform-d) δ ppm 1.49 (9H, s, 
C(CH3)3), 3.21 (1H, br s, OH), 4.56 (1H, dd, J=15.4, 4.9 Hz, H(15)), 4.76 (1H, br. d, 
J=15.0 Hz, H(15)’), 5.08 (1H, d, J=3.8 Hz, H(19)), 5.51 (1H, br s, H(20)), 6.85 - 7.11 
(8H, m, BocNH and ArH), 7.12 - 7.30 (8H, m, ArH), 7.58 - 7.74 (3H, m, ArH), 9.35 
(1H, br s, H(7)); 
13
C NMR (150 MHz, chloroform-d) δ ppm 28.4 (C(CH3)3), 48.3 
(C(15)), 63.8 (C(19)), 76.7 (C(20)), 81.7 (OC(CH3)3), 124.8 (C(3)), 125.9 (C(6)), 126.1 
(C(4)), 126.4 (C(5)), 126.6 (C(28 and 32)), 127.5 (C(10 and 14)), 127.8 (C(11 and 13)), 
128.0 (C(24 and 30)), 128.2 (C(22 and 26)), 128.2 (C(29 and 31)), 128.3 (C(23 and 
25)), 130.3 (C(9)), 130.5 (C(2)), 133.0 (C(1)), 136.4 (C(27)), 139.6 (C(21)), 142.1 
(C(12)), 154.8 (NCOO), 166.1 (C(8)), 182.4 (C(17)); m/z (EI) 595 ([M-H]
-
, 80%); 
HRMS (CI) calcd. for C34H37N4O4S [M+H]
+
 597.2530, found: 597.2516. 
tert-butyl (S)-(2-(4-(((4-benzyl-4,5-dihydrooxazol-2-
yl)amino)methyl)benzamido)phenyl)carbamate ((S)-80a) 
 
To a solution of (S)-79a (0.524 g, 0.98 mmol, 1.0 eq) in ethanol (7 mL) and 
toluene (14 mL) was added freshly prepared yellow mercuric oxide (0.58 g, 2.6 mmol, 
2.7 eq) the resulting mixture was stirred at reflux for 30 min. Cooled to rt and filtered 
through Celite, evaporation of the filtrate gave (S)-80a as a white solid (0.45 g, 0.90 
mmol, 92%), mp 200-201 °C; νmax (cm
-1
) 3308 (NH), 1664 (C=O), 1650 (C=O); 
1
H 
NMR (500 MHz, chloroform-d) δ ppm 1.51 (9H, s, C(CH3)3), 2.66 (1H, dd, J=13.5, 8.5 
Hz, H(21)), 3.06 (1H, dd, J=13.5, 4.7 Hz, H(21)’), 4.03 (1H, t, J=7.1 Hz, H(20)), 4.22 
(1H, t, J=8.2 Hz, H(20)), 4.28 - 4.36 (1H, m, H(19), 4.43 (1H, d, J=15.3 Hz, H(15)), 
4.47 (1H, d, J=15.3 Hz, H(15)’), 6.93 (1H, br s, NHBoc), 7.13 - 7.32 (5H, m, ArH), 
7.38 (2H, d, J=7.9 Hz, H(9 and 14)), 7.79 (1H, d, J=7.7 Hz, H(6)), 7.92 (2H, d, J=7.9 
Hz, H(10 and 14)), 9.19 (1H, br s, H(7)); 
13
C NMR (125 MHz, chloroform-d) δ ppm 
28.4 (C(CH3)3), 42.4 (C(22)), 46.7 (C(15)), 65.1 (C(19)), 72.5 (C(20)), 81.5 (C(21)), 
124.6 (C(3)), 125.8 (C(6)), 126.0 (C(4)), 126.1 (C(5)), 126.5 (C(25)), 127.4 (C(11 and 
13)), 127.8 (C(23 and 24)), 128.6 (C(10 and 14)), 129.3 (C(23 and 25)), 130.0 (C(9)), 
131.0 (C(2)), 133.5 (C(1)), 138.0 (C(22)), 142.9 (C(12)), 154.7 (NCOO), 160.8 (C(17)), 
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165.4 (C(8)); m/z (ESI
-
) 499 ([M-H]
-
, 100%); HRMS C29H31N4O4
-
 requires: 499.2351, 
found:499.2358. 
tert-butyl (R)-(2-(4-(((4-phenyl-4,5-dihydrooxazol-2-
yl)amino)methyl)benzamido)phenyl)carbamate ((R)-80b) 
 
To a solution of amino alcohol (R)-46b (110 mg, 0.8 mmol) in THF (12 mL) was 
added isothiocyanate 77 (337 mg, 0.88 mmol), the resulting solution was stirred at rt for 
18 h. The solvent was evaporated and the residue dissolved in acetone (6 mL), then 
iodomethane (0.1 mL, 1.6 mmol) was added and the solution stirred at rt for 9 h. 
Sodium bicarbonate (sat. aq., 2 mL) was added and the mixture was stirred for 10 min 
before being diluted with sodium bicarbonate (sat. aq., 20 mL) then extracted with ethyl 
acetate (2 × 20 mL). The combined organic layers were washed with brine (20 mL) 
dried Na2SO4 and evaporated to give a white solid (445 mg) that was purified by 
column chromatography on silica gel (5% methanol/ethyl acetate) to give (R)-80b (159 
mg, 0.327 mmol, 41%) as a white solid, mp 104-106 °C; νmax (cm
-1
) 3277 (NH), 1653 
(C=O); 
1
H NMR (300 MHz, chloroform-d) δ ppm 1.48 (9H, s, C(CH3)3), 4.08 (1H, t, 
J=7.5 Hz, H(20)), 4.44 (2H, s, H(15) and H(15)’), 4.63 (1H, t, J=8.6 Hz, H(20)’), 5.09 
(1H, dd, J=8.9, 7.3 Hz, H(19)), 7.03 - 7.39 (13H, m, ArH and BocNH), 7.65 - 7.74 (1H, 
m, ArH), 7.85 (2H, d, J=8.1 Hz, H(10 and 14)), 9.30 (1H, br s, H(7)); 
13
C NMR (75 
MHz, chloroform-d) δ ppm 28.4 (C(CH3)3), 46.7 (C(15)), 67.6 (C(19)), 75.6 (C(20)), 
81.3 (OC(CH3)3), 124.7 (C(3)), 125.8 (C(6)), 125.9 (C(4)), 126.1 (C(5)), 126.6 (C(11 
and 13)), 127.4 (C(22 and 26)), 127.6 (C(24)), 127.9 (C(10 and 14)), 128.8 (C(23 and 
25)), 130.3 (C(9)), 130.9 (C(2)), 133.3 (C(1)), 143.1 (C(21)), 143.6 (C(12)), 154.8 
(NCOO), 161.8 (C(17)), 165.7 (C(8)); m/z (ESI
+
) 487 ([M+H]
+
, 100%); HRMS 
C28H31N4O4
+
 requires: 487.2340, found: 487.2336. 
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tert-butyl (S)-(2-(4-(((4-phenyl-4,5-dihydrooxazol-2-
yl)amino)methyl)benzamido)phenyl)carbamate ((S)-80b) 
 
To a solution of (S)-79b (180 mg, 0.346 mmol, 1.0 eq) in ethanol (3.5 mL) and 
toluene (7 mL) was added yellow mercuric oxide (374 mg, 1.73 mmol, 5.0 eq) in 
portions. The resulting mixture was stirred at reflux for 2 hours. Filtered through Celite 
and the filtrate evaporated to give a white solid. This white solid was dissolved in 
ethanol (3.5 mL) and toluene (7 mL) then yellow mercuric oxide (374 mg, 1.73 mmol, 
5.0 eq) was added and the mixture stirred at reflux for 4 h. The mixture was filtered 
through Celite and yellow mercuric oxide (374 mg, 1.73 mmol, 5.0 eq) was added and 
the mixture was stirred at reflux for 4 h. The mixture was filtered through Celite and 
concentrated in vacuo to give (S)-80b as a foamy white solid (0.127 g, 0.263 mmol, 
76%), mp 100-103 °C; νmax (cm
-1
) 3274 (NH), 1654 (C=O); 
1
H NMR (400 MHz, 
chloroform-d) δ ppm 1.51 (9H, s, C(CH3)3), 4.11 (1H, t, J=7.5 Hz, H(20)), 4.47 (2H, s, 
H(15) and H(15)’), 4.66 (1H, t, J=8.5 Hz, H(20)’), 5.12 (1H, dd, J=9.0, 7.3 Hz, H(19)), 
7.15 (1H, td, J=7.5, 1.6 Hz, H(4)), 7.19 (1H, td, J=7.5, 1.6 Hz, H(5)), 7.24 - 7.30 (5H, 
m, ArH, and BocNH), 7.31 – 7.39 (4H, m, ArH), 7.73 (1H, d, J=7.3 Hz, H(6)), 7.89 
(2H, d, J=8.0 Hz, H(10 and 14)), 9.33 (1H, br s, H(7)); 
13
C NMR (125 MHz, 
chloroform-d) δ ppm 28.7 (C(CH3)3), 47.0 (C(15)), 67.8 (C(19)), 75.8 (C(20)), 81.6 
(OC(CH3)3), 124.9 (C(3)), 126.1 (C(6)), 126.2 (C(4)), 126.3 (C(5)), 126.8 (C(11 and 
13)), 127.7 (C(22 and 26)), 127.9 (C(24)), 128.1 (C(10 and 14)), 129.0 (C(23 and 25)), 
130.5 (C(9)), 131.2 (C(2)), 133.6 (C(1)), 143.3 (C(21)), 143.8 (C(12)), 155.0 (NCOO), 
162.0 (C(17)), 165.9 (C(8)); m/z (ESI
-
) 485 ([M-H]
-
, 95%); HRMS C28H29N4O4
-
 
requires: 485.2194, found: 485.2206. 
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(R)-tert-butyl (2-(4-(((5-phenyl-4,5-dihydrooxazol-2-
yl)amino)methyl)benzamido)phenyl)carbamate ((R)-80d) 
 
To a solution of (R)-2-amino-1-phenylethanol (110 mg, 0.8 mmol) in THF (8 
mL) was added isothiocyanate 77 (307 mg, 0.8 mmol), the resulting solution was stirred 
at rt for 18 h, then evaporated. The residue was dissolved in acetone (4 mL) then 
iodomethane (0.100 mL, 1.600 mmol) was added and the solution stirred at rt for 6 h. 
Sodium bicarbonate (sat. aq., 2 mL) was added, stirred for 10 min then diluted with 
sodium bicarbonate (sat. aq., 20 mL), and extracted with ethyl acetate (2 × 20 mL). 
Combined organics were dried Na2SO4 and evaporated to give a yellow oil that was 
purified by flash column chromatography on silica gel (1-5% (2M ammonia/methanol) 
in dichloromethane) to give (R)-80d (291 mg, 0.598 mmol, 75%) as a white solid, mp 
97-99 °C; νmax (cm
-1
) 3277 (NH), 1659 (C=O); 
1
H NMR (400 MHz, chloroform-d) δ 
ppm 1.48 (9H, s, C(CH3)3), 3.67 (1H, dd, J=12.2, 7.3 Hz, H(19)), 4.14 (1H, dd, J=12.2, 
9.2 Hz, H(19)’), 4.41 (2H, s, H(15) and H(15)’), 5.02 (1H, br s, H(16)), 5.49 (1H, t, 
J=8.3 Hz, H(20)), 7.04 - 7.19 (2H, m, BocNH and ArH), 7.22 - 7.48 (9H, m, ArH), 7.61 
- 7.70 (1H, m, ArH), 7.84 (2H, d, J=8.3 Hz, ArH), 9.48 (1H, br s, H(7)); 
13
C NMR (100 
MHz, chloroform-d) δ ppm 28.3 (C(CH3)3), 46.4 (C(15)), 60.1 (C(19)), 80.9 
(OC(CH3)3), 81.7 (C(20)), 124.5 (C(3)), 125.4 (C(6)), 125.6 (C(4)), 125.7 (C(11 and 
13)), 125.9 (C(5)), 127.1 (C(22 and 26)), 127.8 (C(10 and 14)), 128.4 (C(24)), 128.8 
(C(23 and 25)), 130.5 (C(9)), 130.6 (C(2)), 133.1 (C(1)), 140.3 (C(21)), 142.8 (C(12)), 
154.7 (NCOO), 160.8 (C(17)), 165.7 (C(8)); m/z (ESI
+
) 487 ([M+H]
+
, 100%); HRMS 
C28H31N4O4
+
 requires: 487.2340, found: 487.2342. 
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(S)-tert-butyl (2-(4-(((5-phenyl-4,5-dihydrooxazol-2-
yl)amino)methyl)benzamido)phenyl)carbamate ((S)-80d) 
 
To a solution of (S)-2-amino-1-phenylethanol (110 mg, 0.8 mmol) in THF (8 
mL) was added isothiocyanate 77 (307 mg, 0.8 mmol), the resulting solution was stirred 
at rt for 18 h, then evaporated. The residue was dissolved in acetone (4 mL), then 
iodomethane (0.10 mL, 1.6 mmol) was added and the solution stirred at rt for 4 h. 
Sodium bicarbonate (sat. aq., 2 mL) was added, stirred for 10 min then diluted with 
sodium bicarbonate (sat. aq., 20 mL), and extracted with ethyl acetate (2 × 35 mL). 
Combined organics were dried Na2SO4 and evaporated to give a white solid (396 mg) 
that was purified by flash column chromatography on silica gel (1-5% (2M 
ammonia/methanol) in dichloromethane) to give (S)-80d (275 mg, 0.565 mmol, 71%) 
as a white solid, mp 100-102 °C; νmax (cm
-1
) 3274 (NH), 1655 (C=O); 
1
H NMR (400 
MHz, chloroform-d) δ ppm 1.51 (9H, s, C(CH3)3), 3.73 (1H, dd, J=12.2, 7.3 Hz, H(19)), 
4.20 (1H, dd, J=12.3, 9.2 Hz, H(19)’), 4.49 (2H, s, H(15) and H(15)’), 5.52 (1H, dd, 
J=9.2, 7.3 Hz, H(20)), 7.12 - 7.23 (2H, m, BocNH and ArH), 7.27 - 7.43 (9H, m, ArH), 
7.75 (1H, d, J=7.6 Hz, ArH), 7.91 (2H, d, J=8.1 Hz, H(10 and 14)), 9.31 (1H, br s, 
H(7)); 
13
C NMR (100 MHz, chloroform-d) δ ppm 28.3 (C(CH3)3), 46.6 (C(15)), 60.7 
(C(19)), 81.2 (OC(CH3)3), 81.7 (C(20)), 124.5 (C(3)), 125.6 (C(6)), 125.7 (C(4)), 125.8 
(C(11 and 13)), 125.9 (C(5)), 127.3 (C(22 and 26)), 127.8 (C(10 and 14)), 128.3 
(C(24)), 128.8 (C(23 and 25)), 130.2 (C(9)), 130.8 (C(2)), 133.3 (C(1)), 140.5 (C(21)), 
142.9 (C(12)), 154.6 (NCOO), 160.5 (C(17)), 165.5 (C(8)); m/z (ESI
+
) 487 ([M+H]
+
, 
100%); HRMS C28H31N4O4
+
 requires: 487.2340, found: 487.2327. 
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(S)-tert-butyl (2-(4-(((4-(4-hydroxyphenyl)-4,5-dihydrooxazol-2-
yl)amino)methyl)benzamido)phenyl)carbamate (80e) 
 
To a solution of 79e (270 mg, 0.503 mmol) in acetone (4 mL) was added 
iodomethane (0.047 mL, 0.755 mmol) and the solution stirred at rt for 4 h. More 
iodomethane (0.047 mL, 0.755 mmol) was added and the reaction was stirred at rt for 
17.5 h. Sodium bicarbonate (sat. aq., 2 mL) was added and the mixture was stirred for 
10 min before being diluted with sodium bicarbonate (sat. aq., 20 mL) and water (5 
mL), then extracted with ethyl acetate (2 × 30 mL). The combined organic layers were 
dried Na2SO4 and evaporated to give 80e (252 mg, 0.501 mmol, 100%) as a white solid, 
mp 133-139 °C; νmax (cm
-1
) 3282 (NH), 1650 (C=O); 
1
H NMR (400 MHz, chloroform-
d) δ ppm 1.49 (9H, s, C(CH3)3), 4.09 (1H, t, J=7.5 Hz, H(20)), 4.33 - 4.50 (2H, m, 
H(15) and H(15)’), 4.40 - 4.55 (1H, br s, BocNH), (4.58 (1H, t, J=8.6 Hz, H(20)’), 4.98 
(1H, dd, J=8.8, 7.1 Hz, H(19)), 6.58 (2H, d, J=8.5 Hz, H(23 and 25)), 6.91 (2H, d, J=8.5 
Hz, H(22 and 26), 7.11 - 7.21 (2H, m, H(4) and H(5)), 7.27 - 7.35 (4H, m, H(11 and 
13), H(3) and OH), 7.63 - 7.73 (1H, m, H(6)), 7.83 (2H, d, J=8.3 Hz, H(10 and 14)), 
9.37 (1H, br s, H(7)); 
13
C NMR (125 MHz, chloroform-d) δ ppm 28.3 (C(CH3)3), 46.3 
(C(15)), 66.2 (C(19)), 75.7 (C(20)), 81.3 (OC(CH3)3), 115.9 (C(23 and 25)), 124.6 
(C(3)), 125.6 (C(5)), 125.7 (C(6)), 126.1 (C(4)), 127.2 (C(11 and 13)), 127.5 (C(22 and 
26)), 127.7 (C(10 and 14)), 130.4 (C(9)), 130.6 (C(2)), 132.9 (C(1)), 133.6 (C(21)), 
142.7 (C(12)), 154.6 (NCOO), 156.3 (C(24)), 161.5 (C(17)), 165.8 (C(8)); m/z (ESI
+
) 
503 ([M+H]
+
, 100%); HRMS C28H31N4O5
+
 requires: 503.2289, found: 503.2281. 
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tert-butyl (2-(4-((((4S,5S)-4,5-diphenyl-4,5-dihydrooxazol-2-
yl)amino)methyl)benzamido)phenyl)carbamate ((R,R)-80f) 
 
To a solution of (1S,2S)-2-amino-1,2-diphenylethanol (122 mg, 0.574 mmol) in 
THF (6 mL) was added isothiocyanate 77 (200 mg, 0.522 mmol), the resulting solution 
was stirred at rt for 16 h. The solvent was evaporated and the residue dissolved in 
acetone (3 mL), then iodomethane (0.098 mL, 1.565 mmol) was added and the solution 
stirred at rt for 5.5 h. Sodium bicarbonate (sat. aq., 1.5 mL) was added and the mixture 
was stirred for 10 min before being diluted with sodium bicarbonate (sat. aq., 20 mL) 
and water (5 mL), then extracted with ethyl acetate (2 × 30 mL). The combined organic 
layers were dried Na2SO4 and evaporated to give a white solid (260 mg) that was 
purified by flash column chromatography on silica gel (1-5% (2M ammonia/methanol) 
in dichloromethane) to give (R,R)-80f (165 mg, 0.293 mmol, 56%) as a white solid, mp 
137-139 °C; νmax (cm
-1
) 3271 (NH), 1656 (C=O); 
1
H NMR (400 MHz, chloroform-d) δ 
ppm 1.51 (9H, s, C(CH3)3), 4.15 (1H, br s, H(16)), 4.46 - 4.60 (2H, m, H(15) and 
H(15)’), 4.98 (1H, d, J=6.8 Hz, H(19)), 5.23 (1H, d, J=6.8 Hz, H(20)), 7.08 - 7.47 (16H, 
m, ArH and BocNH), 7.75 (1H, dd, J=7.8, 1.0 Hz, H(6)), 7.92 (2H, d, J=8.1 Hz, H(10 
and 14), 9.32 (1H, br s, H(7)); 
13
C NMR (100 MHz, chloroform-d) δ ppm 28.3 
(C(CH3)3), 46.5 (C(15)), 76.1 (C(19)), 81.2 (OC(CH3)3), 89.6 (C(20)), 124.5 (Ar CH), 
125.7 (C(6)), 125.8 (Ar 4 × CH), 125.9 (Ar CH), 126.5 (Ar 2 × CH), 127.3 (Ar 2 × CH), 
127.6 (Ar CH), 127.8 (C(10 and 14)), 128.6 (Ar CH), 128.7 (Ar 2 × CH), 128.9 (Ar 2 × 
CH), 130.2 (quaternary), 130.8 (quaternary), 133.3 (quaternary), 139.7 (quaternary), 
142.7 (quaternary), 142.9 (quaternary), 154.7 (NCOO), 160.8 (C(17)), 165.5 (C(8)); m/z 
(ESI
+
) 563 ([M+H]
+
, 100%); HRMS C34H35N4O4
+
 requires: 563.2653, found: 563.2639. 
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tert-butyl (2-(4-((((4R,5S)-4,5-diphenyl-4,5-dihydrooxazol-2-
yl)amino)methyl)benzamido)phenyl)carbamate ((R,S)-80f) 
 
To a solution of (1S,2R)-2-amino-1,2-diphenylethanol (171 mg, 0.8 mmol) in 
THF (8 mL) was added isothiocyanate 77 (307 mg, 0.8 mmol), the resulting solution 
was stirred at rt for 18 h, then evaporated. The residue was dissolved in acetone (4 mL), 
then iodomethane (0.100 mL, 1.600 mmol) was added and the solution stirred at rt for 6 
h. Sodium bicarbonate (sat. aq., 2 mL) was added, stirred for 10 min then diluted with 
sodium bicarbonate (sat. aq., 20 mL), and extracted with ethyl acetate (2 × 20 mL). 
Combined organics were dried Na2SO4 and evaporated to give a colourless oil that was 
purified by flash column chromatography on silica gel (1-5% (2M ammonia/methanol) 
in dichloromethane) then with a SCX-2 cartridge (washed with methanol and then 
eluted with 2M ammonia in methanol) to give (R,S)-80f (421 mg, 0.681 mmol, 85%) as 
a white solid, mp 121-123°C; νmax (cm
-1
) 3277 (NH), 1653 (C=O); 
1
H NMR (400 MHz, 
chloroform-d) δ ppm 1.51 (9H, s, C(CH3)3), 4.48 - 4.59 (2H, m, H(15) and H(15)’), 5.40 
(1H, d, J=8.9 Hz, H(19)), 5.84 (1H, d, J=8.9 Hz, H(20)), 6.84 - 6.92 (4H, m, BocNH 
and ArH), 6.96 - 7.09 (6H, m, ArH), 7.10 - 7.22 (2H, m, ArH), 7.28 (1H, dd, J=7.2, 2.1 
Hz, H(6)), 7.35 - 7.46 (3H, m, ArH), 7.74 (1H, d, J=7.6 Hz, ArH), 7.90 (2H, d, J=8.1 
Hz, ArH), 9.36 (1H, br s, H(7)); 
13
C NMR (100 MHz, chloroform-d) δ ppm 28.3 
(C(CH3)3), 46.5 (C(15)), 71.9 (C(19)), 81.1 (OC(CH3)3), 85.8 (C(20)), 124.6 (C(3)), 
125.7 (C(6 and 4)), 126.0 (C(5)), 126.2 (C(10 and 14)), 126.8 (C(30)), 127.4 (C(24) and 
C(11 and 13)), 127.5 (C(28 and 32)), (127.6 (C(22 and 26)), 127.6 (C(29 and 31)), 
127.8 (C(23 and 25)), 130.3 (C(9)), 130.7 (C(2)), 133.2 (C(1)), 136.4 (C(27)), 139.1 
(C(21)), 143.1 (C(12)), 154.7 (NCOO), 161.6 (C(17)), 165.6 (C(8)); m/z (ESI
+
) 563 
([M+H]
+
, 100%); HRMS C34H35N4O4
+
 requires: 563.2653, found: 563.2641.  
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tert-butyl (2-(4-(((4,4-diphenyl-4,5-dihydrooxazol-2-
yl)amino)methyl)benzamido)phenyl)carbamate (80g) 
 
To a solution of 2-amino-2,2-diphenylethanol (46g) (122 mg, 0.574 mmol) in 
THF (6 mL) was added 77 (200 mg, 0.522 mmol), the resulting solution was stirred at rt 
for 24 h, then at reflux for 18 h. The solvent was evaporated and the residue dissolved in 
acetone (3 mL), then iodomethane (0.098 mL, 1.565 mmol) was added and the solution 
stirred at rt for 4 h. Sodium bicarbonate (sat. aq., 1.5 mL) was added and the mixture 
was stirred for 10 min before being diluted with sodium bicarbonate (sat. aq., 20 mL) 
and water (5 mL), then extracted with ethyl acetate (2 × 30 mL). The combined organic 
layers were dried Na2SO4 and evaporated to give a white solid (354 mg) that was 
purified by flash column chromatography on silica gel (1-5% (2M ammonia/methanol) 
in dichloromethane) to give 80g (290 mg, 0.515 mmol, 99%) as a white solid, mp 104-
106 °C; νmax (cm
-1
) 3276 (NH), 1658 (C=O); 
1
H NMR (400 MHz, chloroform-d) δ ppm 
1.50 (9H, s, C(CH3)3), 4.49 (2H, s, H(15) and H(15)’), 4.80 (2H, s, H(20)), 7.08 - 7.39 
(16H, m, ArH and NHBoc), 7.72 (1H, d, J=6.8 Hz, H(6)), 7.87 (2H, d, J=8.3 Hz, H(10 
and 14), 9.26 (1H, br s, H(7)); 
13
C NMR (100 MHz, chloroform-d) δ ppm 28.3 
(C(CH3)3), 46.5 (C(19)), 80.0 (C(20)), 81.2 (OC(CH3)3), 124.6 (C(3)), 125.7 (C(4)), 
125.8 (C(6)), 126.0 (C(5)), 126.6 (C(22, 26, 28 and 32)), 126.9 (C(10 and 14)), 127.4 
(C(11 and 13)), 127.7 (C(24 and 30)), 128.3 (C(23, 25, 29 and 31)), 130.2 (C(9)), 130.8 
(C(2)), 133.1 (C(1)), 143.3 (C(12)), 146.9 (C(21 and 27)), 154.7 (NCOO), 160.1 
(C(17)), 165.6 (C(8)); m/z (ESI
+
) 563 ([M+H]
+
, 100%); HRMS C34H35N4O4
+
 requires: 
563.2653, found: 563.2639. 
7. Experimental 
Christopher Matthews  211 
(R)-tert-butyl (2-(4-(((4-((1H-imidazol-4-yl)methyl)-4,5-dihydrooxazol-2-
yl)amino)methyl)benzamido)phenyl)carbamate ((R)-80h) 
 
To a mixture of (R)-2-amino-3-(1H-imidazol-4-yl)propan-1-ol dihydrochloride 
(123 mg, 0.574 mmol) in THF (10 mL) was added potassium carbonate (159 mg, 1.147 
mmol) and 77 (200 mg, 0.522 mmol) the mixture was stirred at 72 °C for 72 h. 
Potassium carbonate was filtered, the filtrate was evaporated and the residue dissolved 
in acetone (6 mL), then iodomethane (0.065 mL, 1.043 mmol) was added and the 
solution stirred at rt for 18 h. Sodium bicarbonate (sat. aq., 2 mL) was added and the 
mixture was stirred for 10 min before being diluted with sodium bicarbonate (sat. aq., 
20 mL) and water (5 mL), then extracted with ethyl acetate (2 × 20 mL). The combined 
organic layers were washed with brine (20 mL), dried Na2SO4 and evaporated to give a 
yellow solid (250 mg), which was purified by flash column chromatography on silica 
gel (2 to 20% (2M ammonia/methanol) in dichloromethane) to give (R)-80h (110 mg, 
0.224 mmol, 43%) as a white solid, mp 159-163 °C; νmax (cm
-1
) 3664 (NH), 3382 (NH), 
1679 (C=O), 1641 (C=O); 
1
H NMR (500 MHz, DMSO-d6) d ppm 1.46 (9H, s, 
C(CH3)3), 2.62 (1H, dd, J=15.4, 5.8 Hz, H(21)), 3.09 (1H, dd, J=15.4, 7.4 Hz, H(21)’), 
3.75 (1H, dd, J=11.0, 5.5 Hz, H(20)), 4.24 (1H, dd, J=11.0, 7.0 Hz, H(20)), 4.31 (2H, d, 
J=6.0 Hz, H(15) and H(15)’), 4.73 - 4.87 (1H, m, H(19)), 6.53 (1H, t, J=6.0 Hz, H(16)), 
6.62 (1H, s, H(23)), 6.66 (1H, d, J=7.4 Hz, H(24)), 7.12 - 7.26 (2H, m, H(4) and H(5)), 
7.41 (2H, d, J=8.2 Hz, H(11 and 13), 7.49 - 7.61 (3H, m, H(3), H(25) and H(6)), 7.91 
(2H, d, J=8.0 Hz, H(10 and 14)), 8.69 (1H, br s, BocNH), 9.81 (1H, s, N(7)); 
13
C NMR 
(125 MHz, DMSO-d6) δ ppm 28.5 (C(CH3)3), 29.6 (C(21)), 43.1 (C(15)), 50.7 (C(19)), 
55.0 (C(20)), 80.1 (OC(CH3)3), 119.8 (C(23)), 124.4 (C(3)), 124.6 (C(4)), 126.0 (C(5)), 
126.4 (C(6)), 127.4 (C(11 and 13)), 128.0 (C(10 and 14)), 130.3 (C(1)), 131.4 (C(25)), 
132.1 (C(2)), 133.0 (C(9)), 134.7 (C(22)), 145.5 (C(12)), 153.9 (NCOO), 157.9 (C(17)), 
165.6 (C(8)); m/z (ESI
+
) 491 ([M+H]
+
, 100%); HRMS C26H31N6O4
+
 requires: 491.2401, 
found: 491.2390. 
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(S)-tert-butyl (2-(4-(((4-((1H-imidazol-4-yl)methyl)-4,5-dihydrooxazol-2-
yl)amino)methyl)benzamido)phenyl)carbamate ((S)-80h) 
  
To a mixture of (S)-2-amino-3-(1H-imidazol-4-yl)propan-1-ol dihydrochloride 
(178 mg, 0.833 mmol) in THF (6 mL) was added potassium carbonate (230 mg, 1.666 
mmol) followed by a solution of 77 (319 mg, 0.833 mmol) in THF (6 mL). The 
resulting mixture was stirred at rt for 17 h then reflux for 72 h. Potassium carbonate was 
filtered, solvents were evaporated and the residue dissolved in acetone (6 mL), then 
iodomethane (0.104 mL, 1.666 mmol) was added and the solution stirred at rt for 5 h. 
Sodium bicarbonate (sat. aq., 2 mL) was added, stirred for 10 min then diluted with 
sodium bicarbonate (sat. aq., 20 mL), and extracted with ethyl acetate (2 × 20 mL). 
Combined organics were washed with brine (20 mL), dried Na2SO4 and evaporated to 
give 389 mg of a glassy solid, which was purified by flash column chromatography on 
silica gel (2 to 20% (2M ammonia/methanol) in dichloromethane) to give (S)-80h (135 
mg, 0.275 mmol, 33%) as a white solid, mp 155-157 ºC; νmax (cm
-1
) 3310 (NH), 1635 
(C=O); 
1
H NMR (400 MHz, methanol-d4) δ ppm 1.51 (9H, s, C(CH3)3), 2.74 (1H, ddd, 
J=15.6, 5.5, 1.0 Hz, H(21)), 3.23 (1H, ddd, J=15.6, 7.3, 1.0 Hz, H(21)’), 3.87 (1H, dd, 
J=11.4, 5.3 Hz, H(20)), 4.35 (1H, dd, J=11.4, 6.7 Hz, H(20)’), 4.43 (2H, s, H(15) and 
H(15)’), 4.89 - 4.98 (1H, m, H(19)), 6.69 (1H, s, H(23)), 7.19 - 7.29 (2H, m, H(4) and 
H(5)), 7.40 - 7.49 (3H, m, H(11 and 13) and H(3)), 7.57 (1H, s, H(25)), 7.60 - 7.65 (1H, 
m, H(6)), 7.94 (2H, d, J=8.1 Hz, H(10 and 14)); 
13
C NMR (100 MHz, methanol-d4) δ 
ppm 27.2 (C(CH3)3), 28.8 (C(21)), 42.9 (C(15)), 50.6 (C(19)), 54.8 (C(20)), 80.3 
(OC(CH3)3), 118.8 (C(23)), 124.3 (C(6)), 124.9 (C(4)), 125.7 (C(5)), 126.0 (C(2)), 
126.9 (C(11 and 13)), 127.4 (C(10 and 14)), 130.3 (C(2)), 130.9 (C(25)), 131.6 (C(22)), 
132.7 (C(1)), 134.6 (C(9)), 144.6 (C(12)), 154.9 (NCOO), 158.8 (C(17)), 166.7 (C(8)); 
m/z (ESI
+
) 491 ([M+H]
+
, 100%); HRMS C26H31N6O4
+
 requires: 491.2401, found: 
491.2382. 
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tert-butyl (2-(4-(((4-(4-fluorophenyl)-4,5-dihydrooxazol-2-
yl)amino)methyl)benzamido)phenyl)carbamate (80i) 
 
To a solution of amino alcohol 46i (220 mg, 1.42 mmol) in THF (10 mL) was 
added isothiocyanate 77 (272 mg, 0.71 mmol), the resulting solution was stirred at rt for 
18 h. The solvent was evaporated and the residue dissolved in acetone (5 mL), then 
iodomethane (0.088 mL, 1.42 mmol) was added and the solution stirred at rt for 16 h. 
Sodium bicarbonate (sat. aq., 2 mL) was added and the mixture was stirred for 10 min 
before being diluted with sodium bicarbonate (sat. aq., 20 mL) then extracted with ethyl 
acetate (2 × 20 mL). The combined organic layers were washed with brine (20 mL) 
dried Na2SO4 and evaporated to give a white solid (500 mg) that was purified by 
column chromatography on silica gel (ethyl acetate:hexane, 4:1) to give 80i (238 mg, 
0.472 mmol, 67%) as a white solid, mp 105-108 °C; νmax (cm
-1
) 3258 (NH), 1650 
(C=O); 
1
H NMR (400 MHz, chloroform-d) δ ppm 1.51 (9H, s, C(CH3)3), 4.06 (1H, t, 
J=7.7 Hz, H(20)), 4.50 (2H, s, H(15) and H(15)’), 4.65 (1H, t, J=8.5 Hz, H(20)’), 5.11 
(1H, dd, J=8.9, 7.4 Hz, H(19)), 7.02 (2H, t, J=8.7 Hz, ArH), 7.12 - 7.30 (6H, m, ArH), 
7.39 (2H, d, J=8.0 Hz, H(11 and 13)), 7.77 (1H, d, J=7.5 Hz, H(6)), 7.91 (2H, d, J=8.0 
Hz, H(10 and 14)), 9.32 (1H, br s, H(7));
 13
C NMR (125 MHz, chloroform-d) δ ppm 
28.3 (C(CH3)3), 46.6 (C(15)), 66.8 (C(19)), 75.4 (C(20)), 81.3 (OC(CH3)3), 115.4 (d, 
J=22.1 Hz, H(23 and 25)), 124.5 (C(3)), 125.7 (C(6)), 125.9 (C(4) and C(5)), 127.3 
(C(11 and 13)), 127.7 (C(10 and 14)), 128.0 (d, J=8.6 Hz, C(22 and 26), 130.0 (C(9)), 
130.8 (C(2)), 133.3 (C(1)), 139.2 (C(21)), 142.7 (C(12)), 154.6 (NCOO), 162.1 (d, 
J=244.7 Hz, C(24)), 161.5 (C(17)), 165.3 (C(8)); m/z (CI) 505 ([M+H]
+
, 93%); HRMS 
C28H30FN4O4
+
 requires: 505.2246, found: 505.2254. 
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tert-butyl (2-(4-(((4-(3-fluorophenyl)-4,5-dihydrooxazol-2-
yl)amino)methyl)benzamido)phenyl)carbamate (80j) 
 
To a solution of 46j (81 mg, 0.522 mmol) in THF (6 mL) was added 
isothiocyanate 77 (200 mg, 0.522 mmol), the resulting solution was stirred at rt for 16 h. 
The solvent was evaporated and the residue dissolved in acetone (3 mL), then 
iodomethane (0.098 mL, 1.565 mmol) was added and the solution stirred at rt for 4 h. 
Sodium bicarbonate (sat. aq., 1.5 mL) was added and the mixture was stirred for 10 min 
before being diluted with sodium bicarbonate (sat. aq., 20 mL) and water (5 mL), then 
extracted with ethyl acetate (2 × 30 mL), the combined organic layers were washed with 
brine, dried Na2SO4 and evaporated to give a white solid (286 mg). Purification by flash 
column chromatography on silica gel (75-100% ethyl acetate/cyclohexane) gave 80j 
(200 mg, 0.396 mmol, 76%) as a white solid, mp104-107 °C; νmax (cm
-1
) 3283 (NH), 
1652 (C=O); 
1
H NMR (400 MHz, chloroform-d) δ ppm 1.51 (1H, s, C(CH3)3), 3.95 
(1H, br s, H(16)), 4.07 (1H, dd, J=8.1, 7.1 Hz, H(20)), 4.44 - 4.54 (2H, m, H(15) and 
H(15)’), 4.64 (1H, dd, J=9.0, 8.1 Hz, H(20)’), 5.11 (1H, dd, J=9.0, 7.1 Hz, H(19)), 6.91 
- 7.04 (3H, m, H(24), H(26) and BocNH), 7.11 - 7.21 (2H, m, H(4) and H(5)), 7.22 - 
7.32 (3H, m, H(3), H(22) and H(23), 7.36 (2H, d, J=8.3 Hz, H(11 and 13)), 7.73 (1H, 
dd, J=7.8, 1.2 Hz, H(6)), 7.89 (2H, d, J=8.3 Hz, H(10 and 14)), 9.28 (1H, br s, H(7)); 
13
C NMR (100 MHz, chloroform-d) δ ppm 28.3 (C(CH3)3), 46.6 (C(15)), 67.0 (C(19)), 
75.2 (C(20)), 81.2 (OC(CH3)3), 113.3 (d, J=22.0 Hz, C(24)), 114.3 (d, J=21.3 Hz, 
C(26)), 122.0 (d, J=2.2 Hz, C(22)), 124.5 (C(3)), 125.7 (C(5)), 125.8 (C(6)), 125.9 
(C(4)), 127.3 (C(11 and 13)), 127.8 (C(10 and 14)), 130.1 (d, J=8.1 Hz, C(23)), 130.2 
(C(9)), 130.8 (C(2)), 133.3 (C(1)), 142.7 (C(12)), 146.3 (d, J=6.6 Hz, C(21)), 154.6 
(NCOO), 161.8 (C(17)), 163.1 (d, J=245.8 Hz, C(25)), 165.5 (C(8)); m/z (ESI
+
) 505 
([M+H]
+
, 100%); HRMS C28H30FN4O4
+
 requires: 505.2246, found: 505.2240. 
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tert-butyl (2-(4-(((4-(4-(trifluoromethyl)phenyl)-4,5-dihydrooxazol-2-
yl)amino)methyl)benzamido)phenyl)carbamate (80k) 
 
To a solution of 46k (107 mg, 0.522 mmol) in THF (6 mL) was added 77 (200 
mg, 0.522 mmol), the resulting solution was stirred at rt for 17.5 h, then evaporated. The 
residue was dissolved in acetone (3 mL), and iodomethane (0.065 mL, 1.043 mmol) was 
added the solution was then stirred at rt for 6 h, then a further 65 μL of iodomethane 
was added and stirred for another 2.5 h at rt. Sodium bicarbonate (sat. aq., 1.5 mL) was 
added, stirred for 10 min then diluted with sodium bicarbonate (sat. aq., 15 mL), and 
extracted with ethyl acetate (2 × 30 mL). Combined organics were dried Na2SO4 and 
evaporated to give a white solid (300 mg) that was purified by flash column 
chromatography on silica gel (1-5% (2M ammonia/methanol) in dichloromethane) to 
give 80k (200 mg, 0.361 mmol, 69%) as a white solid, mp 114-116 °C; νmax (cm
-1
) 3282 
(NH), 1658 (C=O); 
1
H NMR (400 MHz, chloroform-d) δ ppm 1.49 (9H, s, C(CH3)3), 
4.04 (1H, t, J=7.6 Hz, H(20), 4.44 (2H, s, H(15) and H(15)’), 4.65 (1H, t, J=8.7 Hz, 
H(20)’), 4.94 (1H, br s, H(16)), 5.14 (1H, t, J=8.1 Hz, H(19)), 7.05 - 7.18 (2H, m, ArH), 
7.24 (1H, dd, J=7.6, 1.2 Hz, ArH), 7.31 (2H, d, J=8.1 Hz, ArH), 7.36 (2H, d, J=8.1 Hz, 
ArH), 7.47 (1H, br s, BocNH), 7.57 (2H, d, J=8.1 Hz, ArH), 7.70 (1H, d, J=7.1 Hz, 
H(6)), 7.85 (2H, d, J=8.1 Hz, H(10and 14)), 9.39 (1H, br s, H(7)); 
13
C NMR (100 MHz, 
chloroform-d) δ ppm 28.3 (C(CH3)3), 46.5 (C(15)), 67.0 (C(19)), 75.0 (C(20)), 81.1 
(OC(CH3)3), 124.1 (q, J=272.9 Hz, CF3), 124.5 (C(3)), 125.5 (q, J=3.7 Hz, C(23 and 
25), 125.6 (C(6 and C(4)), 125.9 (C(5)), 126.8 (C(22 and 26)), 127.2 (C(11 and 13)), 
127.7 (C(10 and 14)), 129.6 (q, J=32.3 Hz, C(24)), 130.3 (C(9)), 130.7 (C(2)), 133.2 
(C(1)), 142.8 (C(12)), 147.6 (C(21)), 154.7 (NCOO), 162.1 (C(17)), 165.6 (C(8)); m/z 
(ESI
+
) 387 ([M+H]
+
, 100%); HRMS C29H30N4O4F3
+
 requires: 555.2214, found: 
555.2214. 
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tert-butyl (2-(4-((3-(2-(4-hydroxyphenyl)-2-
(methylthio)ethyl)ureido)methyl)benzamido)phenyl)carbamate (81) 
 
To a mixture of octopamine hydrochloride (159 mg, 0.84 mmol) and potassium 
carbonate (145 mg, 1.05 mmol) in THF (10 mL) was added isothiocyanate 77 (272 mg, 
0.71 mmol), the resulting mixture was stirred at reflux for 90 h. The solvent was 
evaporated and the residue partitioned between ethyl acetate (25 mL) and water (25 
mL), the layers were separated and the aqueous layer was extracted with ethyl acetate 
(25 mL). The combined organic layers were washed with brine (20 mL), dried Na2SO4 
and evaporated. The residue was dissolved in acetone (5 mL), iodomethane (0.087 mL, 
1.4 mmol) was added and the solution was stirred at rt for 16 h, then iodomethane 
(0.087 mL, 1.4 mmol) was added and stirred at rt for 24 h. Sodium bicarbonate (sat. aq., 
2 mL) was added and the mixture was stirred for 10 min before being diluted with 
sodium bicarbonate (sat. aq., 10 mL) then extracted with ethyl acetate (2 × 20 mL). The 
combined organic layers were washed with brine (20 mL) dried Na2SO4 and evaporated 
to give a cream solid (400 mg) that was purified by column chromatography on silica 
gel (5% methanol/ethyl aceate) and again (ethyl acetate:hexane, 3:1) to give 81 (116 
mg, 0.21 mmol, 30%) as a white solid, mp 125-128 °C; νmax (cm
-1
) 3285 (NH), 1640 
(C=O); 
1
H NMR (500 MHz, methanol-d4) δ ppm 1.48 (9H, s, C(CH3)3), 1.92 (3H, s, 
SCH3), 3.43 (1H, dd, J=13.8, 8.3 Hz, H(19)), 3.61 (1H, dd, J=13.8, 6.8 Hz, H(19)’), 
3.84 (1H, dd, J=8.3, 6.8 Hz, H(20)), 4.35 (2H, s, H(15) and H(15)’), 6.72 - 6.78 (2H, m, 
ArH), 7.12 - 7.16 (2H, m, ArH), 7.18 - 7.26 (2H, m, ArH), 7.35 (2H, d, J=8.4 Hz, ArH), 
7.43 (1H, dd, J=7.3, 2.3 Hz, ArH), 7.59 (1H, dd, J=7.3, 1.8 Hz, ArH), 7.86 - 7.94 (3H, 
m, ArH); 
13
C NMR (125 MHz, methanol-d4) δ ppm 14.3 (CH3S), 28.8 (C(CH3)3), 44.4 
(C(15)), 45.9 (C(19)), 52.2 (C(20)), 81.9 (OC(CH3)3), 116.5 (C(23 and 25)), 125.7 
(C(3)), 126.4 (C(6)), 127.3 (C(4)), 127.6 (C(5)), 128.3 (C(11 and 13)), 128.9 (C(10 and 
14)), 130.5 (C(22 and 26)), 131.8 (C(9)), 132.3 (C(2)), 133.2 (C(1)), 134.1 (C(21)), 
146.3 (C(12)), 156.4 (NCOO), 158.0 (C(24)), 160.8 (C(17)), 168.4 (C(8)); m/z (ESI
+
) 
573 ([M+Na]
+
, 28%), 403 ([M-SMe-Boc]
+
, 100%); HRMS C29H34N4NaO5S
+
 requires: 
573.2142, found: 573.2103. 
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tert-butyl (2-(4-((3-(2-hydroxy-2-(4-
hydroxyphenyl)ethyl)thioureido)methyl)benzamido)phenyl)carbamate (82) 
 
To a mixture of octopamine hydrochloride (159 mg, 0.84 mmol) and potassium 
carbonate (145 mg, 1.05 mmol) in THF (10 mL) was added isothiocyanate 77 (268 mg, 
0.7 mmol), the resulting mixture was stirred at reflux for 96 h. The solvent was 
evaporated and the residue partitioned between ethyl acetate (25 mL) and water (25 
mL), the layers were separated and the aqueous layer was extracted with ethyl acetate 
(10 mL). The aqueous layer was neutralised to pH 7 then extracted with ethyl acetate 
(20 mL). The combined organic layers were washed with brine (20 mL), dried MgSO4 
and evaporated to give a white solid (430 mg). Purification by column chromatography 
on silica gel (ethyl acetate:hexane, 2:1) gave 82 as a white solid (351 mg, 0.655 mmol, 
94%), mp 134-139 °C; νmax (cm
-1
) 3276 (NH), 1692 (C=O), 1650 (C=O); 
1
H NMR (500 
MHz, methanol-d4) δ ppm 1.48 (9H, s, C(CH3)3), 3.35 (2H, s, H(15) and H(15)’), 3.61 
(1H, br s, H(19))), 3.83 (1H, br s, H(19)’), 4.60 (1H, s, OH), 4.81 (1H, br s, H(20)), 6.78 
(2H, d, J=8.5 Hz, ArH), 7.15 - 7.27 (4H, m, ArH), 7.36 - 7.48 (3H, m, ArH), 7.60 (1H, 
d, J=7.3 Hz, ArH), 7.91 (2H, d, J=8.2 Hz, ArH); 
13
C NMR (125 MHz, methanol-d4) δ 
ppm 28.7 (C(CH3)3), 49.9 (C(15)), 52.7 (C(19)), 73.3 (C(20)), 81.9 (OC(CH3)3), 116.2 
(C(23 and 25)), 125.6 (C(3)), 126.4 (C(6)), 127.2 (C(4)), 127.5 (C(5)), 128.5 (C(11 and 
13)), 128.6 (C(10 and 14)), 128.8 (C(22 and 26)), 131.6 (C(9)), 133.0 (C(2)), 134.1 
(C(1)), 134.6 (C(21)), 144.8 (C(12)), 156.3 (NCOO), 158.0 (C(24)), 168.3 (C(8)), 184.5 
(br., C(17)); m/z (ESI
+
) 537 ([M+H]
+
, 67%), 519 ([M+H-H2O]
+
, 100%); HRMS 
C28H33N4O5S
+
 requires: 537.2166, found: 537.2191. 
methyl (S)-2-amino-2-phenylacetate hydrochloride (84)
159
 
 
To a suspension of (S)-phenylglycine (2.5 g, 16.5 mmol, 1.0 eq) in methanol (25 
mL) was added thionyl chloride (1.3 mL, 18 mmol, 1.09 eq) dropwise, then stirred at rt 
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for 16 h and evaporated to give 84 as a white solid (3.33 g, 16.5 mmol, 100%), mp 189-
191 °C (lit.
159
 193-195 °C). 
 (S)-2-amino-2-phenylacetamide (85) 
 
A solution of 84 (3.33 g, 16.5 mmol) in concentrated aqueous ammonia (37%, 
12 mL) was stirred at rt for 16 h. The mixture was diluted with water (10 mL) and 
extracted with ethyl acetate (4 × 40 mL), the combined organics were dried Na2SO4, and 
concentrated to give 85 as a white crystalline solid (1.43 g, 9.5 mmol, 58%), mp 134-
135 °C (lit.
160
 138-140 °C); 
1
H NMR (400 MHz, chloroform-d) δ ppm 1.87 (3H, s, 
NH2), 4.54 (1H, s, PhCH), 6.04 (1H, br s, NHH’), 6.92 (1H, br s, NHH’), 7.30 - 7.46 
(5H, m, ArH); 
13
C NMR (125 MHz, chloroform-d) δ ppm 60.3 (CHPh), 127.3 (m-Ph), 
128.5 (p-Ph), 129.3 (o-Ph), 141.3 (i-Ph), 176.3 (C=O). 
(S)-1-phenylethane-1,2-diamine (86) 
 
A 2-neck flask (oven-dried) was fitted with a magnetic stirrer and a reflux 
condenser and then NaBH4 (0.703 g, 18.6 mmol, 2.0 eq) and anhydrous THF (20 ml) 
were added. Then a dropping funnel was fitted and the mixture cooled to 0 °C in an ice 
bath. A solution of iodine (3.29 g, 9.32 mmol, 1.0 eq) in anhydrous THF (10 ml) was 
added dropwise over 30 min, vigorous gas evolution was observed. Then acetamide 85 
(1.4 g, 9.32 mmol, 1.0 eq) was added in one portion and the mixture was heated to 
reflux for 18 h, then cooled to rt and methanol added slowly until solution became clear. 
Stirred for 30 min and then the solvent was evaporated. The resulting white paste was 
dissolved in 20 ml of 20% aq. potassium hydroxide and stirred for 4 h then extracted 
with dichloromethane (3 × 30 ml). The combined organics were washed with brine, and 
dried Na2SO4 and evaporated to give an orange oil which crystallised upon standing 
for16 h. Trituration with a mixture of dichloromethane and hexane gave 86 as a cream 
solid which was still impure but used without further purification (0.5 g, 3.67 mmol, 
39%), mp 178-180 °C (lit.
161
 86-89 °C [for racemate]) 
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(S)-4-phenylimidazolidine-2-thione (87) 
 
To a suspension of 86 (200 mg, 1.47 mmol) in ethanol (8 mL) and water (4 mL) 
was added triethylamine (0.41 mL, 2.94 mmol). To the resulting suspension at 0 °C was 
added dropwise carbon disulfide (0.35 mL, 5.87 mmol), the mixture was then stirred at 
60 °C for 5 h. Cooled to rt then hydrochloric acid (37% aq, 0.2 mL) was added and the 
solution stirred at reflux for 14 h. The ethanol was evaporated and the mixture was 
diluted with potassium hydrogen sulfate (1M, 30 mL) and then extracted with 
dichloromethane (3 × 30 mL). The combined organic layers were dried with Na2SO4 
and evaporated to give a yellow solid that was purified by column chromatography on 
silica gel (ethyl acetate:hexane 1:1 to 3:2) to give 87 (82 mg, 0.457 mmol, 31%) as a 
white solid, mp 159-160 °C (lit.
162
 184 °C [for racemate]); νmax (cm
-1
) 3217 (NH); 
1
H 
NMR (400 MHz, chloroform-d) δ ppm 3.61 (1H, dd, J=9.3, 8.0 Hz, H(1)), 4.13 (1H, t, 
J=9.9 Hz, H(1)’), 5.10 (1H, t, J=8.8 Hz, H(2)), 6.70 (2H, br s, 2 × NH), 7.31 – 7.47 (5H, 
m, ArH); 
13
C NMR (100 MHz, chloroform-d) δ ppm 53.9 (C(1)), 61.4 (C(2)), 126.6 
(C(4 and 8)), 129.1 (C(6)), 129.5 (C(5 and 7)), 140.3 (C(3)), 184.4 (C=S); m/z (EI
+
) 178 
(M
+
, 73%); HRMS C9H10N2S
+
 requires: 178.0565, found: 178.0566. 
(S)-N-(2-aminophenyl)-4-(((4-phenyl-4,5-dihydro-1H-imidazol-2-
yl)thio)methyl)benzamide (88) 
 
To a solution of thione 87 (80 mg, 0.449 mmol) and benzyl chloride 54 (117 mg, 
0.449 mmol) in acetone (5 mL) was added potassium carbonate (93 mg, 0.673 mmol) 
and then the mixture was stirred at reflux for 17 h. Cooled to rt and the solvent was 
evaporated then the residue was partitioned between water (15 mL) and ethyl acetate 
(30 mL), the layers were separated and the aq. layer was extracted with ethyl acetate (30 
mL) then the combined organic layers were washed with brine (15 mL) dried Na2SO4, 
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and evaporated to give a beige solid (200 mg) which was purified by column 
chromatography on silica gel (5% methanol/ethyl acetate) to give a white solid (120 mg, 
0.296 mmol, 66%). A purer sample was obtained by recrystallization from chloroform 
giving 88 (6 mg, 0.015 mmol, 3%) as a white solid, mp 150-151 °C; [α]D
25 -2.1 (c 1.0, 
methanol); νmax (cm
-1
) 3239 (NH), 1688 (C=N), 1642 (C=O); 
1
H NMR (600 MHz, 
chloroform-d) δ ppm 3.58 (1H, br s, H(20)), 3.86 (2H, br s, NH2), 4.12 (1H, br s, 
H(20)’), 4.39 (1H, d, J=13.6 Hz, H(15)), 4.44 (1H, d, J=13.6 Hz, H(15)’), 4.97 (1H, br 
s, H(19)), 6.82 - 6.89 (2H, m, ArH), 7.07 - 7.13 (1H, m, ArH), 7.22 - 7.29 (2H, m, 
ArH), 7.30 - 7.36 (3H, m, ArH), 7.53 (2H, d, J=7.9 Hz, ArH), 7.81 - 7.92 (3H, m, ArH); 
13
C NMR (150 MHz, chloroform-d) δ ppm 35.2 (C(15)), 118.6 (C(3)), 120.0 (C(5)), 
124.7 (C(1)), 125.2 (C(4)), 126.4 (C(11 and 13)), 127.4 (C(6)), 127.7 (C(22 and 26) and 
C(24)), 128.8 (C(23 and 25)), 129.6 (C(23 and 25)), 133.3 (C(9)), 140.7 (C(21)), 141.9 
(C(12)), 143.4 (C(2)), 162.8 (C(17)), 165.5 (C(8)); m/z (ESI
+
) 403 ([M+H]
+
, 100%); 
HRMS C23H23N4OS
+
 requires: 403.1587, found: 403.1577. 
(S)-tert-butyl (2-(4-((3-(2-amino-2-
phenylethyl)thioureido)methyl)benzamido)phenyl)carbamate (89) 
 
To a suspension of (S)-2-amino-2-phenylacetamide (1.65 g, 10.99 mmol) in 
anhydrous THF (20 mL) at 0 °C was added lithium aluminium hydride (2M in THF, 
16.48 mL, 33.0 mmol) dropwise. The resulting solution was allowed to warm to room 
temperature then heated to reflux for 4 h. After cooling to 0°C, excess lithium 
aluminium hydride was decomposed with vigorous stirring by slow addition of 
potassium hydroxide (10% aq, 6 mL). The solid was removed by filtration and washed 
with THF (10 mL) then the filtrate was evaporated to give (S)-1-phenylethane-1,2-
diamine as a yellow oil (2.2 g) that partially crystallized on standing overnight. The 
product was used without further purification despite being impure. 
To a solution of impure (S)-1-phenylethane-1,2-diamine (213 mg, 1.565 mmol) 
in THF (4 mL) was added a solution of 77 (200 mg, 0.522 mmol) in THF (4 mL), the 
resulting solution was stirred at rt for 17.5 h, then evaporated and purified by flash 
column chromatography on silica gel (1-8% (2M ammonia/methanol) in 
dichloromethane) to give 89 (154 mg, 0.296 mmol, 57%) as a white solid, mp 105-106 
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°C; νmax (cm
-1
) 3276 (NH), 1689 (C=O),1660 (C=O); 
1
H NMR (500 MHz, chloroform-
d) δ ppm 1.47 - 1.54 (9H, m, C(CH3)3), 2.32 (4H, br s, NH2, H(16) and H(18)), 3.44 - 
3.56 (1H, m, H(19)), 3.76 (1H, br s, H(19)’), 4.12 (1H, dd, J=8.4, 4.3 Hz, H(20)), 4.74 
(2H, br s, H(15) and H(15)’), 7.03 (1H, br s, BocNH), 7.10 - 7.20 (3H, m, ArH), 7.20 - 
7.44 (7H, m, ArH), 7.59 - 7.70 (1H, m, H(6)), 7.78 (2H, d, J=7.7 Hz, H(10 and 14)), 
9.35 (1H, br s, H(7)); 
13
C NMR (125 MHz, chloroform-d) δ ppm 28.3 (C(CH3)3), 48.0 
(C(15)), 51.8 (C(19)), 55.3 (C(20)), 81.5 (OC(CH3)3), 124.7 (C(3)), 125.8 (C(6) and 
C(5)), 126.2 (C(22 and 26)), 126.3 (C(4)), 127.7 (C(23 and 25)), 127.7 (C(10 and 14))), 
127.8 (C(24)), 128.8 (C(11 and 13)), 130.4 (C(9)), 130.5 (C(2)), 132.9 (C(1)), 142.2 
(C(12 and 21)), 154.7 (NCOO), 165.9 (C(8)), 183.4 (C(17)); m/z (ESI
+
) 520 ([M+H]
+
, 
100%); HRMS C28H34N5O3S
+
 requires: 520.2377, found: 520.2365. 
(S)-tert-butyl (2-(4-(((4-phenyl-4,5-dihydro-1H-imidazol-2-
yl)amino)methyl)benzamido)phenyl)carbamate (90) 
 
To a solution of thiourea 89 (154 mg, 0.296 mmol) in acetone (3 mL) was added 
iodomethane (0.037 mL, 0.593 mmol) and the solution stirred at rt for 18 h. Sodium 
bicarbonate (sat. aq., 1.5 mL) was added and the mixture was stirred for 10 min before 
being diluted with sodium bicarbonate (sat. aq., 20 mL) and water (5 mL), then 
extracted with ethyl acetate (2 × 20 mL). The combined organic layers were dried 
Na2SO4 and evaporated to give 90 (143 mg, 0.294 mmol, 99%) as a cream solid, mp 
130-132 °C; νmax (cm
-1
) 3171 (NH), 1667 (C=O); 
1
H NMR (400 MHz, chloroform-d)  
ppm 1.42 (9H, s, C(CH3)3), 3.35 (1H, t, J=7.0 Hz, H(20)), 3.84 (1H, t, J=8.1 Hz, 
H(20)’), 4.53 (2H, br s, H(15) and H(15)’), 4.86 (1H, br s, H(19)), 7.04 (1H, t, J=7.3 
Hz, H(4)), 7.10 - 7.22 (3H, m, H(11 and 13) and H(5)), 7.22 - 7.37 (6H, m, H(23 and 
25), H(24), H(22 and 26) and BocNH), 7.46 (1H, d, J=7.8 Hz, H(3)), 7.50 (1H, d, J=7.6 
Hz, H(6)), 7.69 (1H, br s, C(20)NH), 7.86 (2H, d, J=6.6 Hz, H(10 and 14)), 8.77 (1H, br 
s, H(16)), 9.83 (1H, br s, H(7)); 
13
C NMR (126 MHz, chloroform-d)  ppm 28.3 
(C(CH3)3), 46.3 (C(15)), 51.2 (C(20)), 58.7 (C(19)), 81.1 (OC(CH3)3), 124.8 (C(3)), 
125.1 (C(6)), 126.1 (C(11 and 13)), 126.1 (C(4)), 126.4 (C(5)), 127.4 (C(10 and 14)), 
128.3 (C(22 and 26)), 128.7 (C(24)), 129.1 (C(23 and 25)), 129.8 (C(9)), 131.5 (C(2)), 
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133.2 (C(1)), 139.0 (C(21)), 140.0 (C(12)), 154.5 (NCOO), 159.3 (C(17)), 166.2 (C(8)); 
m/z (ESI
+
) 486 ([M+H]
+
, 100%); HRMS C28H32N5O3
+
 requires: 486.2500, found: 
486.2496. (~90% purity by LCMS and NMR). 
(S)-N-(2-aminophenyl)-4-(((4-phenyl-4,5-dihydro-1H-imidazol-2-
yl)amino)methyl)benzamide (91) 
 
 
To a solution of 90 (140 mg, 0.288 mmol) in dichloromethane (3 mL) was added 
trifluoroacetic acid (0.444 mL, 5.77 mmol) dropwise. The resulting solution was stirred 
at rt for 2 h, then evaporated and the resulting white solid purified by MDAP to give 91 
(52 mg, 0.135 mmol, 47%) as a white solid, mp 130-133 °C; [α]D
25 +11.1 (c 1.0, 
methanol); νmax (cm
-1
) 3217 (NH), 1672 (C=N), 1613 (C=O); 
1
H NMR (400 MHz, 
methanol-d4) δ ppm 3.41 (1H, dd, J=9.9, 7.2 Hz, H(20)), 4.02 (1H, t, J=9.8 Hz, H(20)’), 
4.47 - 4.59 (2H, m, H(15) and H(15)’), 5.01 (1H, dd, J=9.5, 7.3 Hz, H(19)), 6.79 (1H, t, 
J=7.3 Hz, H(5)), 6.93 (1H, dd, J=8.1, 0.7 Hz, H(3)), 7.10 (1H, td, J=7.6, 1.2 Hz, H(4)), 
7.21 (1H, d, J=7.6 Hz, H(6)), 7.26 - 7.41 (5H, m, PhH), 7.53 (2H, d, J=8.2 Hz, H(11 
and 13)), 8.01 (2H, d, J=8.2 Hz, H(10 and 14)); 
13
C NMR (100 MHz, methanol-d4) δ 
ppm 45.7 (C(15)), 54.0 (C(20)), 61.3 (C(19)), 117.4 (C(3)), 118.3 (C(5)), 123.9 (C(1)), 
125.9 (C(22 and 26)), 126.3 (C(6)), 127.0 (C(10 and 14)), 127.2 (C(4)), 127.5 (C(24)), 
127.8 (C(11 and 13)), 128.4 (C(23 and 25)), 133.2 (C(9)), 142.4 (C(21) and C(2)), 142.6 
(C(12)), 161.3 (C(17)), 167.2 (C(8)); m/z (ESI
+
) 386 ([M+H]
+
, 100%); HRMS 
C23H24N5O
+
 requires: 386.1975, found: 386.1974. 
 (S,E)-N-(2-((tert-butyldimethylsilyl)oxy)ethylidene)-2-methylpropane-2-
sulfinamide (92) 
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A solution of 2-((tert-butyldimethylsilyl)oxy)acetaldehyde (2.5 g, 14.34 mmol) 
in dichloromethane (25 ml) and (S)-2-methylpropane-2-sulfinamide (1.721 g, 14.20 
mmol) was stirred with copper(II) sulfate (5.15 g, 32.3 mmol) at rt for 90 h. The mixture 
was filtered through Celite and washed with dichloromethane, then the filtrate was 
concentrated and purified by flash column chromatography on silica gel (10-30% ethyl 
acetate/cyclohexane) to give 92 (1.665 g, 6.00 mmol, 42%) as a colourless oil; νmax (cm
-
1
) 1629 (C=N); 
1
H NMR (400 MHz, chloroform-d) δ ppm 0.11 (6H, s, C(3)H3 and 
C(4)H3), 0.93 (9H, s, 9 × H(6)), 1.22 (9H, s, 9 × H(8)), 4.56 (2H, d, J=2.9 Hz, 2 × 
H(2)), 8.08 (1H, s, H(1)); 
13
C NMR (100 MHz, chloroform-d) δ ppm -5.3 (C(3)), -5.4 
(C(4)), 18.3 (C(5)), 22.4 (C(6)), 25.8 (C(8)), 56.8 (C(7)), 65.6 (C(2)), 168.7 (C(1)); m/z 
(ESI
+
) 278 ([M+H]
+
, 100). 
(S)-N-((S)-2-((tert-butyldimethylsilyl)oxy)-1-(pyridin-3-yl)ethyl)-2-methylpropane-
2-sulfinamide (93) 
 
To a dried 3-neck flask containing a thermometer and a stirrer bar was added 
anhydrous toluene (30 mL). The flask was cooled to -78 °C, BuLi (2.5 M in hexanes) 
(5.36 mL, 8.58 mmol) was added and the reaction mixture was stirred until the 
temperature returned to -78 °C. A solution of 3-bromopyridine (0.649 mL, 6.74 mmol) 
in anhydrous toluene (3 mL) was added to the reaction mixture a rate such that the 
temperature did not exceed -70 °C, and then the reaction was stirred at -78 °C for 1 
hour. A solution of 92 (1.7 g, 6.13 mmol) in anhydrous toluene (2 mL) was added to the 
reaction mixture at a rate such that the temperature did not exceed -70 °C, and then the 
reaction was stirred at -78 °C for 5 hours. Methanol (1 mL) was added dropwise to 
quench the BuLi, then the mixture was allowed to warm to 20 ºC. Water (40 mL) was 
added and the mixture extracted with ethyl acetate (3 × 75 mL), the combined organics 
were washed with brine (50 mL), dried Na2SO4 and evaporated to give an orange oil 
(2.2 g) which was purified by flash column chromatography on silica gel (15-80% ethyl 
acetate/ dichloromethane) to give 93 (0.820 g, 2.300 mmol, 38%) as a colourless oil.; 
νmax (cm
-1
) 2926 (CH);
 1
H NMR (400 MHz, chloroform-d) δ ppm 0.05 (3H, s, H(3)), 
0.08 (3H, s, H(4)), 0.91 (9H, s, H(6)), 1.24 (9H, s, H(8)), 3.68 (1H, dd, J=10.0, 8.6 Hz, 
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H(2)), 3.84 (1H, dd, J=10.0, 4.2 Hz, H(2)’), 4.30 (1H, d, J=1.7 Hz, NH), 4.52 - 4.61 
(1H, m, H(1)), 7.24 - 7.31 (1H, m, H(11)), 7.62 - 7.69 (1H, m, H(12)), 8.55 (1H, dd, 
J=4.8, 1.6 Hz, H(10)), 8.61 (1H, d, J=2.0 Hz, H(14)); 
13
C NMR (100 MHz, chloroform-
d) δ ppm -5.5 (C(3)), -5.4 (C(4)), 18.2 (C(5)), 22.6 (C(6)), 25.8 (C(8)), 55.7 (C(1)), 57.5 
(C(7)), 67.3 (C(2)), 123.7 (C(11)), 135.3 (C(9)), 136.7 (C(10)), 148.2 (C(12)), 148.5 
(C(14)); m/z (ESI
+
) 357 ([M+H]
+
, 100%); HRMS C17H33N2O2SSi
+ 
requires: 357.2027, 
found: 357.2026. 
(S)-2-amino-2-(pyridin-3-yl)ethanol (94) 
 
To a solution of sulfinamide 93 (0.816 g, 2.288 mmol) in methanol (10 mL) was 
added 4M HCl in dioxane (2.86 mL, 11.44 mmol) at 0 °C. The mixture was stirred at 25 
rtC for 5 h. The mixture was evaporated and the resulting oil was dissolved in methanol 
and loaded onto an SCX-2 cartridge. It was washed with methanol (20 mL) and then 
eluted with 2M ammonia in methanol (50 mL) which was evaporated to give the free 
base 94 (310 mg, 2.244 mmol, 98%) as a yellow oil; νmax (cm
-1
) 3270 (NH/OH); 
1
H 
NMR (400 MHz, methanol-d4) δ ppm 3.68 (1H, dd, J=11.0, 7.0 Hz, H(1)), 3.75 (1H, dd, 
J=11.0, 5.1 Hz, H(1)’), 4.09 (1H, dd, J=7.0, 5.1 Hz, H(2)), 7.45 (1H, dd, J=7.8, 4.9 Hz, 
H(5)), 7.91 (1H, d, J=8.1 Hz, H(4)), 8.47 (1H, dd, J=4.9, 1.5 Hz, H(6)), 8.59 (1H, d, 
J=2.2 Hz, H(8)); 
13
C NMR (100 MHz, methanol-d4) δ ppm 54.9 (C(1)), 66.2 (C(2)), 
123.8 (C(5)), 135.5 (C(4)), 138.0 (C(3)), 147.7 (C(6)), 147.9 (C(8)); m/z (EI
+
) 139 
([M+H]
+
, 100%); HRMS C7H11N2O
+
 requires: 139.0866, found: 139.0862. 
(S)-4-(pyridin-3-yl)oxazolidine-2-thione (95) 
 
To a stirring mixture of 94 (160 mg, 1.158 mmol), potassium carbonate (80 mg, 
0.579 mmol) and carbon disulfide (0.140 mL, 2.316 mmol) in ethanol (1 mL) at 50 °C 
was added hydrogen peroxide (0.152 mL, 1.737 mmol) dropwise [Caution: Exotherm! - 
use a blast shield]. After completion of addition the mixture was cooled to rt and 
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filtered. The filtrate was diluted with ethyl acetate (30 ml) washed with water (2 × 15 
ml), sodium sulfite (10%, 15 mL) and brine, then dried Na2SO4 and evaporated to give a 
yellow solid (57 mg). Purification by flash column chromatography on silica gel (0-5% 
(2M ammonia/methanol) in dichloromethane) gave 95 (29 mg, 0.161 mmol, 14%) as a 
white solid, mp 157-159 °C; νmax (cm
-1
) 3083 (NH); 
1
H NMR (400 MHz, methanol-d4) δ 
ppm 4.52 (1H, dd, J=9.2, 6.2 Hz, H(2)), 5.04 (1H, t, J=9.2 Hz, H(2)’), 5.28 (1H, dd, 
J=9.2, 6.2 Hz, H(1)), 7.53 (1H, dd, J=7.8, 4.9 Hz, H(5)), 7.87 (1H, d, J=7.8 Hz, H(4)), 
8.49 - 8.63 (2H, m, H(6) and H(8)); 
13
C NMR (100 MHz, methanol-d4) δ ppm 57.6 
(C(1)), 76.8 (C(2)), 124.4 (C(4)), 134.8 (C(4)), 136.0 (C(3)), 147.2 (C(6)), 149.1 (C(8)), 
190.2 (C=S); m/z (ESI
+
) 181 ([M+H]
+
, 100%); HRMS C8H9N2S
+
 requires:181.0436, 
found: 181.0430.  
 (S)-N-(2-aminophenyl)-4-(((4-(pyridin-3-yl)-4,5-dihydrooxazol-2-
yl)thio)methyl)benzamide (96) 
 
To a solution of 95 (25 mg, 0.139 mmol) and benzyl chloride 54 (36.2 mg, 0.139 
mmol) in acetone (2 mL) was added potassium carbonate (28.8 mg, 0.208 mmol) and 
then the mixture was stirred at reflux for 17 h. The reaction had dried out overnight so 
acetone (3 mL) was added and then stirred at reflux for 6 h. Cooled to rt and partitioned 
between water (15 ml) and ethyl acetate (20 ml), the aq. layer was extracted with ethyl 
acetate (15 ml) then the combined organics were dried Na2SO4, and evaporated to give a 
yellow solid (57 mg) which was purified by MDAP to give 96 (25 mg, 0.062 mmol, 
45%) as a white solid, mp 107-110 °C; [α]D
25 +22.0 (c 0.25, methanol); νmax (cm
-1
) 3212 
(NH), 1645 (C=O); 
1
H NMR (500 MHz, methanol-d4) δ ppm 4.23 (1H, t, J=8.0 Hz, 
H(20)), 4.38 (1H, d, J=13.7 Hz, H(15)), 4.44 (1H, d, J=13.7 Hz, H(15)’), 4.83 (1H, t, 
J=9.3 Hz, H(20)’), 5.35 (1H, dd, J=9.3, 7.7 Hz, H(19)), 6.80 (1H, t, J=7.4 Hz, H(5)), 
6.93 (1H, d, J=8.0 Hz, H(3)), 7.11 (1H, t, J=7.4 Hz, H(4)), 7.22 (1H, d, J=7.7 Hz, H(6)), 
7.43 (1H, dd, J=7.7, 4.9 Hz, H(23)), 7.60 (3H, d, J=8.0 Hz, H(11 and 13) and H(22), 
7.96 (2H, d, J=8.0 Hz, H(10 and 14)), 8.40 (1H, s, H(26)), 8.49 (1H, d, J=4.7 Hz, 
H(24); 
13
C NMR (125 MHz, methanol-d4) δ ppm 34.8 (C(15)), 67.1 (C(19)), 75.9 
(C(20)), 117.3 (C(3)), 118.3 (C(5)), 123.9 (C(23)), 124.1 (C(1)), 126.3 (C(6)), 127.2 
(C(4)), 127.7 (C(10 and 14)), 128.9 (C(11 and 13)), 133.4 (C(9)), 135.1 (C(22)), 138.3 
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(C(21)), 141.5 (C(2)), 142.4 (C(12)), 147.2 (C(26)), 148.0 (C(24)), 167.1 (C(17)), 167.7 
(C(8)); m/z (ESI
+
) 405 ([M+H]
+
, 100%); HRMS C22H21N4O2S
+
 requires: 405.1380, 
found: 405.1384; 93% purity by LCMS. 
 (S)-tert-butyl (2-(4-(((4-(pyridin-3-yl)-4,5-dihydrooxazol-2-
yl)amino)methyl)benzamido)phenyl)carbamate (97) 
 
To a solution of 94 (155 mg, 1.119 mmol) in THF (8 mL) and methanol (3 mL) 
was added isothiocyanate 77 (330 mg, 0.861 mmol), the solution was stirred at rt for 17 
h, and then solvents were evaporated. The residue was dissolved in acetone (4 mL), then 
iodomethane (0.108 mL, 1.721 mmol) was added and the solution stirred at rt for 5 h. 
Sodium bicarbonate (sat. aq., 2 mL) was added, stirred for 10 min then diluted with 
sodium bicarbonate (sat. aq., 20 mL), and extracted with ethyl acetate (3 × 30 mL). The 
combined organic layers were washed with brine (20 mL), dried Na2SO4 and evaporated 
to give a cream solid (370 mg). Purification by flash column chromatography on silica 
gel (2-10% (2M ammonia/methanol) in dichloromethane) gave 97 (86 mg, 0.176 mmol, 
21%) as a white solid, mp 107-108 °C; νmax (cm
-1
) 3265 (NH), 1651 (C=O); 
1
H NMR 
(400 MHz, chloroform-d) δ ppm 1.50 (9H, s, C(CH3)3), 4.06 (1H, dd, J=7.8, 7.2 Hz, 
H(19)), 4.48 (2H, s, H(15) and H(15)’), 4.66 (1H, dd, J=7.8, 7.0 Hz, H(20)), 5.12 (1H, 
dd, J=8.7, 7.2 Hz, H(20)’), 5.43 (1H, br s, H(16)), 7.09 - 7.22 (2H, m, ArH and 
NHBoc), 7.22 - 7.30 (1H, m, ArH), 7.30 - 7.42 (4H, m, ArH), 7.56 (1H, d, J=7.8 Hz, 
ArH), 7.73 (1H, d, J=6.8 Hz, ArH), 7.88 (2H, d, J=7.8 Hz, H(10 and 14)), 8.42 (1H, s, 
H(26)), 8.49 (1H, d, J=3.7 Hz, H(24)), 9.39 (1H, br s, H(7)); 
13
C NMR (100 MHz, 
chloroform-d) δ ppm 28.3 (C(CH3)3), 46.6 (C(15)), 65.5 (C(19)), 74.9 (C(20)), 81.1 
(OC(CH3)3), 123.6 (C(23)), 124.5 (C(3)), 125.6 (C(6)), 125.7 (C(4)), 126.0 (C(5)), 
127.4 (C(11 and 13)), 127.8 (C(10 and 14)), 130.3 (C(9)), 130.7 (C(2)), 133.5 (C(1)), 
134.2 (C(22)), 139.2 (C(21)), 142.6 (C(12)), 148.2 (C(24)), 148.7 (C(26)), 154.6 
(NCOO), 162.0 (C(17)), 165.7 (C(8)); m/z (ESI
+
) 488 ([M+H]
+
, 100%); HRMS 
C27H30N5O4
+
 requires: 488.2292, found: 488.2285. 
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(S)-N-(2-aminophenyl)-4-(((4-(pyridin-3-yl)-4,5-dihydrooxazol-2-
yl)/amino)methyl)benzamide (98) 
 
To a solution of 97 (80 mg, 0.164 mmol) in dichloromethane (1 mL) was added 
trifluoroacetic acid (0.253 mL, 3.28 mmol). The resulting solution was stirred at rt for 
1.5 h, then quenched by pouring onto sodium bicarbonate (sat. aq., 10 mL) and 
extracted with ethyl acetate (3 × 10 mL). The combined organics were washed with 
brine, dried Na2SO4, and evaporated to give a yellow solid (60 mg) which was purified 
by flash column chromatography on silica gel (2-10% (2M ammonia/methanol) in 
dichloromethane) to give to give 98 (38 mg, 0.098 mmol, 60%) as a white solid, mp 89-
90 °C (dec.); [α]D
25 -20.0 (c 1.0, methanol); νmax (cm
-1
) 3214 (NH), 1652 (C=O); 
1
H 
NMR (400 MHz, methanol-d4) δ ppm 4.12 (1H, dd, J=8.3, 6.6 Hz, H(20)), 4.42 - 4.58 
(2H, m, H(15) and H(15)’), 4.73 (1H, dd, J=9.1, 8.3 Hz, H(20)’), 5.16 (1H, dd, J=9.1, 
6.6 Hz, H(19)), 6.79 (1H, td, J=7.6, 1.0 Hz, H(5)), 6.93 (1H, dd, J=8.1, 1.0 Hz, H(3)), 
7.10 (1H, td, J=7.6, 1.3 Hz, H(4)), 7.22 (1H, d, J=7.6 Hz, H(6)), 7.41 (1H, dd, J=7.8, 
5.1 Hz, H(23), 7.53 (2H, d, J=8.1 Hz, H(11 and 13)), 7.70 (1H, dt, J=7.8, 1.8 Hz, 
H(22)), 8.00 (2H, d, J=8.1 Hz, H(10 and 14)), 8.41 - 8.49 (2H, m, H(24) and H(26); 
13
C 
NMR (100 MHz, methanol-d4) δ ppm 45.5 (C(15)), 64.5 (C(19)), 74.6 (C(20)), 117.3 
(C(3)), 118.3 (C(5)), 123.9 (C(23)), 126.3 (C(6)), 126.9 (C(10 and 14)), 127.1 (C(4)), 
127.7 (C(11 and 13)), 127.7 (C(1)), 133.1 (C(9)), 135.0 (C(22)), 140.1 (C(21)), 142.4 
(C(2)), 143.3 (C(12)), 147.2 (C(26)), 147.7 (C(24)), 163.3 (C(17)), 167.3 (C(8)); m/z 
(ESI
+
) 388 ([M+H]
+
, 100%); HRMS C22H22N5O2
+
 requires: 388.1768, found: 388.1774.  
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 (S,Z)-tert-butyl (2-(4-((2-((tert-
butoxycarbonyl)amino)phenyl)carbamoyl)benzyl)imino)-4-(pyridin-3-
yl)oxazolidine-3-carbothioamido)methyl)benzamido)phenyl)carbamate (99) 
 
To a solution of 94 (79 mg, 0.572 mmol) in THF (3 mL) was added a solution of 
77 (230 mg, 0.600 mmol) in THF (3 mL), the solution was then stirred at rt for 20 h, 
solvents were evaporated and the residue dissolved in Acetone (3 mL), then 
iodomethane (0.072 mL, 1.144 mmol) was added and the solution stirred at rt for 21 h. 
Sodium bicarbonate (sat. aq., 2 mL) was added, stirred for 10 min then diluted with 
sodium bicarbonate (sat. aq., 20 mL), and extracted with ethyl acetate (2 × 20 mL). 
Combined organics were washed with brine (20 mL), dried Na2SO4 and evaporated to 
give 240 mg of a yellow solid, which was purified by flash column chromatography on 
silica gel (0.2 to 3% (2M ammonia/methanol) in dichloromethane) to give 99 (47 mg, 
0.054 mmol, 9%) as a white solid, 87-90 °C; 
1
H NMR (400 MHz, chloroform-d) δ ppm 
1.47 (9H, s), 1.49 (9H, s), 1.93 (1H, br s), 4.35 (1H, dd, J=8.3, 1.8 Hz), 4.53 (1H, d, 
J=17.0 Hz), 4.62 (1H, d, J=17.0 Hz), 4.65 (1H, dd, J=14.8, 3.8 Hz), 4.75 (1H, t, J=8.3 
Hz), 4.86 (1H, dd, J=14.8, 4.5 Hz), 6.26 (1H, dd, J=8.3, 1.8 Hz), 6.95 - 7.08 (5H, m), 
7.09 - 7.19 (3H, m), 7.35 (1H, dd, J=8.1, 4.9 Hz), 7.37 - 7.48 (4H, m), 7.51 (1H, d, 
J=7.8 Hz), 7.60 (1H, d, J=7.6 Hz), 7.67 (1H, dt, J=7.9, 1.9 Hz), 7.80 (2H, d, J=8.1 Hz), 
7.91 (2H, d, J=8.1 Hz), 8.60 (1H, dd, J=4.8, 1.6 Hz), 8.65 (1H, d, J=2.2 Hz), 9.30 (1H, 
br s), 9.45 (1H, br s), 12.14 (1H, t, J=3.8 Hz); 
13
C NMR (100 MHz, chloroform-d) δ 
ppm 28.3, 28.4, 50.1, 50.1, 60.0, 71.5, 80.5, 81.3, 123.8, 124.5, 125.1, 125.3, 125.8, 
125.8, 126.0, 126.2, 127.0, 127.8, 128.2, 128.9, 129.9, 130.1, 130.4, 131.0, 132.5, 
134.1, 134.2, 135.6, 140.3, 143.6, 148.2, 149.6, 150.2, 154.3, 154.7, 165.8, 166.0, 
177.5; m/z (ESI
+
) 871 ([M+H]
+
, 100%); HRMS C47H51N8O7
+
 requires: 871.3596, found: 
871.3587. 
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3-hydroxy-4-phenyl-1H-pyrrole-2,5-dione (100)
127
 
 
To a solution of diethyl oxylate (1 mL, 7.40 mmol) and 2-phenylacetamide (0.5 
g, 3.70 mmol) in anh. THF (11 mL) at 0 °C was added a solution of potassium tert-
butoxide (1.04 g, 9.25 mmol) in anh. THF (9 mL). The mixture was stirred at 0 °C for 
1.5 h then quenched with hydrochloric acid (0.5 M, aq, 20 mL) and extracted with ethyl 
acetate (2 × 20 mL). The combined organic layers were washed with brine (20 mL), 
dried Na2SO4 and evaporated to give a yellow oil that was triturated with diethyl ether 
to give a white solid which was unreacted 2-phenylacetamide. The combined filtrates 
from trituration were evaporated and the residue purified by column chromatography on 
silica gel (ethyl acetate:hexane, 4:1) to give 100 as a yellow solid (26 mg, 0.137 mmol, 
4%), mp 152-158 °C (lit.
127
 214-216 °C); νmax (cm
-1
) 3348 (OH), 3159 (NH), 1632 
(C=O); 
1
H NMR (500 MHz, DMSO-d6) δ ppm 6.93 (1H, t, J=6.9 Hz, p-Ph), 7.19 (2H, t, 
J=7.6 Hz, m-Ph), 8.16 (2H, d, J=7.6 Hz, o-Ph), 9.49 (1H, br s, NH). [15% impurity by 
1
H NMR]. 
2-phenylquinolin-8-ol (101)
128
 
 
In an oven-dried flask was added lithium (83 mg, 12 mmol) and anh. diethyl 
ether (5 mL) then bromobenzene (0.6 mL, 5.7 mmol) dropwise under argon. An 
exotherm was observed and the solvent began to reflux, the mixture was stirred without 
heating for 1 h, then a solution of 8-hydroxyquinoline (0.4 g, 2.75 mmol) in anh. diethyl 
ether (8 mL) was added slowly and the mixture heated to reflux for 1 h. The reaction 
was cooled to rt and air was bubbled through the mixture for 2 h, then water (4 mL) and 
diethyl ether (8 mL) were added and the mixture was neutralised with hydrochloric acid 
(1 M, aq.). The layers were separated and the aqueous layer was extracted with diethyl 
ether (2 × 25 mL). The combined organic layers were dried Na2SO4, and evaporated to 
give a brown oil. Purification by column chromatography on silica gel (ethyl 
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acetate:hexane, 1:19) gave 101 as a white solid (0.424 g, 1.92 mmol, 70 %), mp 55-57 
°C (lit.
163
 55 °C); νmax (cm
-1
) 3385 (OH); 
1
H NMR (400 MHz, chloroform-d) δ ppm 7.23 
(1H, d, J=7.3 Hz, H(8)), 7.36 (1H, d, J=8.0 Hz, H(3)), 7.42 - 7.60 (4H, m, H(7), H(15) 
and H(13 and 17)), 7.92 (1H, d, J=8.8 Hz, H(6)), 8.18 (2H, d, J=7.0 Hz, H(14 and 16)), 
8.23 (1H, d, J=8.5 Hz, H(4)), 8.42 (1H, br s, OH); 
13
C NMR (125 MHz, chloroform-d) δ 
ppm 110.2 (C(8)), 117.6 (C(6)), 119.5 (C(3)), 127.3 (C(5)), 127.4 (C(13 and 17)), 127.5 
(C(15)), 128.8 (C(14 and 16)), 129.6 (C(7)), 137.0 (C(4)), 137.9 (C(10)), 138.7 (C(12)), 
152.3 (C(9)), 154.9 (C(2)). 
(E)-2-(benzylideneamino)phenol (102)
129
 
 
To a solution of 2-hydroxyaniline (0.537 g, 4.92 mmol) in methanol (3 mL) was 
added slowly a solution of benzaldehyde (0.5 mL, 4.92 mmol) in methanol (1.5 mL). 
The solution was stirred at reflux for 3 h, then cooled and placed in the refrigerator 
overnight. A brown solid was filtered and then recrystallized from ethanol to give 102 as 
a grey solid (0.360 g, 1.82 mmol, 37%), mp 90-91 °C (lit.
129
 87 °C); νmax (cm
-1
) 3323 
(OH), 1624 (C=N); 
1
H NMR (400 MHz, chloroform-d) δ ppm 6.95 (1H, td, J=7.7, 1.3 
Hz, H(3)), 7.06 (1H, dd, J=8.2, 1.4 Hz, H(6)), 7.24 (1H, td, J=7.8, 1.5 Hz, H(4)), 7.31 
(1H, br s, OH), 7.34 (1H, dd, J=8.0, 1.3 Hz, H(5)), 7.48 - 7.57 (3H, m, H(12 and 14) 
and H(13)), 7.91 - 8.00 (2H, m, H(11 and 15)), 8.73 (1H, s, H(2)); 
13
C NMR (125 MHz, 
chloroform-d) δ ppm 115.0 (C(3)), 115.8 (C(6)), 120.1 (C(4)), 128.8 (C(12 and 14)), 
128.8 (C(11 and 15)), 128.9 (C(5)), 131.6 (C(13)), 135.5 (C(10)), 135.8 (C(8)), 152.3 
(C(7)), 157.1 (C(2)). 
7-allyl-8-hydroxyquinoline (103)
164
 
 
Acetone (100 mL) was stirred over MgSO4 (2 g) for 10 min then filtered into an 
oven-dried flask. To this flask was added 8-hydroxyquinoline (10 g, 68.9 mmol) and 
potassium carbonate (14.28 g, 103.4 mmol), the mixture was stirred at reflux under a 
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nitrogen atmosphere for 15 min then allyl bromide (6.2 mL, 71.7 mmol) was added and 
the mixture stirred at reflux for 24 h. After cooling the reaction was filtered, the solids 
were washed with acetone (3 × 30 mL) and the filtrate was evaporated. The residue was 
dissolved in diethyl ether (80 mL), washed with potassium hydroxide (5% aq., 80 mL) 
and water (2 × 80 mL), then dried Na2SO4 and evaporated to give a dark brown oil. The 
oil was stirred and heated at 200 °C for 30 min then cooled to rt and purified by column 
chromatography on silica gel (hexane:ethyl acetate, 3:1) to give a dark brown solid 
(11.71 g, 63.2 mmol, 92%), mp 40 – 44 °C (lit.164 42 °C (n-heptane)); νmax (cm
-1
) 3372 
(OH); 
1
H NMR (400 MHz, chloroform-d) δ ppm 3.68 (2H, dt, J=6.5, 1.4 Hz, H(11)), 
5.16 (1H, dq, J=27.9, 1.5 Hz, Ha(13)), 5.14 - 5.16 (1H, m, H, Hb(13)), 6.12 (1H, ddt, 
J=16.9, 10.2, 6.5, 6.5 Hz, H(12)), 7.32 (1H, d, J=8.8 Hz, H(7)), 7.37 - 7.43 (2H, m, H(8) 
and H(3)), 8.14 (1H, dd, J=8.3, 1.5 Hz, H(4)), 8.47 (1H, br s, OH), 8.79 (1H, dd, J=4.3, 
1.5 Hz, H(2)).  
7-allyl-8-methoxyquinoline (104) 
 
To a solution of the hydroxyl compound 103 (3 g, 16.2 mmol) in THF (100 mL) 
was added powdered potassium hydroxide (3.91 g, 69.7 mmol) followed by 
iodomethane (1.51 mL, 24.3 mmol). The mixture was stirred at rt for 18 h then 
inorganics were filtered and the filtrate evaporated to give 104 as a brown oil (3.23 g, 
16.2 mmol, 100%); νmax (cm
-1
) 1638 (C=C); m/z (ESI
+
) 200 ([M+H]
+
, 100%); 
1
H NMR 
(400 MHz, chloroform-d) δ ppm 3.66 (2H, d, J=6.5 Hz, H(11)), 4.13 (3H, s, OCH3), 
5.04 - 5.18 (2H, m, Hb(13) and H(12)), 6.05 (1H, ddt, J=16.8, 10.3, 6.5, Ha(13)), 7.31 - 
7.45 (2H, m, H(7)) and H(3), 7.53 (1H, d, J=8.5 Hz, H(8)), 8.12 (1H, dd, J=8.2, 1.6 Hz, 
H(4)), 8.93 (1H, dd, J=4.1, 1.6 Hz, H(2)); 
13
C NMR (125 MHz, chloroform-d) δ ppm 
34.2 (C(11)), 62.4 (OCH3), 116.0 (C(13)), 120.6 (C(6)), 123.0 (C(3)), 128.6 (C(8)), 
128.8 (C(7)), 132.3 (C(5)), 136.0 (C(4)), 136.9 (C(12)), 142.9 (C(10)), 149.5 (C(2)), 
153.4 (C(9)); HRMS C13H14NO
+
 requires: 200.1070, found: 200.1074. 
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(E)-8-methoxy-7-(prop-1-en-1-yl)quinoline (106) 
 
To a solution of the allyl compound 104 (3.0 g, 15.05 mmol) in anhydrous THF 
(130 mL) was added potassium tert-butoxide (6.75 g, 60.2 mmol) under a nitrogen 
atmosphere. The suspension was stirred at rt for 2 h then poured onto ammonium 
chloride (sat. aq., 50 mL) and extracted with diethyl ether (2 × 150 mL). The combined 
organic layers were washed with brine (100 mL), dried Na2SO4 and evaporated to give 
106 as a brown oil (2.82 g, 14.1 mmol, 94%); νmax (cm
-1
) 1609 (C=C);
 1
H NMR (400 
MHz, chloroform-d) δ ppm 2.01 (3H, dd, J=6.7, 1.6 Hz, H(13)), 4.11 (3H, s, OCH3), 
6.44 (1H, dq, J=15.9, 6.7 Hz, H(12)), 7.02 (1H, dq, J=15.9, 1.6 Hz, H(11)), 7.35 (1H, 
dd, J=8.2, 4.3 Hz, H(3)), 7.51 (1H, d, J=8.8 Hz, H(7)), 7.69 (1H, d, J=8.8 Hz, H(6)), 
8.10 (1H, dd, J=8.2, 1.6 Hz, H(4)), 8.93 (1H, dd, J=4.3, 1.6 Hz, H(2)); 
13
C NMR (125 
MHz, chloroform-d) δ ppm 19.1 (C(13)), 62.5 (OCH3), 120.7 (C(6)), 123.3 (C(3)), 
124.4 (C(7)), 125.3 (C(11)), 128.3 (C(12)), 128.8 (C(5)), 130.2 (C(8)), 136.0 (C(4)), 
143.4 (C(10)), 149.8 (C(2)), 152.1 (C(9)); m/z (ESI
+
) 200 ([M+H]
+
, 100%); HRMS 
C13H14NO
+
 requires: 200.1070, found: 200.1075. 
8-methoxyquinoline-7-carbaldehyde (107) 
 
To a solution of the allyl compound 104 (3.17 g, 15.9 mmol) in dioxane (200 
mL) and water (80 mL) was added osmium tetroxide (4% in water, 1.1 mL, 0.159 
mmol) and then stirred at rt for 15 min. Sodium (meta)periodate (17 g, 79.5 mmol) was 
added portionwise over 30 min and the reaction was stirred at rt for 16 h. Sodium 
thiosulfate (18 g) was added and the reaction poured onto water (500 mL), stirred for 30 
min then the insoluble material was filtered and the dioxane was evaporated. The 
remaining aqueous solution was extracted with chloroform (2 × 150 mL) and ethyl 
acetate (2 × 100 mL), both chlorinated and non-chlorinated organic layers were 
separately washed with brine (100 mL), then combined and dried Na2SO4 and 
evaporated to give 107 as a beige solid (2.59 g, 13.8 mmol, 87%), mp 86-88 °C; νmax 
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(cm
-1
) 1671 (C=O); 
1
H NMR (500 MHz, chloroform-d) δ ppm 4.39 (3H, s, OCH3), 7.52 
(1H, dd, J=8.3, 4.1 Hz, H(3)), 7.58 (1H, d, J=8.7 Hz, H(7)), 7.91 (1H, d, J=8.7 Hz, 
H(6)), 8.17 (1H, dd, J=8.3, 1.7 Hz, H(4)), 8.99 (1H, dd, J=4.1, 1.7 Hz, H(2)), 10.68 (1H, 
d, J=0.8 Hz, H(11)): 
13
C NMR (125 MHz, chloroform-d) δ ppm 64.9 (OCH3), 123.4 
(C(6)), 123.5 (C(7)), 123.6 (C(3)), 127.6 (C(5)), 133.6 (C(8)), 136.5 (C(4)), 143.1 
(C(10)), 150.1 (C(2)), 161.7 (C(9)), 190.2 (C(11)); m/z (ESI
+
) 188 ([M+H]
+
, 95%); 
HRMS C11H10NO2
+
 requires: 188.0706, found: 180.0705. 
ethyl (2E)-5-(8-methoxyquinolin-7-yl)penta-2,4-dienoate (113) 
 
 To a flame dried flask was added arsonium salt 121 (515 mg, 1.03 mmol) and 
anhydrous THF (4 mL) under a nitrogen atmosphere. The suspension was cooled to 0 
°C then n-butyllithium (2.3 M in hexanes, 0.45 mL, 1.03 mmol) was added dropwise 
and stirred for 15 min at 0 °C then 15 min at rt. The aldehyde 107 (175 mg, 0.94 mmol) 
was then added portion-wise over 5 min under a nitrogen atmosphere and stirring 
continued for 16 h at 8rt. The reaction was then concentrated to give an orange solid 
which was purified by column chromatography on silica gel (ethyl acetate:hexane, 1:1) 
to give 113 as a yellow oil that crystallised on standing [a mixture of E and Z isomers] 
(200 mg, 0.706 mmol, 75%). The product was not purified further before 
hydrogenation. 
 (2E)-5-(8-methoxyquinolin-7-yl)-N-phenylpenta-2,4-dienamide (114) 
 
To a suspension of 122 (140 mg, 0.55 mmol) in dichloromethane (2 mL) was 
added oxalyl chloride (0.066 mL, 0.78 mmol) followed by 1 drop of DMF. Stirred at rt 
for 1 h, and at reflux for 1 h, then evaporated and the residue was suspended in 
dichloromethane (2 mL). To this suspension was added aniline (0.047 mL, 0.52 mmol) 
and pyridine (1 mL), the resulting solution was stirred at rt for 16 h. Quenched with 
sodium hydrogen carbonate (sat. aq., 2 mL) and extracted with chloroform (2 × 25 mL), 
the combined organic layers were washed with water (2 × 10 mL), brine (10 mL) then 
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dried Na2SO4 and evaporated. Partial purification by column chromatography on silica 
gel (ethyl acetate:hexane, 2:1) gave 114 as a mixture of E and Z isomers (65 mg, 0.197 
mmol, 38%) which was not purifier further before hydrogenation. 
5-(8-methoxyquinolin-7-yl)-N-phenylpentanamide (116) 
 
To ethyl ester 125 (35 mg, 0.122 mmol) was added a solution of aniline (12 mg, 
0.122 mmol) in anhydrous toluene (1 mL) under a nitrogen atmosphere. To the resulting 
solution was added trimethylaluminium (1M in heptane, 0.12 mL, 0.122 mmol) and 
then stirred at rt for 1 h. Another portion of trimethylaluminium (1M in heptane, 0.037 
mL, 0.37 mmol) was added and the reaction stirred at rt for 16 h. Quenched carefully 
with ammonium chloride (sat. aq., 5 mL) then diluted with ethyl acetate (25 mL) and 
water (20 mL). The aqueous layer was extracted with ethyl acetate (25 mL), and the 
combined organic layers were then washed with brine (20 mL), dried Na2SO4 and 
evaporated. Purification by column chromatography on silica gel (ethyl acetate:hexane, 
3:2) gave 116 as a white solid (25 mg, 0.0748 mmol, 61%), mp 136-137 °C; νmax (cm
-1
) 
3250 (NH), 1686 (C=O); 
1
H NMR (500 MHz, chloroform-d) δ ppm 1.63 - 1.92 (4H, m, 
H(12) and H(13)), 2.35 - 2.47 (2H, m, H(11)), 2.87 - 2.99 (2H, m, H(14)), 4.14 (3H, s, 
OCH3), 7.06 (1H, t, J=7.4 Hz, p-Ph), 7.29 (2H, t, J=7.8 Hz, m-Ph), 7.33 - 7.40 (2H, m, 
H(3) and H(7)), 7.48 - 7.62 (4H, m, o-Ph, H(6) and NH), 8.11 (1H, dd, J=8.2, 1.4 Hz, 
H(4)), 8.92 (1H, dd, J=4.0, 1.5 Hz, H(2)); 
13
C NMR (125 MHz, chloroform-d) δ ppm 
25.3 (C(11)), 29.4 (C(12)), 30.1 (C(13)), 37.5 (C(14)), 62.5 (OCH3), 119.8 (m-Ph), 
120.7 (C(6)), 123.3 (C(3)), 124.0 (C(7)), 128.6 (C(5)), 128.9 (p-Ph), 129.0 (o-Ph), 134.5 
(C(8)), 136.1 (C(4)), 138.3 (i-Ph), 142.9 (C(10)), 149.6 (C(2)), 153.4 (C(9)), 171.5 
(C(15)); m/z (ESI
+
) 335 ([M+H]
+
, 100%); HRMS C21H23N2O2
+
 requires: 335.1754, 
found: 335.1759. 
5-(8-hydroxyquinolin-7-yl)-N-phenylpentanamide (117) 
 
To a solution of 116 (36 mg, 0.12 mmol) in dichloromethane (1 ml) at -10 °C 
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was added boron tribromide (1M in dichloromethane, 0.35 ml, 0.35 mmol) dropwise. 
The resulting mixture was stirred at -10 °C for 5 min then warmed to rt and stirred for 2 
h. Quenched with sodium hydrogen carbonate (sat. aq., 2 ml), diluted with water (15 
ml) and chloroform (25 ml). The aqueous layer was extracted with chloroform (25 mL) 
and the combined organic layers were washed with brine (20 mL) then dried Na2SO4
 
and evaporated to give a yellow solid (30 mg). Purification by column chromatography 
on silica gel (ethyl acetate:hexane, 1:1) gave 117 as a white solid (19 mg, 0.059 mmol, 
49%), mp 157-159 °C; νmax (cm
-1
) 3302 (OH), 1653 (C=O); 
1
H NMR (600 MHz, 
methanol-d4) δ ppm 1.74 - 1.84 (4H, m, H(12) and H(13)), 2.42 (2H, t, J=6.8 Hz, 
H(11)), 2.90 (2H, t, J=7.0 Hz, H(14)), 7.06 (1H, t, J=7.3 Hz, p-Ph), 7.28 (2H, t, J=7.9 
Hz, m-Ph), 7.31 (1H, d, J=8.5 Hz, H(7)), 7.37 (1H, d, J=8.5 Hz, H(6)), 7.42 (1H, dd, 
J=8.3, 4.1 Hz, H(3)), 7.52 (2H, d, J=8.3 Hz, o-Ph), 8.19 (1H, dd, J=8.3, 1.1 Hz, H(4)), 
8.76 (1H, dd, J=4.1, 1.1 Hz, H(2)); 
13
C NMR (150 MHz, methanol-d4) δ ppm 26.8 
(C(11)), 30.6 (C(12)), 30.7 (C(13)), 37.9 (C(14)), 118.4 (C(6)), 121.3 (o-Ph), 122.0 
(C(3)), 125.1 (C(7)), 125.4 (C(5)), 128.6 (C(8)), 129.7 (m-Ph), 130.8 (C(p-Ph)), 137.1 
(C(4)), 139.7 (C(i-Ph)), 139.9 (C(10)), 149.2 (C(2)), 150.9 (C(9)), 174.7 (C(15)); m/z 
(ESI
+
) 321 ([M+H]
+
, 100%); HRMS C20H21N2O2
+
 requires: 321.1598, found: 321.1601. 
7-((2,3-dihydroxy)propyl)-8-methoxyquinoline (118) 
 
To a solution of the allyl compound 104 (0.4 g, 2.01 mmol) in tert-butanol (10 
mL) and water (10 mL) was added potassium ferricyanide (III) (1.98 g, 6.0 mmol), 
potassium carbonate (0.829 g, 6.0 mmol) and osmium tetroxide (4% aq., 0.13 mL, 0.02 
mmol). The mixture was stirred at rt for 24 h then sodium sulphite (0.756 g, 6 mmol) 
was added and stirred at rt for 2.5 h. The tert-butanol was evaporated and the resulting 
mixture was diluted with water (10 mL) then extracted with ethyl acetate (2 × 30 mL), 
the combined organic layers were eashed with brine (30 mL) dried Na2SO4 and 
evaporated to give a yellow oil (0.4 g). Purification by column chromatography on silica 
gel (5% methanol/dichloromethane) gave 118 as a yellow oil (0.378 g, 1.62 mmol, 81 
%); νmax (cm
-1
) 3354 (OH); 
1
H NMR (500 MHz, chloroform-d) δ ppm 2.98 - 3.07 (2H, 
m, H(11)), 3.19 (2H, br s, OH), 3.52 (1H, dd, J=11.4, 6.1 Hz, H(13)), 3.65 (1H, dd, 
J=11.4, 3.4 Hz, H(13)’), 4.01 - 4.08 (1H, m, H(12)), 4.10 (3H, s, OCH3), 7.33 (1H, dd, 
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J=8.3, 4.1 Hz, H(3)), 7.39 (1H, d, J=8.4 Hz, H(6)), 7.47 (1H, d, J=8.4 Hz, H(7)), 8.08 
(1H, dd, J=8.3, 1.5 Hz, H(4)), 8.84 (1H, dd, J=4.1, 1.5 Hz, H(2)); 
13
C NMR (125 MHz, 
chloroform-d) δ ppm 34.6 (C(11)), 62.4 (OCH3), 66.0 (C(13)), 72.6 (C(12)), 120.9 
(C(6)), 123.4 (C(3)), 128.8 (C(5)), 129.9 (C(7)), 130.9 (C(8)), 136.3 (C(4)), 142.4 
(C(10)), 149.6 (C(2)), 153.6 (C(9)); m/z (ESI
+
) 234 ([M+H]
+
, 100%); HRMS 
C13H16NO3
+
 requires: 234.125, found: 234.1121. 
ethyl (E)-4-(diethoxyphosphoryl)but-2-enoate (119)
165
 
 
Ethyl 4-bromocrotonate (80% technical) (1.43 mL, 9.12 mmol) was added to 
triethyl phosphite (1.56 mL, 9.12 mmol) and the mixture was stirred at 130 °C for 4 h 
under reflux. The resulting yellow oil was purified by column chromatography on silica 
gel (ethyl acetate:hexane, 4:1) to give 119 as a colourless oil (1.91 g, 7.62 mmol, 84%); 
νmax (cm
-1
) 1716 (C=O); 
1
H NMR (400 MHz, chloroform-d) δ ppm 1.23 - 1.42 (9H, m, 3 
× CH3CH2O), 2.75 (2H, ddd, J=22.8, 8.0, 1.5 Hz, H(4)), 4.04 - 4.26 (6H, m, CH3CH2O), 
5.91 - 6.01 (1H, m, H(2)), 6.88 (1H, dq, J=15.4, 7.7 Hz, H(3)); 
13
C NMR (125 MHz, 
chloroform-d) δ ppm 14.2 (CO2CH2CH3), 16.4 (d, J=6.7 Hz, POCH2CH3), 30.6 (d, 
J=139.2 Hz, C(4)), 60.4 (CO2CH2CH3), 62.2 (d, J=6.7 Hz, POCH2CH3), 125.8 (d, 
J=13.4 Hz, C(2)), 137.4 (d, J=11.5 Hz, C(3)), 165.6 (d, J=2.9 Hz, C=O). 
(E)-(4-ethoxy-4-oxobut-2-en-1-yl)triphenylphosphonium bromide (120) 
 
To a solution of ethyl-4-bromocrotonate (80% technical grade) (1 mL, 7.26 
mmol) in toluene (5 mL) was added triphenylphosphine (1.98 g, 7.55 mmol) the 
solution was stirred at rt for 16 h then filtered to give a white solid (2.88 g). 
Recrystallization from hot acetonitrile (27 mL) and ethyl acetate (36 mL) gave 120 as a 
white solid (1.42 g, 5.37 mmol, 74 %), mp 176-178 °C (dec) (lit.
166
 189-191 (dec)); νmax 
(cm
-1
) 1714 (C=O); 
1
H NMR (500 MHz, chloroform-d) δ ppm 1.22 (3H, t, J=7.3 Hz, 
OCH2CH3), 4.11 (2H, q, J=7.3 Hz, OCH2CH3), 5.24 (2H, dd, J=16.4, 7.6 Hz, H(4)), 
6.48 (1H, dd, J=15.4, 4.7 Hz, H(2)), 6.70 (1H, dtd, J=15.4, 7.6, 6.6 Hz, H(3)), 7.69 (6H, 
td, J=7.7, 3.5 Hz, m-Ph), 7.80 (3H, td, J=7.4, 1.6 Hz, p-Ph), 7.87 (6H, dd, J=12.6, 7.4 
Hz, o-Ph); 
13
C NMR (125 MHz, chloroform-d) δ ppm 14.1 (OCH2CH3), 27.6 (d, J=49.9 
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Hz, C(4)), 60.8 (OCH2CH3), 117.5 (d, J=86.4 Hz, i-Ph), 130.4 (d, J=12.5 Hz, o-Ph), 
130.8 (d, J=13.4 Hz, C(2)), 132.2 (d, J=9.6 Hz, C(3)), 133.9 (d, J=9.6 Hz, m-Ph), 135.2 
(d, J=2.9 Hz, p-Ph), 165.1 (d, J=2.9 Hz, C=O). 
 (E)-(4-ethoxy-4-oxobut-2-en-1-yl)triphenylarsonium bromide (121)
131
 
 
To a solution of ethyl-4-bromocrotonate (80% technical grade) (2.35 g, 9.74 
mmol) in toluene (1 mL) was added triphenylarsine (2.49 g, 8.12 mmol) the solution 
was stirred at reflux for 1.5 h then left standing at rt for 7 days (flask was left open to 
allow some toluene to evaporate). The white solid was filtered and washed with cold 
toluene (8 mL) then dried under vacuum to give 121 as a white solid (3.05 g, 6.11 
mmol, 75 %), mp 141-145 °C (lit.
131
 151-152); 
1
H NMR (500 MHz, chloroform-d) δ 
ppm 1.22 (3H, t, J=7.1 Hz, OCH2CH3), 4.11 (2H, q, J=7.1 Hz, OCH2CH3), 5.28 (2H, d, 
J=8.2 Hz, H(4)), 6.45 (1H, d, J=15.4 Hz, H(2)), 6.82 (1H, dt, J=15.4, 8.2 Hz, H(3)), 
7.68 (6H, t, J=7.7 Hz, m-Ph), 7.75 (3H, t, J=7.7 Hz, p-Ph), 7.82 (6H, d, J=8.0 Hz, o-Ph); 
13
C NMR (125 MHz, chloroform-d) δ ppm 14.2 (OCH2CH3), 29.9 (C(4)), 60.8 
(OCH2CH3), 120.7 (i-Ph), 130.4 (C(2)), 131.0 (o-Ph), 133.2 (m-Ph), 133.5 (C(3)), 134.4 
(p-Ph), 165.1 (C(1)). 
 (2E)-5-(8-methoxyquinolin-7-yl)penta-2,4-dienoic acid (122) 
 
To a suspension of the phosphonium bromide 120 (400 mg, 1.51 mmol) in 
anhydrous THF (13 mL) was added potassium tert-butoxide (227 mg, 2.02 mmol) under 
a nitrogen atmosphere, after stirring at rt for 1 h the mixture was cooled to 0 °C. To the 
yellow mixture was added a solution of aldehyde 107 (188 mg, 1.01 mmol) in 
anhydrous THF (3 mL) dropwise over 5 min, and then stirred at rt for 1 h. The reaction 
was partitioned between ethyl acetate (50 mL) and water (30 mL), the organic layer was 
washed with brine (30 mL), dried Na2SO4 and evaporated to give a yellow oil (539 mg). 
To a solution of this oil in THF (10 mL) was added lithium hydroxide (0.5 M, aq. 10 
mL) and the mixture stirred at 70 °C for 15 h, Cooled to rt and then washed with diethyl 
ether (10 mL). The aqueous was acidified to pH 5 with 1M hydrochloric acid and then 
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extracted with ethyl acetate (4 × 25 mL), the combined organic layers were dried 
MgSO4 and evaporated to give 122 (inseparable 1:1 mixture of E:Z isomers) as a yellow 
solid (152 mg, 0.595 mmol, 59%); 
1
H NMR (400 MHz, methanol-d4) δ ppm 4.01 (3H, 
s), 4.07 (3H, s), 6.12 (2H, d, J=15.2 Hz), 6.64 (1H, t, J=11.9 Hz), 7.15 - 7.29 (2H, m), 
7.48 - 7.61 (5H, m), 7.63 - 7.77 (3H, m), 7.90 (1H, d, J=8.8 Hz), 8.33 (1H, dd, J=8.3, 
1.5 Hz), 8.37 (1H, dd, J=8.3, 1.8 Hz), 8.83 - 8.94 (2H, m); 
13
C NMR (125 MHz, 
methanol-d4) δ ppm 62.9, 63.6, 123.1, 123.6, 124.5, 125.0, 125.5, 125.6, 129.9, 130.0, 
130.1, 130.2, 130.6, 131.3, 131.7, 134.0, 135.0, 138.2, 138.4, 141.8, 143.2, 143.7, 
146.5, 151.1, 151.2, 155.0, 155.1, 170.2, 170.4. 
5-(8-methoxy-1,2,3,4-tetrahydroquinolin-7-yl)-N-phenylpentanamide (123) 
 
To a solution of 114 (63 mg, 0.191 mmol) in dichloromethane (1 mL) and 
methanol (0.5 mL) was added 10% palladium on activated carbon (19 mg, 0.018 mmol). 
The flask was then evacuated and filled with nitrogen three times to remove oxygen, 
finally the flask was evacuated and then filled with hydrogen gas from a balloon. The 
mixture was stirred vigorously under a hydrogen balloon for 32 h. Then a further 5 mg 
of 10% palladium on activated carbon was added and after evacuating and back filling 
with nitrogen three times then evacuating and back filling with hydrogen gas from a 
balloon the mixture was stirred vigorously under a hydrogen balloon for another 16 h. 
The mixture was filtered through a thin layer of celite and washed with a 1:1 mixture of 
methanol and dichloromethane (5 ml) then the filtrates were evaporated. Purification by 
column chromatography on silica gel (hexane:ethyl acetate, 3:2) gave 123 as a white 
solid (54 mg, 0.160 mmol, 84%), mp 87-88 °C; νmax (cm
-1
) 3298 (NH), 1651 (C=O); 
1
H 
NMR (400 MHz, chloroform-d) δ ppm 1.65 - 1.75 (2H, m, H(12)), 1.76 - 1.85 (2H, m, 
H(13)), 1.91 - 2.00 (2H, m, H(3)), 2.39 (2H, t, J=7.5 Hz, H(14)), 2.64 (2H, t, J=7.4 Hz, 
H(11)), 2.76 (2H, t, J=6.4 Hz, H(4)), 3.29 - 3.37 (2H, m, H(2)), 3.74 (3H, s, OCH3), 
4.30 (1H, br s, H(1)), 6.44 (1H, d, J=7.8 Hz, H(7)), 6.71 (1H, d, J=7.8 Hz, H(6)), 7.11 
(1H, t, J=7.3 Hz, p-Ph), 7.33 (2H, t, J=7.9 Hz, m-Ph), 7.38 (1H, br s, H(16)), 7.52 (2H, 
d, J=7.9 Hz, o-Ph); 
13
C NMR (125 MHz, chloroform-d) δ ppm 22.1 (C(3)), 25.6 (C(4)), 
26.6 (C(11)), 28.9 (C(12)), 30.3 (C(13)), 37.7 (C(14)), 41.6 (C(2)), 59.6 (OCH3), 117.0 
(C(7)), 119.9 (o-Ph), 120.5 (C(5)), 124.2 (C(8)), 125.0 (C(6)), 129.0 (m-Ph), 132.0 (p-
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Ph), 138.1 (C(10)), 138.1 (i-Ph), 144.2 (C(9)), 171.5 (C(15)); m/z (EI
+
) 338 (M
+
, 100%); 
HRMS C21H26N2O2
+
 requires: 338.1994, found: 338.1993. 
ethyl 5-(8-methoxyquinolin-7-yl)pentanoate (125) 
 
To a solution of diene 113 (100 mg, 0.353 mmol) in ethyl acetate (1 mL) was 
added 10% palladium on activated carbon (19 mg, 0.018 mmol). The flask was then 
evacuated and filled with nitrogen three times to remove oxygen, finally the flask was 
evacuated and then filled with hydrogen gas from a balloon. The mixture was stirred 
vigorously under a hydrogen balloon for 5 h then filtered through a thin layer of celite 
and washed with dichloromethane (10 ml) then the filtrates were evaporated. 
Purification by column chromatography on silica gel (hexane:ethyl acetate, 3:2) gave 
125 (24 mg, 0.084 mmol, 24%) as a colourless oil [mixture of ethyl and methyl esters] 
which was not further purified before reaction with aniline. 
7-tert-butyl N-{5-acetamido-1-[(4-methyl-2-oxo-2H-chromen-7-
yl)carbamoyl]pentyl}carbamate (MAL)
85
 
 
To an oven-dried round bottomed flask was added Boc-Lys(Ac)-OH (0.3 g, 1.04 
mmol, 1.0 eq), 7-amino-4-methylcoumarin (0.19 g, 1.08 mmol, 1.04 eq) and anhydrous 
pyridine (8 ml). The solution was cooled to -10 °C (salt-ice bath) and under an nitrogen 
atmosphere phosphoryl chloride (0.11 ml, 1.18 mmol, 1.13 eq) was added dropwise 
over 5 min. The solution was stirred at -10 °C for 30 min then quenched with ice/water 
(30 ml) and extracted with ethyl acetate (3 × 35 ml), some hydrochloric acid (2M aq.) 
was added to aid the separation. Combined organics were washed with sodium 
hydrogen carbonate (sat. aq., 2 × 20 ml) and brine (20 ml) then dried MgSO4 and 
concentrated. Purification by column chromatography on silica gel (5% 
methanol/EtOAC) gave MAL as a beige solid (0.171 g, 0.384 mmol, 37%), mp 101-102 
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°C (lit. 175 °C)
85
; [α]D
20 +3.2 (c 0.5, methanol); νmax (cm
-1
) 3302 (NH), 1730 (C=O), 
1676 (C=O); 
1
H NMR (600 MHz, methanol-d4) δ ppm 1.34 - 1.61 (13H, m, C(CH3)3, 
C(16)H2 and C(15)H2), 1.66 - 1.76 (1H, m, C(14)H), 1.76 - 1.86 (1H, m, C(14)H`), 1.91 
(3H, s, C(10)H3), 2.43 (3H, s, C(20)H3), 3.13 - 3.21 (2H, m, C(17)H2), 4.18 (1H, dd, 
J=8.7, 5.3 Hz, C(13)H), 6.19 (1H, s, C(2)H), 7.40 (1H, dd, J=8.7, 1.5 Hz, C(6)H), 7.64 
(1H, d, J=8.7 Hz, C(5)H), 7.77 (1H, d, J=1.1 Hz, C(8)H); 
13
C NMR (150 MHz, 
methanol-d4) δ ppm 18.6 (C(10)), 22.6 (C(20)), 24.4 (C(15)), 28.8 (C(25)), 30.1 
(C(16)), 33.0 (C(14)), 40.2 (C(17)), 56.9 (C(13)), 80.8 (C(24)), 107.9 (C(2)), 113.6 
(C(8)), 117.1 (C(6)), 117.1 (C(4)), 126.6 (C(5)), 143.4 (C(7)), 155.2 (C(3 and 9)), 158.1 
(C(22)), 163.2 (C(1)), 173.2 (C(19)), 174.2 (C(12)); m/z (ES
+
) 468 ([M+Na]
+
, 100%); 
HRMS C23H31N3O6Na
+
 requires: 468.2111, found: 468.2090. 
benzyl N-(5-{[(tert-butoxy)carbonyl]amino}-5-[(4-methyl-2-oxo-2H-chromen-7-
yl)carbamoyl]pentyl)carbamate (129) 
  
To a solution of N(α)-Boc-N(ε)-Cbz-(L)-lysine (0.380 g, 1.0 mmol, 1.0 eq) and 
7-amino-4-methylcoumarin (0.175 g, 1.0 mmol, 1.0 eq) in anhydrous pyridine (8 ml) at 
-10 °C was added phosphoryl chloride (0.14 ml, 1.5 mmol, 1.5 eq) dropwise over 2 min. 
The solution was then stirred at -10 °C for 1 h, then poured onto 30 ml ice/water and 
extracted with ethyl acetate (40 ml). The organic was washed with hydrochloric acid 
(0.25 M, aq., 35 ml), water (30 ml), brine (20 ml) then dried MgSO4, and evaporated. 
Purification by column chromatography on silica gel (dichloromethane to 20% ethyl 
acetate/dichloromethane) gave 129 as a white foamy solid (0.196 g, 0.365 mmol, 37%), 
mp 78-81 °C; νmax (cm
-1
) 3315 (NH), 1684 (C=O); 
1
H NMR (500 MHz, DMSO-d6) δ 
ppm 1.21 - 1.47 (11H, m, C(CH3)3 and C(3)H2), 1.52 - 1.70 (2H, m, C(2)H2), 2.38 (3H, 
s, C(24)H3), 2.92 - 3.03 (2H, m, C(4)H2), 3.31 - 3.35 (2H, m, C(5)H2), 3.98 - 4.08 (1H, 
m, H(1)), 4.97 (2H, s, C(8)H2), 6.24 (1H, s, H(19)), 7.10 (1H, d, J=7.3 Hz, H(9)), 7.23 
(1H, t, J=5.0 Hz, H(6)), 7.25 - 7.39 (5H, m, Ph), 7.47 (1H, d, J=8.7 Hz, H(23)), 7.70 
(1H, d, J=8.7 Hz, H(22)), 7.76 (1H, s, H(16)), 10.39 (1H, s, br., H(6)); 
13
C NMR (125 
MHz, DMSO-d6) δ ppm 18.0 (C(24)), 22.9 (C(3)), 28.2 (C(12)), 29.1 (C(4)), 31.2 
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(C(2)), 39.9 (C(5)), 55.3 (C(1)), 65.1 (C(8)), 78.1 (C(11)), 105.6 (C(16)), 112.2 (C(19)), 
115.0 (C(21)), 115.2 (C(23)), 125.9 (C(22)), 127.7 (C(26 and 33)), 127.7 (C(28)), 128.3 
(C(27 and 29)), 137.2 (C(25)), 142.3 (C(15)), 153.1 (C(20)), 153.6 (C(17)), 155.6 
(C(10)), 156.1 (C(7)), 160.0 (C(18)), 172.3 (C(13)); m/z (ES
-
) 536 (M
-
, 100%); HRMS 
C29H34N3O7
-
 requires: 536.2397, found: 536.2397. 
tert-butyl N-[(1S)-5-amino-1-[(4-methyl-2-oxo-2H-chromen-7-
yl)carbamoyl]pentyl]carbamate (130) 
 
To a solution of 129 (170 mg, 0.316 mmol) in methanol (5 ml) was added 10% 
activated palladium on activated carbon. The flask was then evacuated and filled with 
nitrogen three times to remove oxygen, finally the flask was evacuated and then filled 
with hydrogen gas from a balloon. The mixture was stirred vigorously under a hydrogen 
balloon for 5 h, then filtered through a thin layer of celite and washed with methanol (10 
ml) the combined filtrates were evaporated. Purification by column chromatography on 
silica gel (1% ammonia (30% aq.), 14% methanol, 85% ethyl acetate to 5% ammonia 
(30% aq.), 15% methanol, 80% ethyl acetate) gave 130 as a cream solid (53 mg, 0.131 
mmol, 42%), mp 98-99 °C; [α]D
20 -9.1 (c 0.5, methanol); ; νmax (cm
-1
) 3299 (NH), 1684 
(broad, 3 × C=O); 
1
H NMR (500 MHz, chloroform-d) δ ppm 1.28 - 1.61 (13H, m, 
C(CH3)3, C(16)H2 and C(15)H2), 1.63 - 1.79 (1H, m, H(14)), 1.80 - 1.94 (1H, m, 
H(14)`), 2.35 (3H, s, C(10)H3), 2.62 (2H, br s, C(17)H2), 2.75 (2H, br s, NH2), 4.35 (1H, 
br s, H(13)), 5.55 (1H, br s, H(19)), 6.10 (1H, br s, H(2)), 7.22 - 7.29 (1H, m, H(6)), 
7.40 (1H, d, J=8.0 Hz, H(5)), 7.66 (1H, s, H(8)), 9.73 (1H, br s, H(11)); 
13
C NMR (125 
MHz, chloroform-d) δ ppm 18.6 (C(10)), 22.9 (C(15)), 28.4 (C(22)), 32.0 (C(16)), 32.2 
(C(14)), 41.3 (C(17)), 55.3 (C(13)), 80.6 (C(21)), 107.2 (C(2)), 113.2 (C(8)), 115.6 
(C(4)), 115.8 (C(6)), 125.0 (C(5)), 141.6 (C(7)), 152.6 (C(9)), 154.0 (C(3)), 156.6 
(C(20)), 161.2 (C(1)), 171.7 (C(12)); m/z (ES
+
) 404 ([M+H]
+
, 98%); HRMS 
C21H30N3O5
+
 requires: 404.2185, found: 404.2180. 
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 (2S)-2,6-diacetamido-N-(4-methyl-2-oxo-2H-chromen-7-yl)hexanamide (131) 
 
To a solution of MAL (0.178 g, 0.40 mmol) in dichloromethane (3 mL) was 
added 2M HCl in diethyl ether (3 mL), a precipitate formed and the suspension was 
stirred at rt for 3 h. A further 3 mL of 2M HCl in diethyl ether was added and then 
stirred at rt for 2.5 h. The solvent was evaporated and the residue partitioned between 
sodium hydrogen carbonate (sat. aq, 40 mL) and ethyl acetate (50 mL), and the aqueous 
layer was extracted with ethyl acetate (2 × 25 mL). The combined organics were washed 
with brine (20 mL), dried Na2SO4 and concentrated to give a beige solid (20 mg). The 
aqueous layer was also evaporated to give a white solid which included some inorganic 
salts (0.525 g).  
To the concentrated aqueous layer suspended in acetonitrile (4 mL) and N,N-
diisopropylethylamine (0.15 mL, 0.88 mmol, 2.2 eq) at -10 °C under nitrogen was added 
acetic anhydride (0.083 mL, 0.88 mmol, 2.2 eq) slowly over 5 min. Stirred for 2 h, 
warming to 0 °C during that time. The reaction was quenched with water (30 mL) and 
then extracted with ethyl acetate (100 mL and 2 × 40 mL) the combined organics were 
washed with brine (30 mL) dried MgSO4 and concentrated to give a white solid (95 
mg). The aqueous layer was extracted with 20% ethanol/chloroform (2 × 40 mL), these 
organics were washed with brine (20 mL) and dried MgSO4 to give more white solid 
(30 mg). TLC showed that both solids contained product, and so they were combined 
and then purified by column chromatography (8% to 10% methanol/ethyl acetate) to 
give 131 as a white solid (91 mg, 0.235 mmol, 59%), mp 243-245 °C; [α]D
20 -7.6 (c 0.5, 
methanol); νmax (cm
-1
) 3304 (NH), 1717 (C=O), 1693 (C=O), 1679 (C=O), 1644 (C=O); 
1
H NMR (500 MHz, DMSO-d6) δ ppm 1.20 - 1.45 (4H, m, H(15) and H(16)), 1.54 - 
1.72 (2H, m, H(14)), 1.76 (3H, s, H(20)), 1.88 (3H, s, H(23)), 2.39 (3H, s, H(10)), 3.00 
(2H, app. q, J=5.8 Hz, H(17)), 4.31 - 4.40 (1H, m, H(13)), 6.26 (1H, s, H(2)), 7.49 (1H, 
d, J=8.7 Hz, H(8)), 7.71 (1H, d, J=8.7 Hz, H(9)), 7.75 - 7.86 (2H, m, H(6) and H(18)), 
8.20 (1H, d, J=7.4 Hz, H(21)), 10.49 (1H, s, H(11)); 
13
C NMR (125 MHz, DMSO-d6) δ 
ppm 18.0 (C(10)), 22.4 (C(15)), 22.6 (C(20)), 23.0 (C(23)), 28.9 (C(16)), 31.5 (C(14)), 
38.3 (C(17)), 53.6 (C(13)), 105.7 (C(6)), 112.3 (C(2)), 115.0 (C(4)), 115.3 (C(8)), 125.9 
(C(9)), 142.2 (C(7)), 153.1 (C(3)), 153.6 (C(5)), 160.0 (C(1)), 169.0 (C(19)), 169.5 
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(C(22)), 171.8 (C(12)); m/z (CI
+
) 388 ([M+H]
+
, 44%), 370 ([M+H-water]
+
, 82%); 
HRMS C20H25N3O5
+
 requires: 388.1873, found: 388.1862. 
7.2 In vitro HDAC inhibition assays 
Recombinant HDAC isoforms were used. HDAC2 (1−488, His-tag), HDAC3-
NCoR1, HDAC6 (His-tag), Fluor-de-Lys SIRT1, Fluor-de-Lys developer II, and TSA 
were purchased from Enzo Life Sciences, and porcine pancreatic trypsin (type IX-S) 
was from Sigma. HDAC1 (C-Flag), HDAC2 (C-His-tag) and HDAC3-NCoR2 were 
purchased from Tebu Bio. HDAC8 was expressed in Escherichia coli BL21 cells and 
purified with a His-tag, which was removed prior to final purification by size exclusion 
chromatography.  
Endpoint assay 
The in vitro HDAC assay used was based on a homogeneous fluorogenic HDAC 
assay.
88
 Inhibitor solutions were prepared by serial dilution of a 5 mM DMSO stock 
solution with assay buffer except for the fragments when screening at 1 mM, these were 
prepared by diluting a 25 mM DMSO stock solution with assay buffer. Assays were 
carried out in a 96-well white non-binding surface microplate, to 10 µL of inhibitor 
solution was added purified recombinant HDAC enzyme (HDAC1, 120 ng; HDAC2, 85 
ng; HDAC3-NCoR1, 25 ng; HDAC6, 280 ng; HDAC8, 400 ng) in 20 μL of assay buffer 
comprising 50 mM Tris/Cl, pH 8.0, 137 mM NaCl, 2.7 mM KCl, 1 mM MgCl2, 1 
mg/mL BSA (for HDAC8 assays the buffer also contained 10% v/v PEG 8000. After 
incubation at 20−23 °C for the appropriate time (HDAC1, 1 h; HDAC2, HDAC3, and 
HDAC6, 3 h; HDAC8, 15 min) the fluorescent substrate (for HDAC1, HDAC2, 
HDAC3-NCoR1, and HDAC8, MAL (20 μL), to give concentrations of 60, 80, 14, and 
200 µM; and for HDAC6, Fluor-de-Lys SIRT1, to give a concentration of 13 µM) was 
added and the plate was incubated for 30-60 min at 37 °C. A developer solution (for 
HDAC1, HDAC2, HDAC3-NCoR1, and HDAC8, 50 μL of 10 mg/mL trypsin and 2 
µM TSA in assay buffer; for HDAC6 Fluor-de-Lys developer II and 2 mM TSA in 50 
mMTris/Cl, pH 8.0, 137 mMNaCl, 2.7 mMKCl, 1 mMMgCl2) was then added and the 
plate incubated for 30 min at rt before the fluorescence was measured on a BMG 
FLUOstar Optima plate reader with excitation at 380 nm and emission at 460 nm. A 
well which contained 20 µL buffer instead of the enzyme solution was used as a zero 
deacetylation control and the fluorescence value of this well was subtracted from all 
other wells. Some wells contained 10 µL buffer instead of an inhibitor solution to be the 
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maximum deacetylation control and the average fluorescence value of these wells was 
used to calculate a percentage inhibition for the other wells. OriginPro 8 was used to 
determine IC50 values from the sigmoidal line fitted to a graph of log[concentration] 
against the average percentage inhibition from two independent experiments, with at 
least six different concentrations. The SEM is the calculated standard error in the IC50 
value of the fitted line. 
‘Progression method’ assay 
Inhibitor solutions were prepared by serial dilution of a 5 mM DMSO stock 
solution with assay buffer. In a 96 well white non-binding surface™ microplate 
fluorescent substrate Ac-Lys(Ac)-AMC (10 µL, 250 µM in assay buffer), inhibitor 
solution (10 µL) and Lys-C peptidase enzyme (10 µL, 0.2 U/mL in assay buffer) were 
added to each well. To a control well, assay buffer (10 µL) was added instead of 
inhibitor solution. Following a 10 min equilibration of both the plate and the enzyme 
solution to assay temperature (30 °C) HDAC3-NCoR1 (20 µL, 5 ng/µL) was added at 
the same time to 8 wells using a multichannel pipette. The plate was then incubated at 
30 °C and the fluorescence of each well measured every minute for 1 h, with excitation 
at 380 nm and emission at 460 nm. 
The data obtained were fitted to the integrated rate equation for slow binding 
inhibitors [𝐹 = 𝑣𝑠𝑡 + (𝑣0 − 𝑣𝑠)(1 − exp(−𝑘𝑜𝑏𝑠𝑡))/𝑘𝑜𝑏𝑠] using OriginPro 8.6. The 
calculated kobs values were then plotted against inhibitor concentration to determine the 
mechanism of inhibition (see Gottesfeld et al. for details).
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Giannini, G.; Cabri, W.; Battistuzzi, G.; Gallo, G.; Ciacci, A.; Vesci, L.; Pisano, 
C.; Hanessian, S. Non-Natural Macrocyclic Inhibitors of Histone Deacetylases: 
Design, Synthesis, and Activity. J. Med. Chem. 2010, 6, 8387–8399. 
(136)  Haus, P.; Meyer-Almes, F.-J.; Franz-Josef, M.-A. A Fluorescence Based Assay 
of the Epigenetic Enzyme Histonedeacetylase 1 (HDAC1) 
http://www.bmglabtech.com/application-notes/fluorescence-
intensity/epigenetics-hdac-optima-220.cfm. 
8. References 
Christopher Matthews  257 
(137)  Delorme, D.; Vaisburg, A.; Moradei, O.; Leit, S.; Frechette, S.; Zhou, Z.; Paquin, 
I.; Gaudette, F.; Isakovic, L.; Bouchain, G.; Raeppel, S. Inhibitors of Histone 
Deacetylase. Pat. CA 2559733 2005, MethylGene. 
(138)  El-deeb, I. M.; Ryu, J. C.; Lee, S. H. Synthesis of New N-Arylpyrimidin-2-
Amine Derivatives Using a Palladium Catalyst. Molecules 2008, 13, 818–830. 
(139)  Ogino, Y.; Ohtake, N.; Nagae, Y.; Matsuda, K.; Ishikawa, M.; Moriya, M.; 
Kanesaka, M.; Mitobe, Y.; Ito, J.; Kanno, T.; Ishihara, A.; Iwaasa, H.; Ohe, T.; 
Kanatani, A.; Fukami, T. Syntheses and Structure–activity Relationships of 
Novel, Potent, and Selective Trans-2-[3-Oxospiro[isobenzofuran-1(3H),1′-
Cyclohexan]-4′-Yl]benzimidazole NPY Y5 Receptor Antagonists. Bioorg. Med. 
Chem. Lett. 2008, 18, 4997–5001. 
(140)  Sun, Q.; Gatto, B.; Yu, C.; Liu, A.; Liu, L. F.; LaVoie, E. J. Synthesis and 
Evaluation of Terbenzimidazoles as Topoisomerase I Inhibitors. J. Med. Chem. 
1995, 38, 3638–3644. 
(141)  Charrier, N.; Demont, E.; Dunsdon, R.; Maile, G.; Naylor, A.; O’Brien, A.; 
Redshaw, S.; Theobald, P.; Vesey, D.; Walter, D.; O’Brien, A. Synthesis of 
Indoles: Efficient Functionalisation of the 7-Position. Synthesis 2006, 20, 3467–
3477. 
(142)  Appleton, J.; Andrews, B.; Rae, I.; Reichert, B. Aromatic Amides. V. 
Intramolecular Hydrogen Bonding in Ortho -Substituted Anilides. Aust. J. Chem. 
1970, 23, 1667. 
(143)  Johnson, P. C.; Wesley, C. J.; Howard, W. J. Carbonyl-Substituted 1-
Sulfonylbenzimidazoles. Pat. US 4118742 1978, Eli Lilly Co. 
(144)  Pearson, A. J.; Chelliah, M. V. Synthesis of a Model Bicyclic CDE Ring System 
of Ristocetin A and Observation of a Facile Inversion of Configuration in a 16-
Membered DE Ring Model Nucleophiles and Chlorophenylalanine Residues 
That Are Connected by a Peptide Chain , Resulting in. J. Org. Chem. 1998, 63, 
3087–3098. 
(145)  Itoh, M.; Hagiwara, D.; Kamiya, T. Peptides. VI. Some Oxime Carbonates as 
Novel T-Butoxycarbonylating Reagents. Bull. Chem. Soc. Jpn. 1977, 50, 718–
721. 
(146)  Konya, K. G.; Paul, T.; Lin, S.; Lusztyk, J.; Ingold, K. U. Laser Flash Photolysis 
Studies on the First Superoxide Thermal Source. First Direct Measurements of 
the Rates of Solvent-Assisted 1,2-Hydrogen Atom Shifts and a Proposed New 
Mechanism for This Unusual Rearrangement. J. Am. Chem. Soc. 2000, 122, 
7518–7527. 
(147)  Petasis, N. A.; Patel, Z. D. Synthesis of Piperazinones and Benzopiperazinones 
from 1,2-Diamines and Organoboronic Acids. Tetrahedron Lett. 2000, 41, 9607–
9611. 
8. References 
Christopher Matthews  258 
(148)  De, K.; Legros, J.; Crousse, B.; Chandrasekaran, S.; Bonnet-Delpon, D. 
Synthesis of Substituted 8-Aminoquinolines and Phenanthrolines through a 
Povarov Approach. Org. Biomol. Chem. 2011, 9, 347–350. 
(149)  McKennon, M. J.; Meyers, a. I.; Drauz, K.; Schwarm, M. A Convenient 
Reduction of Amino Acids and Their Derivatives. J. Org. Chem. 1993, 58, 3568–
3571. 
(150)  Lohray, B. B.; Ahuja, J. R. Synthesis of Homochiral Amino Alcohols, Aziridines 
and Diamines via Homochiral Cyclic Sulphites. J. Chem. Soc., Chem. Commun. 
1991, 95. 
(151)  Fan, M.-J.; Li, G.-Q.; Liang, Y.-M. DABCO Catalyzed Reaction of Various 
Nucleophiles with Activated Alkynes Leading to the Formation of Alkenoic Acid 
Esters, 1,4-Dioxane, Morpholine, and Piperazinone Derivatives. Tetrahedron 
2006, 62, 6782–6791. 
(152)  Murakata, M.; Tsutsui, H.; Hoshino, O. Unprecedented Effects of Achiral 
Oxazolidinones on Enantioselective Radical-Mediated Conjugate Additions 
Using a Chiral Zinc Triflate. Org. Lett. 2001, 3, 299–302. 
(153)  Pan, X.; Jia, L.; Liu, X.; Ma, H.; Yang, W.; Schwarz, J. B. A General 
Asymmetric Synthesis of Phenylglycinols. Tetrahedron: Asymmetry 2011, 22, 
329–337. 
(154)  Hirose, K.; Ogasahara, K.; Nishioka, K.; Tobe, Y.; Naemura, K. Enantioselective 
Complexation of Phenolic Crown Ethers with Chiral Aminoethanol Derivatives: 
Effects of Substituents of Aromatic Rings of Hosts and Guests on Complexation . 
J. Chem. Soc. Perkin Trans. 2 2000, 1984–1993. 
(155)  Chen, N.; Jia, W.; Xu, J. A Versatile Synthesis of Various Substituted Taurines 
from Vicinal Amino Alcohols and Aziridines. Eur. J. Org. Chem. 2009, 2009, 
5841–5846. 
(156)  Kunimoto. Crystal and Molecular Structures of Racemic and Chiral 4-Phenyl-
1,3-Thiazolidine-2-Thiones. Heterocycles 2002, 57, 2011. 
(157)  Wu, Y.; Yang, Y.; Hu, Q. A Facile Access to Chiral 4-Isopropyl-, 4-Benzyl-, and 
4-Phenyloxazolidine-2-Thione. J. Org. Chem 2004, 69, 3990–3992. 
(158)  Kim, T. H.; Cha, M.-H. Efficient Synthesis of 2-Methylaminothiazolines via 
Mitsunobu Reaction of N-(2-Hydroxyethyl)-N′-Methyl-Thioureas. Tetrahedron 
Lett. 1999, 40, 3125–3128. 
(159)  Kudelko, A.; Zieliński, W. An Efficient Synthesis of New 2-Aminomethyl-1,3,4-
Oxadiazoles from Enantiomeric Phenylglycine Hydrazides. Tetrahedron 2009, 
65, 1200–1206. 
(160)  Person, D.; le Corre, M. Nouvelle Voie D’acces Aux Alkylidene-3 
Piperazinediones-2,5. Bull. Soc. Chim. Fr. 1989, 5, 673–676. 
8. References 
Christopher Matthews  259 
(161)  Shatzmiller, S.; Bercovici, S. Use of Α-Bromo Oxime Ethers in the Synthesis of 
1,2-Diamines. Liebigs Ann. der Chemie 1992, 10, 1005–1010. 
(162)  Feist, F.; Arnstein, H. Ueber Aromatische Homologe Des Aethylendiamins. 
Chem. Ber. 1895, 28, 3167–3181. 
(163)  Delapierre, G.; Brunel, J. M.; Constantieux, T.; Buono, G. Design of a New Class 
of Chiral Quinoline–phosphine Ligands. Synthesis and Application in 
Asymmetric Catalysis. Tetrahedron: Asymmetry 2001, 12, 1345–1352. 
(164)  Bahloul, A.; Sebban, A.; Dardari, Z.; Boudouma, M.; Kitane, S.; Belghiti, T.; 
Joly, J.-P. New Heterocycles from 8-Hydroxyquinoline via Dipolar 1,3-
Cycloadditions: Synthesis and Biological Evaluation. J. Heterocycl. Chem. 2003, 
40, 243–248. 
(165)  Jones, I. W.; Hall, H. K. Demonstration of a Convergent Approach to UV-
Polymerizable Lipids bisDenPC and bisSorbPC. Tetrahedron Lett. 2011, 52, 
3699–3701. 
(166)  Howe, R. K. Reactions and Nuclear Magnetic Resonance Studies of Allylic 
Wittig Ylides. J. Am. Chem. Soc. 1971, 93, 3457–3462.  
 
